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Abstract 
 
Idiopathic Mendelian epilepsies have been typically identified as channelopathies. 
Evidence  suggests  that  mutations  in  genes  encoding  GABAA  receptors,  GABAB 
receptors or voltage-dependent calcium channels (VDCCs) may underlie childhood 
absence  epilepsy  (CAE),  an  idiopathic  generalised  epilepsy  with  complex 
inheritance. 
 
The aims of this project were:  
i)  Ascertainment of a patient resource  
ii)  Investigation of candidate genes by linkage analysis  
iii)  Mutation analysis by direct sequencing 
iv)  Construction of single nucleotide polymorphism (SNP) based haplotypes in 
candidate genes 
v)  Intra-familial association analysis using SNP based haplotypes 
 
DNA and clinical data were obtained from: 53 nuclear CAE pedigrees; 29 families 
including individuals with CAE and a broader „absence‟ epilepsy phenotype; 217 
parent-child trios; a North American family in which absence epilepsy segregates 
with episodic ataxia type 2 (EA2) 
 
Sixteen calcium channel genes and seven GABAA and two GABAB receptor subunit 
genes were excluded by linkage analysis. Significant linkage was demonstrated for 
CACNG3  on  chromosome  16p12-p13.1  for  both  CAE  and  the  broader  absence 
phenotype. Positive linkage was also obtained at the GABRA5, GABRB3, GABRG3 
cluster on chromosome 15q11-q13. Non-parametric linkage analysis was significant 
at both the 16p and 15q loci. Two-locus analysis supported a digenic effect from 
these two loci. Sequencing of CACNG3 revealed 34 sequence variants, none clearly 
causal,  although  bioinformatic  analysis  provided  supportive  functional  evidence. 
Association  analysis  showed  significant  transmission  disequilibrium  both  for 
individual  single  nucleotide  polymorphisms  (SNPs)  and  SNP  based  haplotypes 
spanning CACNG3. This work has provided genetic evidence that CACNG3 and at 
least  one  of the  three  GABAA  receptor genes are  susceptibility  loci  for  absence 
epilepsy.  
 
Linkage  analysis  performed  in  the  family  with  absence  epilepsy  and  EA2  was 
suggestive  that  the  VDCC  CACNA1A  was  the  causative  gene.  This  was   4 
subsequently confirmed by sequence analysis in collaboration with the Institute of 
Neurology, UCL. This is the first reported family in which a CACNA1A mutation that 
impairs calcium channel function cosegregates with typical absence seizures and 
3Hz spike-wave discharges on EEG.     5 
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Chapter 1  Epilepsy 
1.1  Historical review 
The term “epilepsy” derives from the Greek επιλʱμβʱνέιν (epilambanein), to 
be attacked, taken hold of or seized (Engel and Pedley 1997). However the 
earliest  descriptions  are  found  in  Mesopotamian,  Egyptian,  Indian  and 
Chinese  literature. The  British  Museum houses  a  Babylonian  tablet  which 
gives a detailed account of epilepsy, including many different seizure types. 
The tablet is a chapter from a Babylonian textbook of medicine dating back to 
2000BC.  Each  seizure  type  is  associated  with  an  evil  god  or  spirit.  An 
Assyrian text of 650BC describes a seizure in terms of demonic possession, 
referring to “eyes moving to the side”, “lip puckering”, “saliva flowing from the 
mouth”, and “hand, leg and trunk jerking like a slaughtered sheep”, and tells 
of circumstances in which the demon can or cannot be “driven out” (Porter 
1997). 
A less supernatural account of epilepsy appears in the Charaka Samhita, 
dated to 400BC, a description of the Ayurvedic medical system of Ancient 
India  developed  during  the  Vedic  period  (4500-1500BC).  Referring  to 
“apasmara”,  meaning  “loss  of  consciousness”,  the  Charaka  Samhita 
describes the causes, symptoms, diagnosis and treatment of epilepsy. 
The Hippocratic text On the Sacred Disease, which dates to 410BC, rejected 
the idea of a divine origin for epilepsy (Porter 1997). Instead, the symptoms 
are  associated  with  phlegm  blocking  the  airways,  causing  the  body  to 
convulse as it struggles to free itself. Galen, an influential Greek physician of 
the second century AD, dissected the brain. He believed that epilepsy was 
caused  by  phlegm  and  bile  accumulating  within  the  cerebral  ventricles. 
However, supernatural views of epilepsy persisted in Europe until the 19th 
Century,  when  the  concept  of  epilepsy  as  a  brain  disorder  became  more 
widely accepted. Suspicion, fear and mistrust of people with epilepsy were 
widespread, and discrimination and punishment was not unusual.    24 
Bromide, the world‟s first effective anti-epileptic drug, was introduced in 1857. 
In  1873  Hughlings  Jackson,  a  London  neurologist  proposed  that  seizures 
were the result of sudden brief electro-chemical discharges in the brain, and 
that the character of the seizures depended on the location and function of 
the site of the discharges. The first experimentally induced seizures recorded 
by electroencephalography were described by Pavel Yurevich Kaufmann, a 
student of Pavlov, in Russia in 1912. Spontaneous brain electrical activity in 
humans recorded from the scalp was reported in 1929 by Dr Hans Berger, a 
professor of psychiatry at the University of Jena in Germany. He was also the 
first person to record human spike-wave activity. Advances over the course 
of the 20th century have included many diagnostic imaging techniques, the 
development of a panoply of antiepileptic drugs and the use of neurosurgical 
therapies. 
In the understanding of the basic processes of epileptogenesis, molecular 
genetics has assumed an increasingly important role, with the discovery of 
single gene disorders and structural gene defects. This is now one of the 
most promising and exciting areas in epilepsy research. 
1.2  Definition of epileptic seizures and epilepsy 
An  epileptic  seizure  is  a  transient  episode  of  abnormal  cortical  neuronal 
activity apparent to the patient or an observer. The abnormal cortical activity 
may be manifest as a motor, sensory, cognitive or psychic disturbance. A 
seizure is diagnosed on clinical criteria, although electrophysiological data 
may be used in determining the precise seizure type. 
Epilepsy is a disorder of the brain characterised by recurrent, unprovoked 
epileptic  seizures.  Therefore  single  epileptic  seizures,  provoked  seizures 
(e.g.  febrile  convulsions,  hypoglycaemic  seizures  or  seizures  occurring 
during drug withdrawal) or seizures that occur during an acute illness (e.g. 
encephalitis)  are  not  classified  as  epilepsy.  An  epilepsy  syndrome  is  a 
complex of signs and symptoms that define a unique epilepsy condition. It is   25 
characterised by a particular pattern of seizure types occurring with certain 
physical and investigative findings. Epilepsy syndromes are generally defined 
in terms of aetiology, seizure type, age of onset, precipitating factors, EEG 
findings,  and  prognosis.  Epilepsy  also  occurs  as  a  feature  of  several 
neurological  and  multi-system  diseases  (e.g.  neurocutaneous  syndromes, 
neurodegenerative disorders).  
1.3  Importance  
Epilepsy is one of the most common serious brain disorders affecting up to 
60 million  people  worldwide  at  any  one  time.  It occurs most frequently  in 
childhood,  adolescence  and  old  age.  The  1998  'European  Declaration  on 
Epilepsy',  estimated  that  epilepsy  costs  the  countries  of  Europe  over  20 
billion euros annually, and a WHO/World Bank study in 1990, „Investing in 
Health‟,  showed  that  epilepsy  accounted  for  nearly  1%  of  the  world‟s 
economic disease burden. In 1997, the World Health Organisation (WHO) 
together  with  two  non-governmental  agencies,  the  International  League 
Against  Epilepsy  (ILAE)  and  International  Bureau  for  Epilepsy  (IBE), 
launched a Global Campaign against Epilepsy. The first three years focussed 
on  increasing  awareness  and  education,  and  the  second  phase  was 
launched in 2001 as part of the World Health Day theme, Mental Health and 
Brain Disorders. In the European White Paper on Epilepsy, presented to the 
European  Parliament  in  March  2001,  the  Call  to  Action  focused  on  three 
areas: eradication of stigma, discrimination in the workplace and inadequate 
research. In 2001, the WHO Global Burden of Disease study reported that, 
for  the  year  2000,  epilepsy  accounted  for  0.5%  of  the  whole  burden  of 
diseases in the world, using the measure „years of life lived with disability‟ 
(Leonardi and Ustun 2002).   26 
1.4  Classification 
Since epilepsy was first recognised there have been descriptions of different 
seizure types. However, the development of the first structured classification 
of seizures began in the 1960's, and was introduced by the ILAE in 1981 
(ILAE 1981). A classification of different epilepsies followed in 1985 (ILAE 
1985),  and  was  revised  in  1989  and  2001  (ILAE  1989;  Engel  2001).  A 
proposed classification at that time was divided into five parts, or axes, which 
facilitate  a  logical  approach  to  diagnosis  and  management  of  individual 
patients. 
1.4.1  Axis 1: Ictal phenomenology 
Axis 1 consists of a description of the ictal semiology, without reference to 
aetiology, anatomy or mechanisms. A standardised Glossary of Descriptive 
Terminology  should  be  used  to  aid  communication  among  clinicians  and 
researchers  (Blume,  Luders  et  al.  2001).  This  descriptive  terminology 
recognises  nine  possible  components  of  seizure  semiology:  i)  Motor 
(elementary  motor  and  automatism);  ii)  Non-motor  (aura,  sensory  and 
dyscognitive); iii) Autonomic; iv) Somatotopic modifiers (laterality, body part 
involved  and  centricity);  v)  Modifiers  and  descriptors  of  seizure  timing 
(incidence, state dependent and catamenial); vi) Duration; vii) Severity; viii) 
Prodrome; ix) Postictal phenomena.  
1.4.2  Axis 2: Seizure type 
Axis 2 is the epileptic seizure type or types experienced by the patient. An 
accepted list of seizure types represents diagnostic entities with aetiologic, 
therapeutic and prognostic implications. These are divided into self-limited 
seizures and continuous seizures (status epilepticus), and further divided into 
generalised and focal seizures (see below). Axis 2 also includes precipitating 
factors for reflex seizures. 
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i.  Generalised seizures 
Generalised  seizures  are  those  whose  initial  semiology  and/or  ictal  EEG 
patterns indicate, or are consistent with, more than minimal involvement of 
both  cerebral  hemispheres.  Consciousness  is  not  always  impaired. 
Generalised  seizures  include  tonic-clonic,  clonic,  tonic,  absence  (typical, 
atypical and myoclonic), myoclonic and atonic seizures. 
ii.  Focal seizures 
Focal seizures are those whose initial semiology and/or ictal EEG patterns 
indicate, or are consistent with, initial activation of only part of one cerebral 
hemisphere.  Although  it  is  recommended  that  the  term  „focal‟  replaces 
„partial‟  or  „localization-related‟,  this  does  not  mean  that  the  epileptogenic 
region is a small, well-delineated focus of neuronal pathology. Focal seizures 
usually  result  from  diffuse,  sometimes  widespread  areas  of  cerebral 
dysfunction. The term „simple‟ is used to describe focal seizures during which 
consciousness is unimpaired, and „complex‟ signifies some degree of altered 
consciousness. 
iii.  Generalised or focal? 
In practice there are a range of conditions between focal and generalised 
epileptogenic  dysfunctions  including  diffuse  hemispheric  abnormalities, 
multifocal abnormalities, and bilaterally symmetrical localised abnormalities. 
Any focal seizure can become secondarily generalised. In fact, apparently 
generalised seizures may be shown to have a focal origin when the EEG is 
examined  in  detail,  indicating  that  a  dichotomous  classification  of  „focal‟ 
versus „generalised‟ is not always appropriate. 
1.4.3  Axis 3: Epilepsy syndrome 
Axis 3 is the epilepsy syndrome diagnosis, which is not always possible to 
make.  The  recommended  list  of  syndromes  is  constantly  evolving  and 
includes syndromes in development. There is a distinction between epilepsy 
syndromes  and  conditions  with  epileptic  seizures  that  do  not  require  a   28 
diagnosis  of  epilepsy  (e.g.  febrile  seizures).  The  terms  „focal‟  and 
„generalised‟ are also applied to epilepsy syndromes, reflecting the seizure 
type.  The  main  epilepsy  syndromes  include  idiopathic  focal  epilepsies  of 
infancy and childhood, familial focal epilepsies, symptomatic focal epilepsies, 
idiopathic  generalised  epilepsies,  reflex  epilepsies,  epileptic 
encephalopathies and progressive myoclonus epilepsies. 
1.4.4  Axis 4: Aetiology 
Axis  4  specifies  the  aetiology  when  it  is  known.  Epilepsy  syndromes  are 
classified as symptomatic, probably symptomatic or idiopathic, according to 
whether a cause is apparent or not.  
i.  Idiopathic epilepsy 
An idiopathic epilepsy is defined as a syndrome that is epilepsy alone, with 
no underlying structural brain lesion or other neurological signs or symptoms. 
These are known or presumed to have a genetic basis and are usually age 
dependent. It is estimated that 40- 60% of all epilepsies may be classified as 
idiopathic (Annegers, Rocca et al. 1996). The majority of idiopathic epilepsies 
show a complex pattern of inheritance. 
ii.  Symptomatic epilepsy 
A  symptomatic  epilepsy  is  defined  as  a  syndrome  in  which  the  epileptic 
seizures  are  the  result  of  one  or more  identifiable  structural  lesion  of  the 
brain. The aetiology may be a disease frequently associated with epilepsy, a 
genetic disorder, a specific pathological substrate, a cerebral malformation or 
tumour, or an environmental insult. 
iii.  Probably symptomatic epilepsy 
The term „cryptogenic‟ has been replaced by „probably symptomatic‟, used to 
define a syndrome that is believed to be symptomatic, but no aetiology has 
been identified.   29 
1.4.5  Axis 5: Impairment 
Axis 5 is an optional designation of the degree of impairment caused by the 
epilepsy.    A  World  Health  Organisation  International  Classification  of 
Functioning  and  Disability  is  in  preparation,  and  may  be  modified  for 
application to epileptic disorders.  
1.4.6  Current proposals on classification 
A draft recommendation regarding the terminology and concepts used in the 
classification of the epilepsies and epileptic seizures was due for discussion 
by  the  ILAE  Commission  on  Classification  and  Terminology  at  the 
International Epilepsy Congress in Budapest, on June 30
th 2009 (ILAE 2009). 
The  emphasis  of  the  draft  report  is  that  the  epilepsies  should  be  flexibly 
organized according to whichever dimensions are most relevant to a specific 
purpose.  The  key  recommendations  related  to  the  following  three  areas 
(Table 1-1): 
i.  Mode of seizure onset and classification of seizures 
Generalised  epileptic  seizures  originate  within  and  involve  bilaterally 
distributed  networks  but  may  be  asymmetric  and  appear  localised  (not 
consistently). Generalised seizure types can be distinguished although there 
may be some overlap. 
Focal seizures originate from unihemispheric networks, with consistent ictal 
onset for each seizure type. They are not classifiable as distinct entities as 
current  understanding  of  mechanisms  does  not  define  a  set  of  natural 
classes. 
ii.  Syndrome versus epilepsy 
The  term  “syndrome”  should  be  restricted  to  those  conditions  reliably 
identified by a cluster of electro-clinical characteristics. Other epilepsies can 
be grouped and organised in terms of other factors, such as cause (where 
known),  seizure  type,  age  of  onset  etc.  The  description  of  syndromes  as 
being  „localization-related‟  versus  „generalised‟,  and  „idiopathic‟,   30 
„symptomatic‟  or  „cryptogenic‟  should  be  abandoned  for  a  more  flexible, 
multidimensional system of organisation. 
iii.  Aetiology 
The  terms,  idiopathic,  symptomatic,  and  cryptogenic  used  to  classify 
epilepsies should be replaced with the terms genetic (or presumed genetic), 
structural/metabolic, and unknown respectively. „Genetic‟, unlike „idiopathic‟, 
should no longer imply „benign‟. „Structural/metabolic‟ includes those genetic 
conditions where a distinct disorder is interposed between the genetic defect 
and  the  epilepsy.  „Epilepsy  of  unknown  cause‟  no  longer  presumes  a 
structural/metabolic  cause,  and  may  include  some  of  the  traditional 
“idiopathic” developmental syndromes. 
For the purposes of this thesis, the terminology of the 1989 classification will 
be used. 
 
Table 1-1 Comparison of 1989/2001 ILAE classification and new proposals 
  1989/2001 Classification  2009 Proposed Classification 
Classification of seizures:     
  Generalised seizures:  More than minimal involvement of 
both cerebral hemispheres 
Multiple seizure types 
Occur in and rapidly engage 
bilaterally distributed networks 
Simplified classification of seizure 
types  
  Focal seizures:  Initial activation of only part of one 
cerebral hemisphere 
Simple or complex. 
Occur in networks limited to one 
hemisphere 
No classification. Described 
according to manifestation 
Classification of syndromes:  Focal or generalised  No classification 
Aetiology:  Idiopathic, symptomatic or 
cryptogenic 
Genetic, structural-metabolic or 
unknown 
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1.5  Basic Mechanisms of epileptogenesis 
Epileptic seizures occur as a result of excessive discharge in hyperexcitable 
neurons.  These  originate  most  commonly  in  cortical  and  hippocampal 
structures,  although  subcortical  structures  may  be  involved.  The  changes 
underlying  neuronal  hyperexcitability  may  involve  increased  excitatory 
synaptic transmission, decreased inhibitory  neurotransmission, altered ion-
channel function or altered intra- or extra-cellular ion concentrations leading 
to  membrane  depolarisation.  Genetically  determined  alterations  of  both 
ligand-gated and voltage-gated ion channels are of particular importance in 
epileptogenesis. Changes in ionic currents mediated by sodium, potassium 
and  calcium  channels,  as  well  as  alteration  in  function  of  acetylcholine, 
glutamate and γ-aminobutyric acid receptors can lead to different types of 
epilepsy. Abnormal activity in single neurons leads to recruitment of a critical 
mass of hyperexcitable cells in highly synchronised activities (Avanzini and 
Franceschetti  2003).  The  neurons  in  an  epileptic  neuronal  aggregate 
consistently discharge in the form of protracted bursts of action potentials – 
called  paroxysmal  depolarisation  shifts.  Propagation  through  normal  or 
pathological pathways then occurs resulting in the clinical manifestation of a 
seizure.  Thus  both  altered  neuronal  excitability  and  neuronal  circuitry  are 
important in the generation and spread of epileptic discharges.   32 
 
Chapter 2  Molecular genetics of epilepsy 
2.1  Introduction 
The heterogeneous nature of epilepsy is reflected in the diversity of its many 
causes.  However,  a  genetic  contribution  to  aetiology  is  estimated  to  be 
present  in  40  %  of  patients,  and  this  proportion  is  higher  in  childhood 
epilepsies.  The  familial  clustering  of  human  epilepsy  has  long  been 
recognised,  and  the  concept  of  a  genetic  predisposition  to  epilepsy  was 
proposed over 40 years ago (Lennox and Lennox 1960). More recent twin 
studies  have  shown  that  genetic  factors  are  particularly  important  in  the 
generalised epilepsies but also play a role in the partial epilepsies (Berkovic, 
Howell et al. 1998). The high frequency of concordant monozygotic twins with 
the  same  major  syndrome  suggests  the  existence  of  syndrome  specific 
genetic  determinants  rather  than  a  single  broad  genetic  predisposition  to 
seizures. 
2.2  Classification of genetic epilepsies 
The human genetic epilepsies can be categorised in several ways, including 
mechanism  of  inheritance,  whether  they  are  idiopathic  (primary)  or 
symptomatic and, where known, which class of gene is involved.  
2.2.1  Mechanism of inheritance 
The mechanism of inheritance identifies three major groups: 
  Mendelian epilepsies, in which mutations in a single gene can account 
for segregation of the disease trait.   33 
  Non-mendelian or „complex‟ epilepsies, in which several loci interact 
with environmental factors to produce the pattern of familial clustering. 
This  group  includes  those  epilepsies  which  exhibit  a  maternal 
inheritance pattern due to mutations in mitochondrial DNA. 
  Chromosomal disorders,  in  which  the epilepsy  results from a  gross 
cytogenetic abnormality. 
2.2.2  Idiopathic and symptomatic epilepsy 
The most commonly observed mendelian epilepsies are „symptomatic‟, in 
which recurrent seizures occur as a result of one or more identifiable 
structural lesions of the brain, and are often one component of a diverse 
neurological phenotype. Over 200 mendelian diseases include epilepsy as 
part of the phenotype. The genetic mutations in these disorders may cause 
abnormal brain development, progressive neurodegeneration or disturbed 
energy metabolism, so the mechanism of seizure generation is often indirect. 
The idiopathic epilepsies, in which seizures occur in individuals who are 
otherwise neurologically and cognitively intact, rarely display a mendelian 
inheritance pattern. The common familial idiopathic epilepsies, such as 
juvenile myoclonic epilepsy (JME), childhood absence epilepsy (CAE) and 
benign childhood epilepsy with centrotemporal spike (BCECTS), tend to 
display „complex‟ inheritance. These epilepsies often show age-dependant 
penetrance with peak onset in childhood. A number of gross chromosomal 
abnormalities are associated with epilepsy (Singh, Gardner et al. 2002). 
2.2.3  Class of gene 
Although rare, the idiopathic mendelian epilepsies have provided the major 
recent  advances  in  the  molecular  basis  of  the  epilepsies.  Mutations  have 
been identified in families segregating benign familial neonatal convulsions 
(BFNC),  autosomal  dominant  nocturnal  frontal  lobe  epilepsy  (ADNFLE), 
generalised epilepsy with febrile seizures plus (GEFS+), childhood absence 
epilepsy  with  febrile  seizures,  autosomal  dominant  partial  epilepsy  with   34 
auditory features (ADPEAF) (Table 2-1). Other than LGI1 and MASS1, all 
mutations occur in genes encoding ion channels, identifying some idiopathic 
mendelian epilepsies as channelopathies.  
Success in determining the molecular genetic basis of the common familial 
epilepsies  has  been  relatively  slow.  No  gene  identified  in  a  mendelian 
epilepsy acts as a major locus in any non-mendelian epilepsy, and the extent 
of  heterogeneity  is  likely  to  be  far  greater  in  the  complex  epilepsies. 
However, the completion of the human genome project and the development 
of high-throughout molecular genetic techniques will significantly increase the 
prospect of identifying the common epilepsy susceptibility genes.   35 
 
GEFS+: Generalised epilepsy with febrile seizures plus; SMEI: Severe myoclonic epilepsy of infancy; BFNIS: 
Benign familial neonatal-infantile seizures; BFNC: Benign familial neonatal convulsions; EA1: Episodic ataxia type1; 
IGE: Idiopathic generalised epilepsy; ADNFLE: Autosomal dominant nocturnal frontal lobe epilepsy; FS: Febrile 
seizures; CAE: Childhood absence epilepsy; JME: Juvenile myoclonic epilepsy; ADPEAF: Autosomal dominant 
partial epilepsy with auditory features
Table 2-1  Genes identified in mendelian epilepsies 
Gene class  Gene  
Gene 
location 
Epilepsy Syndrome  Inheritance  Key References 
Voltage-dependent 
ion channels: 
         
  Sodium 
channels 
SCN1A  2q24  GEFS+/SMEI  AD  Escayg  et  al.  2000; 
Claes et al. 2001 
    SCN2A  2q23-q24  GEFS+/BFNIS  AD  Sugawara  et  al.  2001; 
Heron et al. 2002 
    SCN1B  19q13  GEFS+  AD  Wallace et al. 1998 
             
  Potassium 
channels 
KCNQ2  20q  BFNC  AD  Leppert  et  al.  1989; 
Singh et al. 1998 
    KCNQ3  8q24  Lewis  et  al.  1993; 
Charlier et al. 1998 
    KCNA1  12p13  EA1 with partial epilepsy  AD  Spauschus et al. 1999 
             
  Calcium 
channels 
CACNA1A  19p13  Generalised  epilepsy 
with ataxia 
Sporadic  Jouvenceau et al. 2001 
    CACNB4  2q22-23  IGE/JME/ataxia  AD  Escayg et al. 2000 
             
Ligand-gated  ion 
channels: 
         
  Nicotinic 
acetylcholine 
receptors 
CHRNA4  20q13.2  ADNFLE  AD  Phillips  et  al.  1995; 
Steinlein  et  al.  1995; 
Steinlein et al. 1997 
  CHRNB2  1p21  Phillips et al. 2001 
  CHRNA2  8p21  Aridon et al. 2006 
             
  GABAA receptor  GABRG2  5q34  GEFS+/SMEI 
FS with CAE 
AD 
AD 
Baulac  et  al.  2001; 
Wallace et al. 2001     
    GABRA1  5q34  JME  AD  Cossette et al. 2002 
    GABRD  1p36.3  GEFS+/JME  AD  Dibbens et al. 2004 
             
Epilepsy associated 
repeat genes: 
         




LGI1  10q24  ADPEAF  AD  Kalachikov et al. 2002; 
Scheel et al. 2002 
             
  G-protein-
coupled receptor 
MASS1  5q14  Febrile  and  afebrile 
seizures 
AD  Nakayama et al. 2002   36 
2.3  Genetic heterogeneity 
The  idiopathic mendelian  epilepsies demonstrate both  locus  heterogeneity 
(mutations in more than one gene causing the same clinical phenotype) and 
phenotypic  heterogeneity  (mutations  in  the  same  gene  causing  different 
clinical  phenotypes).  This  is  not  surprising  given  the  complexity  of  the 
pathways involved in neuronal excitability and the diversity of genes likely to 
be involved. 
2.4  Mendelian epilepsy genes 
Over  200  mendelian  diseases  include  epilepsy  as  part  of  the  phenotype, 
including tuberous sclerosis, fragile X syndrome, neurofibromatosis and large 
number  of  metabolic  disorders.  The  small  number  of  primary  epilepsies 
which are inherited in a mendelian fashion are described here. Although they 
are rare and account for only a small number of epilepsy cases, recognition 
of  the  characteristic  features  and  presence  of  a  family  history  enable  a 
correct diagnosis to be made. Identification of genes responsible for some of 
these  disorders  has  provided  valuable  insights  into  the  molecular 
mechanisms underlying epilepsy.  
2.4.1  Benign familial neonatal convulsions (BFNC) 
Benign familial neonatal convulsions is a rare autosomal dominant idiopathic 
epilepsy, first described in 1963, and was the first epileptic syndrome to be 
localised by linkage (Rett and Teubel 1964). Seizures occur in otherwise well 
neonates from the second or third day of life and remit by week two to three. 
The  characteristic  seizures  comprise  tonic  posturing  with  ocular  and 
autonomic features,  followed  by  a  clonic  phases  with  motor  automatisms. 
The  prognosis for neurological  and  intellectual development  is favourable, 
although seizures recur later in life in about 10% of individuals.   37 
BFNC is a good illustration of both clinical and genetic heterogeneity, the 
latter of which can be explained by the underlying molecular genetics. The 
first locus (EBN1) identified in 1989 was localised to chromosome 20q by 
linkage  analysis  in  a  four  generation  family  with  19  affected  individuals 
(Leppert, Anderson et al. 1989). Six French pedigrees confirmed this linkage 
(Malafosse, Leboyer et al. 1992). However, in a study of two North American 
families, one family which showed linkage to EBN1 included family members 
with  seizures  persisting  up  to  2  years  of  age,  and  in  one  individual,  into 
adolescence (Ryan, Wiznitzer et al. 1991). The other family, none of whose 
members  had  seizures  after  two  months  of  age,  could  be  excluded  from 
linkage to EBN1, and was subsequently linked to a second locus (EBN2) on 
chromosome 8q (Lewis, Leach et al. 1993). 
The  gene  for  EBN1,  subsequently  named  KCNQ2,  was  identified  by 
characterisation of a sub-microscopic deletion on chromosome 20q13.3 in 
affected individuals and demonstrated significant homology with a voltage-
dependent  delayed  rectifying  potassium  channel  gene,  KCNQ1(Singh, 
Charlier  et  al.  1998).  Members  of  the  KCNQ  potassium  channel  family 
comprise  six  transmembrane-spanning  segments  (S1-S6),  a  pore  forming 
loop linking S5 and S6, and intracellular N and C termini. These channels 
open on membrane depolarisation and are involved in the repolarisation of 
the action potential and thus in the electrical excitability of nerve and muscle. 
Mutations in KCNQ1 can cause the paroxysmal cardiac dysrhythmias long 
QT  syndrome  and  Jervell-Lange-Nielson  cardioauditory  syndrome  (Wang, 
Curran  et  al.  1996;  Neyroud,  Tesson  et  al.  1997).  Six  allelic  variants  of 
KCNQ2  were  subsequently  identified  to  segregate  with  the  disease  in 
families  with  BFNC,  including  one  family  whose  affected  members 
subsequently  developed  myokymia  (spontaneous  contractions  of  skeletal 
muscle fibres) (Dedek, Kunath et al. 2001). All mutations involved regions of 
the gene important for ion conduction, including the S6 domain, the channel 
pore and the C terminus. Exonic deletions and duplications have now also 
been identified in families with BFNC (Heron, Cox et al. 2007).   38 
Following identification of KCNQ2, a BLAST search was made of the human 
expressed sequence tag (EST) database, to find cDNA sequences showing 
significant homology to KCNQ2. Rather fortuitously, a novel gene, KCNQ3, 
was  identified  with  69%  similarity  to  KCNQ2,  which  mapped  to  the  EBN2 
critical region on chromosome 8q24, and was mutated in affected members 
of  the  BFNC/EBN2  family  (Charlier,  Singh  et  al.  1998).  The  missense 
mutation identified altered a conserved amino acid in the critical pore forming 
region (the same amino acid was mutated in KCNQ1 in a patient with long 
QT syndrome (Wang, Curran et al. 1996)).  
KCNQ2 and KCNQ3 are co-expressed in most areas of the brain, especially 
the hippocampus, neocortex and cerebellum. They coassemble and form a 
heteromeric  channel  with  essentially  identical  biophysical  properties  and 
pharmacologic sensitivities to the native neuronal M-channel (Wang, Pan et 
al. 1998). The M-channel is a slowly activating and deactivating potassium 
conductance  that  plays  a  critical  role  in  determining  the  subthreshold 
electroexcitability  of  neurons.  Therefore  mutations  in  either  KCNQ2  or 
KCNQ3  disrupt  the  native  M-current  and  result  in  an  identical  disease 
phenotype (Figure 2-1(a)). 
A possible third locus for AD BFNC was identified in a 3 generation family 
(Concolino,  Iembo  et  al.  2002).  Linkage  to  KCNQ2  and  KCNQ3  was 
excluded,  but  a  pericentric  inversion  on  chromosome  5  was  found  to 


















Figure 2-1 Voltage-dependent ion channel structure. (a) Mutations at either 
benign familial neonatal convulsions (BFNC) locus, EBN1 (KCNQ2) or EBN2 
(KCNQ3), disrupt the heteromeric M-channel (potassium conductance) and 
result in an identical phenotype. (b) Sodium channels contain a pore forming 
ʱ subunit with two β subunits. (c) Calcium channels contain a pore forming ʱ 
subunit with regulatory β, γ, and ʱ2δ subunits. 
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2.4.2  Benign familial infantile convulsions (BFIC)  
This  mendelian  idiopathic  epilepsy  was  first  described  as  an  autosomal 
dominant disorder in families of Italian origin (Vigevano, Fusco et al. 1992), 
and further families were described in France and Singapore (Lee, Low et al. 
1993; Echenne, Humbertclaude et al. 1994).  Affected individuals manifested 
both  partial  and  generalised  seizures  commencing  at  age  3-12  months.  
Patients responded well to conventional anti-epilepsy drugs and prognosis 
was good with resolution of seizures and no psychomotor retardation. 
Gene  mapping  studies  have  demonstrated  locus  heterogeneity.    A  locus, 
BFIC1,  was  mapped  to  chromosome  19q  by  linkage  analysis  in  Italian 
families (Guipponi, Rivier et al. 1997).  A common haplotype was evident 
suggesting a founder effect.  A second locus, BFIC2, was mapped to 16p12-
q12  (Caraballo,  Pavek  et  al.  2001).    The  disease  genes  have  yet  to  be 
identified and it is possible that BFIC2 is an allelic variant of the gene causing 
infantile convulsions with choreoathetosis (ICCA) which maps to the same 
genomic region (section 2.4.4). 
2.4.3  Benign familial neonatal-infantile seizures (BFNIS)  
As  well  as  BFNC  and  BFIC,  an  intermediate  phenotype  BFNIS  was  first 
described in 1983, with seizure onset from 2 days to 3½ months (Kaplan and 
Lacey  1983).  Missense  mutations  in  the  sodium  channel  subunit  gene 
SCN2A were identified in two families with BFNIS. The different mutations 
identified in the two families both disrupted a conserved leucine, and were 
predicted  to  reduce  the  rate  of  inactivation  of  the  sodium  channel.  The 
number of SCN2A mutations identified was subsequently increased to six, in 
eight families with BFNIS (Berkovic, Heron et al. 2004). Affected individuals 
showed varying seizure frequencies but all seizures remitted by the age of 12 
months.  SCN2A  mutations  also  cause  febrile  seizures  associated  with 
afebrile seizures, part of the GEFS+ spectrum (section 2.4.6)   41 
2.4.4  Familial  infantile  convulsions  and  paroxysmal 
choreoathetosis (ICCA) 
This condition was first described in four families from north western France 
in  which  infantile  convulsions  (onset  3-12  months,  afebrile,  partial  with 
secondary  generalisation,  remittance  by  12  months)  were  inherited  as  an 
autosomal dominant trait in combination with paroxysmal choreoathetosis of 
variable  expression  (Szepetowski,  Rochette  et  al. 1997).   A  genome-wide 
screen  provided  evidence  of  linkage  to  the  pericentromeric  region  of 
chromosome 16 encompassing a 10cM interval 16p12-q12.  Confirmation of 
linkage to this region has subsequently been reported in a Chinese family 
with nine affected members (Lee, Tay et al. 1998).  It is also noteworthy that 
another phenotype, autosomal recessive rolandic epilepsy with paroxysmal 
exercise-induced dystonia and writer‟s cramp maps to a region encompassed 
by the ICCA critical region (Guerrini, Bonanni et al. 1999). 
2.4.5  Autosomal  dominant  nocturnal  frontal  lobe  epilepsy 
(ADNFLE) 
First described in six families from Australia, Canada and the UK, autosomal 
dominant nocturnal frontal lobe epilepsy is characterised by the occurrence 
of  partial  seizures  almost  exclusively  during  sleep,  which  may  be 
misdiagnosed as nightmares or other sleep disorders (Scheffer, Bhatia et al. 
1994). The familial nature is easily missed, as there is a pronounced variation 
in  severity  among  family  members,  and  the  penetrance  is  incomplete 
(approximately 70%). Seizures begin predominantly in childhood, persist into 
adulthood, and occur in clusters soon after falling asleep or before waking. 
An  aura  is  often  reported.  Seizures  are  characterised  by  brief  tonic  or 
hyperkinetic  motor  activity  with  retention  of  consciousness,  although 
secondary generalisation often occurs. Affected individuals are neurologically 
and intellectually normal. Ictal-EEG may show bifrontal sharp and slow wave 
activity. The inter-ictal EEG is usually normal.   42 
Linkage  analysis  in  a  single  large  Australian  pedigree  with  27  individuals 
assigned the gene to chromosome 20q13.2 (Phillips, Scheffer et al. 1995). 
The gene for the 4 subunit of the neuronal nicotinic acetylcholine receptor 
(nAChR), CHRNA4, was known to map to the same chromosomal region, 
and also to be expressed in the frontal cortex. The nAChRs are presynaptic 
ligand-gated ion channels with a role in modulating neurotransmitter release 
during fast synaptic transmission. Mutational analysis of CHRNA4 identified a 
missense mutation that cosegregated with the disease in the chromosome 
20-linked  family  (Steinlein,  Mulley  et  al.  1995).  The  mutation  converts  a 
serine to phenylanaline in the M2 transmembrane domain, a crucial structure 
mediating  ionic  permeability,  and  is  likely  to  be  disease  causing.  The 
mutation  was  not  found  in  333  healthy  controls.  Further  site-specific 
mutations  in  CHRNA4  affecting  pore  forming  amino  acids  have  been 
associated with ADNFLE (Steinlein, Magnusson et al. 1997; Hirose, Iwata et 
al.  1999;  Saenz,  Galan  et  al.  1999;  Phillips,  Marini  et  al.  2000;  Steinlein, 
Stoodt et al. 2000). 
Other families with ADNFLE were not linked to chromosome 20q. A second 
locus was mapped to chromosome 15q24 in one family (Phillips, Scheffer et 
al. 1998). A cluster of nAChR genes (CHRNA3/CHRNA5/CHRNB4) in this 
region seemed good candidates, but no mutations were identified in the pore-
forming regions of these genes. However, mutations have been identified in 
the gene for the 2 subunit of the nAChR, CHRNB2, on chromosome 1p21 
(De  Fusco,  Becchetti  et  al.  2000;  Phillips,  Favre  et  al.  2001).    The  main 
neuronal nAChR has a heteropentameric structure comprised of 4 and 2 
subunits. Thus mutations in the pore forming M2 domains of both CHRNA4 
and CHRNB2  can  produce  similar functional effects  causing  the  ADNFLE 
phenotype. 
Mutations in a third nAChR subunit gene, CHRNA2 on chromosome 8p21, 
have recently been identified in a Sardinian family with nocturnal frontal lobe 
seizures  inherited  in  an  autosomal dominant  pattern  (Aridon,  Marini et  al. 
2006).   43 
2.4.6  Generalised  epilepsy  with  febrile  seizures  plus 
(GEFS+)  
This syndrome was first described in 1997 in an Australian family originating 
from  Yorkshire  in  the  UK  (Scheffer  and  Berkovic  1997).  Genealogical 
information was obtained on 2000 family members dating back to the mid-
1700s, and clinical information obtained on 289 individuals, of which 28 had 
seizures.  The  commonest  phenotype,  denoted  as  „febrile  seizures  plus‟ 
(FS+)  comprised  a  childhood  onset  of  multiple  febrile  seizures  persisting 
beyond the age of 6, as well as a spectrum of afebrile seizures including 
absences, myoclonic seizures, atonic seizures and rarely myoclonic-astatic 
epilepsy. The pattern of inheritance was autosomal dominant. 
A  second  Australian  family  with  generalised  epilepsy  and  febrile  seizures 
plus  (GEFS+)  was  linked  to  chromosome  19q13.1,  and  a  point  mutation 
identified  in  SCN1B,  which  encodes  the  1  subunit  of  the  voltage  gated 
sodium channel (Wallace, Wang et al. 1998).  
Neuronal voltage-gated sodium channels are essential for the generation and 
propagation of the action potential. They contain a large  subunit associated 
with  two  smaller    subunits  (Figure  2-1(b)).  The  pore-forming    subunit 
contains  4  homologous  domains  each  containing  six  membrane-spanning 
units. The  subunits contain a single transmembrane region and modulate 
the gating properties of the channel and are required for normal inactivation 
kinetics. Mutations in  
of  muscle,  including  hyperkalaemic  periodic  paralysis,  paramyotonia 
congenita  (SCN4A),  long  QT  syndrome  (SCN5A)  and  Brugada  syndrome 
(SCN5A)  (Bulman  1997).  Brugada  syndrome  is  associated  with  sudden 
death  due  to  ventricular  fibrillation,  and  fever  may  be  a  trigger.  Sodium 
channels are also modulated by antiepileptic drugs such as phenytoin and 
carbamazepine (Macdonald and Kelly 1994). They are thus good candidate 
genes for epilepsy. 
The SCN1B mutation segregated with disease status in the 19q13.1-linked 
GEFS+  family.  It  changes  a  conserved  cysteine  residue  that  disrupts  a   44 
disulfide bridge normally maintaining an extracellular immunoglobulin-like fold 
in  the  -subunit.  This  alters  the  secondary  structure  of  the  extracellular 
domain,  which  modulates  channel  gating.  The  predicted  effects  of  the 
disruption are to reduce sodium channel expression, slow inactivation, and 
slow recovery from inactivation. Coexpression of  and mutant 1 subunits 
exerts  significant  modulatory  effects  on  the  channel  gating  kinetics  and 
expression  levels.  The  net  effect  is  to  cause  persistent  inward  neuronal 
sodium  currents,  increased  membrane  depolarisation,  and  neuronal 
hyperexcitability.  This  may  also  exaggerate  the    normal  effects  of 
temperature on both conductance and gating of neuronal sodium channels, 
explaining the apparent temperature dependence of the GEFS+ phenotype.  
Two further families with GEFS+ showed linkage to chromosome 2q24, and 
mutations were identified in SCN1A, the gene encoding the sodium channel 
1 subunit (Escayg, MacDonald et al. 2000). De novo mutations in this gene 
have  also  been  identified  in  patients  with  severe  myoclonic  epilepsy  of 
infancy  (section  2.4.7).  A  mutation  in  the  gene  encoding  the  2  sodium 
channel subunit, SCN2A, has now been identified in a patient with febrile 
seizures  associated  with  afebrile  seizures,  consistent  with  GEFS+.  This 
mutation  also  slows  channel  inactivation,  suggesting  involvement  in  the 
epilepsy phenotype (Sugawara, Tsurubuchi et al. 2001). 
The  GEFS+  phenotype  is  not  only  caused  by  mutations  in  voltage-gated 
sodium channels. In one large GEFS+ family, mutations have been identified 
in the GABAA receptor -subunit gene, GABRG2 (Baulac, Huberfeld et al. 
2001).    GABAA  receptors are  anion-selective  ligand-gated  channels which 
mediate fast synaptic inhibition. Binding of GABA opens an integral chloride 
channel,  producing  an  increase  in  membrane  conductance  that  results  in 
inhibition of neuronal activity. The GEFS+ mutation substitutes a serine for a 
methionine in the extracellular loop between transmembrane segments M2 
and  M3,  which  was  shown  to  decrease  the  amplitude  of  GABA-activated 
currents when expressed in xenopus oocytes. A mutation in GABRG2 also 
causes severe myoclonic epilepsy of infancy (section 2.4.7) and a phenotype   45 
of  childhood  absence  epilepsy  and febrile  seizures  (Wallace,  Marini et  al. 
2001).  
A mutation in the GABAA receptor -subunit gene, GABRD, has now been 
identified in a small family with GEFS+ (Dibbens, Feng et al. 2004). 
2.4.7  Severe myoclonic epilepsy of infancy (SMEI) 
SMEI was first reported by Dravet, who described a syndrome with onset of 
prolonged febrile seizures (generalised or unilateral) in the first year of life, 
followed  by  afebrile  seizures  including  tonic-clonic,  myoclonic,  absence 
seizures  and  recurrent  status  epilepticus  (Dravet  1978).  Neurological 
development  appears  normal  before  the  onset  of  seizures  but  becomes 
progressively delayed as seizure frequency increases. 
Heterozygous  de-novo  mutations  were  identified  in  SCN1A  (Claes,  Del-
Favero et al. 2001; Ohmori, Ouchida et al. 2002; Sugawara, Mazaki-Miyazaki 
et  al.  2002).  Mutations  included  insertions,  deletions  and  missense 
mutations,  several  resulting  in  premature  stop  codons  and  truncated 
channels. As SCN1A mutations have been identified in both SMEI and in 
families with GEFS+, and some patients with SMEI have a family history of 
seizures consistent with the spectrum of GEFS+, it has been suggested that 
SMEI  is  the  most  severe  phenotype  in  the  GEFS+  spectrum  (Singh, 
Andermann et al. 2001). A recent study of 333 patients with SMEI identified 
SCN1A  mutations  in  242  (73%),  with  no  obvious  genotype-phenotype 
correlations (Depienne, Trouillard et al. 2009). 
Mutations in GABRG2 have also been identified in a patient with SMEI, who 
belonged to a family with several members with GEFS+ (Harkin, Bowser et 
al. 2002). 
Two  related  syndromes  have  been  described.  SMEI-borderland  (SMEB), 
referring to children who lack several of the key features of SMEI such as 
myoclonic seizures or generalized spike-wave activity, has been attributed to 
SCN1A mutations in 69% of cases (Harkin, McMahon et al. 2007). Intractable   46 
childhood  epilepsy  with  generalized  tonic  clonic  seizures  (ICEGTC),  also 
used to describe children with a phenotype similar to SMEI but without minor 
seizures,  particularly  myoclonic  seizures,  was  identified  to  have  SCN1A 
mutations in 70% of cases (Fujiwara, Sugawara et al. 2003). 
2.4.8  Autosomal  dominant  partial  epilepsy  with  auditory 
features (ADPEA) 
Autosomal  dominant  partial  epilepsy  with  auditory  features  was  first 
described in a three generation family with 11 members diagnosed with an 
idiopathic/cryptogenic epilepsy (Ottman, Risch et al. 1995). The epilepsy was 
clearly localized in all but one of these cases, with both simple and partial 
complex  seizures  progressing  to  secondarily  generalised  tonic-clonic 
seizures. Six of those with idiopathic epilepsy reported auditory disturbances 
as a simple partial component of their seizures. The seizures were infrequent 
with an age of onset between 8 and 19 years.  
A  genome  screen  identified  linkage  over  a  10cM  region  on  chromosome 
10q23.3-24 (Ottman, Risch et al. 1995). This region was narrowed to 3cM by 
a genome screen in a large Basque family segregating lateral temporal lobe 
epilepsy with auditory and visual features (Poza, Saenz et al. 1999). Further 
families confirmed the linkage but failed to narrow the region. Construction of 
a physical map identified 28 putative genes of which 21 were sequenced in 
an  affected  individual  from  three  families,  and  mutations  subsequently 
checked  in  a  further  two  families  (Kalachikov,  Evgrafov  et  al.  2002). 
Mutations were identified in the leucine rich, glioma-inactivated 1 gene (LGI1) 
in  all  affected  individuals  and  obligate  carriers,  as  well  as  six  unaffected 
members,  consistent  with  a  71%  disease  penetrance.  The  five  mutations 
identified were not present in 123 unrelated controls. Analysis of ten families 
with ADPEAF identified LGI1 mutations in 50% of families, with penetrance of 
54% (Ottman, Winawer et al. 2004). LGI1 mutations have not been identified 
in individuals with other forms of temporal lobe epilepsy (Berkovic, Izzillo et 
al. 2004).   47 
LGI1 is a member of the leucine-rich repeat (LRR) superfamily, in particular 
the  adhesive  proteins  and  receptors.  It  was  first  described  following  the 
observation  that  it  was  disrupted  by  translocation  in  a  glioblastoma 
multiforme cell line and in over one quarter of primary tumours. The  LGI1 
protein  consists  of  an  extracellular  domain  with  LRR  repeat  motifs,  a 
transmembrane segment and an intracellular segment of unknown function 
(Somerville,  Chernova  et  al.  2000).  The  extracellular  portion  aligns  most 
closely with a group of proteins, including slit, toll and tartan, involved in CNS 
development  and  in  which  the  LRRs  bind  nerve  growth  factor  and  other 
neurotrophins. Interestingly, a C-terminal repeat motif, now referred to as the 
EAR (epilepsy-associated repeat) domain, has been identified in both LGI1 
and  the  MASS1  gene.  MASS1  is  mutated  in  the  Frings  mouse  model  of 
audiogenic  epilepsy  (Scheel,  Tomiuk  et  al.  2002)  and  in  one  family  with 
febrile and afebrile seizures (Nakayama, Fu et al. 2002). This EAR domain is 
likely  to  play  a  role  in  the  pathogenesis  of  epilepsy.  LGI1  is  expressed 
predominantly  in  brain  (cerebellum,  cortex,  medulla,  occipital  pole,  frontal 
lobe, temporal lobe and putamen), muscle and spinal cord. LGI1 enhances 
AMPA  receptor-mediated  synaptic  transmission  in  hippocampal slices  and 
binds  to  ADAM22  (Fukata,  Adesnik  et  al.  2006).  Of  the  five  mutations 
identified  in  ADPEA,  three  were  missense  mutations  with  predicted 
premature truncation of the LGI1 protein, one was a non-synonymous point 
mutation in the highly conserved extracellular and C-terminal region, and one 
was an intronic mutation predicted to alter a splice site. LGI1 is therefore the 
first  non  ion-channel  gene  identified  as  causing  an  idiopathic  epilepsy  in 
humans. 
 
2.4.9  Familial partial epilepsy with variable foci (FPEVF) 
This  idiopathic  epilepsy  displays  autosomal  dominant  inheritance  with 
reduced  penetrance  and  locus  heterogeneity.  It  was  first  described  in  an 
Australian  pedigree  with  suggestive  linkage  to  chromosome  2  (Scheffer, 
Phillips et al. 1998) and subsequently in two large French-Canadian families   48 
with  linkage  to  chromosome  22q11-q12  (Xiong,  Labuda  et  al.  1999).  The 
phenotype  is  characterised  by  recurring  partial  seizures  originating  from 
different cortical areas, usually in the frontal or temporal lobes. The epileptic 
focus varies between family members. In the Australian family seizures were 
diurnal and the age of onset varied from one year to 44 years. In the French-
Canadian pedigrees age of onset peaked at 5 and 25 years and seizures 
were predominantly or exclusively nocturnal. 
2.4.10 Infantile spasms (West syndrome) 
Infantile spasms are divided into those that are symptomatic and those that 
are cryptogenic or idiopathic. The majority (70-80%) are symptomatic and 
may  be  attributed  to  a  prenatal,  perinatal  or  postnatal  cause,  of  which 
prenatal  aetiologies  are  the  most  common  (50%).  Many  of  theses  are 
genetically  determined,  including  disorders  of  brain  development, 
neurocutaneous  syndromes,  metabolic  disorders  and  chromosomal 
abnormalities.  
Most cases of idiopathic infantile spasms are sporadic, and the recurrence 
risk is less than 1% (Dulac, Feingold et al. 1993). However several familial 
cases  of  early  infantile  epileptic  encephalopathy  progressing  to  infantile 
spasms have been identified consistent with X-linked inheritance. Feinberg 
and  Leahy  first  reported  five  affected  males  in  four  sibships  of  a  three-
generation  family  (Feinberg  and  Leahy  1977).  Subsequently,  five  further 
families have been identified, some of which also include individuals with X-
linked  mental  retardation  without  infantile  spasms  (Rugtveit  1986;  Claes, 
Devriendt et al. 1997; Bruyere, Lewis et al. 1999; Stromme, Sundet et al. 
1999; Stromme, Mangelsdorf et al. 2002). Linkage analysis in these families 
mapped the disease gene to chromosome Xp21.3-Xp22.1 (Claes, Devriendt 
et al. 1997; Bruyere, Lewis et al. 1999; Stromme, Sundet et al. 1999). The 
aristaless-related, homeobox gene, ARX, was considered a candidate on the 
basis of its expression pattern in fetal, infant and adult brain. Screening of 
this gene identified mutations in four of the five families with infantile spasms 
(Stromme, Mangelsdorf et al. 2002). Mutations have also been identified in   49 
families  with  various  combinations  of  mental  retardation  together  with 
myoclonic seizures, spasticity, ataxia, chorea and dystonia, with and without 
infantile spasms (Scheffer, Wallace et al. 2002; Guerrini, Moro et al. 2007). 
Two recurrent mutations identified result in expansion of polyalanine tracts of 
the ARX protein. These are likely to cause protein aggregation, as has been 
demonstrated  in  other  human  diseases  caused  by  alanine  expansions 
(Calado, Tome et al. 2000). Homeobox-containing genes are important in the 
regulation of key stages of development.  ARX encodes one of a class of 
proteins incorporating a C-terminal aristaless domain presumed particularly 
important  in  the  differentiation  and  maintenance  of  specific  neuronal 
subtypes in the cerebral cortex (Bienvenu, Poirier et al. 2002). 
A  family  with  three  siblings  (twin  girls  and  a  boy)  with  severe  mental 
retardation,  seizures  including  infantile  spasms  and  features  of  Rett 
syndrome  displayed  mutations  in  CDKL5  (Weaving,  Christodoulou  et  al. 
2004).  A  recent  review  of  girls  with  epilepsy  associated  with  CDKL5 
mutations, identified three clinical stages: early epilepsy (onset between one 
and  ten  weeks),  epileptic  encephalopathy  with  hypsarrhythmia  and 
developmental  stasis,  and  late  multifocal  and  myoclonic  epilepsy  (Bahi-
Buisson, Kaminska et al. 2008). CDKL5 and MECP2 (the gene responsible 
for  Rett  syndrome)  interact  in  vivo  and  in  vitro  and  they  demonstrate 
overlapping expression during neural maturation and synaptogenesis (Mari, 
Azimonti et al. 2005).   50 
2.5  Non-mendelian epilepsy genes 
Juvenile myoclonic epilepsy, benign childhood epilepsy with centrotemporal 
spikes  and  febrile  seizures  are  discussed  in  this  section.  The  genetics  of 
absence epilepsy will be reviewed in chapter 3. 
2.5.1  Juvenile Myoclonic Epilepsy (JME) 
Juvenile  myoclonic  epilepsy  (JME)  is  one  of  the  idiopathic  generalized 
epilepsies, and accounts for 5 to 10% of all epilepsy.  It was first described as 
a distinct electroclinical syndrome by Janz and Christian in 1957 (Janz and 
Christian 1957).  The onset of seizures occurs usually between the ages of 8 
and 26, with a peak in adolescence.  It is characterized by the presence of 
generalized  myoclonic  seizures  involving  the  upper  limbs  predominantly.  
Myoclonic  seizures  occur  predominantly  in  the  morning,  soon  after 
awakening,  and  are  exacerbated  by  sleep  deprivation  and  alcohol.    In 
addition,  nearly  all  affected  individuals  have  generalized  tonic-clonic 
seizures, often following a series of myoclonic jerks, and about 20-40% have 
absence seizures.  The EEG shows spike and wave or polyspike and wave 
at  a  frequency  of  4  to  6  Hz.    Photosensitivity  is  quite  common.    The 
susceptibility  to  seizures  is  life  long  and  patients  require  long-term 
maintenance  on  antiepileptic  medication.    The  drug  of  choice  is  sodium 
valproate. 
A genetic contribution to the aetiology of JME is well established (Janz 1969; 
Tsuboi and Christian 1973; Sundqvist 1990), but the mode of inheritance is 
uncertain.  Autosomal dominant (Delgado-Escueta, Greenberg et al. 1990), 
autosomal  recessive  (Panayiotopoulos  and  Obeid  1989),  and  two  locus 
models have all been proposed (Greenberg, Delgado-Escueta et al. 1989).   
Evidence  for  linkage  of  the  JME  trait  to  the  serologic  markers  HLA  and 
properdin factor B on chromosome 6p was first found in 1988 (Greenberg, 
Delgado-Escueta et al. 1988), and the locus designated EJM1 (subsequently   51 
renamed  EJM3).    These  findings  were  subsequently  confirmed  in  a 
separately  ascertained  group  of  23  families  using  HLA  serologic  markers 
(Weissbecker, Durner et al. 1991).  Analysis of a subset of these families 
together  with  one  new  family,  using  HLA-DQ  restriction  fragment  length 
polymorphisms (RFLPs), gave similar results (Durner, Sander et al. 1991).  
Further work by Greenberg and Delgado-Escueta (1993) on a larger group of 
35 families once again confirmed linkage to the serologic markers HLA and 
properdin  factor  B,  with  a  maximum  lod  score  of  4.2  (Greenberg  and 
Delgado-Escueta 1993). A study in a single large pedigree of Belize origin 
using microsatellite markers on chromosome 6p gave a maximum lod score 
of    3.67  (=0)  between  the  marker  D6S257  and  a  trait  defined  as  the 
presence of clinical JME or an EEG showing diffuse 3.5-6 Hz multispike and 
slow wave complexes (Liu, Delgado-Escueta et al. 1995). In addition, linkage 
analysis in  28 families  ascertained  through  a  JME  patient  in  which  family 
members  with  IGE  (idiopathic  generalised  epilepsy)  were  classified  as 
affected gave a lod score for the DQB1 locus of 4.2.  The linkage pattern 
observed  suggested  heterogeneity  and  an  excess  of  transmission  from 
mothers  (Greenberg,  Durner  et  al.  2000).  Association  analysis  found 
significant linkage disequilibrium between JME and a haplotype of five SNPs 
and  microsatellites  between  HLA-DQ  and  HLA-DP  on  chromosome  6p21 
(Pal, Evgrafov et al. 2003). DNA sequencing identified two JME-associated 
SNP  variants  in  the  promoter  region  of  BRD2,  a  putative  nuclear 
transcriptional factor, but no potentially causative coding mutations. 
Two studies from a single group have failed to find evidence for the existence 
of  a  locus  on  chromosome  6p  (Whitehouse,  Diebold  et  al.  1993;  Elmslie, 
Williamson et al. 1996).  No significant evidence in favour of linkage was 
obtained under any of the models tested. These results suggest that genetic 
heterogeneity exists within this epilepsy phenotype.  
Chromosomal regions harbouring genes for subunits of the neuronal nicotinic 
acetylcholine receptor were tested for linkage to the JME trait in 34 European 
pedigrees.  Two-point lod scores were negative for all loci except D15S128 
and  D15S118  on  chromosome  15q14.    Seven  additional  marker  loci   52 
encompassing a 20.1-cM region were selected in order to investigate this 
region further.  A maximum multipoint lod score of 4.18 was obtained under 
the assumption of heterogeneity at  = 0.64 (where  is proportion of linked 
families).  Analysis of recombinant events defined the 10-cM interval between 
D15S144 and D15S1012 as being the region in which the gene lies.  The -7 
subunit  of  the  neuronal  nicotinic  acetylcholine  receptor  (CHRNA7)  maps 
within  this  interval  and  therefore  represents  an  excellent  candidate  gene.  
These  results  indicate  that  a  major  susceptibility  locus  for  JME,  termed 
EJM2,  may map to this region of chromosome 15q  (Elmslie, Rees et al. 
1997).  A  further  study  was  undertaken  to  test  this  linkage  finding  and  to 
explore whether this susceptibility locus contributes to the pathogenesis of a 
broader spectrum of IGE syndromes.  Linkage analysis with 7 microsatellite 
markers encompassing the CHRNA7 region failed to replicate evidence of 
linkage in 11 families with at least two JME members.  No evidence in favour 
of linkage to 15q14 was found under a broadened diagnostic scheme in 27 
families  of  JME  probands  or  in  30  families  of  probands  with  idiopathic 
absence  epilepsy  (Sander,  Schulz  et  al.  1999).    A  subsequent  study  has 
clarified the linkage data in relation to the current map of the region study 
(Taske,  Williamson  et  al.  2002).    The  CHRNA7  gene  and  its  partial 
duplication  CHRFAM7A  were  screened  for  mutations,  but  no  causative 
sequence variants could be identified. 
Linkage analysis in families from Belize and Mexico, comprising members 
with JME and asymptomatic individuals with polyspike wave complexes on 
EEG, identified a disease locus at chromosome 6p21.2-p11, termed EJM1 
(Liu,  Delgado-Escueta  et  al.  1995;  Liu,  Delgado-Escueta  et  al.  1996;  Bai, 
Alonso et al. 2002). Heterozygous mutations were identified in the EFHC1 
gene, in both affected individuals and unaffected family members from six 
families, but not in 382 healthy unrelated controls (Suzuki, Delgado-Escueta 
et al. 2004). EFHC1 appeared to increase CACNA1E mediated R-type Ca
2+ 
currents  in  patch  clamp  studies,  and  this  was  reversed  by  the  mutations 
associated  with  JME.  Overexpression  of  EFHC1  in  mouse  hippocampal 
primary culture neurons induced apoptosis, and this was significantly lowered 
by  the  mutations. EFHC1  mutations  have also  been  identified  in  sporadic   53 
individuals  with  juvenile  absence  epilepsy  and  „cryptogenic  temporal  lobe 
epilepsy‟ (Stogmann, Lichtner et al. 2006). 
Linkage analysis in an extended French Canadian autosomal dominant JME 
pedigree mapped the locus to 5q34, and a missense mutation (Ala 322 Asp) 
was identified in this family in the GABRA1 gene (Cossette, Liu et al. 2002). 
Mutations have also been identified in individuals or single families with JME 
in CACNB4 (Escayg, De Waard et al. 2000) and GABRD (Dibbens, Feng et 
al. 2004).  
2.5.2  Benign  Childhood  Epilepsy  With  Centrotemporal 
Spikes (BCECTS) 
The  syndrome  of  benign  childhood  epilepsy  with  centrotemporal  spikes 
(BCECTS), or benign rolandic epilepsy, was first described by Nayrac and 
Beaussart  (1958)  (Nayrac  and  Beaussart  1958).    The  onset  of  seizures 
occurs during  childhood  between  the  ages  of  3  and  13  in  a  child  who  is 
neurologically  intact.    The  typical  seizures  often  occur  at  night  and  are 
preceded by a somatosensory aura around the mouth.  This is followed by 
excessive  salivation,  a  gurgling  noise  and  speech  arrest  with  retention  of 
consciousness.  Unilateral motor seizures of the face follow and can progress 
to a secondary generalized seizure (Panayiotopoulos 1993).  Following the 
seizure, the child may feel numbness or pins and needles in the side of the 
face involved in the seizure. The pattern of the seizures varies diurnally, with 
nocturnal seizures more likely to generalize secondarily (Holmes 1993).  The 
prognosis is good.  Seizures usually resolve within 1 to 3 years of onset, and 
rarely persist beyond 16 years. 
The  EEG  is  characteristic.    High-amplitude  spikes  or  sharp  waves  are 
followed by slow waves, occurring unilaterally or independently bilateral in 
the central (Rolandic) and mid-temporal areas.  About 20% of children who 
have Rolandic discharges on EEG will not have seizures (Beaussart 1972). 
A family history of epilepsy is known to be common among probands with 
BCECTS, although the proportion with a family history varies from study to   54 
study.    Figures  of  9-59%  have  been  obtained  (Blom  and  Heijbel  1975; 
Lerman and Kivity 1975).  A high proportion of relatives also have abnormal 
EEGs. 
Bray  and Wiser  analyzed  the  EEGs  from  the  families  of  40  patients  with 
seizures and centrotemporal spikes and found that 36% of the siblings and 
19% of parents had focal epileptiform activity on the EEG (Bray and Wiser 
1965).    They  postulated  that  an  autosomal  dominant  gene  with 
age-dependent  penetrance  was  responsible  for  producing  centrotemporal 
spikes.    Heijbel  et  al  (1975)  studied  19  probands  with  BCECTS  (Heijbel, 
Blom et al. 1975).  Of 34 siblings 15% had Rolandic discharges and seizures, 
and  a  further  19%  had  Rolandic  discharges  in  isolation.    Their  findings 
tended  to  support  the  suggestion  of  an  autosomal  dominant  gene  with 
age-dependent  penetrance.  However  a  study  of  8  pairs  of  twins  (6 
monozygotic,  2  dizygotic  ),  where  one  twin  had  a  diagnosis  of  BCECTS, 
found no concordance for the phenotype in any of the twin pairs (Vadlamudi, 
Harvey  et  al.  2004).  This  provided  evidence  against  a  strong  genetic 
component. 
Generalized epileptiform activity has also been found in the EEGs of relatives 
of patients with BCECTS.  Degen and Degen found epileptiform activity in the 
EEGs of 26 out of 69 (38%) siblings of 43 probands with BCECTS (Degen 
and Degen 1990).  Among those siblings aged 5 to 12 years, 54% had an 
abnormal EEG, and the proportion declined in the younger and older age 
groups.    This  pattern  of  age-dependent  penetrance  and  the  finding  of 
generalized  EEG  abnormalities  in  the  siblings  of  patients  has  led  to  the 
suggestion  that  BCECTS  and  absence  epilepsy  may  be  linked  (Bray  and 
Wiser 1969). 
Twenty-two nuclear families segregating BCECTS were examined for linkage 
to chromosomal regions known to harbour neuronal nicotinic acetylcholine 
receptor  (nAChR)  subunit  genes.    Evidence  was  found  for  linkage  with 
heterogeneity to a region on chromosome 15q14 in the vicinity of the alpha 7 
nAChR subunit gene, CHRNA7 (Neubauer, Fiedler et al. 1998).   55 
2.5.3  Febrile seizures 
Susceptibility to febrile seizures is known to have a strong genetic basis, and 
a significant proportion of patients have a family history of febrile convulsions 
or other epilepsies. The proportion of probands with an affected first degree 
relative has been estimated as between 8% and 49% (Rich, Annegers et al. 
1987;  Wallace  1988).  The  mode  of  inheritance  seems  to  depend  on  the 
frequency  of  febrile  convulsions  in  the  proband.  Complex  segregation 
analysis  performed  on  467  nuclear families  ascertained  through  probands 
with febrile convulsions showed clear evidence for polygenic inheritance in 
those families in which the proband had a single febrile convulsion  (Rich, 
Annegers et al. 1987). The heritability of liability was estimated at 68% in 
these families. However, in the families of probands with more than three 
febrile convulsions there appeared to be a single major locus contributing to 
seizure  susceptibility.  Another  study  of  the  families  of  52  probands    with 
febrile seizures found that 40 families (77%) had at least one further affected 
member, and these were consistent with an autosomal dominant mode of 
inheritance with reduced penetrance (64%) (Johnson, Kugler et al. 1996). 
The investigation of large pedigrees has led to the identification of at least ten 
putative  loci  for febrile  seizures,  FEB1-10,  including  three  genes  in  which 
mutations have been found: 
  A heterozygous loss-of-function SCN1A mutation was identified in an 
Italian  family  comprising  12  individuals  with  simple  febrile  seizures 
resolving by the age of six (Mantegazza, Gambardella et al. 2005). 
Three family members developed afebrile seizures of mesial temporal 
lobe origin, and two of these had evidence of hippocampal sclerosis 
on MRI.  
  A nonsense mutation in MASS1(GPR98) was identified in a Japanese 
family with febrile and afebrile seizures (Nakayama, Fu et al. 2002). 
The mutation was found in the proband who had febrile and afebrile 
seizures before the age of 4, her brother who had two febrile seizures 
age 6 and 7 years, and their unaffected father. MASS1 encodes a   56 
fragment of a large G protein-coupled receptor containing an epilepsy 
associated repeat (EAR) domain also found in LGI1 (section 2.4.8). 
MASS1 is mutated in the Frings mouse model of audiogenic epilepsy 
(Scheel, Tomiuk et al. 2002) 
  A heterozygous missense mutation in GABRG2 was identified in a 
family whose individuals manifested febrile seizures with or without 
childhood absence epilepsy (Wallace, Marini et al. 2001). A splice site 
mutation  in  GABRG2  was  identified  in  a  similar  family  with  febrile 
seizures and absence epilepsy (Kananura, Haug et al. 2002). A third 
family  with  isolated  febrile  seizures  was  also  found  to  have  a 
missense  mutation  in  GABRG2  (Audenaert,  Schwartz  et  al.  2006).  
Febrile  seizures  occur  as  a  part  of  the  syndrome  of  Generalised 
Epilepsy with Febrile Seizures Plus (GEFS+), for which several genes 
have  been  identified,  including  GABRG2  (section  2.4.6).   57 
 
Chapter 3  Absence epilepsy 
Childhood  absence  epilepsy  (CAE),  juvenile  absence  epilepsy  (JAE)  and 
epilepsy with myoclonic absences comprise a group of idiopathic absence 
epilepsies which vary in their age of onset, seizure frequency and pattern of 
evolution. Eyelid myoclonia with absences, perioral myoclonia with absences 
and episodic ataxia with absences seem to represent further distinct absence 
epilepsy syndromes.  
3.1  Childhood absence epilepsy (CAE) 
CAE  is  an  idiopathic  generalised  epilepsy  of  childhood  which  is  well 
characterised in terms of age of onset, clinical features and EEG findings. 
There is strong evidence for a genetic aetiology. 
3.1.1  Historical background 
Childhood absence epilepsy was probably first described in 1705 by Poupart. 
However a more widely known description is that of Tissot in 1770, who gives 
an account of „petits accés‟ (minor attacks) occurring in a fourteen year old 
girl from the age of seven years: „…the young female patient had frequently 
had  very  short  minor  attacks  which  were  recognised  only  by  an 
instantaneous  loss  of  consciousness  which  stopped  the  patient‟s  speech, 
accompanied by a very slight movement in the eyes‟ (Loiseau 1992). The 
term „petit-mal‟ was first used in 1815 by Esquirol for non-convulsive epileptic 
seizures, and in 1824 Calmeil used the term „absence d‟esprit‟ to describe 
the  „fleeing  of  the  spirit  from  the  eyes  of  the  afflicted  patient‟.  The  term 
pyknolepsy was introduced by Saur in 1916, and described by Adie in 1924 
as „a disease with an explosive onset between the age of 4 and 14 years, of 
frequent,  short,  very  slight,  monotonous  minor  epileptiform  seizures  of 
uniform severity which recur almost daily for weeks, months or years, are   58 
uninfluenced  by  antiepileptic  remedies,  do not  impede  normal mental and 
psychological  development,  and  ultimately  cease  spontaneously  never  to 
return‟. There has subsequently been some confusion around the use of petit 
mal,  as  at  various  times  it  has  been  applied  to  (i)  brief  interruptions  of 
consciousness  associated  with  a  rhythmic  3  cycle/second  discharge  of 
regular spike and wave complexes on the EEG (Gibbs, Davis et al. 1935), (ii) 
a petit mal type of dysrhythmia in a routine EEG record in the absence of 
clinically  obvious  seizures,  even  if  the  particular  patient  has  no  history  of 
epilepsy  (Loiseau  1992)  and  (iii)  a  petit  mal  triad  consisting  of  absences, 
myoclonic seizures and akinetic seizures (Lennox 1945). The International 
Classification  of  Epileptic  Seizures  (Gastaut  1970)  distinguished  typical 
absences from atypical absences, and the term petit mal was discarded. 
3.1.2  Epidemiology 
CAE  represents  approximately  8%  of  epilepsy  in  school  age  children 
(Cavazzuti 1980) and is the most frequent absence epilepsy syndrome. The 
estimated annual incidence of CAE is 6.3-8.0 per 100,000 children aged 1-15 
years (Loiseau, Loiseau et al. 1990). The prevalence of absence seizures, 
including CAE, is 0.1-0.7 per 1000 in children up to the age of 16 years. CAE 
is commoner in girls than boys (Loiseau 1992). 
3.1.3  Clinical features  
A diagnosis of CAE should be restricted to an epilepsy with the following 
characteristics: 
  Onset between 3 and 12 years of age (peak at 6-8 years) 
  Absence  seizures  occurring  in  children  who  are  otherwise 
developmentally and neurologically normal 
  Frequent absence seizures (of any type except myoclonic absences) 
as the initial and predominant seizure type   59 
  Absence  seizures  associated  with  characteristic EEG  changes  (see 
below) 
  Generalised tonic-clonic seizures may also occur 
The  absence  seizures  of  CAE  are  short  (typically  less  than  10  seconds), 
have an abrupt onset and termination and occur frequently throughout the 
day  (up  to  200  per  day).  The  child  shows  a  loss  of  awareness  and 
responsiveness,  with  vacant  eyes  which  may  drift  upwards,  and  stops  all 
ongoing  activities.  However  the  International  Classification  of  Epileptic 
Seizures (ILAE 1981) distinguishes six types of absence seizures, according 
to their associated clinical features, several of which may occur in a given 
patient or during a single absence seizure: 
  Simple absences, with impairment of consciousness only 
  Absences with mild clonic components (often involving eyelids only, 
although  jerking  of  the  head  and  limbs  may  occur).  True  eyelid 
myoclonia with absences represents a distinct epilepsy syndrome. 
  Absences  with  atonic  components.  A  gradual  postural  loss  occurs, 
with drooping of the head and shoulders. A sudden fall to the ground 
usually signifies atypical absences. 
  Absences with tonic components. Increased postural tone of extensor 
muscles  causes  the  eyes  to  rotate  upwards  and  the  head  to  draw 
backwards. 
  Absences with automatisms. These may be perseverative (continuing 
an  activity  such  as  eating  or  walking)  or  de  novo  (lip  licking, 
swallowing, fumbling, mumbling). 
  Absences with autonomic components, including flushing, tachycardia 
and urinary incontinence.   60 
Absence seizures occur spontaneously but a number of precipitating factors 
may be identified. Hyperventilation is an extremely common trigger. Other 
precipitating factors include strong emotions, boredom and exercise. 
3.1.4  EEG characteristics 
The ictal EEG shows bilateral, synchronous, symmetrical discharges of 2.5-
4Hz spike-wave complexes (Figure 3-1). Onset is abrupt and synchronous, 
with the anterior leads usually involved first. The amplitude is highest under 
the fronto-central leads. The initial frequency of the spike-wave complexes is 
3 Hz, which then slows to 2-2.5 Hz as the amplitude decreases towards the 
end of the seizure. Irregular spike-wave discharges and polyspike-waves are 
compatible with a diagnosis of CAE, but are more likely to be associated with 
abnormal  interictal  EEGs,  prolonged  absence  seizures,  multiple  seizure 
types and developmental delay (Holmes, McKeever et al. 1987).  
The interictal EEG is usually normal. Interictal high-voltage 3-4 Hz occipital 
delta  rhythms  may  be  present.  This  posterior  rhythm  is  blocked  by  eye-
opening  and enhanced  by  hyperventilation.  Some  photosensitivity  may  be 
present,  but  marked  photosensitivity  should  be  considered  as  exclusion 
criteria for CAE. 
 
Figure  3-1  EEG  in  childhood  absence  epilepsy,  showing  bilateral, 
synchronous, symmetrical discharges of 3Hz spike-wave complexes   61 
3.1.5  Prognosis 
70-80%  of  patients  with  CAE  have  their  seizures  controlled  by  a  single 
antiepileptic  drug  (usually  ethosuximide,  sodium  valproate  or  lamotrigine). 
There are three long-term outcomes for patients: 
  Patients become seizure free. Remission rates of between 33% and 
79.3% have been reported (Loiseau 1992). The longer the follow up, 
the higher the occurrence of generalised tonic-clonic seizures. In one 
series,  the  average  duration  of  absence  seizures  was  6.6  years 
(Currier,  Kooi  et  al.  1963).  However,  absence  seizures  continue  to 
remit beyond puberty and well into adulthood. 
  Absence seizures persist. This occurs in only about 6% of patients 
(Currier, Kooi et al. 1963). Absence seizures become less frequent 
and tend to be very short. 
  Tonic-clonic  seizures  develop.  These  occur  in  about  16-44%  of 
patients,  usually  between  8  and  15  years  of  age,  but  may  appear 
beyond 30 years (Currier, Kooi et al. 1963; Livingston, Torres et al. 
1965; Loiseau, Duche et al. 1995). Onset of tonic-clonic seizures is 
most  frequently  5-10  years  after  the  onset  of  absence  seizures. 
Several predisposing factors have been identified: 
1.  Absence seizures occurring after 8 years of age 
2.  Female sex 
3.  Poor response to initial treatment 
4.  Incorrect choice of initial drug 
5.  Abnormal background EEG activity (other than posterior delta 
rhythms) or photosensitivity   62 
3.2  Juvenile absence epilepsy 
Juvenile  absence  epilepsy  was  defined  as  a  syndrome  distinct  from  CAE 
following studies of patients with „spike-wave absences‟ by Doose et al in 
1965 (Doose, Volzke et al. 1965) and „age-related minor seizures‟ by Janz in 
1969 (Janz 1969). The Revised International classification of Epilepsies and 
Epileptic Syndromes (ILAE 1989) describes JAE as an age-related idiopathic 
generalised epilepsy with onset of absences around puberty (after 10 years 
of age), less frequent absences than in CAE, a more frequent association 
with generalised tonic clonic seizures and myoclonic seizures occurring not 
infrequently.  JAE is less common than CAE and affects both sexes equally. 
Additional clinical and EEG features have been described by Duncan and 
Panyiotopoulos  (Duncan  and  Panayiotopoulos  1992)  These  include,  in 
comparison  to  CAE,  absences  of  longer  duration  and  with  less  severe 
impairment  of  cognition,  and  a  poorer  prognosis  with  seizures  persisting 
throughout life but decreasing in severity. Myoclonic jerks occur in 15-25% of 
patients.  However  eyelid  or  perioral  myoclonus,  rhythmic  limb  jerking  and 
single or arrhythmic myoclonic jerks of the head, trunk or limbs during the 
absence seizure are not compatible with JAE. The EEG shows generalised 
spike or polyspike and slow wave complexes, starting at 3 Hz (>2.5 Hz) and 
gradually  reducing  in  frequency.  The  inter-ictal  EEG  is  generally  normal. 
Photosensitivity or other sensory precipitants are unusual. 
3.3  Other absence epilepsies 
CAE and JAE are the two IGEs recognised by the International Classification 
of  Epilepsies  and  Epileptic  Syndromes  (ILAE  1989)  in  which  absence 
seizures  are  the  main  seizure  type.  A  third  syndrome,  epilepsy  with 
myoclonic absences, was classified as „cryptogenic or symptomatic‟. Eyelid 
myoclonia with absences and perioral myoclonia with absences seem to be 
two distinct IGE syndromes but have not been recognised as such by the 
ILAE.  A  syndrome  of  episodic  ataxia  with  absences  also  now  appears  to   63 
represent a distinct genetic entity, and this is described in Error! Reference 
source not found.. Epilepsy with myoclonic absences, eyelid myoclonia with 
absences,  perioral  myoclonia  with  absences  and  episodic  ataxia  with 
absences will be described briefly. Absence seizures also occur in JME and 
in epilepsy with generalised tonic-clonic seizures on awakening, but are not 
the predominant seizure type.  
 
3.3.1  Epilepsy with myoclonic absences 
An epilepsy syndrome in which myoclonic absences constitute the only or 
predominant  seizure  type  was  first  described  by  Tassinari  et  al  in  1969 
(Tassinari,  Lyagoubi  et  al.  1969).  Epilepsy  with  myoclonic  absences  was 
included among the cryptogenic or symptomatic generalised epilepsies in the 
International  Classification  of  Epilepsies  and  Epileptic  Syndromes  (ILAE 
1989). It is characterised by absences accompanied by severe bilateral (but 
sometimes asymmetrical) rhythmical myoclonic jerks of shoulders, arms and 
legs,  often  associated  with  a  tonic  contraction  leading  to  progressive 
elevation of the arms. When facial myoclonias occur they tend to be perioral, 
with eyelid involvement rare. Autonomic manifestations include changes in 
respiration  and  urinary  incontinence.  Impairment  of  consciousness  is 
variable,  and  patients  may  be  aware  of  the  jerks.  The  ictal  EEG  shows 
bilateral,  synchronous,  and  symmetrical  spike-wave  discharges  at  3  Hz, 
similar to CAE. Age of onset is 7 years (11 months-12 years), there is a male 
preponderance  and  a  family  history  of  epilepsy  in  about  20%  of  cases 
(Tassinari, Michelucci et al. 1995). Myoclonic absences resolve in about half 
of patients, after a mean period of 5.5 years from onset. A poor prognosis is 
associated with a high incidence of associated seizures, mainly generalised 
tonic clonic seizures and atonic seizures, and inappropriate or inadequate 
medical  therapy.  Refractory  myoclonic  absences  persist  for  20  years  or 
more, and these are associated with a decline in intellectual function.   64 
3.3.2  Eyelid myoclonia with absences 
Jeavons first described eyelid myoclonia with absences as a rare but specific 
entity in 1977 (Jeavons 1977). It is characterised by eyelid myoclonia, typical 
absences and photo-sensitivity (Appleton 1995). Onset occurs in the first ten 
years of life, usually before the age of six. The initial seizure type may be 
absences or eyelid myoclonia, which differs from the eyelid flutter seen in 
CAE. The fast eyelid myoclonic jerks last between 1and 3 seconds and may 
be  accompanied  by  upward  deviation  of  eyes,  head  or shoulders.  A  brief 
absence  usually  occurs  simultaneously.  Limb  myoclonus  is  rare,  but 
automatisms and chewing movements do occur. Photosensitivity is common 
and  present  from  an  early  age.  Cognitive  impairment  does  not  generally 
occur.  The  ictal  EEG  shows  brief  (1-4s)  spike-wave  or  polyspike-wave 
discharges at a frequency of 3-6 Hz, occurring on eye-closure and on photic 
stimulation.  80%  of  patients  are  female  (Appleton  1995).  Remission  of 
seizures  is  rare,  anti-epileptic  medication  may  be  required  for  life  and 
complete seizure control should not be expected. 
 
3.3.3  Perioral myoclonia with absences 
Panayiotopoulos reported two patients in 1992 who could not be satisfactorily 
classified,  in  whom  perioral  myoclonus  was  a  feature  of  absences 
(Panayiotopoulos 1993). At least six further patients have been identified and 
described  (Panayiotopoulos,  Ferrie  et  al.  1995).  The  majority  (75%)  are 
female. Onset is often with a generalised tonic-clonic seizure in childhood or 
early  adolescence,  followed  by  frequent  typical  absence  seizures  with 
rhythmical  myoclonus  of  the perioral or masticatory  facial  muscles.  GTCS 
occur  invariably  and  may  follow  absence  status.  Ictal  EEG  shows  high 
amplitude generalised irregular spike or polyspike and slow wave discharges 
at 3-4Hz. There is no photosensitivity. Seizures may persist throughout life 
and be resistant to medication. 
.   65 
3.4  Genetic basis of absence epilepsy 
A genetic component to aetiology is well established but the mechanism of 
inheritance and the key genes involved are unknown. Approximately 1.6% of 
siblings of probands with CAE will have absence epilepsy, giving a s (the 
risk to a sibling of an affected proband compared with the population risk) of 
at least 27 (Beck-Mannagetta and Janz 1991). Studies of familial clustering 
indicate  that  CAE  has  a  „complex‟  non-mendelian  mode  of  inheritance 
(Gardiner  1995).  A  study  of  concordance  of  seizure  type  and  seizure 
syndrome  within  31  families  with  IGE  found  that  65%  of  families  were 
concordant for seizure type (absence, myoclonic, or both) with an expected 
concordance  by  chance  of  24%  (p<0.0001)  (Winawer,  Rabinowitz  et  al. 
2003). Concordance of epilepsy syndrome (JME versus CAE plus JAE) in 25 
families  was  68%  with  an  expected  concordance  by  chance  of  48% 
(p=0.012).  When  restricted  to  families  with  only  JME,  CAE  and  JAE, 
concordance  of  epilepsy  syndrome  (JME  versus  CAE  plus  JAE)  in  19 
families  was  79%  with  an  expected  concordance  by  chance  of  58% 
(p=0.002). These results provide evidence for distinct genetic effects on both 
seizure type and epilepsy syndrome. One segregation analysis of CAE was 
consistent with an autosomal dominant inheritance with reduced penetrance 
(Buoni, Grosso et al. 1998). 
3.5  Candidate genes for CAE 
A number of candidate genes and chromosomal regions can be identified for 
CAE,  from  studies  on  the  mechanism  by  which  spike-wave  seizures  are 
generated,  the  targets  for  anti-absence  drugs,  isolation  of  genes  causing 
spike-wave seizures in rodents, mendelian epilepsies which include absence 
seizures as part of the phenotype, and initial linkage and association studies 
in man.    66 
3.5.1  Mechanisms of spike-wave seizures generation 
Traditionally spike-wave discharges are considered to be generalised from 
the  onset.  However,  both  frontal  and  centrencephalic  origins  have  been 
demonstrated in patients and animal models, with up to a 40ms time lag in 
the involvement of other cortical regions (Pavone and Niedermeyer 2000).  
Evidence for a key role of the thalamus and cortex in the pathogenesis of 
absence seizures was provided by the demonstration of a focal increase in 
thalamic blood flow on positron emission tomography (PET) (Prevett, Duncan 
et al. 1995), and hypermetabolism in cortical and thalamic areas  (Iannetti, 
Spalice et al. 2001) during an absence seizure. Neuronal elements of the 
thalamocortical loop appear to be crucial for the full expression of spike wave 
discharges (Crunelli and Leresche 2002) (Figure 3-2). The hypothesis that 
spike-wave  discharges  may  develop  by  the  same  thalamocortical  circuits 
which  normally  create  sleep  spindles  under  conditions  of  cortical 
hyperexcitability was proposed by Gloor in 1978 (Gloor 1978). Subsequent 
electrophysiological studies in vitro and in vivo revealed the role of nucleus 
reticularis thalami (NRT) neurons and thalamocortical-corticothalamic circuit 
oscillations  in  the  generation  of  both  spindle  rhythms  and  spike-wave 
discharges (Kostopoulos 2000).   67 
 
 
Figure  3-2  Thalamocortical  excitatory  (+)  and  inhibitory  (-)  connections 
involved in the generation of spike-wave discharges 
 
Animal  models  demonstrate  that  during  spike-wave  discharges,  rhythmic 
depolarisations  of  cortical  neurons  occur  in  phase  with  the  EEG  spike. 
Synchronous cortical volleys of discharges and converging corticothalamic 
inputs result in bursts of excitatory postsynaptic potentials (EPSPs) in the 
NRT in vivo (Giaretta, Avoli et al. 1987). Hyperpolarization followed by the 
EPSP bursts generates a low threshold Ca
2+ potential and a high frequency 
burst  of  action  potentials  corresponding  to  each  EEG  spike.  NRT 
abnormalities  may  be  required  for  the  clinical  manifestation  of  absence 
seizures,  but  may  not  be  essential  for  the  generation  of  spike-wave 
discharges  as  they  still  occur  in  the  ipsilateral  cortex  of  cats  after 
hemithalamectomy, but not in the thalamus after decortication (Steriade and 
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Possible mechanisms for the generation of abnormal spike-wave activities in 
cortical and thalamic neurons include the loss of GABAA receptor-mediated 
inhibition  between  thalamic  reticular  cells,  strong  activation  of  thalamic 
GABAergic  neurons  by  corticothalamic  or  thalamocortical  afferents,  and 
increased  NMDA  (N-methyl-D-aspartic  acid)-mediated  excitation  in  deep 
layers of the cortex or the enhancement of the low threshold Ca
2+ current 
(Pumain, Louvel et al. 1992; Leresche, Parri et al. 1998; Pinault, Leresche et 
al. 1998; Huguenard 1999; Kim, Song et al. 2001; Schuler, Luscher et al. 
2001).  The role of the low threshold Ca
2+ current in thalamocortical activity 
during pharmacologically induced spike-wave discharges is demonstrated by 
CACNA1G  (a  T-type  calcium  channel)  knockout  mice  (Kim,  Song  et  al. 
2001).  These  mice  are  resistant  to  spike-wave  discharges  induced  by  -
butyrolactone. However the authors considered that this could also be related 
to reduced low threshold Ca
2+ potentials in cortical neurons or changes in the 
steady state low threshold Ca
2+ current. Investigation of the contribution of 
GABAA  and  GABAB  receptors  to  thalamic  neuronal  activity  during 
spontaneous spike-wave discharges in WAG/Rij rats by microiontophoretic 
application  of  GABAA  and  GABAB  receptor  antagonists  indicated  that  (1) 
GABAA receptor-mediated events are critical, (2) a contribution from GABAB 
receptors  is  not  necessary  and  (3)  GABAA  receptor  blockade  potentiates 
spike-wave discharge related activity (Staak and Pape 2001). 
 
3.5.2  Animal models of human absence epilepsy 
The molecular basis of epilepsy has been explored in the mouse both  by 
identification of genes underlying naturally occurring epilepsy mutants and by 
exploring the phenotypic consequences of targeting genes which may cause 
epilepsy  on  biological  grounds  (Meisler,  Kearney  et  al.  2001).  Six 
spontaneous AR mouse mutants have spike-wave seizures similar to those 
occurring in human absence epilepsy. Four of these arise from mutations in 
voltage-dependant  calcium  channel  (VDCC)  subunit  genes:  Cacna1a 
(tottering) (Fletcher, Lutz et al. 1996), Cacnb4 (lethargic) (Burgess, Jones et   69 
al. 1997), Cacng2 (stargazer) (Letts, Felix et al. 1998) and Cacna2d2 (ducky) 
(Barclay, Balaguero et al. 2001) (Figure 3-3). VDCCs contain a pore forming 
ʱ subunit with regulatory β, γ, and ʱ2δ subunits (Figure 2-1 (c)). In contrast, 
the slow-wave epilepsy mouse gene, Slc9a1, encodes a Na+/H+ exchanger, 
a  ubiquitous  membrane-bound  enzyme  involved  in  pH  regulation  of  cells 
(Cox, Lutz et al. 1997).  The mocha mouse mutant is hyperactive and has 6-7 
Hz  spike-wave  discharges  on  EEG.  It  is  a  model  for  Hermansky-Pudlack 
syndrome in humans, showing coat and eye colour dilution, reduced levels of 
renal lysosomal enzymes in urine, and prolonged  bleeding due to storage 
pool deficiency in the dense granules of platelets. Mocha is a null allele of the 
Ap3d1, a subunit of the adaptor-protein complex gene. Ap3d1 is implicated in 
intracellular  biogenesis  and  trafficking  of  pigment  granules  and  possibly 
platelet dense granules and neurotransmitter vesicles (Kantheti, Qiao et al. 
1998).  
Gene targeting has produced mice lacking the GABAA receptor 3 subunit 
implicated in the epilepsy of Angelman syndrome and in CAE by linkage and 
association,  and  is  illuminating  the  mechanisms  underlying  spike-wave 
seizures.    Mice  lacking  IG  T-type  Ca
2+  channels  lack  burst  firing  of 
thalamocortical relay neurons and are resistant to generation of spike-wave 
discharges in response to GABAB receptor activation. Spontaneous absence 
seizures  with  generalised  spike-wave  discharges  at  5Hz  are  exhibited  by 
mice with targeted disruption of HCN2, which encodes a hyperpolarisation-
activated  cation  channel  involved  in  the  generation  of  pacemaker 












Figure  3-3  Voltage-dependent  calcium  channel  subunits  and  associated 
mouse models of human spike-wave epilepsy 
 
3.5.3  Targets of anti-absence drugs 
Ethosuximide  is  a  drug  specifically  effective  in  the  control  of  absence 
seizures.  Application  of  ethosuximide  to  thalamocortical  and  nucleus 
reticularis thalami neurones results in a 40% reduction in the amplitude of the 
T-type Ca
2+ current (Coulter, Huguenard et al. 1989; Coulter, Huguenard et 
al. 1990). This has implicated an action of ethosuximide on thalamic T-type 
calcium  channels.  However  other  studies  have  failed  to  demonstrate  an 
effect  of  ethosuximide  on  native  T-type  Ca
2+  currents  in  thalamic  and 
nonthalamic  neurones  (Sayer,  Brown  et  al.  1993;  Leresche,  Parri  et  al. 
1998). Ethosuximide has been observed to decrease the persistent Na
+ and 
sustained  K
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Parri  et  al.  1998).  Recent  evidence  also  suggests  that  targeting  of  the 
thalamus alone may be insufficient, and that actions in the cortex may be 
required for a full anti-absence action for ethosuximide (Richards, Manning et 
al. 2003). 
 
3.5.4  Mendelian epilepsies 
Mutations  in  GABRG2  cause  both  GEFS+,  a  phenotype  which  includes 
absence  seizures,  and  a  phenotype  of  childhood  absence  epilepsy  and 
febrile  seizures  (section  2.4.6).  A  novel  CACNA1A  mutations  have  been 
identified in a boy with progressive and episodic ataxia, learning difficulties 
and  absence  epilepsy  (Hanna,  Jouvenceau  et  al.  2001).  A  heterozygous 
mutation in the VDCC gene  CACNA1A has previously been reported in a 
child with early onset absence epilepsy and cerebellar ataxia (Jouvenceau, 
Eunson et al. 2001). The mutation gave rise to a premature stop codon, with 
complete loss of function of the heterologously expressed mutated CaV2.11 
subunit. A further mutation in CACNA1A, predicted to result in a frameshift 
and premature stop codon, has been reported in association with EA2 and 
unspecified epilepsy (Jen, Kim et al. 2004). 
 
3.5.5  Linkage  and  association  studies  of  human  absence 
epilepsy 
Linkage analysis of a five generation family from Bombay in which affected 
patients  had  a  persisting  form  of  CAE  provided  evidence  for  a  locus  on 
chromosome 8q24 (Fong, Shah et al. 1998). The candidate region for this 
locus,  designated  ECA1,  has  been  refined,  but  a  gene  remains  to  be 
identified (Sugimoto, Morita et al. 2000). Study of another extended pedigree 
in  which  affected  individuals  manifested  both  CAE  and  febrile  seizures 
revealed  a  linked  marker  on  chromosome  5  close  to  a  cluster  of  genes   72 
encoding GABAA receptor subunits (Wallace, Marini et al. 2001). A mutation 
was found in GABRG2 which changes a conserved amino acid and appeared 
to contribute to the CAE phenotype. Mutations in this gene have also been 
identified in a family segregating generalised epilepsy with febrile seizures 
plus (GEFS+) (Baulac, Huberfeld et al. 2001).  
A  possible  association  was  documented  between  a  polymorphism  in 
GABRB3 and patients with CAE (Feucht, Fuchs et al. 1999), and suggestive 
linkage to this gene found in 8 families  (Tanaka, Castroviejo et al. 2000). 
Mutation  screening  of  45  CAE  patients  identified  no  functionally  relevant 
mutations in GABRB3 (Urak, Feucht et al. 2006). However a SNP haplotype 
in  the  region  between  the  promoter  and  intron  3  showed  significant 
association with the CAE phenotype, and reporter gene assays in the human 
neuronal-like cell line NT2 suggested that the disease-associated haplotype 
causes reduced transcriptional activity. Heterozygous mutations in GABRB3 
have been identified in four out of 48 families with CAE from Mexico and 
Honduras, and all mutations demonstrated hyperglycosylation and reduced 
whole cell GABA-evoked current density when expressed in vitro (Tanaka, 
Olsen  et  al.  2008).  GABRB3  maps  to  15q11-q13,  the  region  deleted  in 
Angelman syndrome (Wagstaff, Knoll et al. 1991), and mice with targeted 
disruption of the Gabrb3 gene have the epilepsy phenotype and behavioural 
characteristics of Angelman syndrome (DeLorey, Handforth et al. 1998).  
An  association  has  also  been  documented  between  polymorphisms  in 
CACNA1A and IGE including CAE (Chioza, Wilkie et al. 2001).  
Direct sequencing of CACNA1H, a T-type Ca
2+ channel gene,  in a Chinese 
population identified 12 missense mutations that were only found in patients 
with CAE (14 of 118 patients) and not in any of 230 unrelated controls (Chen, 
Lu et al. 2003). The mutations occurred in highly conserved residues of the 
calcium channel gene, and are likely to be functionally significant. However 
each mutation was also identified in an apparently unaffected parent of each 
of  the  14  affected  children,  suggesting  that  CACNA1H  is  one  of  perhaps 
several susceptibility genes. Evaluation of Caucasian European patients with 
CAE  found  no  evidence  of  linkage  to  CACNA1H  in  44  pedigrees  and  no   73 
CACNA1H variants were identified in 220 unrelated patients (Chioza, Everett 
et al. 2006). CACNA1H was subsequently screened in 240 epilepsy patients 
(Heron, Khosravani et al. 2007). Over 100 variants were detected, including 
19 missense mutations in subjects with childhood absence, juvenile absence, 
juvenile  myoclonic  and  myoclonic  astatic  epilepsies,  as  well  as  febrile 
seizures and temporal lobe epilepsies. Nine of eleven variants tested altered 
channel  properties.  The  authors  proposed  that  the  variants  identified 
contribute to an individual‟s susceptibility to epilepsy but are not sufficient to 
cause epilepsy on their own.  
Linkage analysis in 65 CAE pedigrees found suggestive evidence for linkage 
to CLCN2 with heterogeneity (Everett, Chioza et al. 2007). Mutation analysis 
identified  45  sequence  variants  in  CLCN2  and  intrafamilial  association 
analysis found suggestive evidence for transmission disequilibrium with the 
CAE phenotype.   74 
 
Chapter 4  Identification of Human Disease Genes 
4.1  Introduction 
Since  the  early  1980‟s,  advances  in  molecular  biological  techniques  have 
provided a range of approaches to the investigation of the molecular basis of 
human inherited disease. Prior to this, very few human disease genes had 
been  identified,  mainly  for  conditions  in  which  the  underlying  biochemical 
mechanisms had been elucidated. Modern techniques involving recombinant 
DNA  technology  and  the  polymerase  chain  reaction  (PCR)  have  been 
applied with most success to mendelian diseases, and strategies for tackling 
these disorders are now well established. These include positional cloning, 
candidate  gene  identification  and mutational  analysis,  which  have  allowed 
the identification of several mendelian epilepsy genes. The complex genetic 
diseases, however, have generally proved resistant to these strategies. The 
completion  of  the  human  genome  mapping  project  and  progress  in  the 
construction  of  a  haplotype  map  (HapMap)  of  the  human  genome  has 
allowed new approaches to the investigation of complex diseases. 
4.2  Evolution of Molecular Genetics 
4.2.1  Mendelian  and non-mendelian inheritance 
Gregor Mendel (1822-1884) proposed a theory of particulate inheritance, in 
which characteristics were determined by discrete units of inheritance (later 
known as genes) that were passed from one generation to the next. Mendel‟s 
experiments involving the cultivation of pea plants allowed him to formulate 
his laws of heredity.   75 
4.2.2  Mendel’s law of segregation 
This  introduces  the  concept  of  genes  and  alleles  (alternative  versions  of 
genes). These terms were not actually used by Mendel, but the essence of 
what Mendel discovered was:  
1.  Alternative „alleles‟ account for variations in inherited characters. 
2.  For each character, an organism inherits two „genes‟, one from each 
parent. 
3.  If two alleles differ (a heterozygote), then one, the „dominant allele‟, is 
fully expressed in the organism, whilst the other, the „recessive allele‟, 
has no noticeable effect. 
4.  The two genes for each character segregate during gamete production 
(meiosis). 
4.2.3  Mendel’s law of independent assortment 
The most important principle of this law is that the emergence of one trait will 
not affect the emergence of another. This results in the observed 3:1 ratio 
between  dominant  and  recessive  phenotypes  for  a  single  trait,  whilst 
phenotypes comprising two traits show a 9:3:3:1 ratio. 
4.2.4  Mendelian patterns of inheritance 
Autosomal or X-linked traits can be dominant or recessive. This does not 
apply to Y-linked traits as there is at most one Y chromosome. Males are 
hemizygous for loci on the X and Y chromosomes. There are therefore five 
basic  mendelian  pedigree  patterns:  i)  autosomal  dominant,  ii)  autosomal 
recessive, iii) X-linked recessive, iv) X-linked dominant, v) Y-linked. 
   76 




II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8










II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
III:1 III:2 III:3 III:4 III:5 III:6 III:8 III:9 III:10
III:5 III:7
I:1 I:2
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
III:1 III:2 III:3 III:4 III:6 III:8 III:9 III:10 III:11
III:9 III:7
I:1 I:2
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
III:1 III:2 III:3 III:4 III:5 III:6 III:8 III:10 III:11
i) Autosomal dominant 
ii) Autosomal recessive 
v) Y-linked 
iv) X-linked dominant 
iii) X-linked recessive 
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4.2.5  Non-mendelian ‘complex’ inheritance 
By 1900, Mendel‟s work had been rediscovered and formed the basis of the 
Mendelian school of genetics. However, a rival school, based on the tradition 
of biometrics developed by Francis Galton, argued that continuously variable 
quantitative variable characters (such as height, strength, intelligence) could 
not  be  explained  by  mendelian  genetics  and  were  not  inherited  in  a 
mendelian  fashion.  In  1918,  RA  Fisher  demonstrated  that  traits  with 
quantitative variation and complex inheritance patterns could be explained by 
the  interaction  of  many  independent  mendelian  factors  (polygenic 
inheritance). This applies to most clinical syndromes which are determined 
by a complex interaction of factors involved in physiological or developmental 
processes. The genetic architecture of complex diseases may comprise a 
few interacting loci (oligogenic), many loci each with small effect (polygenic), 
or the interaction of genetic and environmental factors (multifactorial). Non-
penetrance or variable expression of an apparently dominant disease, where 
different  „affected‟  family  members  show  different  clinical  features  (or  no 
features at all), is likely to be a reflection of a single major causative locus 
interacting with modifying loci or environmental factors. 
4.2.6  DNA/RNA and polypeptides 
In  1943,  Oswald  Avery  discovered  evidence  that  molecules  of  DNA 
(deoxyribonucleic acid) store the genetic information which determines the 
characteristics of living organisms. James Watson and Francis Crick at the 
Cavendish Laboratories in Cambridge, using the x-ray crystallography data 
generated  by  Maurice  Wilkins  and  Rosalind  Franklin  at  King‟s  College 
London,  determined  the  double  helix  structure  of  DNA  in  1953.  They 
demonstrated that the four bases, adenine, guanine, cytosine and thymine, 
which  form  the  genetic  code,  are  arranged  in  hydrogen-bonded  pairs  of 
adenine-thymine and guanine-cytosine which hold the two strands together. 
This  structure  explained  how  a  gene  could  replicate,  as  the  double  helix 
could split and each strand on its own could build its counterpart from free 
bases, thus forming two new but identical DNA molecules.    78 
By 1960, it was still not clear how the basic genetic information encoded by 
DNA  was  expressed.  It  was  known  that  the  polypeptide  proteins  that 
determine a cell‟s physiology, morphology and development are encoded by 
individual  genes  in  chromosomes.  In  1960,  Francois  Jacob  and  Matthew 
Meselson  determined  that  proteins  are  assembled  on  ribosomes  in  the 
cytoplasm  of  the  cell.  The  following  year,  Jacob  and  Jacques  Monod 
hypothesised that a special form of RNA synthesised from the DNA template 
of genes is transported to the ribosome where this messenger RNA (mRNA), 
complementary to the genetic DNA sequence, provides the information for 
polypeptide  synthesis.  This  mRNA  hypothesis  was  confirmed  by  Sydney 
Brenner, Jacob, and Meselson in 1964. It had previously been demonstrated 
in 1961, by Francis Crick and co-workers, that the actual instructions for a 
polypeptide exist as a series of overlapping, three-base code words, each 
“triplet” specifying one of the 20 amino acids. 
4.2.7  Mapping of genes 
Genetic mapping relies on the principle that the segregation of two loci during 
meiotic recombination depends on the distance between them. If two loci are 
on different chromosomes they will segregate independently. If they lie on the 
same chromosome, they will segregate together unless a cross-over occurs 
between the two loci during meiosis. The further apart the two loci are on a 
chromosome, the more likely it is that a crossover will separate them. The 
recombination fraction is a measure of the genetic distance between the two 
loci, and this genetic distance can be used to estimate the physical distance 
using  a  mapping  function.  Genetic  linkage  studies  measure  the  genetic 
distance between markers of known chromosomal location and a putative 
disease locus.  
In 1911, Thomas Huntley Morgan first used the principles of linkage analysis 
to propose that the genes for white eyes, yellow body, and miniature wings in 
Drosophila are linked together on the X chromosome. Two years later, A. H. 
Sturtevant, an undergraduate working with Morgan at Columbia, provided the 
experimental basis for the linkage concept in Drosophila and produced the   79 
first  genetic  map.  Early  linkage  studies  in  humans  used  blood  group  and 
serum protein (with variant electrophoretic mobility) markers to determine the 
chromosomal  location  of  disease  genes.  Mapping  disease  genes  more 
accurately became a realistic possibility in the 1980s with the discovery that 
variations  in  human  DNA  could  be  used  as  genetic  markers  in  linkage 
studies. The first genetic linkage map in humans, using restriction-fragment 
length polymorphism (RFLP) markers was published in 1980 (Botstein, White 
et al. 1980). These were typed by hybridizing southern blots of restriction 
digests  with  radiolabelled  probes.  Subsequently,  abundant  highly 
polymorphic  short  tandem  repeat  DNA  sequences  were  discovered  which 
enabled the mapping of a larger number of mendelian disease loci (Weber 
and May 1989).Disease genes could then be identified by positional cloning 
(section 4.5.2) 
Linkage analysis has proved extremely powerful when applied to mendelian 
phenotypes. It has also led to the identification of genes responsible for rare 
subsets  of more  common familial  disorders such  as  diabetes,  alzheimer‟s 
disease and breast cancer. However, the majority of genes for the common 
„complex‟  diseases  have  proven  resistant  to  linkage  analysis,  due  to  the 
probable existence of multiple genes with small effect and weak genotype-
phenotype correlations. Approaches using candidate genes or high-density 
genome  scans  dependent  on  linkage  disequilibrium  may  prove  more 
successful.     80 
4.3  Molecular genetic techniques 
4.3.1  Polymerase chain reaction(PCR) 
PCR  is  an  extremely  powerful  method  for  synthesizing  and  amplifying  a 
specific  DNA  sequence  within  a  source  of  DNA  in  vitro.  It  requires  the 
presence  of  a  heat  stable  DNA  polymerase  for  synthesis  of  new  DNA 
strands. The theory of PCR was first described in 1971 by Kleppe (Kleppe, 
Ohtsuka et al. 1971). However, the first heat-stable DNA polymerase was not 
discovered until 1975, when taq polymerase was isolated from the thermus 
aquaticus  microorganism  in  the  hot  springs  of  Yellowstone  National  Park. 
Large scale automation of DNA amplification was then developed in 1983, 
when Kary Mullis, working at the Perkin-Elmer Cetus Corporation, realised its 
immense  potential  (Saiki,  Scharf  et  al.  1985).  To  enable  selective 
amplification, the DNA sequence flanking the target region must be known. 
This is used to construct two oligonucleotide primer sequences, which will 
bind  to  complementary  DNA  sequences  flanking  the  target  region,  when 
added to denatured genomic DNA. To allow the synthesis of new DNA, the 
four deoxynucleoside triphosphates (dATP, dCTP, dGTP and dTTP) must be 
present in the reaction. 
The PCR reaction involves three steps repeated sequentially: denaturation, 
reannealing and DNA synthesis (Figure 4-2). Each cycle results in doubling 
of the target DNA present. 
PCR  has  a  wide  range  of  applications,  including  typing  genetic  markers, 
mutation screening, DNA cloning and DNA sequencing.    81 
 
Figure 4-2 Polymerase chain reaction 
 
4.3.2  Genetic marker typing 
Restriction  site  polymorphisms  (RSPs)  are  biallelic  markers,  either 
possessing  or  lacking  a  specific  restriction  site.  Conventionally,  these  are 
assayed by digesting genomic DNA with the restriction endonuclease specific 
for that restriction site. This results in fragments whose length depends on 
the presence or absence of the restriction site. These fragments are then 
size-fractionated  by  agarose  gel  electrophoresis,  with  smaller  fragments 
travelling  more  rapidly  and  therefore  further  through  the  gel.  The  DNA 
fragments  are  detected  by  Southern  blot  hybridisation.  This  involves 
denaturing  the  DNA  fragments  in  alkali,  transfer  by  blotting  onto  a 
nitrocellulose  membrane,  hybridising  with  a  radiolabelled  single  stranded 
DNA probe and detection of the radiolabelled fragments using a x-ray film. As 
a  an  easier  alternative,  RSPs  can  be  typed  by  using  PCR to  amplify  the 
region containing the restriction site and then cutting the PCR product with 
DNA synthesis 
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the restriction enzyme. PCR amplifies enough of the target DNA sequence to 
allow visualization of the fragments following agarose gel electrophoresis.  
Simple sequence length polymorphisms (SSLPs) are much more powerful 
than  RSPs  when  used  as  genetic  markers,  as  they  tend  to  be  highly 
polymorphic.  An  SSLP  consists  of  a  short  nucleotide  sequence  that  is 
tandemly repeated a variable number of times. Each allele of a particular 
marker  is  determined  by  the  number  of  repeat  sequences.  The  most 
commonly  used  SSLPs  are  dinucleotide  (e.g.  (CA)n),  trinucleotide  or 
tetranucleotide repeats. Typing of SSLPs involves PCR amplification using 
primers flanking the repeat region. The size of the PCR product indicates the 
particular  allele  of  the  SSLP.  By  fluorescent  labelling  of  one  of  the  PCR 
primers,  the  PCR  products  can  be  separated  by  polyacrylamide  gel 
electrophoresis and detected by laser excitation. 
4.3.3  DNA sequencing 
The basis for virtually all DNA sequencing is the dideoxy-chain terminating 
reaction, developed by Sanger in 1975. A sequencing reaction consists of a 
single  stranded  DNA  template  (multiple  copies)  and  a  complementary 
sequencing primer which binds to the template and flanks the region to be 
sequenced.  DNA  polymerase  and  the  four  deoxynucleoside  triphosphate 
(dNTP)  DNA  precursors  are  added  for  synthesis  of  complementary  DNA 
strands. In addition, a low concentration of one of four dideoxynucleoside 
triphosphates  (ddNTPs)  is  included  which  correspond  to  the  four  dNTPs. 
These  ddNTPs  act  as  terminators  of  DNA  chain  synthesis.  These  are 
incorporated  normally  into  the  growing  DNA  chain,  but  as  they  lack  a 
hydroxyl group at the 3‟ carbon position, they cannot form a phosphodiester 
bond  with  the  5‟  carbon  of  the  next  dNTP  in  the  sequence,  and  DNA 
synthesis  terminates.  As  the  DNA  sequencing  reaction  proceeds,  chain 
termination occurs randomly whenever a ddNTPs is incorporated instead of 
the  corresponding  dNTP.  This  results  in  a  population  of  DNA  strands  of 
varying lengths, each terminating at the 3‟ end with the particular ddNTP in 
the reaction. Traditionally, four parallel reactions are run, each with one of the   83 
four ddNTPs. The products are separated on a denaturing polyacrylamide 
gel.  By  incorporating  radioisotope  labelled  nucleotides,  the  band  positions 
can be detected by exposure to x-ray film. 
Modern  sequencing  reactions  use  fluorescent  labelling  of  ddNTPs.  By 
labelling each of the four ddNTPs with a different coloured label, they can be 
combined in a single sequencing reaction and the products separated in a 
single lane. As the laser causes the dyes to fluoresce, each fluoresces at a 
different wavelength and can be detected automatically and converted into 



















Figure 4-3 Automated DNA sequencing using fluorescent primers. Random 
incorporation of the labelled ddNTPs produces a series of DNA fragments in 
which chain growth has been terminated at each successive position. 
DNA template 
Primer 
5‟  3‟ 
5‟    A A T T A G C C A G  
5‟  3‟ 
5‟    A A T T A G C  
5‟  3‟ 
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3‟  5‟ 
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3‟  5‟ 
Sequencing   
electropherogram:   85 
4.3.4  Single nucleotide polymorphism (SNP) genotyping and 
microarrays 
SNPs are DNA sequence variations that occur when a single nucleotide is 
altered.  A  variation  can  (and  probably  does)  occur  at  any  of  the 
approximately 3,000,000,000 nucleotides in the human genome, but to be 
considered a SNP, it must occur in at least 1% of the population. SNPs occur 
every 100 to 300 bases along the human genome, accounting for about 90% 
of all human genetic variation. SNPs and SNP haplotypes can be used as 
genetic markers for genome-wide and candidate-gene association studies. 
The availability of high density SNP maps with knowledge of the haplotype 
structure of the human genome will provide an extremely valuable tool for the 
investigation  of  complex  genetic  diseases.  In  1999  the  SNP  consortium 
(TSC)  was  established  between  pharmaceutical  companies  and  the 
Wellcome  Trust,  with  the  aim  of  mapping  300,000  common  SNPs.  By 
February 2003, 3.7 million SNPs had been mapped. In 2002 the international 
HapMap project was established to develop a haplotype map of the human 
genome  and  to  identify  which  200,000  to  1  million  tagging  SNPs  provide 
almost as much mapping information as the 10 million SNPs in total.  The 
phase II HapMap published in 2007 characterised over 3.1 million human 
SNPs  genotyped  in  270  individuals  from  four  geographically  diverse 
populations and include 25–35% of common SNP variation in the populations 
surveyed. 
A  number  of  SNP  genotyping  methods  have  been  developed.  An  ideal 
method  should  be  easy,  quick,  robust,  flexible  and  automated  for  high 
throughput. Important aspects of methodology include allelic discrimination, 
assay  format,  and  detection  technique  (Kwok  2001).  Some  illustrative 
methodologies will be briefly described. All depend on PCR amplification of 
the genomic DNA prior to genotyping. Melting curve SNP analysis (McSNP) 
is described in section 6.7.1   86 
4.3.5  Allele specific hybridisation 
Techniques such as that developed by Affymetrix and the Whitehead institute 
involve hybridisation on a GeneChip microarray.  Allele specific hybridisation 
uses allele specific probes which only anneal to the target DNA when there is 
a  perfect  match.  The  allele  specific  probes  are  immobilized  on  a  solid 
support, and after PCR amplification of the target DNA and hybridization to 
the microarray, the unbound targets are washed away and the hybridised 
DNA visualised by fluorescent labelling. The PCR assays allow a degree of 
multiplexing,  but  the  detectable  SNPs  are  limited  to  those  on  the  pre-
designed microarray. 
4.3.6  Dynamic allele specific hybridisation (DASH) 
This method investigates allele-specific hybridisation by using the difference 
in  melting  temperature  between  annealing  of  the  allele-specific  probe  to 
matched and mis-matched DNA. Hybridisation is monitored over a range of 
temperatures and formation of double stranded DNA detected using a DNA 
intercalating dye, such as Syber Green I, which fluoresces in the presence of 
double-stranded  DNA.  Assays  can  be  designed  for  almost  all  SNPs. 
However, the PCR amplified target DNA must be rendered single-stranded 
by used of biotinylated PCR primers which allow the product to be captured 
on a solid support, denatured, and the unlabelled strand washed away.  
4.3.7  Homogeneous  hybridisation  with  fluorescence 
resonance energy transfer (FRET) 
Techniques such as Molecular Beacon and TaqMan (section 6.7.1) use the 
principle of fluorescence resonance energy transfer. A fluorescent reporter is 
held in close association with a universal quencher such that fluorescence is 
only observed when the reporter and quencher are separated. The reporter 
and  quencher  can  be  held  by  a  molecular  beacon  which  is  a  stem-loop 
structure  in  which  binding  to  target  DNA  exactly  complementary  to  the 
sequence of the loop portion forces open the stem and allows fluorescence.   87 
A  single  base  mismatch  reduces  the  strength  of  hybridisation  so  that  the 
stem-loop  structure  remains  intact.  In  both  the  Molecular  Beacon  and 
TaqMan assays, the increase in fluorescence can be monitored in real time, 
or two differently labelled allele specific probes can be used, and the signal 
ratio of the two probes measured at completion of the PCR. 
4.3.8  DNA polymerase-assisted genotyping 
Minisequencing,  or  single  nucleotide  primer  extension,  uses  a  primer  that 
anneals  to  the  target  DNA  immediately  adjacent  to  the  SNP.  Primer 
extension  by  DNA  polymerase  only  occurs  with  the  nucleotide 
complementary to the nucleotide at the site of the SNP, and this is detected 
by differential fluorescent labelling of the four ddNTPs. Modifications include 
the  use  of  HAPTEN-labelled  nucleotide  analogues  that  are  detected 
colometrically in an ELISA (enzyme-linked immunosorbent assay), and the 
Amplifluor® SNPs Genotyping System is based on competitive allele-specific 
PCR,  using  two  fluorescently  labelled  Amplifluor®  SNP  Primers in  a  one-
step, single-tube reaction with standard PCR. Pyrosequencing detects the 
pyrophosphate which is released whenever a dNTP is incorporated during 
primer  extension  (see  section  6.7.3).  Mass  spectrometry  or  MALDI-TOF 
(matrix-associated laser desorption time-of-flight mass spectrometry) can be 
used  to  detect  the  primer  extension  products.  This  can  be  an  extremely 
sensitive method, and allows multiplexing, but is expensive. 
As with allele specific hybridisation, single nucleotide primer extension can 
be  used  with  microarray  technology  for  parallel  genotyping  of  SNPs.  The 
power  of  discrimination  between  genotypes  appears  to  be  significantly 
greater than for allele specific hybridisation. Minisequencing on microarrays 
uses one primer for each SNP immobilised on a solid support. After primer 
extension with labelled ddNTPs, the genotypes are detected by fluorescence 
scanning.  An  alternative  microarray  method  is  allele-specific  primer 
extension, where two allele-specific primers per SNP are immobilised and 
extended with fluorescent oligonucleotides and templates of target DNA (or 
RNA created by RNA polymerase and then used as templates with reverse   88 
transcriptase).  Microarrays  can  also  be  used  in  conjunction  with  cyclic 
nucleotide primer extension reactions in solution using tagged primers and 
complementary  oligonucleotide  tags  on  the  microarray.  The  microarray  is 
used  to  capture  and  sort  the  minisequencing  products  by  hybridisation. 
Tagged  primers  can  also  be  used  with  arrays  of  microspheres,  where 
different classes of microspheres, each with a specific tag, are detected by 
fluorescence in a flow cytometer, and the genotype of the SNP is determined 
by the captured fluorescent product. 
4.3.9  Ligation methods 
Methods such as the oligonucleotide ligation assay utilise DNA ligases which 
only ligate hybridised probes and target DNA when there is a perfect match. 
This  can  be  combined  with  colimetric  detection  methods,  fluorescently 
labelled ligation probes and microarray formats. 
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4.4  Genome Mapping Projects 
4.4.1  Human genome project 
The human genome project was a collaboration involving 20 groups from the 
United States, United Kingdom, Japan, France, Germany and China. In 1988 
the US national Research Council published a report entitled „Mapping and 
Sequencing  the  Human  Genome‟.  This  recommended  a  programme  to 
include: the creation of genetic, physical and sequence maps of the human 
genome; similar projects in model organisms (bacteria, yeast, worms, flies 
and mice); the development of supportive technology; research into related 
ethical,  legal  and  social  issues.  Genomic  research  programmes  were 
launched by the Department of Energy and the National Institute of Health in 
the US, the Medical Research Council and the Wellcome Trust in the UK, as 
well  as  other bodies  in  Europe and  Japan.  By  1990  the  Human  Genome 
Project had been launched as a 15 year project and the Human Genome 
Organisation (HUGO) to coordinate international genome research. A draft 
genome sequence was published in February 2001, covering about 94% of 
the human genome. The sequencing of the human genome was  declared 
complete  in  April  2003  (99%  of  gene-containing  part  of  human  sequence 
finished  to  99.99%  accuracy).  However  the  completed  sequences  of 
individual chromosome continue to be released until 2006. By March 2003, 
15,000  full-length  human  cDNAs  had  been  identified  and  these  could  be 
compared with those of other organisms with sequenced genomes. The total 
number  of  human  genes  was  less  than  predicted  at  around  25,000,  with 
alternative splicing resulting in around 100,000 proteins. 
4.4.2  Model organisms 
Comparison of genome sequences from evolutionarily diverse species is a 
powerful  tool  for  identifying  functionally  important  conserved  genomic 
elements,  defining  the  functional  nature  of  some  sequences,  establishing   90 
relationships  between  genotype  and  biological  function,  providing  insights 
into  the  distinct  anatomical,  physiological  and  developmental  features  of 
different organisms, defining the genetic basis for speciation and facilitating 
the characterization of mutational processes. 
The  first  multicellular  eukaryotic  genome  to  be  completed  was  the 
Caenorhabditis elegans genome, carried out by the Sanger Centre and the 
Genome  Sequencing  Centre  at  Washington  University  (C.  Elegans 
Sequencing  Consortium  1998).  The  sequence  of  the  Drosophila 
melanogaster  genome,  originally  determined  in  a  collaboration  between 
Celera and the Berkeley Drosophila Genome Project, was published in 2000 
(Adams, Celniker et al. 2000). The results of an international collaboration to 
produce a high-quality draft sequence of the mouse genome were published 
in 2002, as well as an initial comparative analysis of the mouse and human 
genomes  (Waterston,  Lindblad-Toh  et  al.  2002).  The  complete  genome 
sequences of Plasmodium falciparum (Gardner, Hall et al. 2002), the main 
cause of human malaria, Plasmodium yoelii (Carlton, Angiuoli et al. 2002), 
the infectious agent in rodent malaria and the malaria mosquito Anopheles 
gambiae (Holt, Subramanian et al. 2002), were published simultaneously in 
October 2002. As of June 2003, the Rat Genome Sequencing Consortium, 
led by the Baylor College of Medicine Human Genome Sequencing Centre, 
had  released  a draft genome  assembly  of the  Rattus norvegicus  genome 
covering more than 90% of the estimated 2.8 Gb genome. In February 2001 
the Sanger Institute started sequencing the genome of the zebrafish (Danio 
rerio) following  two  strategies:  clone  mapping  and  sequencing  from  BAC 
(bacterial artificial chromosome) and PAC (P1-derived artificial chromosome) 
libraries and whole genome shotgun sequencing with subsequent assembly. 
It is expected that 90% of the zebrafish genome will be available by the end 
of 2009. 
4.4.3  The future of genome research 
A number of future projects for genome research were proposed following 
the completion of the human genome project (Collins, Green et al. 2003).   91 
These challenges were related to three major themes -  genomics to biology, 
genomics  to  health  and  genomics  to  society,  and  to  six  elements  – 
resources; technology development; computational biology; training; ethical, 
legal and social implications; and education. Within the genomics to biology 
theme,  the  key  targets  included:  i)  identifying  all  structural  and  functional 
components,  including  protein-coding  and  non  protein-coding  regulatory 
sequences encoded in the human genome (the aim of the Encyclopaedia of 
DNA Elements (ENCODE) Project launched by the National Human Genome 
Research Institute); ii) elucidating how genes and gene products interact and 
how the contribute to functioning of cells and organisms; iii) developing a 
complete description of the genetic variation in the human genome and its 
relationship  to  disease  and  response  to  drugs  (for  example  the  SNP 
Consortium  and  the  International  HapMap  project);  iv)  understanding 
evolutionary  mechanisms;  and  v)  disseminating  genome  information  as 
effectively as possible. Much of this work is ongoing. 
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4.5  Identifying mendelian disease genes 
Positional cloning, including positional candidate gene approaches, together 
with mutational analysis has been particularly successful in the identification 
of  mendelian  disease  genes.  Diseases  with  „complex‟  inheritance  have 
generally required alternative approaches, such as association analysis.  
4.5.1  Functional Cloning 
A disease gene is identified on the basis of information about its function, 
such  as  the  biochemical  abnormality  underlying  the  disease.  Historically, 
isolation of a purified gene product has allowed amino acid sequencing and 
identification  of  regions  with  minimal  codon  degeneracy  (ie  relatively  few 
codon permutations can encode the amino acid sequence). This enabled the 
synthesis  of  labelled  oligonucleotides  corresponding  to  all  possible  codon 
permutations,  which  were  then  used  to  screen  cDNA  libraries,  identify  a 
cDNA  clone,  and  screen  a  genomic  DNA  library  to  fully  characterize  the 
gene. This approach was used to identify the factor VIII gene responsible for 
Haemophilia A. An alternative approach involves raising antibodies against 
the  normal  protein  product,  and  then  using  the  antibodies  to  screen 
expression cDNA libraries. 
 
4.5.2  Positional Cloning  
This  approach  uses  linkage  analysis  to  map  a  gene  locus  to  a  small 
chromosomal  region.  Linkage  analysis  tests  polymorphic  genetic  markers 
distributed  across  the  genome  (a  „genome-wide‟  scan)  for  co-segregation 
(linkage)  with  the  disease  phenotype.  A  single  large  pedigree  or  several 
small  pedigrees  are  required.  A  „linked‟  marker  has  undergone  few 
recombinations with the causative gene during meiosis and therefore lies on 
the same chromosomal segment (Figure 4-4). A physical map of a linked   93 
chromosomal region can then be constructed, and coding DNA sequences 
identified for mutation screening. Linkage analysis as a method for mapping 
disease genes in man was revolutionised by the development of methods for 
detecting polymorphism at the DNA level as well as a comprehensive genetic 
marker  map  of  the  human  genome  consisting  of  5,264  simple  sequence 









Figure  4-4  Linkage  analysis.  During  prophase  of  meiosis  1,  pairs  of 
homologous  chromosomes  synapse  and  exchange  segments.  Alleles  at  3 
loci are shown -  A, B, C on the blue (paternal) chromosome and a, b, c on 
the red (maternal) chromosome.  Recombination between closely spaced loci 
(A and B) is likely to occur much less frequently than between well separated 
loci (A and C). If A is the disease gene and B and C are polymorphic genetic 
markers, linkage analysis allows the disease gene to be mapped relative to 
the markers B and C. 
c  C  c  C  c  C 
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Positional cloning has led to the identification of disease genes for a large 
number of mendelian disorders including several epilepsies. There has been 
some  limited  success  in  non-mendelian  disorders  such  as  Crohn  disease 
(Hugot, Chamaillard et al. 2001; Ogura, Bonen et al. 2001). However, the 
statistical power of this approach is greatly reduced by genetic heterogeneity, 
uncertainty concerning the mode of inheritance and penetrance of disease 
alleles, and several other confounding factors.  
 
4.5.3  Genetic Mapping 
The genetic distance between loci is defined by the recombination fraction. A 
recombination  fraction  of  1%  signifies  a  crossover  occurring  in  1%  of 
meioses. Genetic distance is measured in centimorgans (cM), ie two loci that 
show  1%  recombination  are  1  cM  apart  on  a  genetic  map.  However  the 
relationship between recombination fraction and genetic map distance is not 
linear,  as  recombination  fraction  cannot  exceed  50%  (two  loci  which 
segregate independently will be recombinant on average 50% of the time). 
Recombination  fraction  ()  and  genetic  distance  in  centimorgans  (D)  are 
related by a mapping function. A commonly used mapping function is the 
Kosambi  function  (Kosambi  1944),  which  takes  into  account  interference 
(inhibition  of  chiasma  formation  by  the  presence  of  a  nearby  previous 
chiasma): 
D = 1/4ln{(1+2)/(1-2)} 
 
4.5.4  Genetic Markers 
The development of human genetic markers is described in section 4.2.7 and 
section 4.3.2. For a particular marker, the proportion of informative meioses 
(those meioses for which the segregation of alleles can be determined) for 
linkage analysis depends on the informativeness of the marker. A meiosis   95 
can  only  be  informative  if  the  individual  is  heterozygous  for  a  particular 
marker.    The  heterozygosity  of  a  marker  indicates  the  proportion  of 
individuals  within  a  population  heterozygous  at  the  marker  locus.  The 
polymorphism  information  content  (PIC)  refers  to  the  proportion  of 
informative meioses. A PIC of 0 indicates a marker that is never informative 
and a PIC of 1 indicates a marker that is always informative. 
4.5.5  Linkage analysis 
The  likelihood  that  two  loci, or a marker and disease  are  linked  is tested 
using two-point LOD score analysis (Morton 1955). The LOD score, Z, is the 
logarithm  of  odds  that  the  loci  are  linked  with  a  particular  recombination 
fraction, , rather than unlinked =0.5). Each meiosis is considered in turn to 
calculate the overall LOD. The LOD score is calculated over a range of   
values to find the maximum values. The traditional criteria for positive linkage 
for a mendelian trait is Z=3.0 (corresponding to odds of 1000:1), with a 5% 
chance of error. The criteria for exclusion of linkage is Z<-2.0.  
Multipoint linkage analysis allows multiple loci to be analysed simultaneously. 
This can compensate for uninformative markers at particular meioses and for 
missing  marker  data  by  extracting  data  simultaneously  from  neighbouring 
markers and allowing construction of marker haplotypes. 
Standard  LOD  score  analysis  requires  a  precise  genetic  model  to  be 
specified, including the mode of inheritance, gene frequency and penetrance 
of each genotype. This data is often an approximation or estimate. Model-
free,  or  non-parametric  analysis  tests  allele  sharing  amongst  affected 
individuals in pedigrees, without any assumptions about model of inheritance. 
This  bypasses  the  inherent  problems  of  parametric  analysis  such  as 
misspecification of parameters. Model-free analysis must distinguish between 
allele  sharing  identical  by  state  (IBS)  from  alleles  that  are  identical  by 
descent  (IBD).  Identity  by  descent  signifies  shared alleles  that have  been 
inherited from a common ancestral chromosome, whereas identity by state 
refers to alleles that are shared coincidentally but do not have a common   96 
ancestral  origin.  Exclusion  of  IBS  can  be  increased  by  construction  of 
multilocus haplotypes. 
 
4.5.6  Positional candidate cloning 
The availability of detailed genetic and physical maps, including the human 
genome  project,  has  allowed  for  much  easier  identification  of  a  potential 
causative  gene.  The  positional  candidate  approach  involves  (i)  linkage 
analysis  to  localize  a  disease  gene  to  a  chromosomal  subregion  (ii) 
searching databases for a candidate gene within that subregion, based on 
known gene function and an understanding of the disease pathophysiology 
and (iii) testing the candidate gene for disease-causing mutations. 
4.5.7  Mutational analysis 
Several methodologies are available for the identification of potential disease 
causing  mutations  in  candidate  genes.  These  include  single  strand 
conformational  polymorphism  (SSCP),  heteroduplex  analysis  and 
oligonucleotide arrays. Direct sequencing is ultimately required to confirm a 
sequence  change.  Functionally  important  regions  of  the  gene  are  initially 
screened  for  mutations,  and  any  identified  sequence  variant  is  then 
evaluated to determine its significance. The association of a mutation with 
the disease trait can be investigated both in family-based linkage studies and 
population-based  association  studies  (section  4.6.2).  The  functional 
consequences of a sequence variation depend in part on the location relative 
to  the  gene,  pathogenic  mutations  often  occurring  within  the  coding 
sequence of the gene but also occurring in intragenic noncoding sequences 
or regulatory sequences outside exons. A functional variant is also likely to 
alter a  highly  conserved amino acid or affect  a  splice  site or stop  codon. 
Ultimately, the effect of a mutation on gene expression and protein function 
may be investigated using a variety of in-vivo and in-vitro techniques.   97 
4.6  Identifying  genes  for  diseases  with  ‘complex’ 
inheritance 
4.6.1  Genetic architecture of ‘complex’ disease 
Genetic  architecture  has  a  major  influence  on  the  optimal  strategy  for 
detecting susceptibility loci responsible for „complex‟ disease traits.  Alleles at 
loci determining Mendelian traits are rare (low frequency) and of major effect 
(highly penetrant).  The same trait may be caused by rare, high penetrance 
alleles at distinct loci (locus heterogeneity). At a given locus many different 
disease alleles may occur (allelic heterogeneity). 
Alleles at susceptibility loci are of small effect and likely to be of relatively 
high frequency (>1%).  The number of loci, the magnitude of their individual 
effect  on  risk,  their  mode  of  interaction  and  the  number  and  population 
frequency of susceptibility alleles underlying any particular trait is unknown.  
Oligogenic traits with a few loci of significant effect represent one end of the 
spectrum, with truly polygenic traits caused by numerous loci of small effect 
at  the  other  end.    The  „common-disease-common  variant‟  hypothesis 
assumes that there is allelic homogeneity at each locus with the susceptibility 
allele present at high frequency (>5-10%) (Wright and Hastie 2001). 
The methods of linkage analysis and positional cloning which are so powerful 
when applied to Mendelian disorders are much less useful for those traits 
which  display  „complex‟  inheritance.    Although  there  is  increased  familial 
clustering,  segregation  in  families  cannot  be  explained  by  the  effect  of  a 
locus with dominant or recessive disease alleles.  Interaction of several loci, 
each exerting a small effect, together with environmental factors is assumed. 
The power of linkage analysis is low if individual loci exert a small effect on 
the phenotype or if there is extensive locus heterogeneity.  Thus, adequate 
power  to  detect  linkage  can  only  be  attained  with  numbers  of  pedigrees 
above  the  number  it  may  be  practicable  to  ascertain.    Numerous  linkage 
analyses using a „genome-wide‟ approach in complex traits have failed to 
identify linked loci which have been highly significant (statistically), replicable   98 
or have led on to positional cloning of a susceptibility gene.  In „complex‟ 
traits, linkage cannot provide high-resolution localisation and positive results 
usually  cover  very  large  chromosomal  regions.    Therefore  an  alternative 
approach such as association analysis is often required. 
4.6.2  Association analysis 
Association  studies  detect  non-random  associations  between  a  trait  and 
either an allele or group of alleles in linkage disequilibrium (LD).  LD is the 
non-random  occurrence  of  specific  alleles  at  adjacent  loci  (a  haplotype).  
Association studies test for marker–disease correlations by investigating LD 
in a population. LD is measured between the disease and marker alleles, or 
preferably a haplotype of several markers, in unrelated individuals. 
LD can be measured in several ways. A commonly used parameter of LD is 
D‟.  D‟ is related to the basic measure of LD, D, which is a measure of the 
deviation of haplotype frequencies from the equilibrium state, ie: 
D=p(AB)-p(A)p(B)   
where  A  and  B  are  alleles  at  two  linked  SNPs  and  p(X)  represents  the 
frequency of the X allele or haplotype. D‟ is the ratio of D compared to its 
maximum value Dmax  (or compared to its minimum value, Dmin, when D<0). 
Complete LD is denoted by D‟=1, and repeated recombination results in D‟ 
approaching zero. 
SNPs  are  particularly  suited  as  markers  for  association  analysis.  SNPs 
constitute the majority of the variation between human genomes, which on 
average differ by 0.1%.  Most of these SNPs are „neutral‟ but a subset with 
functional consequences is likely to include the allelic variation that accounts 
for common disease traits.  
The  control  sample  of  chromosomes  can  be  taken  from  an  unaffected 
population. An alternative strategy is intra-familial association analysis, such 
as the transmission disequilibrium test (TDT) which uses internal controls. 
The TDT compares the transmission of alleles from heterozygous parents to   99 
affected offspring (Spielman, McGinnis et al. 1993). The affection status of 
the parents is not relevant, and a single parent can be used. Each marker 
allele is tested by selecting all parents that are heterozygous for that allele 
and  counting  how  many  times,  n,  the  allele  is  transmitted  to  the  affected 
offspring. This is compared with the number of times the alternative allele is 
transmitted.  
The TDT test statistic, (ntransmittednuntransmitted)
2/(ntransmitted+nuntransmitted), has a 
2 
distribution with 1 degree of freedom. The pedigree disequilibrium test, PDT, 
is an extended test for intra-familial association that analyses LD in extended 
pedigrees using all potentially informative data (Martin, Monks et al. 2000; 
Martin, Bass et al. 2001). 
Allelic association has greater power to detect susceptibility alleles of smaller 
effect, but is critically dependent on the „common-disease-common variant‟ 
hypothesis being true for a particular trait (Reich and Lander 2001).  If a wide 
diversity of low-frequency alleles causes susceptibility, association would be 
difficult or impossible to detect. 
Association  studies  can  be  used  in  combination  with  linkage  analysis  to 
narrow a candidate region identified by linkage, or can be applied directly to 
test  candidate  genes.  Chromosomal  or  genome-wide  association  studies 
have become a realistic possibility with the development of whole-genome 
association maps. 
4.6.3  Association analysis used in combination with linkage 
analysis 
Linkage operates over long distances, typically of the order of greater than 
1Mb. Association analysis operates over much shorter distances (less than 
100kb) and therefore can be used in certain situations to narrow a candidate 
region identified by linkage. However it is important to note that this is not 
always  the  case,  and  LD  may  not  be  significant  in  a  region  identified  by 
linkage  analysis.  For  example,  if  there  is  a  high  degree  of  allelic 
heterogeneity then no individual susceptibility allele will be detectable by LD   100 
with neighbouring markers. Similarly, for very old susceptibility alleles, LD in 
the region may no longer be present due to successive recombination. 
4.6.4  Candidate gene association analysis 
Association analysis can be used to test candidate genes identified on the 
basis  of  known  gene  function  and  an  understanding  of  the  disease 
pathophysiology. Intragenic SNPs are identified from SNP databases or by 
direct sequencing in a control population. The number of SNPs required to be 
tested  can  be  significantly  reduced  by  the  identification  of  the  LD  block 
structure of the region encompassing the candidate gene. Extensive blocks 
of LD are present in the human genome, at least in the Northern European 
population,  which  create  haplotypes  between  25  and  100  kb  long  (Daly, 
Rioux  et  al.  2001).    LD  blocks  are  defined  by  an  intermarker  LD  of  |D‟| 
greater than a predetermined value, commonly 0.7. An entire gene may lie 
within an LD block, or may span multiple blocks. Within an LD block, it is 
unnecessary to genotype every SNP. A subset of SNPs will represent the 
majority of the genetic variation within an LD block and can be designated as 
haplotype tagging SNPs (htSNPs). Typing the htSNPs alone will be sufficient 
to identify the common haplotypes, and will significantly reduce the amount of 
genotyping required. 
4.6.5  Whole genome association analysis 
A  genome  wide  association  study  searches  the  whole  genome  for 
susceptibility alleles with no previous assumptions about the likely location. 
This has become a practical possibility with the development of rapid, high-
throughput,  cheap  SNP  genotyping  technology  and  increasingly 
comprehensive SNP databases incorporating the LD structure of the human 
genome (e.g. dbSNP, HapMap).  Fortunately it is not necessary to genotype 
all of the approximately 11 million SNPs with allele frequency greater than 
1%. As discussed in section 4.6.4, the pattern of LD allows haplotype tagging 
SNPs to be selected that capture most of the common genetic variation in a 
region. The stronger the LD in a particular region, the less htSNPs needed to   101 
be typed to capture the variation. On the basis of the HapMap data, it is 
estimated that a few hundred thousand htSNPs will be required to cover the 
whole genome (Hirschhorn and Daly 2005).  HtSNPs are usually selected to 
detect  relatively  common  haplotypes  (frequency>5%).  Therefore  rarer 
susceptibility alleles may be missed by this approach. However rare SNPs 
with  minor  allele  frequency  <5%  still  tend  to  lie  on  a  single  commoner 
haplotype, as rare SNPs are likely to have arisen recently so that they have 
not had time to either disappear or become common, and the LD block has 
not been eroded by recombination (Hirschhorn and Daly 2005). Thus rarer 
alleles that are highly penetrant and  still account for a significant proportion 
of  the  genetic  trait  in  question  should  still  be  detectable  by  the  htSNP 
approach (Kamatani, Sekine et al. 2004). 
An alternative approach which has been suggested to reduce the number of 
SNPs  typed  is  a  sequence-based  approach.  This  targets  SNPs  in  DNA 
sequences  that  are  likely  to  be  of  functional  importance,  including  coding 
regions of genes (particularly missense SNPs), splice sites, promoter regions 
and sequences  of DNA that are highly conserved between species (Botstein 
and Risch 2003). This approach may identify susceptibility alleles of lower 
frequency than the haplotype-based approach, but would miss functionally 
important changes in non-coding or non-conserved regions. 
Several other factor need to be considered in the design of a genome wide 
association study. These include: 
i.  Sample size 
Large sample sizes are needed to detect variants of modest effect. Power to 
detect  a  significant  association  is  further  decreased  by  the  problem  of 
multiple hypothesis testing  (due  to  the  large  number of  SNPs  tested  in a 
genome-wide association study) and p-values must be corrected for this (see 
point  ii).  One  possible  strategy  for  reducing  sample  size  is  a  multistage 
approach  where  an  initial  population  is typed for all  SNPs, and  a  second 
independent  population  is  used  to  retest  only  those  SNPs  with  putative 
associations.  Another  strategy  to  increase  the  power  of  a  population  to 
demonstrate a positive association for rare susceptibility alleles is to study a   102 
founder population, one that has expanded from a bottleneck of relatively few 
individuals in the recent past (less than 100 generations). Rare alleles are 
likely  to  be  found  on  a  single  large  shared  haplotype  in  the  founder 
population, so that fewer markers need to be genotyped. 
ii.  Significance thresholds 
The  multiple  testing  performed  during  a  genome-wide  association  study 
requires  a  correction  in  p-value.  The  standard  is  a  Bonferroni  correction 
which assumes that all tests are independent: 
pcorrected = 1 -  (1-puncorrected)
n 
However this may be an over correction as it does not take into account LD 
between  markers  and  marker  redundancy.  Other  strategies  for  estimating 
statistical significance include permutation testing (where the data sets for 
the  cases  and  controls  are  repeatedly  mixed  up,  resorted  randomly  and 
retested to produce a null distribution of best test statistics for comparison 
with the best actual test result) and Bayesian approaches. 
iii.  False positives 
False positive associations can arise due to population stratification, where 
the  study  population  consists  of  more  than  one  genetically  distinct  group 
(admixture), and these subgroups are not equally represented in the cases 
and controls. Thus a difference in marker allele frequencies between cases 
and controls can simply represent the different genetic subgroups and have 
no  relationship  to  the  trait  under  study.  Population  stratification  can  be 
detected and corrected for by evaluating large numbers of unlinked markers, 
of  which  there  is  an  abundance  in  a  genome-wide  association  study 
(Pritchard, Stephens et al. 2000). Intra-familial association studies also avoid 
the  problem  of  population  stratification.  Other  sources  of  false-positive 
associations include technical artefacts and statistical fluctuations. 
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Chapter 5  Patients and Families 
5.1  Summary 
This  section  describes  the  ascertainment  and  characterisation  of  the  total 
family  resource,  in  collaboration  with  a  network  of  paediatricians  and 
paediatric neurologists in the UK and abroad.  
Criteria  for  affectedness  status  were  a  clinical  diagnosis  of  CAE  or  JAE 
according to ILAE criteria. The referring paediatrician usually made the initial 
diagnosis but confirmatory documentation of the clinical phenotype and EEG 
data were obtained in all cases. The clinical phenotype of affected individuals 
was recorded in an electronic database. This data was subjected to security 
control.  
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5.2  Family Resource 
A  resource  of  patients  and  families  with  IGE  was  previously  ascertained 
during a BIOMED 2 funded Concerted Action on Genetic Analysis of Epilepsy 
(1993-1996). This resource, which includes 78 pedigrees in which at least 
one individual has absence epilepsy, has been employed predominantly for a 
genome wide IGE screen. 
Multi-centre ethical approval for the current study was obtained through the 
North Thames Multi-centre Research Ethics Committee (reference number 
MREC/99/2/61) 
Collaboration with clinicians in both the UK and Europe has increased the 
patient resource to 299 families including 405 affected individuals (CAE, JAE 
or  AE  as  discussed  in  section  5.2).  82  families  contain  more  than  one 
affected individual. Detailed clinical information has been documented and 
DNA has been obtained from all affected individuals and, where possible, 
parents  and  unaffected  siblings.  DNA  was  also  obtained  from  a  family  in 
which absence epilepsy segregates with episodic ataxia type 2 (EA2) in an 
autosomal dominant fashion through three generations. The patient resource 
was ascertained in the following ways. 
5.2.1  Recruitment in the United Kingdom 
1.  A mailshot was sent to 322 consultant paediatricians in the North and 
South Thames Regions, identified from the Royal College of Paediatrics 
and Child Health (RCPCH) handbook (Appendix 1a). The mailshot was 
also sent to 37 consultant paediatric neurologists throughout the UK, 
identified  from  the  British  Paediatric  Neurology  Association  (BPNA) 
membership  list.  124  paediatricians  ultimately  expressed  interest  in 
collaborating and provided patients for the study.   106 
2.  Collaborations  were  established  with  neurophysiology  departments 
performing  paediatric  EEGs  throughout  the  UK  (Appendix  2).  EEG 
records were searched for reports consistent with a diagnosis of CAE or 
JAE.  A  letter  was  then  sent  to  the  referring  consultant  in  order  to 
confirm the diagnosis and to request permission to pass on information 
about the study to the family (Appendix 1b).  
3.  Details of the study including a call for patients were published in the 
BPNA newsletter in January 2002 (PART 4Chapter 17Appendix 3). A 
project  summary  was  also  circulated  at  the  BPNA  Annual  Meeting 
(PART 4Chapter 17Appendix 4). 
4.  A collaboration was established with Dr AJ Makoff and Dr L Nashef in 
the epilepsy genetics research group at the Institute of Psychiatry in 
London.  Clinical  information  and  DNA  samples  from  35  absence 
patients were contributed to this study. 
5.2.2  Recruitment outside the United Kingdom 
1.  Collaborations  were  established  with  paediatric  neurologists  and 
epilepsy  genetics  researchers  throughout  Europe  (PART  4Chapter 
17Appendix 5). Several of these originated from the Concerted Action 
on  Genetic  Analysis  of  Epilepsy  (1993-1996)  and  the  subsequent 
European  Consortium  on  the  Genetics  of  Idiopathic  Generalised 
Epilepsy. 
2.  Members of the Canadian Epilepsy Database and Registry  (CEDaR) 
agreed  to  collaborate  following  a  meeting  at  the  American  Epilepsy 
Society Annual Meeting in Seattle in 2002 (Appendix 5)    107 
5.3  Criteria for affectedness status 
Criteria  for  affectedness  status  were  a  clinical  diagnosis  of  CAE  or  JAE 
according to ILAE criteria (ILAE 1989). An additional category of absence 
epilepsy,  AE,  was  use  to  include  individuals  with  a  childhood  onset  of 
absence seizures but who did not meet the strict criteria for CAE. 
5.3.1  Childhood absence epilepsy 
Inclusion criteria: 
Brief (4 to 20 seconds, exceptionally longer) and usually frequent (tens 
per day) absence seizures (of any type except myoclonic absences)  
with abrupt and severe impairment of consciousness as predominant 
seizure type. Automatisms may occur. 
Onset between 2 and 12 years 
Generalised tonic-clonic seizures or unclassified seizures may also occur 
Seizures may persist into adulthood 
Normal neurological examination and development  
Ictal  EEG  showing  bilateral,  synchronous,  symmetrical  high  amplitude 
discharges  of  2.5-4  Hz  spike  and  double  spike  and  slow  wave 




Prominent  myoclonus  (brief  jerks  at  onset  of  absence  seizure  do  not 
exclude patient) 
Eyelid myoclonus (fluttering of eyelids during absence seizure does not 
exclude patient) 
Significant developmental delay 
Persistent or focal neurological deficit   108 
Polyspike-wave  complexes  in  the  ictal  EEG,  or  clear  evidence  of 
photosensitivity  
Clear  abnormalities  on  neuroimaging  (although  most  patients  will  not 
have had neuroimaging performed) 
 
5.3.2  Juvenile absence epilepsy 
For the purposes of this study, the following criteria were used to distinguish 
JAE from CAE: 
Onset of absences after 12 years of age 
Less frequent absences than in CAE 
A frequent association with generalised tonic clonic seizures 
Myoclonic seizures occurring not infrequently 
Ictal EEG may show polyspike-wave complexes at a frequency of 3.5Hz 
to 4.5 Hz. Photosensitivity may be present. 
5.3.3  Absence epilepsy 
Individuals were identified with many of the features of CAE and an onset of 
absence seizures below the age of 12 years, but who could not be classified 
as CAE due to certain atypical features. For the purpose of this study, these 
individuals were classified as absence epilepsy (AE). The atypical features 
included: 
  Onset of absences below the age of 2 years 
  Prominent myoclonus (other than eyelid myoclonus) as a feature of 
absence seizures 
  Prolonged absence seizures 
  Atypical EEG features including polyspike-wave complexes in the ictal 
EEG, or clear evidence of photosensitivity    109 
5.4  Recruitment procedure 
Potential  participants  were  identified  by  the  methods  above.  Whenever 
possible, initial contact with a family regarding the study was made by their 
own consultant paediatrician. A letter of invitation to participate was then sent 
together with information sheets in three versions – for adults, teenagers and 
younger  children  (Appendix  6,  Appendix  7).  All  positive  responses  were 
followed up by a phone call and, when indicated, a home visit to confirm the 
clinical  details  and  obtain  informed  consent  for  all  participating  family 
members.  Consent  forms  were  signed  by  participating  subjects  or,  when 
appropriate, parents or guardians (Appendix 8). 
5.5  Clinical data 
Clinical data was obtained in the following ways: 
1.  Direct questioning of affected individuals and family members 
2.  Direct questioning of referring clinician 
3.  Clinical documentation and correspondence from referring clinician 
4.  Description of ictal events from EEG reports including video telemetry 
where available 
Data was initially recorded in Family Clinical Data Sets (Appendix 9). It was 
then  stored  electronically  in  a  secured  Microsoft®  Access  Database.  The 
Access  database  was  organised  into  three  tables  -  Family  Investigator, 
Family Overview and Clinical Data (Table 5-1). Data could be entered using 
data  entry  forms  (Figure  5-1,  Figure  5-2).  Blank  versions  of  the  Access 
database were emailed to collaborators to enable data on their local patients 
to be entered directly on a local computer. This secured data could then be 
emailed back and added to the master database. Instructions on data entry 
were  provided  for  collaborators  (Appendix  10).  The  database  could  be 
queried to identify subgroups of subjects with particular characteristics.   110 
5.6  DNA collection 
DNA  was  obtained  from  all  participating  family  members,  including 
unaffected  parents  and  siblings.  Samples  were  collected  by  one  of  two 
methods.  
5.6.1  Venous blood sampling 
Venous EDTA blood samples were collected (5ml from children, up to 20ml 
from adults) whenever possible for the high DNA yield. A topical anaesthetic 
cream  (Emla  or  Ametop)  was  used  for  children.  For  some  local  families, 
home visits were organised to perform venepuncture. In other cases, local 
GPs or hospital  phlebotomy departments agreed to perform venepuncture 
and  the  blood  samples  were  sent  to  University  College  London  for  DNA 
extraction. Whenever possible, blood was taken at the same time as routine 
specimens  during  clinic  appointments.  Instructions  for  blood  sample 
collection and transport were provided (Appendix 11a). When blood samples 
were taken outside the UK, the blood was frozen and transported on dry ice 
or DNA was extracted locally. 
5.6.2  Buccal cell sampling 
Buccal  cells  were  obtained  using  cheek  swabs  when  venepuncture  was 
difficult  to  perform  or  family  members  were  unwilling  to  give  blood.  Five 
sterile  swabs  were  provided  for  each  individual  and  cheek  swab  kits 
(including instructions, preservative solution and stamped addressed padded 
envelopes  for  return  of  samples)  were  posted  directly  to  the  families 
(Appendix 11b).   111 




Family ID 3 digit code, one record per family
Country
Epilepsies This represents all the epilepsies/seizures in the family, each 
represented by a 2-letter code:
CA: CAE, JA: JAE, JM: JME, IG: IGE, EM: EMA, FC: Febrile 
convulsions,
PS: Photosensitive seizures, OE: Other epilepsy








Family ID 3 digit code
Individual ID 3 digit code. The usual individual IDs are: father 101, mother 102, children 201, 202, 203 etc)
Full ID 6 digit code - a combination of the family ID and the individual ID
Country














Seizures GSA:  generalised seizure, absence, GSM:  generalised seizure, 
myoclonic
GTCS:  generalised tonic-clonic seizure, FC:  febrile convulsion







Date of EEG Up to three EEGs can be recorded
Normal?













Focal abnormalities  112 








































Figure 5-2 Clinical database - screen shots showing clinical data entry forms 
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5.7  Nuclear pedigrees 
5.7.1  Pedigrees used for initial linkage analysis 
An initial cohort of 33 nuclear families was used to test 30 candidate gene 
loci  (seventeen  VDCC  subunit  genes,  ten  GABAAR  subunit  genes,  two 
GABAB receptor genes and the ECA1 locus on 8q24) by linkage analysis 
(Figure  5-3,Table  7-1).  The  families  were  ascertained  from  European 
populations  including  the  UK,  France,  Germany,  Denmark,  Finland  and 
Greece.  All  families  included  two  or  more  individuals  with  a  provisional 
diagnosis of CAE or JAE. The 33 families included 172 individuals of which 
83 were classified as affected. DNA was not available on 6 unaffected and 2 
affected individuals. Of the affected individuals, 11 did not have EEG data 
available, but otherwise had typical CAE or JAE. For this preliminary linkage 
analysis, polyspike-wave complexes in the ictal EEG (1 individual), or clear 
evidence  of  photosensitivity  (7  individuals)  were  not  used  as  exclusion 
criteria for CAE. Five individuals were classified as affection status unknown 
for the linkage analysis. Of these, 2 had generalised spike-waves on EEG but 
no clinical seizures, 2 had generalised tonic-clonic seizures only, and one 















Figure 5-3 Thirty three nuclear pedigrees used for initial linkage analysis
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5.7.2  Pedigrees used for definitive linkage analysis 
Following  the  preliminary  linkage  analysis,  candidate  gene  loci  showing 
positive linkage were tested in an expanded collection of families. Four of the 
original 33 families (families 376, 383, 398, 399) as well as 10 individuals 
from two other families (families 381, 394) were not included as new data 
became available which cast doubt on affectedness status as defined below. 
A total of 82 families were included and analysed in two ways with different 
criteria for affectedness status: 
i.   Affectedness status ‘CAE’ using strict criteria 
A cohort of 53 nuclear pedigrees included two or more first degree relatives 
with a diagnosis of CAE according to strict criteria (Figure 5-4,Table 5-2). 
Twenty-two of the original 33 families were included. The 53 families included 
275 individuals of which 120 with CAE were classified as „affected‟. Eleven 
individuals were classified as affection status „unknown‟ (two AE, two with 
spike-wave EEG but no seizures, five with a different IGE and two with no 
clinical  data  available).    DNA  was  not  available  on  19  individuals  (15 
unaffected,  2  affected  and  2  affection  status  unknown).  Additional  clinical 
information is provided in Appendix 12. 
ii.   Affectedness status ‘absence’ including CAE, JAE, AE 
A  cohort  of  82  families,  comprising  418  individuals,  included  the  53  CAE 
families. The 29 additional families (Figure 5-5, Table 5-3) comprised two or 
more first degree relatives with a diagnosis of absence epilepsy consistent 
with CAE (section 5.3.1), JAE (section 5.3.2) or AE (section 5.3.3).  The 82 
families comprised a total of 418 individuals of whom 185 were classified as 
„affected‟ (129 CAE, 28 JAE, and 28 AE). Twenty individuals were classified 
as affection status „unknown‟. DNA was not available on 29 individuals (21 
unaffected,  3  affected  and  5  affection  status  unknown).  Additional  clinical 














Figure 5-4 53 nuclear pedigrees used for definitive linkage analysis with affectedness status „CAE‟ (continued on next 
page)
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Figure 5.4 continued 53  nuclear pedigrees used for definitive linkage analysis with affectedness status „CAE‟ (continued 
from previous page)
201  202 
302  301 
101 102 
433 
202  201 
102  101 
434 
202  201 
102  101 
435 
203  202  201 
101 102 
436 
202  201 
101 102 
437 
202  201 
101  102 
442 
203  202 
101 102 
443 
201  203  202 
101 102 
445 
201  202  201 
101 102 
446 
202  201 
101 102 
447 
202  201 
102  103  101 
001 002 
450 
203  202  201 
101 102 
461 
203  202 
102  101 
466 
201  203  202 




201  204  203  202 
101 102 
529 




102  101 
577 
301 302 
201  204  203  202 
101 102 
586 
202  201 
101 102 
871 




302  301 
203  202  201 
101 202 
875 
202  201 
101 102 
877 
202  201 
101 102 
878 
202  201 
101  104  103  102 
001 002 
879 
203  202  201 
101 102 
880 
202  101  102 
202  201 
001 002 
885 



























Figure 5-5  29 additional nuclear pedigrees used for definitive linkage analysis with affectedness status „absence‟ including 
CAE, JAE, AE
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Table 5-2 Families used for CAE linkage. Only individuals with a diagnosis of 
CAE (classified „affected‟) or AE, IGE or GSWD EEG (classified „unknown‟) 
are shown. 
Family  Individual  Sex  Epilepsy  Age at onset  Seizures  EEG 
5  204  F  CAE  4  GSA  GSWD 
  207  M  CAE  5  GSA  GSWD 
26  202  M  CAE  6  GSA, FS  GSWD 
  204  F  CAE  6  GSA, FS  GSWD 
27  202  F  AE  4  GSA, GTCS  GSWD, PS 
  301  F  CAE  7  GSA, GTCS  GSWD 
  302  M  CAE  7  GSA, GTCS  GSWD 
92  102  F  IGE    GTCS   
  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
202  101  M  CAE  5  GSA, GTCS  GSWD 
  201  F  CAE  3  GSA, FS  GSWD 
  202  F  CAE  3  GSA  GSWD 
  203  F  CAE  6  GSA  GSWD 
317  201  F  CAE  5  GSA, GTCS  GSWD 
  202  M  CAE  5  GSA  GSWD 
321  101  M  CAE  9  GSA, GTCS  GSWD 
  201  F  CAE  6  GSA  GSWD 
  202  F  CAE  3  GSA  GSWD 
  204  F  CAE  3  GSA, FS  GSWD 
346  201  F  CAE  2  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
348  203  M  CAE  3  GSA  GSWD 
  206  M  CAE  3  GSA  GSWD 
353  101  M  CAE  10  GSA  GSWD 
  201  M  CAE  6  GSA  GSWD 
  202  M  CAE  9  GSA  GSWD 
358  102  F  CAE  4  GSA  GSWD 
  201  F  CAE  5  GSA  GSWD 
372  102  F  CAE  6  GSA, GTCS  GSWD 
  201  F  CAE  4  GSA  GSWD 
  202  F  CAE  5  GSA, GTCS  GSWD 
381  101  M  CAE  2-12  GSA, GTCS  GSWD 
  201  F  CAE  5  GSA  GSWD 
  202  M  CAE  5  GSA  GSWD 
  203  M  CAE  6  GSA  GSWD 
382  102  F  Unknown    None  GSWD 
  201  M  CAE  7  GSA  GSWD 
  202  F  CAE  6  GSA  GSWD 
394  301  M  CAE  7  GSA  GSWD 
  302  M  CAE  8  GSA  GSWD 
395  102  F  Unknown    None  GSWD 
  201  M  CAE  4  GSA  GSWD 
  203  M  CAE  3  GSA  GSWD 
397  102  F  CAE  5  GSA  GSWD 
  201  F  CAE  3  GSA, GTCS  GSWD 
  202  F  CAE  3  GSA  GSWD   121 
 
Family  Individual  Sex  Epilepsy  Age at onset  Seizures  EEG 
401  101  F  IGE  20  GTCS   
  201  M  CAE  4  GSA, GTCS  GSWD 
  202  F  CAE  3  GSA, GTCS  GSWD 
402  201  F  CAE  12  GSA, GTCS  GSWD 
  202  F  CAE  11  GSA  GSWD 
403  201  F  CAE  3  GSA, GTCS  GSWD 
  202  M  CAE  3  GSA, FS  GSWD 
404  101  M  IGE  20  GTCS   
  202  F  CAE  6  GSA, GTCS  GSWD 
  302  F  CAE  7  GSA  GSWD 
  303  M  CAE  7  GSA  GSWD 
  304  M  CAE  5  GSA  GSWD 
405  201  M  CAE  6  GSA  GSWD 
  202  M  CAE  3  GSA  GSWD 
407  102  F  CAE  5  GSA  GSWD 
  201  F  CAE  3  GSA  GSWD 
  202  F  CAE  5  GSA  GSWD 
421  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
422  103  M  IGE  9  GTCS   
  201  F  CAE  6  GSA  GSWD 
  202  M  CAE  12  GSA  GSWD 
432  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
433  202  F  CAE  2-12  GSA  GSWD 
  301  F  CAE  2-12  GSA  GSWD 
434  201  M  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
435  201  M  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
436  201  F  CAE  2-12  GSA  GSWD 
  202  M  CAE  2-12  GSA  GSWD 
437  201  M  CAE  2-12  GSA  GSWD 
  202  M  CAE  2-12  GSA, GTCS  GSWD 
442  201  F  CAE  2-12  GSA, GTCS  GSWD 
  202  M  CAE  2-12  GSA, GTCS  GSWD 
443  202  F  CAE  2-12  GSA  GSWD 
  203  F  CAE  2-12  GSA  GSWD 
445  202  M  CAE  2-12  GSA, FS  GSWD 
  203  F  CAE  2-12  GSA  GSWD 
446  201  M  CAE  2-12  GSA  GSWD 
  202  M  CAE  2-12  GSA  GSWD 
447  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
450  201  M  CAE  2-12  GSA  GSWD 
  202  M  CAE  2-12  GSA  GSWD 
461  201  F  CAE  2-12  GSA  GSWD 
  202  M  CAE  2-12  GSA  GSWD 
466  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
527  201  F  CAE  7  GSA  GSWD 
  202  F  CAE  3  GSA  GSWD   122 
Family  Individual  Sex  Epilepsy  Age at onset  Seizures  EEG 
529  202  F  CAE  7  GSA  GSWD 
  301  M  CAE  5  GSA  GSWD 
530  201  M  CAE  5  GSA  GSWD 
  202  M  CAE  5  GSA  GSWD 
577  201  M  CAE  10  GSA  GSWD 
  202  F  CAE  7  GSA  GSWD 
586  202  F  CAE  5  GSA  GSWD 
  301  F  AE  5  GSAmy  GPSWD 
  302  M  CAE  7  GSA  GSWD 
871  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
872  201  M  CAE  2-12  GSA  GSWD 
  203  F  CAE  2-12  GSA  GSWD 
874  102  F  CAE  2-12  GSA  GSWD 
  201  M  CAE  2-12  GSA  GSWD 
  202  F  IGE  2-12  GTCS   
875  201  F  CAE  2-12  GSA  GSWD 
  301  F  CAE  2-12  GSA  GSWD 
  302  F  CAE  2-12  GSA  GSWD 
877  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
878  201  M  CAE  2-12  GSA  GSWD 
  202  M  CAE  2-12  GSA  GSWD 
879  102  F  CAE  2-12  GSA  GSWD 
  103  F  CAE  2-12  GSA  GSWD 
  201  F  CAE  2-12  GSA  GSWD 
880  201  F  CAE  2-12  GSA  GSWD 
  202  F  CAE  2-12  GSA  GSWD 
885  102  F  CAE  2-12  GSA  GSWD 
  201  F  CAE  2-12  GSA  GSWD 
 
CAE: childhood absence epilepsy; JAE: juvenile absence epilepsy; AE: absence epilepsy; 
GSA: generalised absence seizure; GSAmy: generalised absence seizure with myoclonus; 
FS:  febrile  seizure;  GSWD:  generalised  spike-wave  discharges;  GPSWD:  generalised 
polyspike-wave discharges   123 
Table 5-3 Additional families used for 'absence' linkage. Only individuals with 
a  diagnosis  of  CAE  or  AE  (classified  „affected‟)  or  IGE  or  GSWD  EEG 
(classified „unknown‟) are shown. 
Family  Individual  Sex  Epilepsy  Age at onset  Seizures  EEG 
9  201  F  AE  4  GSAmy  GPSWD 
  202  F  AE  2  GSA, GTCS  GSWD, FD 
96  301  F  AE  7  GSA  GPSWD 
  302  M  AE  6  GSA  GPSWD 
137  101  M  IGE  18  GTCS, MS  GSWD 
  202  F  IGE  12  GTCS, MS  GSWD 
  301  F  AE  1  GSAmy  GPSWD 
  302  M  AE  1  GSAmy  GPSWD 
173  201  F  CAE  6  GSA  GSWD 
  202  F  AE  5  GSA  GPSWD 
342  201  F  AE  11  GSAmy  GPSWD 
  202  F  AE  <13  GSAmy, 
GTCS 
GPSWD 
393  201  F  CAE  8  GSA  GSWD 
  202  M  JAE  15  GSA, GTCS  GPSWD 
396  101  M  CAE  2-12  GSA  GSWD 
  201  F  AE  3  GSA  GPSWD 
  202  M  CAE  6  GSA  GSWD 
400  201  M  AE  5  GSA, GTCS  GPSWD 
  202  F  CAE  5  GSA, GTCS  GSWD 
426  103  F  AE  <13  GSA  GPSWD 
  201  F  CAE  6  GSA  GSWD 
429  101  M  AE  <13  GSA  GPSWD 
  203  F  AE  <13  GSA  GPSWD 
430  202  F  AE  <13  GSA  GPSWD 
  301  M  AE  <13  GSA  GPSWD 
431  201  F  JAE  13+  GSA, FS  GPSWD 
  202  F  JAE  13+  GSA,  FS, 
GTCS 
GPSWD 
438  201  F  JAE  13+  GSA, GTCS  GPSWD 
  301  F  JAE  13+  GSA, GTCS  GPSWD 
  302  M  JAE  13+  GSA, GTCS  GPSWD 
439  201  F  JAE  13+  GSA  GPSWD 
  202  F  JAE  13+  GSA, GTCS  GPSWD 
440  202  F  CAE    GSA  GSWD 
  203  M  JAE  13+  GSA  GPSWD 
441  202  F  CAE  2-12  GSA  GSWD 
  203  M  JAE  13+  GSA  GPSWD 
444  201  M  AE  <13  GSA  GPSWD 
  202  M  AE  <13  GSA  GPSWD 
448  201  M  AE  <13  GSA, FS  GPSWD 
  202  M  AE  <13  GSA  GPSWD 
449  201  F  JAE  13+  GSA, GTCS  GPSWD 
  202  F  JAE  13+  GSA  GPSWD 
451  202  F  JAE  13+  GSA, FS  GPSWD 
  203  F  JAE  13+  GSA  GPSWD 
452  995  M  AE  <13  GSA  GPSWD 
  996  F  AE  <13  GSA  GPSWD   124 
Family  Individual  Sex  Epilepsy  Age at onset  Seizures  EEG 
525  201  F  AE  10  GSA  GPSWD 
  202  F  AE  12  GSA, GTCS  GSWD 
  203  F  CAE  6  GSA  GSWD 
528  101  M  IGE  11  GSA, GTCS   
  204  F  AE  5  GSA  GPSWD 
  301  M  IGE  2  GSA, GTCS  Non-specific 
abnormalities 
  302  M  AE  1  GSA  GSWD 
873  101  M  JAE  2-12  GSA  GPSWD 
  201  F  JAE  2-12  GSA  GPSWD 
  202  F  JAE  2-12  GSA  GPSWD 
876  201  M  JAE  2-12  GSA  GPSWD 
  202  F  JAE  2-12  GSA  GPSWD 
881  201  M  JAE  2-12  GSA  GPSWD 
  202  F  JAE  2-12  GSA  GPSWD 
  203  M  JAE  2-12  GSA  GPSWD 
882  201  M  JAE  2-12  GSA  GPSWD 
  202  M  JAE  2-12  GSA  GPSWD 
883  201  F  JAE  2-12  GSA  GPSWD 
  202  F  JAE  2-12  GSA  GPSWD 
884  201  F  JAE  2-12  GSA  GPSWD 
  202  F  JAE  2-12  GSA  GPSWD 
 
CAE: childhood absence epilepsy; JAE: juvenile absence epilepsy; AE: absence epilepsy; 
GSA: generalised absence seizure; GSAmy: generalised absence seizure with myoclonus; 
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5.8  Additional  parent-child  trios  used  for  association 
analysis 
Two hundred and seventeen additional parent-child trios were ascertained. 
Each trio comprised an affected child (204 CAE, 5 JAE and 8 AE) and two 
parents (2 CAE, 1JAE, 4 IGE, 427 unaffected). See Appendix 13 for clinical 
details. The complete cohort of pedigrees and trios was used for association 
analysis using intragenic SNPs, as described in Chapter 9.   126 
5.9  Family with absence epilepsy and episodic ataxia 
A collaboration was established with Dr SL Jaffe, Department of Neurology, 
Louisiana  State  University  School of  Medicine,  Shreveport,  USA.  Dr  Jaffe 
identified a North American family in which six members in three generations 
exhibited  a  typical  primary  generalized  3Hz  spike-wave  EEG  abnormality 
(Table 5-4, Figure 5-6)(Imbrici, Jaffe et al. 2004). Five of these individuals 
exhibited  clinical  absence  epilepsy  with  variable  degrees  of  episodic  and 
anticonvulsant drug induced cerebellar ataxia (AEA). 
One  individual  had  a  typical  3Hz  spike–wave  EEG  but  had  no  clinical 
phenotype,  and  was  neurologically  normal  (individual  319).  Dr  Jaffe  had 
previously performed clinical, EEG and in some cases brain imaging on 11 
genetically related individuals and one non-blood relative who had married 
into the family.  
Two individuals were characterised in detail: 
Individual  210  was  diagnosed  with  EA2  with  absence  epilepsy.  She 
presented at the age of 39 years with a history of „dizzy‟ attacks from her 
teenage years. A typical attack consisted of sudden onset disequilibrium with 
associated headache and nausea, lasted between one and eight hours and 
could  be  precipitated  by  stress  and  anxiety.  There  was  also  a  history  of 
vacant episodes suggestive of absence seizures from late childhood which 
subsided in adult life. Typically these episodes lasted a few seconds with 
immediate  recovery,  but  on  some  occasions,  there  were  more  prolonged 
atypical  absence  episodes.  On  one  occasion  a  prolonged fugue-like  state 
lasting  several  hours  was  accompanied  by  generalized  3  Hz  spike–wave 
discharges. MRI brain scan demonstrated cerebellar vermian atrophy. Her 
symptoms remitted on a combination of acetazolamide and carbamazepine, 
although the ataxia was worsened by increased drug levels. 
Individual  320  presented  with  a  more  severe  younger  onset  phenotype 
similar  to  the  case  of  EA2/epilepsy  reported  by  Jouvenceau  et  al.   127 
(Jouvenceau, Eunson et al. 2001). Typical brief absence seizures developed 
from age 4 years. Early motor milestones were delayed and he had learning 
difficulties. An initial EEG showed a generalised polyspike–wave abnormality; 
further  EEGs  demonstrated  generalized  3  Hz  spike–wave  discharges. 
Seizures were difficult to control, and AEDs such as phenytoin at low doses 
would precipitate cerebellar ataxia with impaired consciousness at times. On 
one occasion, he developed extreme cerebellar ataxia and a decreased level 
of consciousness. Examination at the age of 10 years revealed moderate 
cerebellar signs.  
 
Table 5-4 Family with absence epilepsy and ataxia 
Individual  Sex  Age at onset  Seizures  Ataxia  EEG 
102  F  Teens  AS  EA, CA  3Hz SWD 
208  F  57  -  CA  3Hz SWD 
210  F  13  AS  EA  3Hz SWD 
212  F  10  AS  EA, CAA  3Hz SWD 
319  M  -  -  -  3Hz SWD 
320  M  4  AS  EA, CA, CAA  3Hz SWD 
           
AS:  absence  seizures;  CA:  clinical  signs  of  cerebellar  ataxia;  CAA:  significant 
worsening of cerebellar ataxia on exposure to AEDs; SWD: spike-wave discharges 
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Chapter 6  Laboratory Methods 
6.1  Summary 
 
This chapter outlines the laboratory methodology employed from the arrival 
of the blood and buccal samples to the evaluation of the results. Standard 
solutions for molecular biological work were used. 
Departmental laboratory procedures had previously been standardised and 
included the following criteria: 
1.  A copy of the departmental laboratory safety document was received 
and relevant safety issues were noted.  
2.  Sterile disposable gloves and white coats were worn at all times 
3.  Care was taken to ensure the accurate labelling of samples.  
4.  Standard precautions were taken to minimise the possibility of DNA 
contamination.  
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6.2   Genomic  DNA  extraction  from  whole  blood  (Miller, 
Dykes et al. 1988) 
5-20 ml blood samples were obtained and added to 50-200l 0.34M EDTA or 
acid  citrate  dextrose  (ACD).  EBV  transformed  lymphocyte  cell  lines  were 
established at CAMR Porton Down using blood samples from a subset of 
affected individuals (Appendix 14).  
On  arrival  in  the  laboratory  blood  samples  were  decanted  into  a  50  ml 
labelled conical tube (Falcon) and centrifuged at 4
oC for 15 minutes at 1750g 
in an MSE Mistral 61 centrifuge. The plasma and cell fractions were then 
separated. DNA extraction was performed immediately on the cell fraction 
where possible, or else this was stored at -20
oC and thawed when required. 
The solutions and protocol used for DNA extraction are described below: 
Solution 1: 
To make up 1 litre of concentration X3 
10mls       1M Tris HCL 
1.02g       MgCl2 ( 5ml 1M ) 
10mls       Triton X  - 100 
109.54g     Sucrose 
0.2g       Sodium Azide 
Make up to 1 Litre with distilled water. 
 
Solution 2:  
To make up a litre of 1X concentration 
50mls     1M Tris HCL 
40mls      0.5M EDTA 
20g or 200mls   10% SDS 
 
Solution 3 
This is a supersaturated NaCl solution.  
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Stratagene method for DNA extraction from whole blood 
1.  The blood samples were thawed where necessary and made up to 45-50 mls with 
distilled water. These solutions were left on ice for 5 minutes and then centrifuged at 
approximately 1500g for 15 minutes at 4oC.  
2.  The supernatants were removed by pouring gently to leave around 10mls. 
3.  15ml of (3X) Solution 1 and 30 ml of distilled water were added and the samples 
mixed thoroughly to disperse pellet. 
4.  The samples were incubated on ice for 2 minutes. 
5.  The samples were centrifuged at approximately 1500g at 4 
oC for 15 minutes. 
6.  The supernatants were removed by pouring gently to leave a light pink  pellet.  If a 
dark red pellet was present steps 1 - 4 were repeated.  
7.  The pellets were resuspended in 11 mls of solution 2 and vortexed vigorously. 
8.  Pronase was added to yield a final concentration of 100g/ml. 
9.  The samples were incubated at 60 o C with shaking for 1 hour or 37 
oC overnight. 
10.  The tubes were incubated on ice for 10 minutes. 
11.  4ml of Solution 3 was added to each sample and the tubes were inverted several 
times to mix.  
12.  The samples were incubated on ice for 5 minutes. 
13.  The samples were centrifuged at approximately 1500g for 15 minutes at 4
oC. 
14.  The supernatants were transferred using a large bore pipette to sterile 50ml conical 
tubes that were labelled with the sample codes.  
15.  RNase was added to yield a final concentration of 20g/ml. 
16.  The samples were incubated at 37
oC for 15 minutes. 
17.  Adding two volumes of 100% ethanol precipitated the DNA.  
18.  The DNA was removed by spooling out with a glass rod (or by centrifuging gently to 
leave a DNA pellet ) 
19.  The DNA was rinsed on the rod in 70% ethanol and dried by briefly in air. 
20.  The DNA was resuspended in 500g of Tris - EDTA buffer and stored at 4
oC. 
21.  Stock DNA was stored at -20
oC and working concentrations of 10ng/l were made 
using sterile distilled water and stored at 4
oC. 
 
The  initial  supernatant  was  kept  until  it  was  confirmed  that  DNA  had  been  isolated.  A 
modified Stratagene method, using smaller solution volumes, was used to extract DNA from 
small blood volumes (1-2ml). On occasions when DNA was not isolated a DNA extraction kit 
(Pharmacia Biotech) was used to isolate small amounts of DNA from the supernatant.    
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The  chloroform  phenol  extraction  method  outlined  below  was  used  to 
improve the purity of DNA when necessary.  
1.  One volume of phenol was added to each DNA sample 
2.  The sample was centrifuged at high speed for 2 minutes.  
3.  The  upper  phase  was  pipetted  into  a  separate  clean  eppendorf  and  the  phenol 
phase was discarded into the phenol waste bucket. 
4.  One  volume  of  chloroform:isoamyl  alcohol  (CHCL3.IAA  24:1)  Was  added  to  the 
sample 
5.  The sample was centrifuged at high speed for 1 minute. 
6.  The upper phase was pipetted into a clean eppendorf and the phenol phase was 
discarded into the chloroform / phenol waste bucket. 
7.  1/10th of a volume of 3MNaOAC pH 5.2 was added to the sample. 
8.  Two volumes of 100% Ethanol were added to precipitate the DNA. 
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6.3  Genomic DNA extraction from buccal cells  
The  cheek  swabs  were  stored  in  a preservative  solution  of 0.05M  EDTA, 
0.5% SDS. If extraction could not be performed within 10 days, the swabs 
were frozen at -20
 oC and thawed for DNA extraction. 
Cheek  swab  DNA  extraction  method  (provided  by  Dr  Mark  Thomas,  Department  of 
Biology, UCL): 
1.  To each cheek swab in its  EDTA/SDS  solution, 0.8 ml of water/proteinase K mix (40µl 
of 10 mg/ml proteinase K in  20 ml of sterile distilled water) was added and incubated at 
56C  for between 30 and 60 minutes minimum (samples could be incubated for up to 3 
hours). 
2.  0.6 ml of a phenol/chloroform (1:1) mix was placed in each of 24 numbered microfuge 
tubes in a rack. 0.8 ml of the EDTA/SDS solution from the cheek swab collection tube 
was  added  to  the  numbered  microfuge  tubes  containing  the  phenol/chloroform.  The 
remaining cheek swab solution was stored at -20
oC. 
3.  Samples were mixed and centrifuged for 10 minutes at maximum speed in a microfuge. 
4.  0.6 ml of chloroform and 30 µl of 5 M NaCl were placed in each of 24 clean microfuge 
tubes in a rack. The aqueous (upper) phase from the centrifuged sample tubes was 
transferred  into  the  numbered  microfuge  tubes  containing  chloroform  and  5M  NaCl 
(care was taken to avoid transferring any of the white material at the interface between 
the two phases of the phenol/chloroform). 
5.  Samples were mixed and centrifuged for 10 minutes at maximum speed in a microfuge. 
6.  0.7 ml of chloroform was placed in each of 24 clean microfuge tubes in a rack. The 
aqueous  (upper)  phase  from  the  centrifuged  sample  tubes  was  transferred  into  the 
numbered microfuge tubes containing chloroform (care was taken to avoid transferring 
any of the white material at the interface between the two phases). 
7.  Samples were mixed and centrifuged for 10 minutes at maximum speed in a microfuge. 
8.  0.7 ml of isopropanol was placed in each of 24 clean screw top-microfuge tubes in a 
rack. The aqueous (upper) phase from the centrifuged sample tubes was transferred 
into the numbered microfuge tubes containing  isopropanol (care was taken to  avoid 
transferring any of the white material at the interface between the two phases). 
9.  The microfuge tubes were mixed and placed in a freezer for at least 2 hours (samples 
could be stored in this state indefinitely). 
10. The microfuge tubes were centrifuged for 12 minutes at maximum speed in a microfuge.   134 
11. The supernatant was carefully poured from the sample tubes and allowed to drain by 
placing the tube inverted at a 45˚ angle on some tissue paper for about 1 minute. This 
left the precipitated DNA stuck to the walls of the screw-top microfuge tubes. 
12. To each sample tube, 0.8 ml of 70 % ethanol was added and the tubes were centrifuged 
for 10 minutes at maximum speed in a microfuge (with the tubes are orientated so that 
the DNA pellet was outermost in the centrifuge rotor).  
13. The supernatant was carefully poured from the sample tubes and allowed to drain by 
placing the tube inverted at a 45˚ angle on some tissue paper for about 20 mins. This 
left the precipitated DNA on the walls of the screw-top microfuge tubes. 
14. To each sample tube, 200 µl of TE (pH 9.0) was added. The tubes were incubated at 
56˚C for 10 min in a water bath, mixing occasionally. They were then centrifuged briefly 
and stored at -20˚C. 
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6.4  Quantitation of DNA 
Two  methods  of  DNA  quantitation  were  used:  spectrophotometry  and 
PicoGreen fluorescence. 
6.4.1  Spectrophotometry 
The quantity of genomic DNA that had been isolated was estimated using an 
M3 02 Spectrophotometer (Cam-Spec Ltd). The DNA was diluted to 1:200 
and  the  optical  density  (OD)  of  this  solution  was  then  obtained  at  a 
wavelength of 260nm and 280nm.  
At 260nm a reading of 1 OD corresponds to a DNA concentration of 50g/ml. 
The concentration of the stock DNA could therefore be calculated using the 
formula: 
DNA concentration in g/ml = OD260nm X 50 X 200  g/ml 
The  concentration  of  DNA  obtained  ranged  from  50g/ml  (50ng/l)  to 
500g/ml (500ng/l) indicating a total yield of DNA between 25g and 250g. 
The  stock  DNA  was  then  diluted  to  make  working  DNA  samples  of  5-
10ng/ml. The stock DNA was stored at -20
oC and the working DNA samples 
were stored at 4
oC. 
The purity of the DNA sample was also measured by calculating the ratio 
OD260nm/OD280nm. Acceptable values for this ratio lie between 1.8 and 
2.0. Values below this prevent accurate quantification of the concentration of 
nucleic  acid  and  in  these  situations  the  DNA  sample  was  further  purified 
using a chloral/phenol extraction method as detailed above. 
6.4.2  PicoGreen fluorescence 
PicoGreen  is  a  fluorescent  dye  that  undergoes  a  marked  fluorescence 
enhancement upon binding to double-stranded DNA (dsDNA). This can be   136 
measured  using  a  microplate  fluorometer,  and  is  an  accurate  method  for 
determining dsDNA concentrations in solution (Singer, Jones et al. 1997). In 
collaboration with Professor Paul Mckeigue at the London School of Hygiene 
and Tropical Medicine, DNA quantitation was performed on samples in a 96-
well plate format using a an automated fluorometer. 
6.5  Whole genome amplification 
For samples where the yield of DNA was very low, or where most of the 
stored DNA had been used previously, whole genome amplification was used 
to  increase  the  DNA  available.    The  method  of  multiple  displacement 
amplification  (MDA),  which  uses  Phi29  DNA  polymerase  and  random 
exonuclease  primers  to  synthesize  high  fidelity  genomic  DNA,  has  been 
shown  to  yield  an  average  DNA  product  >  10  kb  in  length  with  relatively 
uniform amplification across the genome and an error rate of 1 in 10
6–10
7 
(Esteban, Salas et al. 1993; Dean, Hosono et al. 2002). The DNA generated 
is  an  accurate  representation  of  genomic  DNA  when  used  for  SNP 
genotyping (Tranah, Lescault et al. 2003). 
Whole  genome  amplification method using  the TempliPhi Amplification  Kit 
(Amersham Biosciences Piscataway, NJ) (Tranah, Lescault et al. 2003): 
1.   1 μl DNA was diluted in 5 μl sample buffer in 0.2 ml tubes 
2.   Samples were incubated for 3 min at 95C and then placed on ice.  
3.  5 μl reaction buffer and 0.2 μl enzyme mix were added to each sample 
in 10 μl reactions.  
4.  DNA samples were incubated for 6 h at 30 ◦C.  
5.  After incubation, samples were heated to 65 ◦C for 10 min to inactive 
the enzyme. 
 
DNA was quantified as described above. 
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6.6  Genotyping 
6.6.1  Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was used to amplify genomic DNA for 
genotyping.  Fluorescently  labelled  primers  were  selected  to  amplify  DNA 
sequences encompassing simple sequence length polymorphisms (SSLPs).  
SSLPs were selected to encompass candidate genes, and were identified 
from genetic databases such as Genethon and the UCSC Genome Browser. 
Novel  SSLPs  were  identified  from  the  publicly  available  genomic  DNA 
sequence and custom primers were designed using Primer3 software from 
the  Whitehead  Institute  for  Biomedical  Research  (Rozen  and  Skaletsky 
2000)(Appendix  15).  Commercially  available  primers  were  obtained  from 
Research  Genetics.  Custom  labelled  primers  were  obtained  from  MWG 
Biotech  UK  Ltd.  Primers  were  fluorescently  labelled  with  one  of  three 
fluorescent dyes (HEX,TET and FAM) which appear as yellow, green and 
blue respectively under the ABI laser filter conditions used.  
A  15  l  standard  reaction  volume  used  for  genotyping  and  each  reaction 
mixture contained 25-50ng of DNA (5-10l). DNA samples for amplification 
were pipetted into wells of a 96 well microtitre plate (Hybaid). A mastermix 
incorporating the remaining ingredients of the reaction was then added using 
a dedicated DNA free pipette. The mastermix comprised: 
                Final Concentration 
PCR Buffer X 10 (Gibco)    1.5l        1X 
MgCl2  50mM  (Gibco)     0.6l        2.0mM 
dNTPs 25mM        0.3l        0.5mM 
Forward Primer (8M)      0.5l        0.25M 
Reverse Primer (8M)      0.5l        0.25M 
Taq (5units/l)        0.05l        0.25units 
Sterile distilled water      1.55-6.55l 
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The  PCR/mastermix  mixture  was  covered  with  one  drop  of  mineral  oil 
(Sigma) to prevent evaporation. The microtitre plate was protected with a thin 
self adhesive film and placed on an Omnigene thermocycler (Hybaid).  
The standard PCR protocol for the thermocycler is as follows: 
1 cycle: 
Denaturation  94oC    1 min 30 seconds 
Annealing  55oC    30 seconds 
Extension  72oC    30 seconds 
 
30 cycles:                   
Denaturation  94oC    30 seconds 
Annealing  55oC    30 seconds 
Extension  72oC    30 seconds 
 
1 cycle:               
Denaturation  94oC    30 seconds 
Annealing  55oC    30 seconds 
Extension  72oC    2 minutes 
                   
  
Gel  electrophoresis  was  used  to  assess  the  success  of  the  PCR.  This 
enabled the PCR products to be visualised under ultraviolet light (Figure 6-1). 
The process comprised: 
1.  5l of the PCR product was added to 3l of bromophenol blue loading 
buffer 
2.  The fragments were separated by electrophoresis at 100 volts on a 2% 
agarose minigel in 1XTBE buffer.  
3.  The  gel  was  stained  with  ethidium  bromide  and  visualised  under 
ultraviolet light.  
4.  A standard 1kb ladder was used to confirm that the correct size product 
had been amplified. 















Figure 6-1 Agarose Gel showing size marker and amplified DNA fragments 
 
In situations where a specific product of the correct size was not identified the 
PCR was optimised by varying the annealing temperature or by performing a 
magnesium titration.  
Once  a  PCR  product  had  been  successively  amplified  the  96  well  plates 
were stored at 4
oC.  
Wells for loading PCR product/ 
bromophenol blue gel mix 
Absent band indicating 
failed PCR 
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6.6.2  Polyacrylamide gel electrophoresis 
Allele  sizing  of  the  PCR  products  was  performed  by  electrophoresis  on a 
denaturing  6%  Polyacrylamide  gel.  A  Sequagel  reagent  kit  (National 
Diagnostics) was used to prepare the gel mix as follows: 
32ml     Sequagel 6 mix  
8ml     Sequagel buffer  
300ml     10% Ammonium Persulphate  
 
The glass plates were washed, rinsed with distilled water and allowed to dry 
before  being  assembled  according  to  the  manufacturer‟s  instructions  using 
0.4mm spacers. The polyacrylamide solution was poured between the glass 
plates using the sliding plate method and the sharks tooth comb inserted. The 
gel was then left to polymerise for 2-3hours.  
The  polymerised  gel  was  loaded  into  the  ABI  373  and  a  plate  check 
performed  to  establish  that  the  plates  and  polyacrylamide  were  free  from 
contamination. Freshly diluted 1X TBE buffer was prepared and added to the 
two buffer chambers placed at the bottom and the top of the gel plates prior 
to running the gel electrophoresis (Figure 6-2). 


















Figure 6-2 Polyacrylamide gel loaded into ABI373 sequencer 
Lane loaded with PCR product/ 
TAMRA/buffer mix 
Polyacrylamide 
gel between glass 
plates 
Buffer 
Buffer   142 
6.6.3  Allele detection 
Allele  detection  was  performed  on  an  Applied  Biosystems  373A  semi-
automated sequencer (ABI373A) with GENESCAN software (Perkin Elmer). 
The main elements of allele detection were as follows. 
1.  The ABI373A can allow the simultaneous analysis of between 36 and 
64 lanes. In general, a 48 well polyacrylamide gel was prepared. 
2.  Each lane can potentially contain up to 24 different markers. Typically 
5-6  PCR  products  were  loaded  together  in  each  lane.  The  PCR 
products  to  be  analysed  were  pooled  together  according  to  their 
fluorescent label and allele sizes (Table 6-1). 
3.  A DNA size standard labelled with TAMRA was used. This shows up 
as red under standard laser filter conditions.  
4.  Each lane was loaded with a pooled aliquot containing: 0.1-0.2 ml of 
each  PCR  product;  0.5l  of  500-TAMRA  standard;  4l  of  blue 
formamide buffer (5 parts deionised formamide, 1 part 25mM EDTA 
containing 50 mg/ml blue dextran). The pooled PCR products were 
denatured  at  94
oC  for  3  minutes  before  being  placed  on  ice  and 
loaded into the wells.  
5.  Gel  electrophoresis  was  used  to  separate  the  PCR  products.  The 
Genotyping  gels  were  run  under  standard  conditions  using 
GENESCAN software for 3-5 hours at 620 volts using filter set B. 
6.  Laser  based  technology  was  used  to  size  the  PCR  products  in 
comparison to the standard (Figure 6-3).  
7.  Once  the  GENESCAN  run  was  completed  the  information  was 
extracted  from  the  gel  using  the  GENESCAN  and  GENOTYPER 
software as described below.   143 
 Table 6-1 Example of microsatellite pool in a genescan 
LOCUS  ASSAY  LABEL  SIZE 
D3S3582  AFMa231xe9  HEX  220-236 
D3S1588  AFM287yd9  TET  212-236 
D3S1289  AFM198yf2  FAM  197-215 
D1S212  AFM212xb10  TET  105-125 















Figure  6-3:  Genotyper  gel  comparing  allele  sizes  to  marker  sizes.  The 
yellow,  green  and  blue  fluorescent  dyes  indicate  the  DNA  fragments  that 
have been amplified. These are sized by comparison to the size standard 
that is labelled in red.   144 
GENESCAN (Applied Biosystems) program.  
The details of the TAMRA labelled molecular weight standard were entered. 
The fluorescently labelled PCR product alleles in each lane of the gel were 
aligned  with the TAMRA  standard and the allele  size  information  contained 
within each lane extracted. GENESCAN uses the size standard to calculate the 
allele sizes of the PCR products. The GENESCAN algorithms automatically 
identify and size each PCR product peak relative to the internal size standard, 
as well as providing peak area and peak height information. This data can then 
be imported into GENOTYPER for further analysis. 
GENOTYPER (Applied Biosystems) program. 
The  GENOTYPER  software  uses  the  size  and  fluorescent  labelling 
characteristics of each SSLP marker to analyse the data from the genescan 
gel.  The  results  for  each  marker  can  be  viewed  in  the  form  of  an 
electropherogram, The allele sizes for each marker are calculated and output 
in tabular form, and can be checked manually against the electropherograms 









Figure 6-4 Allele Sizes. The x axis represents allele size and the y axis the 
intensity of the fluorescence recorded.  145 
6.7  Single nucleotide polymorphism analysis 
Several  methods  for  SNP  typing  were  explored,  including  melting  curve 
analysis  of  SNPs  (McSNP
®)  (6.7.1),  TaqMan
®  (section  6.7.1), 
Pyrosequencing
® (section 6.7.3) and Amplifluor
® (section 4.3.8). Initial SNP 
typing  by  Taqman  and  Pyrosequencing  was  performed  by  the  SNP 
genotyping  services  at  MRC  Geneservice,  HGMP.  The  majority  of  SNPs 
were typed by KBiosciences (http://www.kbioscience.co.uk) using Amplifluor
® 
and TaqMan
® chemistries.  
6.7.1  McSNP  
McSNP combines restriction enzyme digestion with melting curve analysis 
(Figure  6-5).    Restriction  enzyme  digestion  is  used  to  discriminate  SNP 
alleles by selectively cleaving DNA.  In the instances where a SNP does not 
cause a restriction enzyme site difference (approximately 50% of SNPs), a 
restriction site for one of the SNP alleles can be introduced by designing one 
of  the  PCR  primers with  a  mismatch  near the  3‟ end. This increases  the 
proportion of SNPs suitable for restriction enzyme analysis to about 98%. 
Melting  curve  analysis  is  a  technique  for  detecting  double-stranded  DNA 
fragments of varying lengths. The melting temperature, Tm, of a particular 
fragment is dependent on the fragment length, sequence composition, and 
GC content. The DNA fragments are slowly heated in the presence of a DNA 
intercalating dye, SYBR Green I, which fluoresces in the presence of double 
stranded  DNA.  When  the  melting  temperature  of  a  particular  fragment  is 
reached,  the  fluorescence  decreases.  Real-time  fluorescent  monitoring  is 
performed with a DASH machine (section 4.3.6) which produces a melting 
curve for the DNA fragments in the sample. The pattern of melting curve 
peaks  reflects  the  DNA  fragments  present.    McSNP  is  suited  for  high-
throughput SNP genotyping.  
In  collaboration  with  Professor  Paul  Mckeigue  at  the  London  School  of 
Hygiene  and  Tropical  Medicine,  attempts  were  made  to  establish  an   146 
automated  SNP  genotyping  facility  using  the  McSNP  protocol,  with  a 
software  package  and  DASH  machine  from  ThermoHybaid.  Despite 
significant  time  and  effort  spent  on  this  project,  unfortunately  several 
problems were encountered which ultimately led to alternative SNP typing 
methods being used. The main problems were as follows: 
1.  Robot malfunction. Two robots were installed for automated handling 
of DNA samples and reagents in 96 well plate formats. Software and 
hardware problems resulted in prolonged robot malfunction. 
2.  Assay  design  software.  Software  was  provided  by  Hybaid  to 
identify/create  restriction  sites  for  differentiating  SNP  alleles  and  to 
design PCR primers. This software never functioned successfully and 
was unable to design assays for the majority of SNPs. 
3.  SNP assays that were successfully designed were run on the DASH 
machine, but the melting curves obtained could not differentiate the 
SNP alleles. 
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6.7.2  TaqMan 
TaqMan  uses  the  principle  of  fluorescence  resonance  energy  transfer 
(FRET),  as  described  in  section  4.3.7.  The  TaqMan  assay  involves 
alternative  allele-specific  probes  which  are  used  during  PCR  amplification 
(Figure 6-6). Each probe is doubly labelled with a 3‟ fluorescent reporter and 
a 5‟ universal quencher. During the annealing phase of the PCR reaction the 
probe hybridises to the target DNA, and during the extension phase, the 5‟-3‟ 
exonuclease  activity  of  Taq  DNA  polymerase  degrades  only  perfectly 
matched, annealed probes which separates the quencher from the reporter 
and  produces  fluorescence.    Mismatched  probes  are  displaced  from  the 



















Figure 6-6 TaqMan SNP genotyping 
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6.7.3  Pyrosequencing 
Pyrosequencing  detects  the pyrophosphate which  is released  whenever a 
dNTP is incorporated during primer extension (Figure 6-7). A primer is used 
that  anneals  to  the  target  DNA  immediately  adjacent  to  the  SNP.  Primer 
extension  by  DNA  polymerase  only  occurs  with  the  nucleotide 
complementary  to  the  nucleotide  at  the  site  of  the  SNP.  The  released 
pyrophosphate triggers enzymatic conversion of luciferin to oxyluciferin which 
generates  visible  light.  The  four  nucleotides  are  sequentially  added  and 
degraded by apyrase to determine short DNA sequences flanking a SNP (or 
several closely spaced SNPs). 
In this study pyrosequencing was used predominantly for validation of novel 










Figure 6-7 Pyrosequencing reaction 
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6.8  Sequencing of Candidate Genes 
Exonic  DNA  and  surrounding  intronic  and  promoter  sequence  DNA  of 
CACNG3 was sequenced in a subset of affected individuals. The genomic 
sequence  had  been  published  previously.  Primers  were  designed  for 
amplification of the selected sequences using Primer3 software (Table 6-2). 
PCR conditions were optimised for each pair of primers. The thermocycler 
conditions were as outlined previously (section 6.6.1).  
 
Table  6-2  PCR  primers  used  to  amplify  CACNG3  exons  for  sequencing 
Primers  were  designed  using  Primer3  software  http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi.  The  PCR  products  for  CACNG3EX1A  and 
CACNG3EX1B overlap by 69 bp. The PCR products for CACNG3EX4A and 
CACNG3EX4B overlap by 85 bp.  
Primer Name  Exon  Forward  Reverse 
Product 
size (bp) 
Exon  size 
(bp) 
CACNG3EX1A(F/R)  1a  aagcagacctaacttcacctgc  aggtccgtggtgctgaag  968  1411 
CACNG3EX1B(F/R)  1b  aagcctaggcgttaagacga  ctccaaacacccaccagaat  992 
CACNG3EX2(F/R)  2  gttgatgactgatcccgttg  atgatcctcccaccttagcc  951  84 
CACNG3EX3(F/R)  3  agaatgggcgtttgagagc  atgagggtctcactgtgctg  964  141 
CACNG3EX4A(F/R)  4a  ggcagaggcgtgtatcttgt  ccatgcaacctcagagacat  948 
1064 
CACNG3EX4B(F/R)  4b  cccgtctgaactgacctctg  aactctgtggaggagagtgct  918 
 
6.8.1  Purification of PCR products 
Amplified PCR products were purified using the Quiagen PCR Purification Kit. 
This utilises a column containing a silica gel membrane which binds DNA in 
high-salt  buffer  and  elutes  the  DNA  with  low-salt  buffer  or  water.  This 
purification  procedure  removes  primers,  nucleotides,  enzymes,  mineral  oil, 
salts, agarose, ethidium bromide, and other impurities from DNA samples. The 
Kit was used according to the manufacturer‟s instructions. 
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6.8.2  Dideoxy-DNA sequencing 
The majority of sequencing was carried out on an automated ABI 377 DNA 
sequencer by the sequencing service at the Advanced Biotechnology Centre 
(ABC), Imperial College London. Sequencing was also performed at UCL on 
the ABI 373 sequencer. In both cases the dideoxy-DNA sequencing method 
was used, as described in section 4.3.3. 
6.8.3  Sequencing using ABI 373A 
1.  Sequencing  kit.  The  TaqFS  Dye  Terminator  Cycle  Sequencing  Kit 
(Perkin Elmer) was used. The kit contains AmpliTaq DNA Polymerase 
FS,  dNTPs,  dideoxynucleotide  terminators and  buffer in  a  premix  and 
was used according to manufacturer‟s instructions.  
2.  Sequencing cycle. The sequencing cycle was performed using a Cetus 
thermocycler (Perkin Elmer) with the following settings: 
25 cycles: 
Denaturing 96
oC   for 30sec 
  Annealing  50
oC   for 15sec 
  Extension  60
oC  for 4 minutes 
  Hold  4
oC 
 
3.  Purification  of  products.  The  products  were  purified  using  ethanol 
precipitation and the pellets were re-suspended in a blue dextran loading 
buffer.  Pellets were stored at –20
oC prior to being re-suspended in loading 
buffer if necessary.  
4.  Sequencing  gel.  The  sequencing  gel  was  prepared  from  the  following 
ingredients: 
Urea          30g 
40% Acrylamide (Bio Rad)      9ml 
dd.H2O          23ml 
Amberlite mixed bed resin      0.5g 
10% Ammonium persulphate    300l 
TEMED          33l   153 
The urea, acrylamide, amberlite mixed bed resin and distilled water were 
mixed together at room temperature for 30 minutes before being filtered 
through  a  0.2  micron  cellulose  acetate  filter  and  degassed.  The  TBE, 
ammonium persulphate and TEMED were then added to this solution to 
enable polymerisation and the gel was poured between the sequencing 
plates. The gel was then left to set for 2-3hours.  
 
5.  Gel electrophoresis. ABI sequencing software was used. Prior to sample 
loading, the gel was pre-run for 1 hour in the ABI 373a using 1X TBE 
buffer.  A comb with the required number of lanes was inserted into the 
gel and the DNA sample for sequencing was loaded. The Gel was run 
overnight for 12 hours using filter set A. 
6.  Both  forward  and  reverse  sequences  were  obtained  to  minimise 
sequencing errors. 
 
6.8.4  Sequence analysis 
The output from sequencing at both UCL and Imperial College was obtained 
as  a  four  colour  sequence  electropherogram  which  could  be  checked 
manually  and  edited  for  sequencing  errors  (Figure  6-8).  The  Sequence 
Navigator  program  (Perkin  Elmer)  was  used  to  compare  the  published 






Figure 6-8 Sequence navigator output.   154 
 
Chapter 7  Candidate gene selection 
7.1  Introduction 
Thirty-four  ion  channel  genes  were  selected  for  testing  in  the  initial  33 
absence  families  by  linkage  analysis  (Table  7-1).  These  included  voltage 
dependent calcium channels, GABAA and GABAB receptors. The ECA1 locus 
on chromosome 8q24 was also tested (Fong, Shah et al. 1998; Sugimoto, 
Morita et al. 2000). Genes were selected on the following basis:  
  Expression pattern in brain 
  A role in the generation of spike-wave seizures 
  Potential targets for anti-absence drugs 
  Genes known to cause spike-wave seizures in rodents or epilepsies in 
humans which include absence seizures as part of the phenotype 
  Genes implicated in previous linkage and association studies. 
7.2  Voltage dependent calcium channels (VDCC) 
Seventeen VDCC subunit gene regions were selected for linkage testing in 
the  33  families.  These  markers  represented  genes  encoding  seven   
subunits, one 2 subunit, one  subunit and eight  subunits. Twenty-one 
SSLPs were selected to encompass the relevant loci. Five of these markers 
were  intragenic  polymorphisms:  D19S1150  (CACNA1A),  D3S1568 
(CACNA2D2),  A1GUCL  (CACNA1G),  D22S426  (CACNG2),  and  D2S2236 
(CACNB4). 
 
VDCCs are involved in several calcium dependent processes, including entry 
of  calcium  ions  into  excitable  cells,  muscle  contraction,  hormone  or 
neurotransmitter  release,  and  gene  expression.  The  channel  activity  is   155 
directed  by  a  pore-forming  alpha-1  subunit  (Figure  3-3).  The  auxiliary 
subunits beta, gamma and alpha-2-delta regulate channel activity. There are 
at least 10 classes of alpha-1 subunits: 1A, B, C, D, E, F, G, H, I and S; 4 
beta subunits: 1, 2, 3, 4; 8 gamma subunits:  1,2,3,4,5,6,7,8; 4 alpha-2-
delta subunits: 1, 2, 3, 4.  There is strong evidence for a role for VDCCs 
in the generation of absence seizures. VDCCs are involved in thalamocortical 
spike-wave activity (section 3.5.1). Mutations in VDCC genes cause absence 
seizures in humans and mice (sections 3.5.2, 3.5.4). The anti-absence drug 
ethosuximide  may  have  an  action  on  the  T-type  Calcium  current  (section 
3.5.3). 
7.2.1  CACNA1A 
CACNA1A  encodes  the  1A  subunit  which  gives  rise  to  P  and/or  Q-type 
calcium  currents.  These  are  high-voltage  activated  (HVA)  currents. 
CACNA1A  is  expressed  specifically  in  brain  and  is  mainly  found  in  the 
cerebellum, cerebral cortex, thalamus and hypothalamus. P/Q type calcium 
channels  mediate  the  entry  of  calcium  ions  into  excitable  cells  and  are 
involved  in  calcium-dependent  processes  including  muscle  contraction, 
hormone  or  neurotransmitter  release,  gene  expression,  cell  motility,  cell 
division and cell death. Mutations in CACNA1A cause a range of neurological 
disorders,  including  familial  hemiplegic  migraine  (Ophoff,  Terwindt  et  al. 
1996), episodic ataxia type 2 (Ophoff, Terwindt et al. 1996), spinocerebellar 
ataxia  type  6  (Zhuchenko,  Bailey  et  al.  1997)  and  absence  epilepsy  with 
episodic ataxia (Jouvenceau, Eunson et al. 2001). Cacna1a mutations cause 
the tottering phenotype in mice (section 3.5.2). A significant association has 
been demonstrated between a CACNA1A intragenic SNP and patients with 
IGE (Chioza, Wilkie et al. 2001). 
7.2.2  CACNA1B 
CACNA1B encodes the 1B subunit which gives rise to the N-type calcium 
current, a HVA current. It is highly expressed in the central nervous system.   156 
Calcium  channels  containing  1B  subunit  may  play  a  role  in  directed 
migration of immature neurons (Komuro and Rakic 1992). 
7.2.3  CACNA1D 
CACNA1D encodes the 1D subunit which gives rise to the L-type calcium 
current,  a  HVA  current.  CACNA1D  is  expressed  in  brain,  mainly  in 
hippocampus, basal ganglia, habenula and thalamus. It is also expressed in 
pancreatic  islet  cells.  Functionally,  L-type  calcium  channels  in 
suprachiasmatic  neurons  contribute  to  the  generation  of  spontaneous 
oscillations  in  membrane  potential,  which  are  tightly  coupled  to  spike 
generation (Pennartz, de Jeu et al. 2002).  
 
7.2.4  CACNA1E 
CACNA1E encodes the 1E subunit which gives rise to the R-type calcium 
current, a HVA current. CACNA1E is expressed in brain and kidney. Calcium 
channels containing 1E subunits may be involved in the modulation of firing 
patterns of neurons and synaptic plasticity (Breustedt, Vogt et al. 2003). R-
type currents are inhibited by Lamotrigine (Hainsworth, McNaughton et al. 
2003). EFHC1, mutations of which can cause JME, was shown to enhance  
the  R-type  current  in  vitro  (Suzuki,  Delgado-Escueta  et  al.  2004).  This 
enhancement  was  partly  reversed  by  mutations  associated  with  JME, 
suggesting that disruption of R-type calcium current homeostasis is involved 
in seizure generation.  
7.2.5  CACNA1G 
CACNA1G  encodes  the  1G  subunit  which  gives  rise  to  the  T-type 
(transient,  low-threshold)  calcium  current,  a  low-voltage  activated  (LVA) 
current.  CACNA1G  is  highly  expressed  in  brain,  mainly  amygdala, 
subthalamic  nuclei,  cerebellum  and  thalamus.  It  is  also  moderately 
expressed in heart; with low expression in placenta, kidney and lung, colon   157 
and  bone  marrow.  T-type  channels  serve  pacemaking  functions  in  both 
central  neurons  and  cardiac  nodal  cells,  support  calcium  signalling  in 
secretory  cells  and  vascular  smooth muscle  (Yunker and  McEnery  2003). 
They have a major role in modulation of neuronal oscillations, resonance, 
and  rebound  burst  firing.    CACNA1G  knockout  mice  are  resistant  to  the 
generation  of  spike  wave  discharges  in  response  to  GABAB  receptor 
activation (Kim, Song et al. 2001). The thalamocortical relay neurons of the 
knockout mice lacked the burst mode firing of action potentials, but showed 
the  normal  pattern  of  tonic  mode  firing.  The  CACNA1G  mediated  t-type 
calcium  current  appears  to  modulate  the  intrinsic  firing  pattern  in  the 
thalamocortical  pathway,  which  generates  the  GABAB  receptor-mediated 
spike-wave discharges typical of absence seizures. 
7.2.6  CACNA1H 
CACNA1H encodes the 1H subunit which gives rise to a T-type calcium 
current.  It is expressed in brain, including thalamic reticular neurons, basal 
ganglia, olfactory bulb, hippocampus, caudal hypothalamus sensory ganglia, 
pituitary, and dentate gyrus (Talley, Cribbs et al. 1999). It is also expressed in 
kidney, liver, and heart. Sequencing of CACNA1H found 12 nonsynonymous 
SNPs in CAE patients (Chen, Lu et al. 2003). Functional characterisation of 5 
of  these  SNPs  in  rat  channels  found  increased  calcium  influx  during 
physiological  activation  and,  for  two  SNPs,  an  increased  propensity  to 
channel  opening  (Khosravani,  Altier  et  al.  2004).  Thirteen  SNPs  were 
introduced into human channels for functional characterisation. Eleven SNPs 
altered some aspect of channel gating, in at least one case in a manner that 
would lead to enhanced burst firing of neurons (Vitko, Chen et al. 2005). 
7.2.7  CACNA1I 
CACNA1I  encodes  the  1I  subunit  which  gives  rise  to  a  T-type  calcium 
current.  It is expressed predominantly in brain, thalamic reticular neurons, 
subthalamic nucleus, basal ganglia, olfactory bulb, hippocampus, and caudal 
hypothalamus.  Alternative  splicing  of  CACNA1I  appears  to  provide  a   158 
mechanism for controlling the latency and duration of low-threshold spikes in 
neurones (Murbartian, Arias et al. 2004). 
7.2.8  CACNB4 
CACNB4 encodes the  subunit of the VDCC. The subunit contributes to 
the  function  of  the  calcium  channel  by  increasing  peak  calcium  current, 
shifting the voltage dependencies of activation and inactivation, modulating G 
protein  inhibition  and  controlling  -1  subunit  membrane  targeting(Dolphin 
2003). CACNB4 is expressed predominantly in the brain (cerebellum) and 
kidney.  Cacnb4  mutations  cause  the  lethargic  phenotype  in  mice, 
characterised by absence seizures and ataxia (section 3.5.2).  CACNB4 was 
screened for mutations in small pedigrees with familial epilepsy and ataxia 
(Escayg, De Waard et al. 2000). A premature-termination mutation R482X 
was identified in a patient with JME, and a missense mutation identified both 
in a German family with generalized epilepsy and praxis-induced seizures 
and in a French Canadian family with episodic ataxia.  
7.2.9  CACNG1-8 
These  genes  encode  the  subunits  of  the  VDCC.  They  may  also  act  as 
AMPA receptor regulatory proteins. CACNG4, CACNG5 and CACNG1 occur 
in a cluster on chromosome 17. CACNG7, CACNG8 and CACNG6 occur in a 
cluster on chromosome 19. CACNG1 is predominantly expressed in muscle, 
whereas  CACNG2,  CACNG3  and  CACNG4  are  almost  exclusively 
expressed in brain (CACNG2: cerebellum, cerebral cortex, hippocampus and 
thalamus; CACNG3: cerebral cortex and amygdala; CACNG4: basal ganglia) 
(Moss,  Dolphin  et  al.  2003).    CACNG5  is  expressed  in  CNS  as  well  as 
kidney,  thymus,  prostate  and  testis.  CACNG6  and  CACNG7  are  widely 
expressed in multiple tissues including brain. CACNG8 is expressed only in 
brain. The overall effect of the various  subunits on VDCC activity appears 
to be a small downregulation of calcium channel activity (Black 2003). The 
stargazer  mouse,  characterised  by  ataxia,  periodic  head  elevation  with   159 
upward  gaze,  and  seizures  including  behavioural  arrest  associated  with 
spike-wave discharges, is caused by mutations in  Cacng2 (section 3.5.2). 
Studies of stargazer have shown that  the 2 subunit interacts with AMPA 
receptors and regulates their delivery of AMPA receptors to the postsynaptic 
cell membrane (Chen, Chetkovich et al. 2000). It is likely that other subunits 
are also involved in protein targeting. 
7.2.10 CACNA2D2 
CACNA2D2 encodes the  subunit of the VDCC. It is expressed in brain 
as  well  as  lung,  testis,  heart,  and  pancreas.  The    subunits  appear  to 
stimulate  functional  expression  by  increasing  the  number  of  functional 
calcium  channels  at  the  plasma  membrane.  Mutations  in  Cacna2d2  were 
found to underlie the ducky mouse phenotype as well as two further mouse 
mutants du(2J) and Entla (Barclay, Balaguero et al. 2001; Brill, Klocke et al. 
2004).  These  all  exhibit  generalised  spike-wave  discharges  on  EEG 
associated with behavioural arrest. 
7.3  GABAA receptors (GABAARs) 
Markers for ten  GABAAR subunit  genes,  which  occur in  three  clusters on 
chromosomes 5q, 4p and 15q, were also tested for linkage. These comprised 
five  subunits (1, 2, 4, 5, 6), three  subunits (1, 2, 3) and two  
subunits (2, 3). Six polymorphic markers were typed in all individuals. 
 
Functional  GABAARs  are  formed  by  the  assembly  of  multiple  subunit 
subtypes  (into  a  pentamer. 
GABAARs control opening of the chloride channel. When GABA binds to the 
receptor  complex,  the  channel  is  opened  and  chloride  anions  enter  the 
neuron.  GABAARs  are  the  primary  mediators  of  fast  inhibitory  synaptic 
transmission in the central nervoussystem. They are strongly implicated in 
the  generation  of  abnormal  spike-wave  activities  in  cortical  and  thalamic   160 
neurons  (section  3.5.1).  GABAARs  are  associated  with  binding  sites  for 
benzodiazepine and barbiturate AEDs (antiepileptic drugs) in the form of a 
receptor complex.  
 
GABAARs have frequently been shown to play a role in animal models of 
seizures. Examples include: Injection of various antagonists of the GABAA 
receptor induced spike-and-wave discharges in GAERS (Vergnes, Boehrer et 
al.  2000);  Disruption  of  the  gabrb3  gene,  contained  within  the  Angelman 
Syndrome deletion region, in mice produces EEG abnormalities and seizures 
as  well  as  behavioural  abnormalities  (DeLorey,  Handforth  et  al.  1998); 
Application  of  the  GABAA  receptor  antagonist  bicuculline  significantly 
increased  the  magnitude  of  SWD-related  burst  firing  in  thalamocortical 
neurones  in  the WAG/Rij  strain  of  rats  (Staak  and  Pape  2001);  Selective 
inhibition  of  the  expression  of  the  GABAA  receptor  2  subunit  in  the  rat 
hippocampus by means of antisense oligonucleotides leads to spontaneous 
electrographic seizures (Karle, Woldbye et al. 1998); In seizure-prone (Fast 
kindling) and  seizure-resistant  (Slow  kindling)  rat  models,  both  the  mRNA 
and protein levels of the major GABAAR -subunit expressed in adult brain 
(1), as well as those highly expressed during development (2, 3, and 5), 
were  differentially  expressed  in  both  models  compared  with  normal 
controls(Poulter, Brown et al. 1999). 
 
Mutations  in  several  GABAAR  genes  have  now  been  identified  in  human 
IGEs, including GEFS+ and a phenotype of childhood absence epilepsy and 
febrile  seizures  (GABRG2,  section  2.4.6)  and  autosomal  dominant  JME 
(GABRA1, section 2.5.1). A heterozygous variant in GABRD (Glu177Ala) is 
associated  with  GEFS+,  and  this  variant  results  in  a  decreased  GABAA 
receptor current amplitude (Dibbens, Feng et al. 2004).   161 
7.4  GABAB receptors (GABABRs) 
Seven markers were typed to test the two GABAB receptor genes, GABBR1 
and GABBR2 on chromosomes 6p21.3 and 9q22.1 respectively.  
 
The  functional  GABABR  is  a  heterodimer  consisting  of  two  seven-
transmembrane proteins, GABBR1 and GABBR2. Unlike GABAA receptors, 
GABAB receptors do not form ion channels, but address second messenger 
systems  through  the  binding  and  activation  of  G-proteins.  Pre-synaptic 
GABABRs  inhibit  neurotransmitter  release  by  down-regulating  high-voltage 
activated  calcium  channels,  whereas  postsynaptic  GABABRs  decrease 
neuronal excitability by activating a prominent inwardly rectifying potassium 
(Kir)  conductance  that  underlies  the  late  inhibitory  postsynaptic  potentials 
(Bettler, Kaupmann et al. 2004). Human GABABR2 and GABABR1 mRNAs 
are  exclusively  expressed  in  brain  and  differentially  expressed  in  the 
amygdala, putamen, and caudate nucleus (Martin, Russek et al. 1999). 
 
GABBR1-null  mice  exhibit  spontaneous  seizures  as  well  as  hyperalgesia, 
hyperlocomotor  activity,  and  memory  impairment  (Schuler,  Luscher  et  al. 
2001).  In  lethargic  mice,  antagonists  of  the  GABAB  receptor  suppress 
seizures, whereas agonists of GABAB receptors exacerbate them, suggesting 
enhanced  GABAB  receptor-mediated  synaptic  responses  may  underlie 
absence  seizures  in  lethargic  mice  (Hosford,  Clark  et  al.  1992).  In  two 
experimental animal models of generalized absence seizures (one in which 
the seizures are induced by GHB (Gamma-hydroxybutyric acid) and the other 
in  which  the  seizures  are  induced  by  administration  of  low-dose 
pentylenetetrazole),  all  specific  GABAB-receptor  antagonists  produced 
blockade  of  experimental  absence  seizures;  pretreatment  with  GABAB-
receptor agonists resulted in generalized absence status epilepticus lasting 
for hours (Snead 1996).   162 
7.5  ECA1 locus 
The  ECA1  locus  on  8q24  was  tested  using  the  marker  D8S534  (section 
3.5.5).  163 
Table 7-1 Candidate genes tested and markers used. A1GUCL is a novel marker (see Appendix 15)




Exons  Marker position 
(distances in kb) 
Voltage-dependent 
Calcium Channels 
CACNA1A  1A  19p13.3  D19S1150  299  7.8  48  CACNA1A(Intron 7: D19S1150) 
  CACNA1B  1B  9q24  D9S158  244  7  46  D9S158-1723-CACNA1B 
  CACNA1D  1D  3p14-p21  D3S3582,  D3S1568, 
D3S1588, D3S1289 




  CACNA2D2  22      141  5.5  39   
  CACNA1E  1E  1q31-q32  D1S212, D1S2848  318  9.7  48  D1S212-3370-CACNA1E-4064-
D1S2848 
  CACNA1G  1G  17q22  A1GUCL  66  7.8  38  CACNA1G(Intron 2: A1GUCL) 
  CACNA1H  1H  16p12-p13.3  D16S521,  D16S3024, 
D16S420 
68  8.1  35  D16S521-1109-CACNA1H-382-
D16S3024-22549-D16S420-30-
CACNG3 
  CACNG3  3      107  2.7  4   
  CACNA1I  1I  22q12-q13  D22S283,  D22S426, 
D22S1156, D22S284   
119  10  37  D22S283-209-CACNG2(Intron 
3:  D22S426)-1283-D22S1156-
1585-CACNA1I-231-D22S284 
  CACNG2  2      139  1.5  4   
  CACNB4  4  2q23  D2S2236, D2S2299  261  3.2  14  CACNB4(Intron  12:  D2S2236)-
681-D2S2299 
  CACNG5  5  17q24  D17S807, D17S1821  12  1.3  4  D17S807-14-CACNG5-80-
CACNG4-11-CACNG1-233-
D17S1821 
  CACNG4  4      68  3.4  4   
  CACNG1  1      8  0.8  5   
  CACNG7   19q13.4  D19S572  20  1.8  4  D19S572-390-CACNG7-20-
CACNG8-9-CACNG6 
  CACNG8       30  1.6  5   
  CACNG6       20  1.4  4     164 
Table 7-1 continued. Candidate genes tested and markers used.




Exons  Marker position 
(distances in kb) 
GABAA receptors  GABRA1  ʱ1  5q31.1-
q33.2 
D5S2112, D5S422  52  3.7  11  D5S2112-4038-GABRB2-138-
GABRA6-145-GABRA1-168-
GABRG2-571-D5S422 
  GABRA6  ʱ 6      16  1.7  9   
  GABRB2  β2      254  2  11   
  GABRG2  γ2      88  3.9  10   
  GABRA2  ʱ2  4p13-p12    140  2.4  10  GABRA2-529-GABRA4-38-
GABRB1(Intron 
8:GABRB1(GATA)) 
  GABRA4  ʱ4    GABRB1(GATA)  75  11  9   
  GABRB1  β1      395  3.4  9   
  GABRB3  β3  15q11-q13  GABRB3(CA), 
155CA2, A55CA1 




  GABRA5  ʱ5      17  0.8  6   
  GABRG3  γ3      52  0.9  5   
GABAB receptors  GABBR1    6p21.3  D6S265,  D6S478, 
D6S1281 
31  4.4  23  D6S1281-4273-GABBR1-205-
D6S478-113-D6S265 
  GABBR2    9q22.1  D9S1816,  D9S1809, 
D9S272, D9S176 
421  5.8  19  D9S1816-281-D9S1809-2492-
GABBR2-280-D9S272-307-
D9S176 
Unknown  ECA1    8q24  D8S534        ECA1(D8S534)   165 
 
Chapter 8  Linkage analysis  
All  linkage  programmes  were  run  via  the  website  of  the  Research  and 
Bioinformatic Divisions, UK Human Genome Mapping Project (HGMP) based 
in  Hinxton,  Cambridge,  or  run  directly  on  a  stand  alone  PC  using  freely 
available software.  
8.1  Files needed for linkage analysis 
The  linkage  analysis  software  requires  several  input  files.  The  two  files 
required universally are the pedigree file, which provides data about pedigree 
structure and members, and the locus data file which provides information 
about the genetic loci typed in the pedigree. Additional files are required for 
certain analysis software, and these will be described in the relevant section.  
8.1.1  Pedigree file 
The pedigree file provides information about the structure of each pedigree, 
the sex and affection status of each individual, and genotyping data for the 
marker loci tested. The pattern of the pedigree file is shown in Table 8-1.   166 
 
Table 8-1 Structure of linkage pedigree file. The header row is shown for 
information only and does not form part of the pedigree file. The pedigree 
must  contain  both  parents  or  neither.  Two  marker  loci  are  shown  for 
illustration. 
 
8.1.2  Locus data file 
The locus data file provides information about the loci (disease and marker) 
included  in  the  pedigree  file  and  the  type  of  analysis  to  be  performed.  A 
typical locus data file contains 3 sections, as follows: 
(section 1) 
3 0 0 5   
0 0.0 0.0 0   
1 2 3 
(sections 2) 
1 2   
0.995 0.005   
1  
0.001 0.5 0.5   
3 11  # D16S420 
0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.09 
3 3  # CACNG3EX1CA 
0.33 0.33 0.34 
(section 3) 
0  0   
0.0 0.0025 






0  if  not  in 
pedigree 
Mother  










Alleles  at 
marker 
locus  1 
0=unknown 
Alleles  at 
marker 
locus  2 
0=unknown 
5  101  0  0  2  1  2  3  0  0 
5  102  0  0  1  1  1  10  1  2 
5  202  102  101  2  1  1  2  1  2 
5  204  102  101  2  2  2  10  0  0 
5  207  102  101  1  2  1  2  1  2 
26  101  0  0  1  1  3  4  1  1 
26  102  0  0  2  1  2  4  1  2 
26  202  101  102  1  2  2  3  1  1 
26  204  101  102  2  2  2  3  1  1 
26  206  101  102  1  1  2  4  1  1   167 
Section 1. This contains general information on loci and locus order. 
Line 1 contains 4 parameters: the number of loci to be coded; a risk locus 
(0=no  risk  calculations  to  be  performed);  sex-linked  or  autosomal  data 
(0=autosomal); and a program code (5 indicates MLINK is to be used for 
analysis). 
Line 2 contains 4 parameters: a mutation locus (0=mutation rate zero); male 
mutation  rate;  female  mutation  rate;  linkage  disequilibrium  (0  if  loci  are 
assumed to be in linkage equilibrium) 
Line 3 gives the order of the loci along the chromosome 
 
Section 2. This section of the locus data file contains detailed information for 
each locus.  
Line 1 contains 2 parameters: a code to indicate the locus type (1=affection 
locus, 3=numbered alleles); the number of alleles 
The subsequent lines for each locus depend on the locus type. 
For an affection locus, the subsequent lines are: 
  Line 2 gives the allele frequency for each allele 
  Line 3 gives the number of liability classes, useful if the disease has 
an age dependent penetrance 
  Line 4 gives the penetrance values for each genotype. For two alleles, 
1 and 2, the genotype order is 11 (penetrance close to 0 if this is the 
wild  type  allele),  12  (penetrance  ≈1 for a   fully  penetrant  dominant  
mendelian disorder, ≈ 0 for a recessive disease) and 22 (penetrance 
≈1 for a dominant or  recessive mendelian disorder) 
For numbered alleles, the subsequent line is: 
  Line 2 gives the allele frequency for each allele   168 
Section 3. The third section of the locus data file determines what analysis is 
to be performed.  
Line 1 defines whether there is a sex-difference in recombination fractions 
(0=no sex difference) and whether an interference parameter is to be used 
(0=no interference). 
Line 2 specifies the initial recombination fraction(s) between the loci. For n 
loci, n-1 recombination fractions are required. To measure the LOD score at 
theta=0 the first value should be 0. 
Line 3 depends on the program being used. For MLINK, the first parameter 
defines  which  recombination  fractions  to  vary  on  subsequent  evaluations 
(1=first recombination fraction only). The second parameter is the value to 
increment the recombination fraction by each time, and the third parameter is 
the value at which to stop.   169 
8.2  Parameters for linkage analysis 
Parametric  linkage  analysis  was  performed  under  the  assumption  of  AD 
inheritance with 50% and 70% penetrance. These parameters correspond to 
the  available  data  on  mendelian  segregation  in  this  trait.  They  are 
conservative  and  the  low  penetrance  reduces  the  risk  of  false  negative 
results. A disease allele frequency of 0.01 and a phenocopy rate of 0.0001 
were assumed. A disease allele frequency of 1% allows the variant to be 
classified as a polymorphism which would be consistent with the so-called 
common disease/common variant hypothesis (although this is a conservative 
estimate of disease allele frequency).  A phenocopy rate of 0.0001 reflects 
the likely heterogeneous architecture of CAE. 
8.3  Power  of  family  resource  to  detect  linkage  –  SLINK 
software 
The  power  of  the  family  resource  to  detect  linkage  was  calculated  using 
SLINK  (Ott  1989;  Weeks,  Ott  et  al.  1990).  SLINK  randomly  simulates 
multilocus marker data under the condition of linkage or non-linkage and then 
analyses the results. The simulation algorithm first calculates the conditional 
probabilities  of  all  the  possible  multilocus  genotypes  in  a  pedigree  and 
randomly assigns one of these genotypes (g1) to individual 1. Taking into 
account  the  genotype  just  generated,  the  multilocus  genotype  conditional 
probabilities  are  recalculated  and  a  genotype  (g2)  randomly  assigned  to 
individual  2.  This  process  of  successive  risk  calculations  continues  until 
multilocus genotypes have been assigned to all individuals in the pedigree. 
The user defines the number of replicates to be performed. 
SLINK  calculates  the  maximum  LOD  under  conditions  of  homogeneity  or 
heterogeneity  and  at  various  recombination  fractions.  The  maximum  LOD   170 
score at any recombination fraction is also calculated, as well as the power of 
the dataset to produce LOD scores of a given magnitude.  
SLINK requires 5 input files: 
1.  Simdata.dat is a standard locus data file which contains information 
about  the  allele frequencies  of the affection  locus  and  the  markers under 
study.  
2.  Simped.dat  is  a  standard  pedigree  file  which  contains  information 
about  the pedigree  including  each  individual‟s  availability  code  as  defined 
below: 
Code  Trait  Markers 
0  Known disease phenotype as defined  Marker genotype unavailable 
1  Use simulated disease phenotype  Simulate 
2  Known disease phenotype as defined  Simulate 
3  Use simulated disease phenotype  Marker genotype unavailable 
 
3.  Slinkin.dat contains information about the way in which the simulation 
is to be conducted. This includes the number of replicates to be simulated 
and  the  proportion  of  heterogeneity  (unlinked  families).  The  format  of 
slinkin.dat is as follows: 
57   (a random number seed) 
100   (the number of simulated pedigrees to produce) 
1   (indicates the affection locus is the first locus in the pedigree and locus data files) 
0.0   (the proportion of unlinked families) 
 
4.   Limit.dat provides LOD score values for which the simulation program 
will report how many replicates produce a LOD score exceeding these. The 
format of limit.dat is a single line as follows: 
 
2 3 4  (the number of replicates with a LOD exceeding 2, 3 and 4 will be calculated)   171 
 
5.   Datafile.dat  is a standard locus data file very similar to simdata.dat, 
which is used by the MSIM program to analyse the output data from SLINK 
and  UNKNOWN.  The  recombination  fraction  in  the  penultimate  line  is 
changed  to  0.0,  so  that  the  starting  recombination  for  calculation  of  LOD 
scores is zero. 
 
The simulation is run in three stages: 
1.  SLINK – this produces the simulated marker data 
2.  UNKNOWN  –  this  checks  through  the  pedigrees,  eliminates 
impossible genotypes and formats the data for MSIM 
3.  MSIM  –  this  is  a  modified  version  of  MLINK  (Section  8.5)  which 
calculates lod scores for each simulated data set. 
 
When SLINK generates data under heterogeneity, the LOD scores calculated 
by  MSIM  are  too  low,  and  the  estimates  of  theta  are  too  high,  as  MSIM 
assumes  homogeneity  (ʱ=1).    ELODHET  is  an  additional  program  which 
analyses the LODFILE.DAT file created by MSIM under heterogeneity.  
 
8.3.1  Simulation  with  thirty-three  absence  pedigrees 
(section 5.7.1) 
Assuming  locus  homogeneity  and  autosomal  dominant  inheritance  with 
penetrance  of  70%,  the  estimated  probability  of  obtaining  a  LOD  score 
greater than 3 at =0 (as candidate genes are being analysed) was 95.6%. 
Allowing for heterogeneity with 70% of the families linked, there was a 45.1% 
probability of obtaining a LOD score greater than 3, and a 73.9% probability 
of obtaining a LOD score greater than 2.    172 
8.3.2  Simulation  with  fifty-three  CAE  pedigrees  (section 
5.7.2) 
Assuming locus homogeneity, the estimated probability of obtaining a LOD 
score greater than 3 at =0 (as candidate genes are being analysed) was 
99.4%. Allowing for heterogeneity with 70% of the families linked, there was 
a 59.3% probability of obtaining a LOD score greater than 3, and an 82.0% 
probability of obtaining a LOD score greater than 2. 
 
8.4  Preparation  of  linkage  pedigree  file  and  checking  for 
mendelian errors – GAS software 
GAS (Genetic Analysis System, © Alan Young 1993-1998) version 2.3 was 
used to prepare the linkage pedigree file and to check for mendelian errors in 
the marker data. GAS requires a modified locus data file (.gas), a pedigree 
file (.ped) and an allele data file (.siz) (Appendix 16). The GAS program is 
able to read genotypic data in the allele data file, given in terms of the lengths 
of CA-repeats, and to process it into a form suitable for linkage analysis. The 
locus  data file  includes  a  command  to  read  allele-size  family  data  and  to 
convert allele size into an allele number. An adaptive binning method is used 
to determine which alleles are the same and which are different and to label 
alleles according to three parameters: 
diffsize    (two alleles differing by more than this are different) 
samesize  (two alleles differing by less than this are the same) 
orderfirst   (alleles are labelled in the order they are read) 
An additional parameter, global, ensures the same bins are used for every 
family in the dataset. This is important if the data is to be used for association 
analysis.   173 
When GAS cannot decide how to score an ambiguous allele the options are 
given to put the ambiguous allele into a nearby bin, to create a new bin or to 
score the allele as unknown.  
The pedigree file provides information about the structure of each pedigree, 
the sex and affection status of each individual, but contains no genotyping 
data.  
GAS checks the allele data for consistency - ie. that the alleles are sensible, 
distinct and do not imply illegitimacy. An output log file gives a warning if the 
allele  lengths  are  outside  of  defined  limits,  or  if  a  child  has  a  genotype 
inconsistent  with  that  of  their  parents  and  any  full  siblings.  When 
inconsistencies are encountered, the original electropherogram data must be 
checked to identify the source of the error so that necessary corrections can 
be made. The GAS program is then rerun. 
The GAS output file is a standard linkage pedigree file including genotyping 
data for the marker loci tested. 
8.5  Two-point linkage analysis – LINKAGE software 
MLINK  version  5.2,  part  of  the  LINKAGE  package,  was  used  to  perform 
multilocus  two  point  linkage  analysis  (Lathrop  and  Lalouel  1984;  Lathrop, 
Lalouel et al. 1984). MLINK calculates two-point linkage between the disease 
locus and a marker locus. For each pedigree, the logarithm of the likelihood 
at each value of the recombination fraction, , is calculated and the sum of 
these is the total log likelihood for the pedigree set. The difference between 
the total log likelihood at a particular value of  and the log likelihood at =0.5 
gives the overall LOD score.  
The  input  files  for  MLINK  are  the  locus  data  file  (section  8.1.2)  and  the 
pedigree file (section 8.1.1). The pedigree file (.ped) was first preprocessed 
using MAKEPED, which renumbers consecutively the subjects within each 
pedigree, assigns a „proband‟ for each pedigree, and reformats the data. The   174 
modified pedigree file (.ppd) was next run through UNKNOWN, which checks 
through  the  pedigrees,  eliminates  impossible  genotypes  (although  these 
should  previously  have  been  identified  by  GAS)  and  formats  the  data  for 
MLINK.  
MLINK requires the two output files from UNKNOWN as well as the locus 
data file, and then calculates the log likelihoods and LOD scores. In order for 
MLINK  to  analyse  each  marker  in  the  locus  data  file  in  turn,  the  linkage 
control program (LCP) was used. LCP is programmed to automatically copy 
and rename files, extract data for a subset of loci from the pedigree and locus 
files and call up MLINK to analyse the data. The linkage reporting program 
(LRP) was then used to generate a table of LOD scores from the output of 
LCP. LRP produces the LODs at each value of  for each pedigree as well as 
the total LOD. 
8.6   Two-point linkage analysis with locus heterogeneity – 
TABLE software. 
LRP simply adds the LODs from different pedigrees in order to obtain an 
overall  LOD  at  each  value  of  .  This  assumes  locus  homogeneity.    The 
individual pedigree LODs can also be combined under the assumption that 
only  a  proportion  (ʱ)  show  linkage,  ie  locus  heterogeneity.  The  TABLE 
program can be used to analyse the output from LCP and calculate the total 
LOD under the assumption of both homogeneity and heterogeneity (HLOD). 
The HLOD is shown at each value of   together with the value of ʱ that 
maximises it.   175 
8.7  Parametric  and  non-parametric  multipoint  linkage 
analysis – GENEHUNTER software 
GENEHUNTER  2.1  was  used  to  perform  multipoint  linkage 
analysis(Kruglyak,  Daly  et  al.  1996). This allows  multiple  linked  loci to be 
analysed  simultaneously.  This  compensates  for  uninformative  markers  at 
particular  meioses  and  for  missing  marker  data  by  extracting  data 
simultaneously  from  neighbouring  markers  and  allowing  construction  of 
marker haplotypes.  
The input files for GENEHUNTER are a pedigree file (.ped) which has been 
generated by GAS, and a modified locus data file (.dat) (Appendix 17) which 
includes the genetics distance between each marker specified. 
GENEHUNTER  generates  a  multipoint  parametric  LOD  score  calculated 
using the transmission model specified in the locus data file. A heterogeneity 
LOD  is  also  generated  across  the  map  together  with  the  value  of  ʱ  that 
maximises it. 
GENEHUNTER also calculates a non-parametric or model-free linkage score 
(NPL  score)  together  with  its  associated  p-value.  The  NPL  score  is  a 
measure of allele sharing identical by descent between either affected sib 
pairs (NPLpairs) or between all affected members in a pedigree (NPLall).  
A graphical representation of the multipoint LOD score and NPL score across 
the map is generated in postscript form. 
GENEHUNTER  also  maps  the  information  content,  a  measure  of  the 
proportion  of  the  total  inheritance  information  extracted  by  the  available 
marker data, as well as constructing the most likely marker haplotypes. 
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8.8  Parametric  and  non-parametric  multipoint  linkage 
analysis  with  two  trait  loci  –  GENEHUNTER-TWOLOCUS 
software 
In  the  initial  analysis  of  candidate  genes,  two  loci  were  consistent  with 
linkage to the disease locus. Absence epilepsy is likely to be a multigenic 
trait, and it was therefore decided to perform a two-trait-locus study by testing 
both  loci  simultaneously  with  GENEHUNTER-TWOLOCUS  (Strauch, 
Fimmers et al. 2000).  This uses two unlinked marker maps. The genetic 
positions of both trait loci are varied on their respective marker maps, as in 
GENEHUNTER. The inheritance vector approach is used to determine how 
many alleles a set of individuals share identical by descent. A parametric 
(LOD) and nonparametric (NPL) score is generated for the two-locus trait 
model. 
GENEHUNTER-TWOLOCUS first loads three input files, two standard locus 
data files (one for each of the marker maps) and a third file specifying two-
disease-locus-model  parameters  for  LOD  score  analysis.    The  third  file 
contains the allele frequencies for each of the disease loci, the number of 
liability  classes  and  two-locus,  parent-of-origin  specific  penetrances 
(Appendix 18). For each liability class, a four-by-four matrix with two-locus, 
parent-of-origin  specific  penetrances  is  specified.  The  rows  of  the  matrix 
represent the genotype at disease locus 1, in the order w/w, m/w, w/m, m/m, 
where w and m represent the wild-type and mutant alleles respectively and 
the  paternally  inherited  allele  is  given  first.  The  columns  of  the  matrix 
represent the genotype at disease locus 2 ordered in the same way. The 
penetrance  matrices  used  are  illustrated  in  Figure  8-1.  Three  parametric 
models were used.  The multiplicative model tests the hypothesis that only a 
simultaneous dominant mutant allele at the trait loci on both chromosome 15 
and  16  leads  to  the  disease.  The  heterogeneity  model  assumes  that  a 
dominant mutant allele at either trait loci is sufficient to cause the disease. 
The additive model combines the multiplicative and heterogeneity models, so 
that a dominant mutant allele at either trait loci can cause the disease, but   177 
the  likelihood  of  disease  is  significantly  increased  if  mutant  alleles  are 
present on both chromosomes 15 and 16. 
GENEHUNTER-TWOLOCUS  then  scans  two  standard  pedigree  files, 
containing  the  marker  genotypes  for  the  first  and  second  marker  map 
respectively. The scan command also requires a parameter specifying the 
position of the first disease locus on the first marker map which is held fixed 
during the analysis. 
 
The  sequence  of  commands  to  run  GENEHUNTER-TWOLOCUS  is  as 
follows: 
load chr16.dat chr15.dat model.dat 
skip large off       (include large pedigrees) 
haplo on          (construct haplotypes) 
photo chr1516.out      (save session to file) 
scan chr16.ped chr15.ped 0.23 (fix first disease locus at 
position 0.23) 
total stat het  (combine all pedigrees with 
heterogeneity)  
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Figure 8-1  Penetrance matrices used in GENEHUNTER-TWOLOCUS. The 
paternally inherited allele is always given first. 
a) Multiplicative model. The mutant allele at both disease loci produces a 
dominant  effect,  as  long  as  at  least  one  mutant  allele  is present  at  each 
locus. 
     
Disease  
locus 2  
      w/w  m/w  w/m  m/m 
Disease 
locus 1  
w/w  0.00  0.00  0.00  0.00 
m/w  0.00  0.90  0.90  0.90 
w/m  0.00  0.90  0.90  0.90 
m/m  0.00  0.90  0.90  0.90 
 
b) Heterogeneity model. The mutant allele at either disease locus exerts a 
dominant effect, so that either is sufficient to cause the disease. 
     
Disease  
locus 2  
      w/w  m/w  w/m  m/m 
Disease 
locus 1  
w/w  0.00  0.90  0.90  0.90 
m/w  0.90  0.90  0.90  0.90 
w/m  0.90  0.90  0.90  0.90 
m/m  0.90  0.90  0.90  0.90 
 
c) Additive model. A dominant mutant allele at either trait loci can cause the 
disease,  but  the  likelihood  of  disease  is  significantly  increased  if  mutant 
alleles are present at both loci. 
     
Disease  
locus 2  
      w/w  m/w  w/m  m/m 
Disease 
locus 1  
w/w  0.00  0.45  0.45  0.45 
m/w  0.45  0.90  0.90  0.90 
w/m  0.45  0.90  0.90  0.90 
m/m  0.45  0.90  0.90  0.90 
 
   179 
 
Chapter 9  Association analysis 
All  association  analysis  programmes  were  run  via  the  website  of  the 
Research and Bioinformatic Divisions, UK Human Genome Mapping Project 
(HGMP) based in Hinxton, Cambridge, or run directly on a stand alone PC.  
9.1  Transmission  disequilibrium  test  with  SSLPs  – 
GENEHUNTER software 
Linkage  disequilibrium  in  informative  trios  within  the  pedigrees  used  for 
linkage was tested using the TDT command in GENEHUNTER (PART 11.1). 
Only  transmissions  from  heterozygote  parents  are  counted,  including  the 
cases where one parent is missing but the included parent and offspring are 
both distinct heterozygotes. The TDT was performed on single markers as 
well as marker pairs, marker triplets and marker quadruplets using the TDT2, 
TDT3 and TDT3 commands respectively.  
9.2  Pedigree disequilibrium test - PDT software 
The PDT is an extension of the TDT to use all potentially informative data in 
extended pedigrees for analysis of linkage disequilibrium (Martin, Monks et 
al. 2000; Martin, Bass et al. 2001). The PDT is a valid test of linkage and 
association  in  general  pedigrees  even  in  the  presence  of  population 
stratification  and  calculates  two  alternatives  of  the  test  statistic.  The  AVE 
PDT  weights  each  individual  family‟s  contribution  equally,  regardless  of 
pedigree  size  and  complexity  while  the  SUM  PDT  weights  families 
proportional to these factors. The input files for PDT are a standard locus 
data file and a pedigree file which has been processed through MAKEPED. 
The  output  data  includes  the  number  of  informative  families  used,  the 
number of informative triads used, the number of discordant sib pairs used,   180 
the test result for each alleles and a global statistic for the marker locus. PDT 
was performed using both individual markers and SNP haplotypes. 
9.3  Selection of SNPs 
SNPs were chosen at ~10kb intervals encompassing the promoter through to 
the 3' UTR of CACNG3 (Figure 9-1).  The SNPs have been numbered from 
one  to  23  for  ease  of  reference.    One  of  these  is  a  novel  SNP  (SNP6) 
identified via sequencing of a subset of the nuclear pedigrees; the remaining 
22 can be found on the NCBI SNP database (Table 9-1). These SNPs were 









Figure  9-1  Position  of  23  SNPs  type  in  the  entire  family  resource  of  AE 
pedigrees  and  trios.  Image  modified  from  the  UCSC  Genome  Browser 
(http://genome.cse.ucsc.edu/cgi-bin/hgGateway)   181 
Table 9-1 Details of CACNG3 SNPs used for association analysis 
SNP 
NUMBER  refSNP ID 
MINOR ALLELE FREQUENCY 






SNP1  rs198175  0.42
2(allele1)  G  A 
SNP2  rs447292  0.30
1  G  A 
SNP3  rs4787924  0.47
2(allele1)  A  G 
SNP4  rs2239341  0.21
1  A  C 
SNP5  rs1494550  0.26
1  T  C 
SNP6  c-254delT  0.07
3  T  delT 
SNP7  rs965830  0.47
2(allele1)  T  G 
SNP8  rs2214437  0.50
1  T  A 
SNP9  rs2238499  0.20
1  G  A 
SNP10  rs2238500  0.46
1(allele1)  G  A 
SNP11  rs2247011  0.26
1  A  G 
SNP12  rs739747  0.27
1(allele1)  A  T 
SNP13  rs1557809  0.20
1  T  C 
SNP14  rs7200040  0.35
1(allele1)  A  G 
SNP15  rs757200  0.25
1  C  T 
SNP16  rs2238511  0.34
1  T  C 
SNP17  rs2238518  0.46
1  T  C 
SNP18  rs2238521  0.26
1  G  A 
SNP19  rs2189290  0.36
1  T  C 
SNP20  rs714822  0.14
1  C  G 
SNP21  rs960350  0.38
1  T  C 
SNP22  rs12932291  0.10
2  C  G 
SNP23  rs985729  0.48
1(allele1)  T  C 
1  =  data  derived  from  NCBI  SNP  database; 
2  =  data  derived  from 
KBioscience  validation; 
3  =  data  derived  from  study  population  182 
9.4  Linkage disequilibrium map construction, identification 
of haplotype block structure– HAPLOVIEW software 
Haploview was used to construct an LD map across regions of interest using 
the SNPs typed in that region (Barrett, Fry et al. 2005). Haploview generates 
a  graphical  representation  of  LD  using  a  colour  scheme  to  represent  the 
strength of the LD. Blocks were defined as a solid spine of LD ie the first and 
last marker in a block are in strong LD with all intermediate markers (allowing 
for one slight mismatch). The intermediate markers are not necessarily  in 
strong LD with one another. Haplotype blocks were defined using a value of 
D‟ = 0.7 as the criteria for strong LD.  
The  PDT  was  then  performed  using  both  individual  SNPs  and  the  SNP 
haplotypes  identified.  Each  haplotype  was  treated  as  a  single  allele  at  a 
multi-allelic locus, as PDT cannot simultaneously analyse multiple loci. 
Data was input into Haploview in standard LINKAGE pedigree file format. 
9.5  Association analysis using tagging SNPs. 
Haploview was also used to select a set of tagging SNPs. Two strategies 
were  used.  The  first  strategy  selects  tagging  SNPs  which  will  define  all 
haplotypes above a certain (adjustable) frequency threshold. A frequency of 
1%  was  used.  The  second  strategy  uses  aggressive  tagging  based  on 
Tagger (de Bakker, Yelensky et al. 2005). This combines a pairwise and a 
multimarker approach. Initially a minimal set of markers is selected such that 
all alleles to be captured are correlated at an r
2 greater than an adjustable 
threshold with a marker in that set. An r
2  threshold of 0.8 was used. Multi-
marker tests constructed from the set of markers chosen as pairwise tags are 
then used to try to capture SNPs which could not be captured in the pairwise 
step. Finally the tag list is minimised where possible by replacing certain tags 
with  multimarker  tests.  Multimarker  tests  are  constructed  only  from  SNPs   183 
which are in strong LD with each other, as measured by a pairwise LOD 
score. This avoids overfitting. The default cutoff of LOD=3.0 was used. 
The  PDT  result  obtained  with  the  tagging  SNPs  was  compared  with  the 
haplotype PDT.   184 
Chapter 10  Sequencing of CACNG3 
Exonic  DNA  and  surrounding  intronic  and  promoter  sequence  DNA  of 
CACNG3  was  sequenced  in  73  individuals  (Figure  10-1).  Cases  were 
predominantly  chosen  from  families  which  demonstrated  linkage  to  the 
CACNG3 locus. These consisted of 46 individuals with CAE selected from 43 
of the families used for CAE linkage (including 3 sib pairs); 25 individuals (7 
CAE, 5 JAE and 13 AE) selected from 23 of the additional families included 
in the AE linkage (including 2 sib pairs); 2 individuals with CAE selected from 
2 of the trios included in the SNP based association analysis (Table 10-1). A 
full list of the individuals selected for sequencing is given in Appendix 19. 
Following  the  SNP  based  association  analysis,  further  sequencing  of 
approximately  34kb  of  genomic  DNA  (chromosome  16,  NCBI  Build  36.1 
position 24155960- 24190949) encompassing SNPs 1-9 from 24 unrelated 
affected individuals was performed. Cases were chosen whose haplotypes 
demonstrated the most significant disease association. 
Identified  variants  were  assessed  for  any  potential  functional  affect  by 
searching for predicted regulatory motifs contained within the TransFac and 
Biobases databases via the Softberry NSITE portal. The FPROM program, 
also via the Softberry portal, was used to predict the position of potential 
promoters  and  enhancers.  FPROM  identifies  characteristics  of  functional 
motifs  and  oligonucleotide  compositions  of  potential  transcription  start 
positions (Solovyev and Shahmuradov 2003). The GeneSplicer program was 
used to predict whether any variant might affect the splicing of the gene by 
identifying exon-intron boundaries and scoring them (Pertea, Lin et al. 2001). 
The  program  ESEfinder  was  used  to  predict  the  presence  of  any  exonic 
splicing enhancers (ESEs) in exon 1  (Cartegni, Wang et al. 2003) Exonic 
enhancers  serve  as  binding  sites  for  specific  serine/arginine-rich  (SR) 
proteins. SR proteins bound to ESEs can promote exon definition by directly 
recruiting the splicing machinery and by antagonizing the action of nearby 
silencer elements.  SR proteins are characterised by RNA-recognition motifs 
(RRM) and a distinctive C-terminal domain highly enriched in RS dipeptides 
(the  RS  domain).  Substrate  specificity  is  determined  by  the  RRMs,  which   185 
mediate  sequence-specific  binding  to  the  RNA,  whereas  the  RS  domain 
appears  to  be  involved  mainly  in  protein-protein  interactions.  ESEfinder 
identifies putative binding sites for four SR-rich proteins. 
Variants  were  also  checked  for  sequence  conservation  between  humans, 
Pan troglodytes (chimpanzees), Mus musculus (house mouse) and Rattus 





Figure 10-1 Genomic structure of CACNG3. Image modified from the UCSC 
Genome Browser (http://genome.cse.ucsc.edu/cgi-bin/hgGateway). 
 
 
Table 10-1 Summary of individuals selected for CACNG3 sequencing. 
    Families: 
   
43 CAE linkage families 
(3 sib pairs) 
23 AE linkage families 
(2 sib pairs)  2 trios 
Individuals:  CAE  46  7  2 
  JAE    5   
  AE    13   






PART 3  Results   187 
Chapter 11  Initial  investigation  of  candidate  gene 
loci in absence pedigrees 
The initial cohort of 33 families (Figure 5-3) was used to test 30 candidate 
gene  loci,  represented  by  markers  localising  to  seventeen  VDCC  subunit 
genes,  ten  GABAAR  subunit  genes,  two  GABAB  receptor  genes  and  the 
ECA1 locus on 8q24, and analysed by by linkage and association analysis. 
Two-point  LOD  scores  are  presented  for  genes  tested  by  a  single  SSR 
polymorphism. Loci at which LOD scores were positive were tested for allelic 
association  using  the  Pedigree  Disequilibrium  Test  (PDT).  Where  genes 
were  tested  by  two  or  more  markers,  the  multipoint  LOD  scores  are 
presented at the recombination fractions corresponding to the known gene 
locations. 
11.1  Voltage-dependent  calcium  channel  (VDCC)  subunit 
genes 
Six loci intragenic or in close proximity to eight VDCC subunit genes were 
tested  using  single  SSLPs.  The  two-point  LOD  scores  assuming  locus 
homogeneity at various recombination fractions,  , are presented in Table 
11-1.  The  three  intragenic  markers,  D19S1150  (CACNA1A),  D3S1568 
(CACNA2D2), A1GUCL (CACNA1G), all gave exclusionary LOD scores at 
=0. The HLODs at these loci were zero, and inspection of the segregation of 
alleles showed, as expected, only a small minority of pedigrees consistent 
with  linkage.  The  SSRs  selected  to  test  the  VDCC  subunits  CACNA1B 
(D9S158)  and  the  CACNG6,  CACNG7,  CACNG8  cluster  (D19S572)  both 
map  to  within  5cM  of  the  genes  under  investigation.  Both  markers  gave 
exclusionary LOD scores up to a recombination fraction of =0.1. The LOD 
score at D16S420, which lies 31 kb telomeric to CACNG3, was -3.34 at =0. 
The HLOD however was 0.55 (=0.35) and the NPL score 1.21. The PDT 
showed no evidence of allelic association at D16S420.   188 
Six SSLP loci encompassing ten VDCC subunits were tested using between 
two  and  four  SSLP  polymorphisms  to  encompass  each  locus.  The  four 
markers  on  chromosome  3p14-p21  (D3S3582,  D3S1568,  D3S1588, 
D3S1289) gave a LOD score of –11.5 at the value of  corresponding to the 
location of CACNA1D (Figure 11-1(c)). Four markers on chromosome 22q12-
q13  (D22S1156, D22S284, D22S283, D22S426) gave a LOD score of –4.54 
at  the    corresponding  to  CACNG2,  and  a  LOD  score  of  –6.54  at  the   
corresponding to CACNA1I (Figure 11-2(c)). CACNB4 was tested using two 
markers on chromosome 2q23 (D2S2236, D2S2299) giving a LOD score of –
6.9 at the relevant recombination fraction (Figure 11-1(b)). The HLODs at 
each  of  these  loci  were  zero.  The  cluster  of  three  VDCC    subunits 
(CACNG5, CACNG4, CACNG1) on chromosome 17 is encompassed by two 
markers  (D17S807,  D17S1821)  (Figure  11-2(b)).    The  maximum  (least 
negative) LOD score between these two markers was –6.9, with an HLOD of 
zero. CACNA1E was tested using two markers on chromosome 1q31-q32 
(D1S212,  D1S2848) which  gave  a  LOD  score  of  –3.6  at  the  approximate 
location  of  CACNA1E  (Figure  11-1(a)).  The  two  markers  on  chromosome 
16p12-p13.3  (D16S521,  D16S3024)  gave  a  LOD  score  of  –6.7  at  the   
corresponding to CACNA1H (Figure 11-2(a)).    189 
 
Table 11-1 Two-point LOD scores for 33 CAE pedigrees at six single SSLP 
loci to which eight voltage-dependent calcium channel subunit genes map. 
D19S1150, A1GUCL and D3S1568 are intragenic markers.     
 
      LOD score at recombination fraction,  
Gene  Location  Marker  0.00  0.01  0.05  0.10  0.20  0.30  0.40 
CACNA1A  19p13.3  D19S1150  -15.16  -11.86  -7.22  -4.63  -2.02  -0.77  -0.18 
CACNA1B  9q24  D9S158  -13.09  -9.75  -5.53  -3.38  -1.39  -0.55  -0.18 
CACNA1G  17q22  A1GUCL  -6.48  -4.81  -2.70  -1.65  -0.68  -0.25  -0.05 
CACNA2D2  3p14-21  D3S1568  -7.60  -5.47  -2.60  -1.19  -0.10  0.16  0.11 
CACNG3  16p12-p13.1  D16S420  -3.34    -2.06    -0.40     0.34     0.67     0.42     0.09 
CACNG6 
19q13.4 
               
CACNG7  D19S572  -11.30    -8.48    -4.95    -3.10    -1.28    -0.45    -0.10  
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Figure 11-1 Thirty-three absence pedigrees: multipoint parametric and 
non-parametric  linkage  analysis  at  VDCC  loci  CACNA1E,  CACNB4, 
CACNA1D, CACNA2D2 




















































































































CACNA1D  191 
Figure 11-2 Thirty-three absence pedigrees: multipoint parametric and 
non-parametric  linkage  analysis  at  VDCC  loci  CACNA1H,  CACNG1, 
CACNG4, CACNG5, CACNA1I, CACNG2 





































a) Chromosome 16p13.3: CACNA1H 






































b) Chromosome 17q14: CACNG1, CACNG4, 
CACNG5 

















































c) Chromosome 22q12-13: CACNA1I, CACNG2   192 
11.2  GABAAR subunit genes 
The  cluster  of  four  GABAAR  subunits  (GABRB2,  GABRA6,  GABRA1, 
GABRG2)  on  chromosome  5q31.1-q33.2,  were  tested  using  two  markers 
(D5S2112, D5S422) spanning the genes. The maximum LOD score across 
this region was –11.8, thus excluding all four genes (Figure 11-3). GABRB1 
on  chromosome  4p13-p12  was  tested  using  an  intragenic  tetranucleotide 
repeat polymorphism (GABRB1(GATA)). The LOD score at =0 was –11.6. 
GABRA4 and GABRA2 lie telomeric to GABRB1, at physical distances of 190 
kb and 607 kb respectively. The LOD score at =0.5 from GABRB1 was –4.8, 
thus  also  excluding  GABRA4  and  GABRA  (Table  11-2).  Three  SSR  loci 
(GABRB3(CA), 155CA2, A55CA1) were used to test the cluster of GABAAR 
subunits  (GABRA5,  GABRB3,  GABRG3)  on  chromosome  15q11-q13. 
Although the maximum LOD across this region was –5.6, the HLOD was 0.69 
at the GABRB3 intragenic marker (155CA2) with a corresponding alpha of 
0.33. Similarly, the HLOD was 0.78 at A55CA1 (adjacent to the 5‟ end of 
GABRA5)  with  a  corresponding  alpha  of  0.35  (Figure  11-4).  The 
corresponding NPL scores at these two markers were both 2.49 (p=0.005). 
GABRG3 physically maps just outside the region encompassed by the three 
SSR  loci,  approximately  23  kb  telomeric  to  GABRA5.  Examination  of  the 
haplotypes showed that 20 of the 33 families were consistent with linkage at 
the A55CA1 locus. Thus a proportion of families could not be excluded from 
linkage to GABRA5, GABRB3 or GABRG3. The PDT did not demonstrate 
allelic association at these loci. 
   193 
Table 11-2 Two-point LOD scores for 33 CAE pedigrees at GABRB1(GATA) 
at which three GABAAR subunit genes map. GABRB1(GATA) is intragenic to 
GABRB1 
      LOD score at recombination fraction,  
Gene  Location  Marker  0.00  0.01  0.05  0.10  0.20  0.30  0.40 
GABRB1                   
GABRA4  4p13-12  GABRB1(GATA)  -11.56  -8.55  -4.77  -2.91  -1.20  -0.44  -0.11 
GABRA2                   






Figure 11-3 Thirty-three absence pedigrees: multipoint parametric and non-
parametric  linkage  analysis  at  chromosome  region  5q31.1-33.2 














Figure 11-4 Thirty-three absence pedigrees: multipoint parametric and non-
parametric linkage analysis at chromosome region 15q11-13 encompassing 
GABRB3, GABRA5, GABRG3 





























































































b) Heterogeneity LOD (HLOD) and corresponding 
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11.3  GABABR subunit genes 
The  GABAB  receptor  gene  GABBR1  on  chromosome  6p21.3  was  tested 
using three markers (D6S625, D6S478, D6S1281) spanning approximately 
3cM. GABBR1 lies between D6S478 and D6S1281. The LOD score at the  
corresponding  to  GABBR1  was  -18.16  with  an  HLOD  of  zero  (Figure 
11-5(a)). GABBR2 on chromosome 9q22.1 was tested using four markers 
(D9S1816,  D9S1809,  D9S272,  D9S176).  GABBR2  lies  between  D9S1809 
and D9S272, and the LOD score at this location was approximately -10 with 
an HLOD of zero (Figure 11-5(b)). 
11.4  ECA1 locus 
The ECA1 locus on 8q24 was tested using the marker D8S534. The LOD 













Figure 11-5 Thirty-three absence pedigrees: multipoint parametric and non-
parametric linkage analysis at chromosome regions encompassing GABBR1 
and GABBR2 
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Chapter 12  Further investigation of candidate gene 
loci implicated by initial linkage analysis 
Following  the  preliminary  linkage  analysis,  candidate  gene  loci  showing 
positive linkage were tested in the expanded collection of 53 CAE families, 
82  absence  families  and  217  parent-child  trios.  Maximum  HLODs  are 
summarised in Table 12-1. Maximum NPL scores are summarised in Table 
12-2. 
12.1  Voltage-dependent calcium channel gene: CACNG3 
CACNG3 showed evidence of possible linkage with a positive HLOD in the 
initial cohort of 33 absence pedigrees.  CACNG3  was therefore tested by 
linkage in the larger cohorts of CAE and AE pedigrees using three SSLP 
markers  spanning  the  gene,  D16S420  and  two  novel  SSLPs, 
CACNG3EX1CA and UCL10321 (Figure 12-1, Appendix 15). D16S420 lies 
31kb  5‟  (telomeric)  to  CACNG3.  CACNG3EX1CA  is  a  CA  repeat 
polymorphism which lies 73bp 5' to  CACNG3 exon 1. UCL10321 is a CA 
repeat 135kb 3' (centromeric) to CACNG3. 
12.1.1 Fifty-three CAE families: linkage analysis of CACNG3 
Parametric  linkage  analysis  was  performed  in  the  53  CAE  families  using 
GENEHUNTER assuming  AD inheritance with  penetrance of  0.7  and  0.5. 
Criteria  for  affectedness  was  „childhood  absence  epilepsy‟  as  defined  in 
section 5.3.1. The LOD scores remained negative in this larger cohort of CAE 
families:  maximum  LOD=  -2.3  with  penetrance=0.7  and  LOD=  -1.6  with 
penetrance=0.5  (Figure  12-2(a)).  However,  the  HLOD  increased  to  3.22 
(alpha=0.58) with penetrance of 0.7, and 3.03 (alpha=0.61) with penetrance 
of 0.5 (Figure 12-2(b,c)). HLOD was maximal between CACNG3EX1CA and 
UCL10321. The NPL score also increased to a maximum of 2.59 (p=0.003).    198 
The  transmission  disequilibrium  test  performed  on  each  SSLP  in  turn 
produced a significant association with the disease phenotype for allele 1 of 
CACNG3EX1CA, which was transmitted from a heterozygous parent to an 
affected offspring 45 times, and untransmitted 21 times (
2=8.73, p=0.003) 
(Appendix 20a). Allele 2 of CACNG3EX1CA was associated with a protective 
effect (transmitted 22, untransmitted 44,  
2=7.33, p=0.007). Two alleles of 
UCL10321  also  showed  borderline  significant  associations,  one  positive 
association  with  the  disease  phenotype  (transmitted  9,  untransmitted  2, 

2=4.45, p=0.035), and one negative association with the disease phenotype 
(transmitted 27, untransmitted 49, 
2=6.37, p=0.012). 
The PDT also produced a significant association with the disease phenotype 
for allele 1 of CACNG3EX1CA (p=0.005) and a negative association for allele 













Figure  12-1  Position  of  three  SSLPs,  D16S420,  CACNG3EX1CA  and 
UCL10321 relative to the VDCC gene, CACNG3. Image modified from the 



























Figure  12-2  Fifty-three  CAE  pedigrees:  Multipoint  parametric  (AD 
inheritance, penetrance 0.7 and 0.5) and non-parametric linkage analysis at 
CACNG3 locus on chromosome 16p12-13.3 
b) Heterogeneity LOD (HLOD) and corresponding 



















































c) Heterogeneity LOD (HLOD) and corresponding 



















































a) LOD (assuming AD inheritance) and NPL 
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12.1.2  Eighty-two  absence  families:  linkage  analysis  of 
CACNG3 
CACNG3  was  then  tested  in  the  eighty-two  absence  families  by  linkage 
analysis with criteria for affectedness CAE, JAE or AE as defined in section 
1.1.  Parametric  linkage  analysis  was  performed  using  GENEHUNTER 
assuming AD inheritance with penetrance of 0.7 and 0.5. The homogeneity 
LODs were negative with penetrances of 0.7 and 0.5 (maximum LODs -5.6 
and -4.5 respectively) (Figure 12-3(a)). The maximum HLOD with penetrance 
0.7  was  3.44  (alpha=0.52)  (Figure  12-3(b)).  The  maximum  HLOD  with 
penetrance 0.5 was 3.36 (alpha=0.55) (Figure 12-3(c)). HLOD was maximal 
between markers CACNG3EX1CA and UCL10321. The maximum NPL score 
was 2.74 (p=0.002) at marker UCL10321. 
The transmission disequilibrium test performed on each SSLP in turn again 
produced  a  significant  result  for  allele  1  of  CACNG3EX1CA,  which  was 
transmitted from a heterozygous parent to an affected offspring 63 times, and 
untransmitted  36  times  (
2=7.36,  p=0.007)  (Appendix  20b).  Allele  2  of 
CACNG3EX1CA was associated with a weakly protective effect (transmitted 
38, untransmitted 63, 
2=6.19, p=0.013). 
The PDT also showed a positive association with the disease phenotype for 
allele 1 of CACNG3EX1CA (p=0.009) and a negative association for allele 2 




















Figure  12-3  Eighty-two  Absence  pedigrees:  Multipoint  parametric  (AD 
inheritance, penetrance 0.7 and 0.5) and non-parametric linkage analysis at 
CACNG3 locus on chromosome 16p12-13.3 
 
a) LOD (assuming AD inheritance) and NPL 




















































b) Heterogeneity LOD (HLOD) and corresponding 



















































c) Heterogeneity LOD (HLOD) and corresponding 
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12.2  GABAAR subunit gene cluster on chromosome 15q11-
13 
The  GABAAR  subunits  GABRBB3,  GABRA5,  GABRG3  also  showed 
evidence  of  weak  linkage  with  a  positive  HLOD in  the  initial cohort  of  33 
absence pedigrees. This cluster of GABAAR subunits on chromosome 15q 
was  therefore  tested  by  linkage  in  the  larger  cohorts  of  CAE  and  AE 
pedigrees. Four SSLP markers were used; GABRB3(CA), 155CA2, A55CA1 
as  used  in  the  preliminary  linkage  (Table  7-1),  and  an  additional  marker 
D15S156 which encompasses the telomeric end of the cluster and lies 29kb 
3‟ to GABRG3 (Figure 12-4). 
12.2.1 Fifty-three CAE families: linkage analysis of GABRB3, 
GABRA5, GABRG3 
Parametric  linkage  analysis  was  performed  in  the  53  CAE  families  using 
GENEHUNTER assuming  AD inheritance with  penetrance of  0.7  and  0.5. 
Criteria  for  affectedness  was  „childhood  absence  epilepsy‟  as  defined  in 
section 5.3.1. The LOD scores remained very negative in the larger cohort of 
CAE  families:  maximum  LOD=  -9.4  with  penetrance=0.7  and  maximum 
LOD= -6.9 with penetrance=0.5 (Figure 12-5(a)). The HLOD increased to a 
maximum of 0.97 (alpha=0.32) with penetrance of 0.7, and 1.18 (alpha=0.38) 
with penetrance of 0.5 (Figure 12-5(b,c). The peak HLOD occurred at marker 
155CA2 which is intragenic to GABRB3.  
The  NPL  score  increased  to  a  maximum  of  3.05  (p=0.0006)  at  marker 
D15S156  (Figure  12-5(a)).  The  discrepancy  between  the  HLOD  and  NPL 
scores suggested that the data may be more consistent with a non-dominant 
mode of inheritance. Parametric linkage analysis was therefore performed 
assuming AR inheritance with penetrance of 0.7 and 0.5 (Figure 12-6). The 
LOD scores remained negative, but the HLODs increased to a maximum of 
1.34  (alpha=0.34)  with  penetrance  of  0.7,  and  1.84  (alpha=0.46)  with 
penetrance  of  0.5.  The  peak  HLODs  now  occurred  adjacent  to  marker 
D15S156.   203 
The  transmission  disequilibrium  test  performed  on  each  SSLP  in  turn 
identified one allele of 155CA2 which may be associated with a protective 
effect,  as  it  was  only  transmitted  once  from  a  heterozygous  parent  to  an 
affected offspring, but untransmitted 10 times (
2=7.36, p=0.007) (Appendix 
21a).  A  borderline  significant  protective  effect  was  also  associated  with 
another allele of 155CA2 (transmitted 8, untransmitted 20, 
2=5.14, p=0.02) 
and  one  allele  of  A55CA1  (transmitted  19,  untransmitted  37,  
2=5.79, 
p=0.02).  Another  allele  of  A55CA1  showed  a  weak  association  with  the 
disease phenotype (transmitted 14, untransmitted 5, 
2=4.26, p=0.04). 
The PDT also showed a negative association with the disease phenotype for 
two alleles of 155CA2 (p=0.02 and 0.03) and a negative association for one 









Figure  12-4  Position  of  four  SSLPs,  GABRB3CA,  155CA2,  A55CA1  and 
D15S156    relative  to  the  GABAAR  gene  cluster,  GABRB3,  GABRA5  and 
GABRG3  on  chromosome  15q11-13  .  Image  modified  from  the  UCSC 



























Figure  12-5  Fifty-three  CAE  pedigrees:  Multipoint  parametric  (AD 
inheritance, penetrance 0.7 and 0.5) and non-parametric linkage analysis at 
GABAAR gene cluster,  GABRB3, GABRA5 and GABRG3 on chromosome 
15q11-13 
 
b) Heterogeneity LOD (HLOD) and corresponding 























































c) Heterogeneity LOD (HLOD) and corresponding 
























































a) LOD (assuming AD inheritance) and NPL 












































































Figure  12-6  Fifty-three  CAE  pedigrees:  Multipoint  parametric  (AR 
inheritance, penetrance 0.7 and 0.5) and non-parametric linkage analysis at 
GABAAR gene cluster, GABRB3, GABRA5 and GABRG3 on chromosome 
15q11-13 
a) LOD (assuming AR inheritance) and NPL 
























































b) Heterogeneity LOD (HLOD) and corresponding 

























































c) Heterogeneity LOD (HLOD) and corresponding 
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12.2.2  Eighty-two  Absence  families:  linkage  analysis  of 
GABRBB3, GABRA5, GABRG3 
GABRBB3,  GABRA5  and  GABRG3  were  then  tested  in  the  eighty-two 
absence families by linkage analysis with criteria for affectedness CAE, JAE 
or AE as defined in section 1.1. Parametric linkage analysis was performed 
using GENEHUNTER assuming AD inheritance with penetrance of 0.7 and 
0.5. The maximum LOD scores remained very negative in the larger cohort of 
AE families: maximum LOD= -12.0 with penetrance=0.7 and LOD= -9.1 with 
penetrance=0.5  (Figure  12-7(a)).  The  maximum  HLOD  was  2.04 
(alpha=0.40) with penetrance of 0.7, and 2.31 (alpha=0.45) with penetrance 
of 0.5 (Figure 12-7(b,c)). The peak HLOD again occurred at marker 155CA2, 
intragenic to GABRB3. 
LOD  scores  were  also  calculated  assuming  AR  inheritance  (Figure  12-8).  
The  homogeneity  LODs  remained  very  negative  throughout,  and  the 
maximum  HLODs  were  1.83  (alpha=0.28)  with  penetrance  0.7,  and  2.07 
(alpha=0.35) with penetrance 0.5, at the position of marker 155CA2. 
The maximum NPL score was now 3.74 (p=.0.00004), also at the intragenic 
GABRB3 marker 155CA2.  
The  transmission  disequilibrium  test  performed  on  each  SSLP  in  turn 
identified  one  allele  of  GABRB3CA  which  showed  a  weakly  positive 
association  with  the  disease  phenotype  (transmitted  14,  untransmitted  5, 

2=4.26, p=0.04), and one allele of A55CA1 with a weakly negative effect 
(transmitted 26, untransmitted 46, 
2=5.56, p=0.02) (Appendix 21b). 
The  PDT  also  showed  a  negative  association  for  one  allele  of  marker 




















Figure  12-7  Eighty-two  Absence  pedigrees:  Multipoint  parametric  (AD 
inheritance, penetrance 0.7 and 0.5) and non-parametric linkage analysis at 
GABAAR gene cluster,  GABRB3, GABRA5 and GABRG3 on chromosome 
15q11-13 
a) LOD (assuming AD inheritance) and NPL 





















































b) Heterogeneity LOD (HLOD) and corresponding 





















































c) Heterogeneity LOD (HLOD) and corresponding 








































































Figure  12-8  Eighty-two  Absence  pedigrees:  Multipoint  parametric  (AR 
inheritance, penetrance 0.7 and 0.5) and non-parametric linkage analysis at 
GABAAR gene cluster,  GABRB3, GABRA5 and GABRG3 on chromosome 
15q11-13
a) LOD (assuming AR inheritance) and NPL 






















































b) Heterogeneity LOD (HLOD) and corresponding 






















































c) Heterogeneity LOD (HLOD) and corresponding 
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Table 12-1  Maximum HLODs at CACNG3 on chromosome 16p12-13.3 and GABRB3, GABRA5, GABRG3 on chromosome 
15q11-13) for two phenotypes, CAE and Absence 






Alpha  Information  Marker position 
CACNG3  (16p12-
13.3)  53 CAE pedigrees  AD  0.7  3.22  0.58  0.87  CACNG3EX1CA 




82  Absence 
pedigrees  AD  0.7  3.44  0.53  0.85 
CACNG3EX1CA-
UCL10321 
      0.5  3.36  0.55  0.88  UCL10321 
GABRB3,  GABRA5, 
GABRG3 (15q11-13)  53 CAE pedigrees  AD  0.7  0.97  0.32  0.95  155CA2 
      0.5  1.18  0.38  0.95  155CA2 
    AR  0.7  1.34  0.34  0.84  A55CA1-D15S156 
      0.5  1.84  0.46  0.84  A55CA1-D15S156 
 
82  Absence 
pedigrees  AD  0.7  2.04  0.40  0.97  155CA2 
      0.5  2.31  0.45  0.97  155CA2 
    AR  0.7  1.83  0.28  0.97  155CA2 
      0.5  2.07  0.35  0.97  155CA2 
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Table 12-2 Maximum NPL scores at CACNG3 on chromosome 16p12-13.3 
and  GABRB3,  GABRA5,  GABRG3  on  chromosome  15q11-13)  for  two 







p-value  Information   Marker position 
CACNG3  
(16p12-13.3) 
53  CAE 
pedigrees  2.59  0.00303  0.91  CACNG3EX1CA 
 
82  Absence 





53  CAE 
pedigrees  3.05  0.00059  0.90  D15S156 
 
82  Absence 
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12.3  Multilocus linkage analysis 
The CACNG3 locus on chromosome 16p12-p13.1 and the GABAAR subunit 
cluster  on  chromosome  15q11-13  were  tested  simultaneously  using 
GENEHUNTER-TWOLOCUS. Three  dominant  digenic  models  were  tested 
(penetrance  matrices  shown  in  Figure  8-1).  The  results  of  the  two-locus 
parametric  and  non-parametric  linkage  analysis  are  compared  with  the 
single-locus linkage results in Table 12-3 and Table 12-4. 
12.3.1 Fifty-three CAE families: two-locus linkage analysis 
In the 53 CAE families, the multiplicative model produced the maximum two-
locus HLOD, 4.84 (alpha =0.54) at marker D16S420 on chromosome 16 and  
155CA2 on chromosome 15, corresponding to the 5‟ end of CACNG3 and 
the 5‟ end of GABRB3 respectively (Figure 12-9(a)). The heterogeneity and 
additive  models  yielded  maximum  HLOD  scores  of  3.02  and  4.01, 
respectively.  The  maximum  NPL  score  was  3.99  (p=0.000012)  at  marker 
UCL10321 on chromosome 16, which lies 3‟ of CACNG3, and D15S156 on 
chromosome 15, lying 3‟ of GABRG3 (Figure 12-9(b)). This p value reflects a 
test  of  the  null  hypothesis  that  both  disease  loci  are  unlinked  to  their 
corresponding marker maps. 
12.3.2 Eighty-two  Absence  families:  two-locus  linkage 
analysis 
The multiplicative model again produced the maximum two-locus HLOD, 5.71 
(alpha=0.47)  between  markers  CACNG3EX1CA  and  UCL10321  on 
chromosome  16  (centromeric  to  CACNG3),  and  at  marker  155CA2  on 
chromosome 15 (5‟ end of GABRB3) (Figure 12-10(a)). The heterogeneity 
and  additive  models  produced  maximum  HLOD  scores  of  2.82  and  4.67, 
respectively. The maximum NPL was 4.57 (p=0.0000007459) at UCL10321 




















Figure  12-9  Fifty-three  CAE  pedigrees:  Two-locus  (a)  parametric 
(multiplicative model) and (b) non-parametric linkage analysis at  CACNG3 
locus  on  chromosome  16p12-13.3  and  GABAAR  gene  cluster,  GABRB3, 
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Figure  12-10  Eighty  two  Absence  pedigrees:  Two-locus  (a)  parametric 
(multiplicative model) and (b) non-parametric linkage analysis at  CACNG3 
locus  on  chromosome  16p12-13.3  and  GABAAR  gene  cluster,  GABRB3, 
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Table  12-3  Comparison  of  parametric  linkage  results  from  2-locus  and 




Patient resource  Max 
HLOD 






Two  loci 
16p & 15q 
Multiplicative model:           
 
53 CAE pedigrees  4.84  0.54  0.91  D16S420  155CA2 
 
82  Absence 
pedigrees  5.71  0.47  0.90 
CACNG3EX1CA-
UCL10321  155CA2 
             
  Heterogeneity model:           
 
53 CAE pedigrees  3.02  0.69  0.92  D16S420  155CA2 
 
82  Absence 
pedigrees  2.82  0.56  0.91  D16S420  GABRB3(CA) 
             
  Additive model:           




82  Absence 
pedigrees  4.67  0.81  0.91 
CACNG3EX1CA-
UCL10321  155CA2 
             
CACNG3 
(16p12-
13.3)  53 CAE pedigrees  3.22  0.58  0.87  CACNG3EX1CA   
 
82  Absence 
pedigrees  3.44  0.53  0.85 
CACNG3EX1CA-
UCL10321   









82  Absence 
pedigrees  2.31  0.45  0.97    155CA2 
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Table 12-4 Comparison of non-parametric linkage results from 2-locus and 
single-locus analyses for CACNG3 and the 15q GABAA receptor gene cluster 
Loci 
tested 
Patient resource  Max 
NPL 






Two  loci 
16p & 15q  53 CAE pedigrees  3.99  0.000012  0.89  UCL10321  D15S156 
 
82  Absence 
pedigrees  4.57  7.46E-07  0.91  UCL10321  155CA2 
             
CACNG3  
(16p12-
13.3)  53 CAE pedigrees  2.59  0.00303  0.91  CACNG3EX1CA   
 
82  Absence 
pedigrees  2.74  0.00195  0.88  UCL10321   




(15q11-13)  53 CAE pedigrees  3.05  0.00059  0.9    D15S156 
 
82  Absence 
pedigrees  3.75  0.00004  0.97    155CA2   216 
Chapter 13  Sequencing  of  CACNG3  coding 
sequence 
Direct  sequencing  of  exonic  DNA  and  surrounding  intronic  and  promoter 
sequence DNA of CACNG3 in 73 individuals identified 34 sequence variants 
(Figure 13-1). Four were upstream of the gene, five in the 5‟UTR, six in intron 
1, five in intron 2, nine in intron 3, one in exon 4, two in the 3‟UTR and two 
downstream of the gene. Sixteen were novel variants, and the remaining 18 
were known SNPs. 
Details  of  all  variants  found  are  given  in  Table  13-1.  The  one  coding 
sequence  variant  was  identified  in  4  cases,  rs12928078,  which  is  a 
synonymous SNP (c.2121A G, P307P). 
The minor allele frequency (MAF) of each variant in the sequenced cases 
was compared with that quoted in the NCBI database (if that information was 
available), as an initial assessment of a possible causal effect. The two SNPs 
showing the greatest difference in MAF between cases and controls were 
rs1494550  (0.340  vs  0.209)  and  rs12932291  (0.238  vs  0.129).  SNP 
rs1494550 also showed the maximum MAF in the sequenced cases. These 
two  SNPs  were  therefore  selected  for  typing  in  the  whole  resource  and 
included in the association analysis (Chapter 14). 
Sequence conservation in three species for each variant is shown in Table 
13-1.  Eight SNPs occurred in sequence known to be conserved in all three 
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Figure 13-1 Maps illustrating locations of all variants in CACNG3 found by 
sequencing of 73 affected individuals.   218 
 
Table 13-1 Details of variants found during sequencing of CACNG3 exons and neighbouring intronic regions. 






MAF  (NCBI  SNP 
database) 
Case Population 
MAF  (73 
sequenced 
cases) 
Conserved  in 
Pan 
troglodytes 
Conserved  in 
Rattus 
norvegicus 
Conserved  in 
Mus musculus 
rs1494550  24174105  T  C  0.209  0.340  (0.287
2)  Yes  Yes  Yes 
s1  24174172  G  C    0.009  Yes  Yes  Yes 
rs1494551  24174285  A  G  0.278  0.198  Yes  No  No 
s2  24174371  C  T    0.019  Yes  Unknown  Unknown 
s3  24174934  C  A    0.017  Unknown  No  Unknown 
s4   24174980  T  delT  0.074
1  0.058
  (0.054
2)  Yes  Yes  Unknown 
rs5816246  24175122  CA  delCA    0.185  Unknown  Yes  Yes 
s5  24175161  T  A    0.141  Unknown  Yes  No 
s6  24175163  A  T    0.043  Unknown  Yes  Yes 
s7  24175353  C  T    0.021  Yes  Yes  Yes 
s8  24265409  A  delA    0.016  Yes  Unknown  Unknown 
rs7204923  24265452  C  G    0.008  Yes  Unknown  Unknown 
rs9929027  24265457  C  T  0.044  0.008  Yes  Unknown  Unknown 
rs9929254  24265484  G  A  0.055  0.008  Yes  Unknown  Unknown 
rs5816249  24265501  G  delG    0.159  Yes  Unknown  Unknown 
s9  24265507  A  G    0.008  No  Unknown  Unknown 
rs9940070  24265687  T  C  0.003  0.016  No  No  No   219 
1 Based on 94 ECACC (European Collection of Cell Cultures) controls 
2 Based on 299 genotyped unrelated affecteds 






MAF  (NCBI  SNP 
database) 
Case Population 
MAF  (73 
sequenced 
cases) 
Conserved  in 
Pan 
troglodytes 
Conserved  in 
Rattus 
norvegicus 
Conserved  in 
Mus musculus 
rs9929298  24265719  C  G  0.053  0.016  No  No  No 
rs9929236  24265745  A  G  0.053  0.016  No  Unknown  Unknown 
s10  24273508  C  T    0.008  Yes  Yes  Yes 
rs5816250  24273995  A  delA    0.134  Yes  Yes  Yes 
rs714822  24274017  C  G  0.127  0.176  No  No  No 
s11  24274030  T  C    0.010  Yes  No  No 
rs5816251  24274096  AA  delAA    0.038  Yes  Partial  No 
rs5816252  24274201  –  delC    0.278  Yes  Yes  Yes 
rs9934500  24274463  A  C    0.206  Yes  Unknown  Unknown 
rs1076217  24274472  T  C    0.250  Yes  Unknown  Unknown 
s12  24279944  T  C    0.010  Yes  No  No 
s13  24280054  T  C    0.011  Yes  No  No 
rs12928078  24280658  G  A  0.051  0.045  Unknown  Yes  Yes 
s14  24280881  –  insT    0.056  Unknown  Yes  Yes 
s15  24281176  C  T    0.008  Yes  Yes  Yes 
rs12932291  24281270  C  G  0.129  0.238  Yes  Yes  Yes 
s16  24281402  G  A    0.244  Yes  Unknown  No   220 
13.1  Bioinformatic analysis of variants 
Identified  variants  were  assessed  for  any  potential  functional  affect  by 
searching  for  predicted  regulatory  motifs,  splice  sites  and  exonic  splicing 
enhancers (ESEs) as described in Chapter 10. 
13.1.1 Exonic splicing enhancer motifs 
ESE  finder  identified  14  exonic  splicing  enhancer  binding  motifs, 
encompassing a total of seven SNPs (including the synonymous exon 4 SNP 
rs12928078) which could potentially be altered by an identified variant (Table 
13-2). These alterations can cause aberrant splicing and subsequently result 
in exon skipping. Eight putative ESE motifs, containing a total of six of the 
SNPs, were abolished by the variant SNP allele (ie the score, which is a 
measure of agreement between the putative ESE motif and the consensus 
sequences for a specific SR protein, was below the threshold value for that 
protein). The scores at six other ESE motifs, encompassing five SNPs, were 
altered by the variant allele (five increased, one decreased), but the scores 
remained above the threshold for both alleles of each SNP. 
13.1.2 Splice site prediction 
Many donor and acceptor sites were predicted by Genesplicer, three of which 
could potentially be affected by the variants identified through sequencing 
(Table  13-3).  A  novel  acceptor  site  is  created  when  the  non-reference 
sequence form of rs1494550 is present. Another acceptor site predicted to 
exist  becomes  significantly  stronger  when  the  variant form of  SNP  s11  is 
present. The variant form of SNP s16 alters the position of a potential donor 
site. 
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Table  13-2  Analysis  of  exonic  splicing  enhancers  potentially  altered  by 
variants  identified  in  CACNG3.  The  position  of  the  indicated  variant  is 















s3  5'UTR  C/A  SC35  2.383  CGCCCCCA  3.329  3.605 
s5  5'UTR  T/A  SF2/ASF  1.956  CACACTC  2.262  deleted 
      SRp40  2.670  TCACACA  3.637  deleted 
s6  5'UTR  A/T  SF2/ASF  1.956  CACACAG  3.285  2.162 
      SRp40  2.670  TCACACA  3.637  deleted 
      SRp40  2.670  ACACAGA  2.893  3.943 
s7  5'UTR  C/T  SF2/ASF  1.956  CCCCCGG  3.143  3.746 
      SF2/ASF  1.956  CCCCGGA  3.266  deleted 
rs12928078  Exon 4  G/A  SF2/ASF  1.956  CGGCCAA  2.324  2.772 
      SRp55  2.676  TCCGGC  3.018  deleted 
      SC35  2.383  GGCCAACA  3.608  deleted 
s14  3'UTR  -/insT  SRp40  2.670  TTTCAAG  4.397  deleted 
s15  3'UTR  C/T  SF2/ASF  1.956  GCCCCGA  2.293  deleted 
      SC35  2.383  GAGCCCCG  3.139  3.783 
 
 
Table 13-3 Splice sites predicted by Genesplicer, potentially affected by the 
identified variants. The position of the indicated variant is identified in bold. 
The splice-site dinucleotide is underlined. Strength of site according to the 
scoring of Pertea et al (Pertea, Lin et al. 2001). 
a) With all variants in the reference sequence form: 
SNP  Start position  Sequence  End position  Score 
Splice 
site type  Direction  
s11  24274030  ttgaaagaga   24274039  4.91 
   
acceptor  reverse 
s16  24281402  atgtccaa...gctgg   24281471  1.47 
      
donor  reverse 
             
             
 b) With all variants in the non-reference sequence form: 
SNP  Start position  Sequence  End position  Score 
Splice 
site type  Direction  
rs1494550  24174105  cta  24174107  4.64 
   
acceptor  reverse 
s11  24274030  ctgaaagaga   24274039  8.70 
   
acceptor  reverse 
s16  24281402  gtgtccaaa  24281410  1.53 
      
donor  forward 
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13.1.3 Other regulatory motifs 
A search for regulatory motifs which could potentially be disrupted by any of 
the  variants  bases  on  the  Transfac  and  Biobase  databases 
(http://linux1.softberry.com/berry.phtml?topic=nsite&group=programs&subgro
up=promoter) did not identify any clear candidates. 
 
13.1.4 Summary of likely functional variants (Figure 13-2) 
On the basis of the above bioinformatics analyses, the variants most likely to 
be functional are rs1494550 (splice site), s5 (ESE), s6 (ESE), s7 (ESE), s11 
(splice  site),  rs12928078  (ESE),  S14  (ESE),  S15  (ESE).  The  variants 
rs1494550 and rs12932291 showed the greatest difference in MAF between 
cases and controls. These two SNPs, as well as s7 and s15, are shown to be 
conserved at the nucleotide level in the chimpanzee.   223 

















Figure 13-2 Maps illustrating locations of those variants in CACNG3 most 
likely to be functional (underlined variants). 
  Alters ESE       
Alters splice site 
Greatest MAF difference between cases and controls   
Conserved in chimpanzee  224 
Chapter 14  SNP  based  association  analysis  of 
CACNG3 
As  no  clear  functional  candidates  in  CACNG3  had  been  identified  by 
sequencing of exonic DNA and surrounding intronic and promoter sequence 
in affected individuals, further SNP based analysis was performed to identify 
the LD block structure across the gene and to investigate association with the 
disease phenotypes in the entire resource of 82 extended pedigrees and 217 
trios. 
14.1  LD block structure of CACNG3  
Analysis of LD based on the entire resource of 82 pedigrees and 217 trios 
identified  5  LD  blocks  (Figure  14-1).  Block  1  encompassed  exon  1  of 
CACNG3, block 4 exon 2, and block 5 exons 3 and 4. This was compared 
with  the  LD  block  structure  predicted  by  the  HapMap  project  genotyped 
SNPs (based on CEPH caucasian data for 233 SNPs). The HapMap data 
identified 21 blocks of LD across the same region (Figure 14-2). 
To  test  whether  a  small  subset  of  trios  would  generate  a  similar  block 
structure  to  the  entire  resource,  the  SNP  data  from  31  trios,  selected 
randomly,  was analysed independently. As  with the entire resource, 5 LD 
blocks  were  identified  (Figure  14-3).  There  was  some  variation  in  the 
boundary SNPs of blocks 1 and 2, but blocks 3-5 were identical. 
 
 














Figure  14-1  Block 
structure  of  CACNG3 
locus  based  on  entire 
patient  resource  as 
defined  by  Haploview 
using a minimum D‟ of 0.7. 
 










Figure 14-2 Block structure 
of CACNG3 locus based on 
HapMap  genotyped  SNPs 
as  defined  by  Haploview 
using a minimum D‟ of 0.7. 
The  block  structure  based 
on  the  patient  resource  is 
included for comparison. 
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Figure  14-3  Block  structure 
of CACNG3 locus based on 
subset of 31 trios as defined 
by  Haploview  using  a 
minimum D‟ of 0.7. The block 
structure based on the entire 
resource  is  included  for 
comparison. 
 
Block 1 Block 5 Block 4 Block 3 Block 2
Block 1 Block 5 Block 4 Block 3 Block 2
Block structure from 
entire resource:
Block structure from 
31 trio subset:  228 
14.2  Tagging SNPs for CACNG3 
Tagging SNP analysis using the two methodologies employed by Haploview 
produced  similar  results.  Using  the  LD  block  structure  and  a  haplotype 
frequency cut off of 1%, 19 tag SNPs were identified (Appendix 24a). The 
block haplotypes with frequency greater than 1% and the relevant tag SNPs 
are shown in Figure 14-4. The Tagger methodology identified 18 tag SNPs 
(Appendix 24a). The SNPs captured by the tag SNPs are shown in Appendix 
24b. 
For comparison, tag SNPs were also identified using the subset of 31 trios 
(Appendix 24a). Using the LD block structure and a haplotype frequency cut 
off  of  1%,  20  tag  SNPs  were  identified  (incorporating  the  19  tag  SNPs 
identified in the whole resource). The Tagger methodology identified 19 tag 
SNPs (15 of which corresponded to those identified in the whole resource). 
The HapMap SNP data across the same region was also used to identify tag 
SNPs. Of the 233 SNPs in total, 85 tag SNPs were identified using the LD 
block structure, and 76 SNPs identified by Tagger. 
 
 
Figure 14-4 CACNG3 LD block haplotypes with frequency >1%, using the 
entire resource. Tag SNPs are indicated with arrows. The multiallelic D' is 
shown between blocks, representing the level of recombination between the 
two blocks.   229 
14.3  Association analysis of CACNG3 – individual SNPs 
14.3.1 Criteria for affectedness CAE 
Two  SNPs,  SNP8  and  SNP11,  showed  significant  transmission 
disequilibrium (p0.01) by PDT with at least one of the test statistics (Table 
14-1a). Both SNPs lie in intron 1; SNP8 in LD block 1 and SNP11 in LD block 
2. 
14.3.2 Criteria for affectedness CAE, JAE or AE 
Three  SNPs,  SNP3,  SNP7  and  SNP8,  showed  significant  transmission 
disequilibrium by PDT with at least one of the test statistics (Table 14-1b). All 
three SNPs are in LD block 1. SNP3 is located 2.3 kb upstream of CACNG3 
and SNP7 and SNP8 are located in intron 1. The full list of PDT results can 
be found in Appendix 25. 
 
Table  14-1  SNPs  showing  statistically  significant  disease  association 
(p0.01) in at least one PDT test statistic in the entire resource. 
a) Affectedness criteria CAE: 
        SUM PDT  AVE PDT   
SNP  Allele  Transmitted  Not transmitted  Z (1df)  p-value  Z (1df)  p-value 
8  2(A)  266  222  2.64  0.008  2.47  0.013 
11  2(G)  179  139  2.90  0.004  2.49  0.013 
               
               
b) Affectedness criteria CAE, JAE or AE: 
        SUM PDT  AVE PDT   
SNP  Allele  Transmitted  Not transmitted  Z (1df)  p-value  Z (1df)  p-value 
3  2(G)  331  279  2.68  0.007  2.46  0.014 
7  2(G)  298  248  2.67  0.008  2.52  0.012 
8  2(A)  312  256  2.98  0.003  2.75  0.006   230 
14.4  Haplotype-based association analysis of CACNG3 
Block-based haplotype analysis was performed on the entire data set using 
the  PDT.  A  „sliding  widow‟  approach  was  used  on  LD  blocks  1  and  2  to 
identify  associated  haplotypes,  as  no  single  complete  haplotype  was 
sufficiently  common  to  allow  demonstration  of  disease  association  on  the 
global level. 
14.4.1 Affectedness criteria CAE 
Using the sliding window approach, there are 9 haplotypes (2-4 SNPs) in 
block  1,  consisting  of  combinations  of  SNPs  2-8,  which  demonstrate 
significant  overtransmission  and  disease  association  with  CAE  (p0.05; 
Table 14-2a). The individual overtransmitted haplotypes within each window, 
when combined, form a larger haplotype composed of alleles 2211122. The 
frequency of this haplotype in the parental population is 26.4%. 
The sliding window approach also produced some significant associations in 
LD block 2 (SNPs 10-13) (Table 14-2b). The combination of the individual 
overtransmitted haplotypes produced two haplotypes across the whole block, 
2211 and 2221. The frequency of haplotype 2211 in the parental population 
was 23.8%, and the frequency of haplotype 2221 was 3.2%. 
Full  details of  the  significant PDT results for affection  status  CAE  can be 
found in Appendix 26. 
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Table 14-2 SNP based sliding-window analysis of LD blocks 1 and 2 of CACNG3 showing windows which demonstrate 
significant  (P0.05)  global  transmission  disequilibrium  in  the  entire  resource  when  analysed  using  the  PDT  with 
affectedness criteria CAE.  Only haplotypes showing significant (P0.05) overtransmission are shown 
a) LD block 1:                   
SNP  Frequency      SUM PDT  GLOBAL    AVE PDT  GLOBAL   
2  3  4  5  6  7  8 
 in  parents 



















2  2            31.5  195  154  2.18  0.029  9.00(3)  0.029  2.69  0.007  9.43(3)  0.024 
  2  1          46.2  250  208  2.54  0.011  8.44(3)  0.038  2.38  0.017  7.21(3)  0.066 
    1  1        49.2  263  223  2.41  0.016  7.80(3)  0.050  2.24  0.025  6.62(3)  0.085 
    1  1  1      41.9  215  167  2.90  0.004  15.46(6)  0.017  2.83  0.005  15.29(6)  0.018 
      1  1  2    38.6  206  155  3.09  0.002  19.47(7)  0.007  3.08  0.002  19.71(7)  0.006 
      1  1  2  2  37.9  198  145  3.26  0.001  26.20(12)  0.010  3.35  0.001  26.76(12)  0.008 
        1  2    41.0  219  168  3.09  0.002  16.19(3)  0.001  3.08  0.002  16.25(3)  0.001 
        1  2  2  40.4  211  157  3.31  0.001  24.24(6)  0.001  3.43  0.001  25.12(6)  0.000 
          2  2  46.9  259  210  2.95  0.003  15.15(3)  0.002  2.91  0.004  14.58(3)  0.002   232 
 
 
b) LD block 2:               
SNP  Frequency      SUM PDT  GLOBAL    AVE PDT  GLOBAL   
10  11  12  13 
 in parents 



















2  2      29.9  169  123  3.32  0.001  11.21(3)  0.011  3.09  0.002  10.72(3)  0.013 
  2  1    23.9  96  71  2.27  0.023  12.58(3)  0.006  2.23  0.026  12.37(3)  0.006 
2  2  1    23.4  93  68  2.30  0.021      2.30  0.021     
2  2  2    4.4  19  11  2.13  0.033  14.01(7)  0.051  2.65  0.008  16.36(7)  0.022 
  2  1  1  24.4  95  69  2.35  0.019  9.45(6)  0.150  2.35  0.019  12.14(6)  0.059   233 
14.4.2 Affectedness criteria CAE, JAE or AE 
With the broader affectedness criteria of CAE, JAE or AE, the sliding window 
approach identified 13 haplotypes in block 1 (SNPs 2-8), which demonstrate 
significant overtransmission and disease association (p0.05; Table 14-3a). 
The  larger  haplotype  formed  by  the  individual  overtransmitted  haplotypes 
within each window again consists of the alleles 2211122, as was found with 
affectedness criteria CAE only. 
The sliding window results in LD block 2 (SNPs 10-13) are shown in Table 
14-3b.  Seven  haplotypes  demonstrate  a  significant  disease  association 
(p0.05).  The  combination  of  the  individual  overtransmitted  haplotypes 
produced three haplotypes across the whole block, 2211 and 2221 (as with 
affectedness criteria CAE) and 2222. The frequency of haplotype 2222 in the 
parental population was 1.7%. 
Full details of the significant PDT results for affection status CAE, JAE or AE 
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Table 14-3 SNP based sliding-window analysis of LD blocks 1 and 2 of CACNG3 showing windows which demonstrate 
significant  (P0.05)  global  transmission  disequilibrium  in  the  entire  resource  when  analysed  using  the  PDT  with 
affectedness criteria CAE, JAE or AE.  Only haplotypes showing significant (P0.05) overtransmission are shown 
 
a) LD block 1                   
SNP  Frequency      SUM PDT  GLOBAL    AVE PDT  GLOBAL   
2  3  4  5  6  7  8 
 in  parents 



















2  2            31.9  236  187  2.56  0.011  10.74(3)  0.013  2.67  0.008  9.83(3)  0.020 
2  2  1          31.6  212  165  2.55  0.011  15.97(7)  0.025  2.67  0.008  15.10(7)  0.035 
  2  1          46.1  303  252  2.70  0.007  10.19(3)  0.017  2.60  0.009  8.96(3)  0.030 
  2  1  1  1      36.4  224  172  3.22  0.001  21.27(11)  0.031  3.15  0.002  21.12(11)  0.032 
    1  1        48.8  313  269  2.42  0.016  8.38(3)  0.039  2.26  0.024  7.17(3)  0.067 
    1  1  1      41.9  255  204  3.08  0.002  16.21(6)  0.013  2.93  0.003  15.25(6)  0.018 
    1  1  1  2    36.9  224  174  3.11  0.002  21.49(11)  0.029  2.93  0.003  20.97(11)  0.034 
    1  1  1  2  2  36.5  217  167  3.17  0.002  26.82(16)  0.044  3.03  0.003  25.93(16)  0.055 
      1  1  2    38.5  242  188  3.27  0.001  22.30(7)  0.002  3.17  0.002  22.71(7)  0.002 
      1  1  2  2  38  234  178  3.44  0.001  29.11(12)  0.004  3.44  0.001  29.78(12)  0.003 
        1  2    40.9  259  204  3.31  0.001  17.40(3)  0.001  3.17  0.002  16.99(3)  0.001 
        1  2  2  40.4  251  193  3.52  0.000  25.96(6)  0.000  3.52  0.000  26.28(6)  0.000 
          2  2  46.9  313  253  3.19  0.001  17.64(3)  0.001  3.19  0.001  17.23(3)  0.001   235 
 
 
b) LD block 2                   
SNP  Frequency      SUM PDT  GLOBAL    AVE PDT  GLOBAL   
10  11  12  13 
 in  parents 

















2  2      29.6  199  151  2.72  0.007  7.50(3)  0.058  2.87  0.004  9.04(3)  0.029 
  2  1    23.5  103  75  2.45  0.014      2.35  0.019     
  2  2    5.4  24  17  2.11  0.035  15.27(3)  0.002  2.11  0.035  14.52(3)  0.002 
2  2  1    23.1  100  72  2.49  0.013      2.42  0.015     
2  2  2    4.4  21  12  2.12  0.034  15.07(7)  0.035  2.31  0.021  15.36(7)  0.032 
  2  1  1  24.0  102  73  2.53  0.011      2.46  0.014     
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Chapter 15  Linkage  analysis  of  the  family  with 
absence epilepsy and episodic ataxia 
As mutations in CACNA1A have previously been identified in individuals with 
absence  epilepsy  and  episodic  ataxia,  CACNA1A  was  tested  by  linkage 
analysis in the family described in section 5.9.  
DNA  was  available  from  eleven  family  members  (not  individual  101), 
including  the five  with  the  AEA  phenotype.  The  maximum  simulated  LOD 
score  using  SLINK  was  2.4  at  θ=0,  under  the  assumption  of  autosomal 
dominant inheritance with 100% penetrance. CACNA1A was tested initially 
by linkage analysis using the intragenic marker D19S1150 plus another six 
SSLPs.  The  seven  markers  span  5.4Mb  encompassing  CACNA1A,  and 
include  three  CACNA1A  intragenic  polymorphisms:  AAG18(Trettel, 
Mantuano et al. 2000) (intron 3), D19S1150(Ophoff, Terwindt et al. 1996) 
(intron 7) and A1ACAG(Ophoff, Terwindt et al. 1996) (CAG repeat in the 3‟ 
untranslated region) (Figure 15-1).  
Five of the seven microsatellite markers (D19S413, D19S914, D19S1150, 
D19S840, and D19S226) were informative in this family. The five affected 
individuals  shared  a  single  common  haplotype  between  D19S413  and 
D19S840  (Figure  15-2).  This  haplotype  was  not  shared  by  any  of  the 
unaffected individuals including individual 319 who had a typical 3 Hz spike–
wave  EEG  but  no  clinical  phenotype  and  was  neurologically  normal. 
Assuming AD inheritance with penetrance=1, phenocopy rate=0 and disease 
allele frequency=0.005, the multipoint LOD score across this haplotype was 
2.1 (Figure 15-3). The AEA phenotype in this pedigree was thus consistent 
with linkage to CACNA1A. 
Subsequent DNA sequencing of each exon and the flanking intronic regions 
of  CACNA1A  was  performed  in  all  available  family  members  at  the 
Department  of  Molecular  Neuroscience  and  Clinical  and  Experimental 
Epilepsy, Institute of Neurology, University College London.   237 
This sequencing identified a heterozygous point mutation (G439A) in exon 3 
of CACNA1A, which results in a substitution of lysine for glutamic acid at 
codon 147 (E147K). This previously unreported change segregated with the 
AEA  disease  phenotype.  The  mutation  was  not  detected  in  unaffected 
individuals or in the patient with an abnormal EEG but no clinical phenotype 
(individual 319). All family members were sequenced. The mutation identified 
results in the loss of a Taq1 restriction site. This mutation was absent from a 
panel of 200 control chromosomes, and segregation of the mutant with the 
AEA  disease  was  confirmed  in  the  family.  The  mutation  affects  a  highly 
conserved residue within the second transmembrane segment of domain I of 








b) Detailed view of intragenic markers 
 
 
Figure 15-1 Position of seven SSLPs relative to CACNA1A on chromosome 
19p13.3.  Image  modified  from  the  UCSC  Genome  Browser 
(http://genome.cse.ucsc.edu/cgi-bin/hgGateway) 
 













Figure 15-2 Haplotypes of AEA family members using seven microsatellite 












Figure  15-3  AEA  family:  Parametric  linkage  analysis,  assuming  AD 
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Chapter 16  Genetic  analysis  of  human  absence 
epilepsy 
16.1  Summary 
The aim of this project was to elucidate the molecular genetic basis of human 
absence epilepsy. The genetic analysis of complex traits is complicated by 
several issues which are now well recognized: the uncertainty of the genetic 
architecture of the condition, the selection of criteria which best delineate the 
phenotype,  the  lack  of  correlation  between  phenotype  and  genotype,  the 
degree  of  locus  and  allelic  heterogeneity  and  variable  expressivity,  all  of 
which  influence  the  optimum  strategy  for  investigation.  The  approach 
employed  here  involved  (i)  ascertainment  of  a  patient  resource  including 
affected  sibling  pairs,  trios  of  affected  individuals  with  both  parents,  and 
extended nuclear pedigrees and (ii) investigation of candidate genes using 
linkage  analysis,  SNP-based association analysis and  mutation  screening.  
Ion channel genes emerged as excellent candidates. Linkage analysis was 
performed using two phenotypic criteria, a  specific diagnosis of Childhood 
Absence Epilepsy and a broader category of „absence‟ which included CAE, 
JAE  and  individuals  with  many  of  the  features  of  CAE  and  an  onset  of 
absence seizures below the age of 12 years, but who could not be classified 
as CAE due to certain atypical features. Two loci showed positive linkage: 
CACNG3  on  chromosome  16p12-13.3  and  the  GABAAR  gene  cluster 
GABRB3,  GABRA5  and  GABRG3  on  chromosome  15q11-13.  Multilocus 
linkage  analysis  was  consistent  with  a  digenic  effect  from  these  loci. 
Sequence  analysis  of  CACNG3  identified  34  sequence  variants  but  no 
definite  functional  changes.  SNP  based  association  analysis  of  CACNG3 
showed  significant  transmission  disequilibrium  for  SNPs  in  intron  1 
(affectedness  criteria  CAE  or  Absence)  and  upstream  of  the  gene 
(affectedness criteria Absence only). The LD block structure across the gene 
was identified, and the sliding window approach revealed haplotypes in LD 
block 1 (encompassing exon 1) and LD block 2 (encompassing part of intron   241 
1) which were significantly associated with both CAE and Absence. This data 
provides supportive evidence for functional variants in both CACNG3 and at 
least one of the GABAAR genes on chromosome 15q. Further sequence and 
association  analysis  of  CACNG3  has  subsequently  been  performed, 
providing  additional  evidence  for  CACNG3  as  a  susceptibility  locus  in  a 
subset of patients with CAE (Everett, Chioza et al. 2007). 
16.2  Selection of phenotype 
CAE  is  an  idiopathic  generalised  epilepsy  of  childhood  which  is  a  well 
characterised  and  consistent  phenotype  in  terms  of  age  of  onset,  clinical 
features and EEG findings. There is strong evidence for a genetic aetiology, 
with a concordance in phenotype of 28% between probands with CAE and 
first and second degree relatives with epilepsy (Marini, Scheffer et al. 2004). 
Therefore the ascertainment of patients with the specific diagnosis of CAE for 
this study provides a homogeneous clinical phenotype with an expectation of 
a  common  genetic  aetiology.  However,  there  is  also  a  strong  genetic 
relationship  between  CAE  and  JAE,  with  31%  of  affected  relatives  of  a 
proband  with  JAE  having  CAE.  This  supports  the  existence  of  common 
susceptibility  loci  for  absence  epilepsy,  including  CAE  and  JAE.  It  was 
therefore decided to investigate, as well as pure CAE, the broader phenotype 
of „absence epilepsy‟, incorporating CAE and JAE. Clustering of other IGE 
phenotypes  is  also  seen  in  families  with  a  proband  with  CAE,  and  rarely 
absence epilepsy may evolve into another IGE phenotype such as JME. This 
raises the question of susceptibility loci for an even broader phenotype of 
IGE,  and  other  studies  have  attempted  to  identify  these  genes  (Sander, 
Schulz et al. 2000; Sander, Windemuth et al. 2003).   242 
16.3  Patient recruitment 
A problem frequently encountered in genetic studies of complex diseases is 
recruitment of sufficient patients, particularly when the genetic architecture of 
the condition is not known. This project is a good example of international 
collaboration, with families recruited from both Northern Europe and Canada.  
As far as possible the families were limited to those of Northern European 
origin  (allowing  for  the  inevitable  uncertainty  and  complexity  of  the 
geographical origin of many families), in order to provide a degree of genetic 
homogeneity. The potential importance of this has been exemplified by the 
report of putative mutations in the T-type calcium channel gene CACNA1H in 
childhood  absence epilepsy  patients  of  Han  ethnicity  recruited  from  North 
China  (Chen,  Lu  et  al.  2003).  Our study  found  no  evidence  of  linkage  to 
CACNA1H  and  subsequent  sequence  analysis  in  220  of  these  European 
patients failed to identify any of the Chinese variations (Chioza, Everett et al. 
2006). A study of CAE patients in Australia also failed to replicate the findings 
of  the  Chinese  study  (Heron,  Phillips  et  al.  2004).  Further  screening  of 
CACNA1H  in  epilepsy  patients,  predominantly  white,  with  diagnoses 
including CAE, did detect some potential functional variants, but all variants 
were also identified in unaffected individuals (Heron, Khosravani et al. 2007). 
Genetic heterogeneity between different populations is one explanation for 
the variability in replication of the Chinese study, and we have attempted to 
reduce  this  factor  by  restricting  the  geographical  origin  of  our  patient 
population. 
Recruitment  of  patients  for  a  genetic  study  entails  important  ethical 
considerations  which  have  implications  for  patient  confidentiality  and 
informed consent. These include the process of identifying suitable patients 
for invitation to participate in the study; the collection of DNA samples by 
invasive techniques (e.g. venesection) in children too young to give consent; 
the implications of identifying putative susceptibility alleles in asymptomatic 
family  members  and,  by  inference,  in  non-participating  relatives;  and  the 
potential  use  of  DNA  samples  for  future  studies.  These  issues  were 
addressed in the application for ethical approval to the North Thames Multi-  243 
centre Research Ethics Committee, and, when relevant, were discussed with 
participating families during the consenting process. 
 
16.4  Laboratory methodology 
DNA has traditionally been extracted from venous blood, which provides high 
yields of good quality DNA. Despite this, after genotyping numerous markers 
and sequencing large sections of DNA, stores of DNA can become very low. 
Also,  obtaining  blood  samples  from  children  is  often  time  consuming,  
technically difficult, distressing to the child, unacceptable to the parents and 
difficult  to  justify  for  the  purpose  of  genetic  research.  The  use  of  buccal 
swabs  to  obtain  specimens  avoids  these  difficulties  and  samples  can  be 
collected by post. The quantity of DNA obtained from cheek swabs is much 
lower than that obtained from blood. Whole genome amplification by multiple 
displacement  amplification  provided  a  quick,  easy  and  reliable  method  of 
increasing DNA stores (Dean, Hosono et al. 2002). Therefore in the latter 
stages of patient recruitment, cheek swabs became the method of choice for 
DNA  collection  and  this  was  much  more  acceptable  to  parents  of  young 
children. 
The    selection  of  polymorphic  markers  for  testing  of  candidate  genes  by 
linkage analysis has been greatly facilitated by the completion of the human 
genome project and the publication of large-scale genome wide linkage maps 
(Dib, Faure et al. 1996; Kong, Gudbjartsson et al. 2002; Kong, Murphy et al. 
2004). In this study, this has enabled the identification of markers flanking or 
intragenic  to  the  candidate  genes  under  investigation  with  data  on  both 
physical and genetic map distances. In only a minority of cases physical map 
distances were used to estimate linkage map distances. The availability of 
sequence  information  also  allowed  three  novel  repeat  markers  to  be 
identified in the vicinity of two candidate genes (CACNG3 and CACNA1G).    244 
A wide variety of SNP genotyping methods are now available, as described 
in  sections  4.3.4-4.3.9  and  section  6.7.  Melting  curve  analysis  of  SNPs 
(McSNP
®) (6.7.1) was initially selected for this project. The combination of a 
tried  and  tested  approach  to  allele  discrimination,  restriction  enzyme 
digestion, with a novel method for detecting DNA fragments, melting curve 
analysis, promised a low-cost, accurate, high-throughput genotyping method 
(Akey, Sosnoski et al. 2001; Ye, Parra et al. 2002). However attempts to 
establish a McSNP facility in collaboration with the London School of Hygiene 
and Tropical Medicine was beset by a range of problems, as described in 
section 6.7.1. These were predominantly failures of equipment and software 
beyond our control, which exemplifies the difficulties in establishing a new 
technical  facility  from  scratch  when  funds  are  limited.  Ultimately  it  was 
decided  to  use  established  facilities  providing  TaqMan
®  (section  1.1.1), 
Pyrosequencing
®  (section  6.7.3)  and  Amplifluor
®  (section  4.3.8). 
Pyrosequencing  was  particularly  suited  for  validation  of  novel  SNPs  in  a 
panel of control DNAs. 
16.5  Candidate gene selection 
Candidate  genes  can  be  identified  for  many  „complex‟  traits,  on  both 
functional  grounds,  and  by  the  segregation  of  many  of  these  traits  in  a 
monogenic fashion in rare extended multigenerational pedigrees. The genes 
identified  in  such  rare  subtypes  are  also  candidates  for  „susceptibility‟ 
sequence variants in the „complex‟ trait. However, although many biologically 
plausible  candidate  genes  exist for any  trait,  it  is only  a  small minority  of 
these in which sequence variants will actually exist in the population at allele 
frequencies high enough to account for common traits. Also, many genes 
causing  monogenic  subtypes  of  „complex‟  traits  have  been  tested  as 
susceptibility loci in the more common traits, but with little success. 
The absence epilepsies should have a particular advantage as a phenotype 
for genetic analysis. The molecular neurophysiological basis of spike-wave 
discharges,  the  neurophysiological  hallmark of  these  epilepsies, has  been   245 
extensively  investigated  in  rodents  and  humans.  There  is  now  strong 
evidence that the generation of spike-wave seizures is determined, in part, by 
interactions  between  voltage-dependent  calcium  channels  and  GABA 
receptors,  and  that  these  genes  are  implicated  in  their  aetiology  (section 
3.5.1).  Of particular interest are the four voltage-dependant calcium channel 
subunit  genes  identified  in  mouse  mutants  with  spike-wave  seizures, 
Cacna1a,  Cacnb4,  Cacng2  and  Cacna2d2  (section  3.5.2).  Of  these, 
CACNA1A  and  CACNB4  have  previously  been  implicated  in  human 
epilepsies.  GABAA  receptors  mutations  have  also  been  identified  in  both 
rodent and human spike-wave epilepsies, and are implicated in Angelman 
Syndrome  (section  7.3).  In  contrast,  the  presence  of  functional  GABAB 
receptors appears to be necessary for the generation of absence seizures in 
mice (section 7.4). Further supportive evidence for a role for several of these 
genes in spike-wave epilepsy is provided by previous linkage and association 
studies,  expression  patterns  in  brain  and  mechanisms  of  action  of 
antiepileptic drugs, as discussed in section 3.5. 
16.6  Approaches to genetic analysis  
The relative power of either parametric or non-parametric linkage analysis or 
association studies in the investigation of traits with „complex‟ inheritance is 
highly dependent on the underlying genetic architecture, which can only be 
estimated.  Association  analysis  has  greater  power  to  detect  loci  of  minor 
effect with ascertainable patient numbers provided a high degree of allelic 
diversity is not present and susceptibility alleles are present at frequencies 
conferring sufficient power. Linkage is not dependent on allelic homogeneity, 
but requires sibling pairs or nuclear pedigrees with an adequate proportion of 
linked families. 
Thresholds for statistical significance depend upon the prior probability that 
one of the markers tested is linked to or associated with the trait, and the 
influence  of  multiple  testing  (Freimer  and  Sabatti  2004).  The  traditional 
stringent  threshold  for  significant  linkage  (LOD  score>3,  p<10
-4)  was   246 
proposed when few markers were available and the prior probability that one 
of these markers was linked to the gene of interest was very small (Morton 
1955). With genome wide scans using multiple markers, or candidate gene 
approaches testing several strong functional candidates, the prior probability 
that some marker is linked to the locus of interest becomes much greater. 
However  statistical  testing  of  multiple  independent  markers  increases  the 
likelihood  of  a  false  positive  result,  and  requires  correction  for  multiple 
comparisons.  Statically  approaches  using  either  Bonferroni  correction  or 
Gaussian process approximations for linkage statistics have generated very 
similar  LOD  score  thresholds  (3-3.5)  and  shown  that  little  additional 
adjustment  is  needed  for  very  closely  spaced  markers  (where  testing  of 
adjacent  markers  may  not  be  independent  as  linkage  data  is  effectively 
replicated). Thus the original criteria for significant linkage remain applicable 
to this study.  
The significance threshold for association studies is more problematic, and 
there is no consensus.  Some authors have suggested significant p-values of 
lower than ~10
-7 (Freimer and Sabatti 2005). However this assumes a prior 
probability  of  ~1/30000  that  a  candidate  gene  is  associated  with  the  trait 
under investigation (ie the gene has been picked at random), which is an 
extremely  conservative,  least  favourable  scenario.  The  prior  probability  of 
association  of  a  trait  to  a  single  marker  is  much  lower  than  the  prior 
probability of linkage, as association extends over much shorter distances 
than  linkage.  This  factor  is  reduced  by  testing  only  variants  in  strong 
candidate genes, rather than a genome-wide association study. The need to 
correct for multiple comparisons is also reduced by identifying the common 
SNP haplotypes and testing for association using these rather than individual 
SNPs. Testing many individual SNPs for association will increase the false 
positive rate due to multiple testing, unless the SNPs are all in perfect LD 
with  each  other.  However,  where  LD  is  present,  corrections  for  multiple 
testing would overcorrect for the false positive rate (Nyholt 2004). Methods 
have  been  suggested  for  calculating  the  effective  number  of  independent 
tests and  correcting for multiple  testing  (Meng,  Zaykin  et  al. 2003;  Nyholt   247 
2004).  However  these  methods  have  not  been  validated  and  remain  the 
subject of debate (Nyholt 2005; Salyakina, Seaman et al. 2005). 
Significance  levels  for  two-locus  LOD  scores  are  even  harder  to  assess, 
particularly  when  maximised  over  disease-model  parameters.  Significance 
again depends on assumptions about prior probability of linkage to the two 
loci. Inflation of two-locus LOD scores should be expected when compared to 
the  single  locus  results.  If  maximized  over  two  recombination  fractions, 
Strauch et al have calculated that a single-locus LOD score of 3 corresponds 
to a two-locus LOD score of 3.5 (Strauch, Fimmers et al. 2000).  
16.7  Results of preliminary candidate gene analysis 
Thirty  candidate  gene  loci  were  tested  in  the  initial  cohort  of  33  absence 
families.  The  negative  LOD  scores  obtained  under  locus  homogeneity 
provided strong evidence that 26 gene loci do not account independently for 
the trait in a majority of the families (sixteen VDCC subunit genes, seven 
GABAAR subunit genes, two GABAB receptor genes and the ECA1 locus).   
CACNG3, the VDCC on 16p12-p13.1 and the cluster of GABAAR subunits 
(GABRA5,  GABRB3,  GABRG3)  on  chromosome  15q11-q13  could  not  be 
excluded from linkage in a proportion of  families. Although both loci gave 
negative homogeneity LODs, the HLODS and NPL scores were positive. The 
data  did  not  therefore  exclude  the  possibility  that  sequence  variants  in 
CACNG3 or in any of the GABAA receptor subunit genes in the 15q cluster 
may  contribute  to  phenotype  in  a  proportion  of  families.  These  loci  were 
therefore  tested  in  the  larger  collection  of  CAE  families,  AE  families  and 
parent-child trios.   248 
16.8  CACNG3 analysis 
Both  parametric  and  non-parametric  linkage  analysis  provided  significant 
evidence for linkage, indicating CACNG3 is a susceptibility loci for Absence 
in  a  subset  of  the  82  nuclear  pedigrees  analysed.    Analysis  of  individual 
SSLPs  using  the  TDT  and  PDT  produced  significant  associations. 
Sequencing of coding regions did not identify any plausible causal sequence 
variants.  
Variation  in  non-protein  coding  DNA  sequences  can  disrupt  normal  gene 
function by several mechanisms. For example, gene expression is controlled 
by transcription regulatory elements which can be intronic or reside up- or 
downstream  of  the  transcription  unit  (Kleinjan  and  van  Heyningen  2005). 
Similarly, non-coding splicing regulatory elements are important in preventing 
exon skipping, intron retention or creation of aberrant splice  sites (Baralle 
and  Baralle  2005).  Therefore  several  methods  were  employed  to  identify 
potential non-coding causative alleles. Variants in non-coding sequence with 
possible functional effects were identified, including two potential splice site 
variants  and  six  ESE  motif  variants.  However  identification  of  functional 
variants in regulatory elements by sequence inspection is difficult and thus 
searching for pathogenic variations in these sequences requires an indirect 
approach. 
The  approach  adopted  for  further  analysis  of  CACNG3  comprised  (i) 
identifying commons SNPs spanning the gene, (ii) establishing the pattern of 
LD  across  CACNG3  and  (iii)  performing  association  analysis  with  both 
individual SNPs and SNP haplotypes.  
16.8.1 CACNG3 LD block structure and tag SNPs 
The NCBI SNP database allowed selection of SNPs spanning the gene. One 
additional  novel  SNP  was  included  in  the  LD  analysis.  At  the  time  of 
selection,  all  but  four  of  the  NCBI  SNPs  had  minor  allele  frequency  data 
available.  The  missing  allele  frequency  data  was  obtained  by  typing  the 
SNPs in a control population using pyrosequencing. Analysis of LD based on   249 
the  entire  resource  of  pedigrees  and  trios  identified  5  LD  blocks.  In 
comparison, the HapMap data using a much larger number of SNPs (233) 
identified 21 blocks of LD across the same region. Several small LD blocks 
have  been  missed  by  using  a  restricted  number  of  SNPs,  whilst  other 
neighbouring  LD  blocks  have  been  incorporated  in  a  single  larger  block. 
Inevitably, typing a greater numbers of SNP reveals a more detailed pattern 
of LD across the region.  However, for the purposes of association analysis, 
the  aim  is  to  identify  large  LD  blocks  for  which  a  subset  of  SNPs  will 
represent  the  majority  of  the  genetic  variation  by  tagging  the  common 
haplotypes. It has been shown that analysis using incomplete, more spaced 
out sets of SNPs can be almost as powerful as SNPs selected from complete 
panels, and that tests using exhaustive multimarker tests improves power to 
detect less common causal alleles but can actually reduce power when the 
causal SNP is common (de Bakker, Yelensky et al. 2005). The likelihood that 
a significant positive association will be missed by failing to identify detailed 
LD structure is small. 
The LD block  structure  generated  by  a  small  subset of 31 trios was  also 
compared  with  that  generated  by  the  entire  resource.  There  was  some 
variation in the boundary SNPs of two of the five LD blocks. However the 
tagging  SNPs  identified  by  either  of  the  two  methodologies  (haplotype 
frequency  and  tagger)  were  similar.    In  future  larger  studies  investigating 
other  chromosomal  regions,  it  would  be  a  reasonable  strategy  to  use  a 
subset of trios to identify the LD block structure and tagging SNPs, and only 
to type the tagging SNPs in the entire resource. For the purposes of this 
study,  as  the  selection  of  tag  SNPs  did  not  significantly  reduce  the  total 
number of SNPs originally selected, it was decided to type all 23 SNPs in all 
individuals. 
The  HapMap  SNP  data  generated  a  larger  number  of  tag  SNPs  (85  by 
haplotype frequency, 76 by tagger), reflecting the more detailed pattern of 
LD. However, as discussed above, the additional tag SNPs are unlikely to 
reveal a significant positive association with a common causal allele that has 
been  missed  by  the  restricted  set.  The  HapMap  data  was  obviously  not   250 
generated  from  this  study  population.  However  it  has  now  been 
demonstrated that tag SNPs identified from HapMap population data can be 
transferred to different study populations with little loss in power to detect an 
association (de Bakker, Burtt et al. 2006). 
16.8.2 CACNG3 association analysis 
Association analysis of CACNG3 was performed using individual SNPs and 
SNP  haplotypes.  This  strategy  relied  on  the  assumption  that  any  causal 
SNPs were of high enough allele frequency and were in sufficiently tight LD 
with the typed SNPs to be detected. The likelihood of a false negative result 
becomes significant if these assumptions are not valid (de Bakker, Yelensky 
et al. 2005). There also remains the possibility that a causal variant might lie 
outside the associated interval, which can be difficult to define. 
Using the narrow phenotype of CAE, individual SNP analysis identified two 
SNPs in LD block 1, both in intron 1, which showed significant transmission 
disequilibrium. The broader „absence‟ phenotype also identified two intron 1 
SNPs  with  significant  transmission  disequilibrium,  as  well  as  one  SNP 
upstream of exon 1. All three SNPs were also in LD block 1. The „sliding 
window‟ approach identified nine haplotypes (using narrow CAE phenotype) 
and 13 haplotypes (using broader „absence‟ phenotype) comprising SNPs 2-
8  within  LD  block  1  that  demonstrated  transmission  disequilibrium.  These 
haplotypes together form an extended haplotype of alleles 2211122. The only 
SNP with potential functional implications is SNP 5 (rs1494550), in which the 
minor allele is predicted to create a splice acceptor site. However, individually 
this SNP does not show significant transmission disequilibrium.  
Haplotypes were also identified by the sliding window approach in LD block 2 
that demonstrated transmission disequilibrium. These did not form a single 
extended phenotype, either for the narrow CAE phenotype or the broader 
„absence‟  phenotype,  and  none  of  the  SNPs  could  be  implicated  on 
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These positive associations can only be considered as provisional due to the 
limitations discussed in section 16.6, including issues around multiple testing. 
Independent replication of these results is required. 
16.8.3 CACNG3 sequence analysis 
Direct  sequencing  of  exonic  DNA  and  surrounding  intronic  and  promoter 
sequence DNA of CACNG3 in 73 individuals identified 34 sequence variants.  
Of these, eight variants showed possible functional significance on the basis 
of  bioinformatics  analysis,  and  four  of  these  (rs1494550,  s5,  s6,  s7).are 
located in LD block 1. Mean allele frequency data in a control population, 
from the NCBI SNP database, is only available for one of these, rs1494550. 
The difference in MAF of the reference allele between cases and controls 
(0.340 vs 0.209) is suggestive, although rs1494550 did not show significant 
transmission disequilibrium in the study population. If the difference between 
case and control MAF is real, the variant allele, predicted to create a splice 
acceptor  site,  is  associated  with  an  increased  risk  of  CAE.  However 
rs1494550 is nongenic and lies 270 bases upstream of the CACNG3 5‟UTR. 
It is still possible that rs1494550 is exerting a regulatory effect on CACNG3, 
similar to that described in alpha-thalassaemia (De Gobbi, Viprakasit et al. 
2006). Alternatively rs1494550 does not have a functional effect but is in LD 
with an unidentified causal variant. 
The other potentially functional variants within LD block1, s5, s6 and s7, all 
lie within the CACNG3 5‟ UTR, and are predicted to alter splicing enhancer 
binding  motifs.  S7  is  conserved  in  the  chimpanzee.  However  all  three 
variants were found at very low frequencies in the sequenced cases. 
Further  analysis  of  the  region  comprising  LD  block  1  has  now  been 
performed (Everett, Chioza et al. 2007). Re-sequencing of 35 kb of genomic 
sequence in 48 chromosomes identified a total of 72 sequence variants. One 
additional  variant,  rs2021512,  has  shown  significant  transmission 
disequilibrium  when  typed  in  the  entire  patient  resource  (p=0.005),  with 
overtransmission  of  the  reference  allele.  This  variant  creates  a  novel   252 
acceptor  site.  However  it  is  also  nongenic  and  lies  approximately  14kb 
upstream of CACNG3. 
16.8.4 CACNG3 – interpretation of results 
Several explanations for the observed results can be postulated. 
i.  The  observed  linkage  is  a  false  positive  and  CACNG3  is  not  a 
susceptibility locus for CAE. However, the employed criteria for significant 
linkage are fairly stringent. 
ii.  The  observed  transmission  disequilibrium  is  also  a  false  positive. 
The TDT and PDT were used  to reduce this likelihood  as the results are 
unaffected  by  population  stratification.  However,  significance  thresholds 
remain contentious, as discussed in section 16.6 
iii. The linkage and association results are real, but the causal variants 
have not been identified by the current sequence analysis as they lie 
outside the sequenced region. LD has now been shown to exist over long 
ranges, sometimes hundreds of kilobases. Within these regions of long range 
LD, clusters of genetically indistinguishable SNPs (giSNPs) exist, which are 
in perfect LD with each other (Lawrence, Evans et al. 2005). Approximately 
50% of SNPs appear to have at least one giSNP. 
iv. The linkage and association results are real, but the causal variants 
are  too  rare  or  heterogeneous  to  have  been  detected  in  the  limited 
number of sequenced chromosomes. 
v.  Causal  variants  for  CAE  have  been  identified,  but  the  functional 
consequences of these variants are yet to be demonstrated. 
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16.9  GABAAR gene cluster on 15q 
The  parametric  linkage  analysis  for  the  GABAAR  cluster  did  not  reach 
accepted  criteria  for  significant  linkage.  However,  the  maximum  HLOD  of 
2.31  at  marker  155CA2,  the  broader  „Absence‟  phenotype,  could  be 
considered  „suggestive‟  of  linkage.  The  non-parametric  linkage  analysis, 
generated a maximum NPL score of 3.75 (p=0.00004), which is a significant 
result. This may be a reflection of the fact that a susceptibility locus exists in 
this  region,  but  does  not  conform  to  the  genetic  model  specified  in  the 
parametric linkage analysis. Absence epilepsy is inherited in a complex „non-
mendelian‟  manner,  and  therefore  the  application  of  a  strictly  mendelian 
model to any susceptibility locus is likely to be an approximation. 
The maximum HLOD and NPL scores were generated at marker 155CA2. 
The  transmission  disequilibrium  test  also  identified  one  allele  of  155CA2 
which  may  be  associated  with  a  protective  effect  (
2=7.36,  p=0.007), 
although this applies to the narrower CAE phenotype. 155CA2 is intragenic 
to  GABRB3,  the  gene  contained  within  the  Angelman  Syndrome  deletion 
region that has been shown to produces EEG abnormalities and seizures in 
mice. One study has identified a  GABRB3 promoter haplotype associated 
with childhood absence epilepsy (p=0.007075) (Urak, Feucht et al. 2006). A 
functional  GABRB3  exon  1a  promoter  polymorphism  was  identified  which 
displayed a reduced transcriptional activity.  However, a subsequent larger 
study with 250 CAE patients failed to replicate an association of the promoter 
polymorphism  with  CAE  (Hempelmann,  Cobilanschi  et  al.  2007). 
Heterozygous mutations in GABRB3 have now been identified in four out of 
48  families  with  CAE  from  Mexico  and  Honduras,  and  all  mutations 
demonstrated  hyperglycosylation  and  reduced  whole  cell  GABA-evoked 
current density when expressed in vitro (Tanaka, Olsen et al. 2008). Further 
investigation  of  GABRB3  as  well  as  GABRA5  and  GABRG3  will  require 
sequencing  across  the  whole  genomic  region  and  further  association 
analysis using SNP haplotypes.   254 
16.10   Multilocus analysis 
The CACNG3 locus on chromosome 16p12-p13.1 and the GABAAR subunit 
cluster on chromosome 15q11-13 both showed evidence of linkage to the 
Absence and CAE phenotypes. Absence epilepsy is likely to be a multigenic 
trait, and it was therefore decided to perform a two-trait-locus study by testing 
both  loci  simultaneously  with  GENEHUNTER-TWOLOCUS(Strauch, 
Fimmers  et  al.  2000).    The  non-parametric  scores  increased  for  both 
phenotypic classifications, supporting the hypothesis that both chromosomal 
loci  harbour  susceptibility  alleles  for  the  Absence  phenotype.  A  digenic 
dominant  effect  was  also  tested  using  three  parametric  models.  The 
multiplicative  model  produced  the  greatest  increase  in  the  HLOD  when 
compared to the single locus analysis, particularly for the broader Absence 
phenotype. This provides an insight into how the two loci may act together. 
The multiplicative model reflects that individuals with a susceptibility allele at 
both loci have a high probability of manifesting the trait. The results therefore 
support the hypothesis that susceptibility alleles at the loci on chromosomes 
15  and  16 may  both be  required  to  develop  the  disease.  In  contrast,  the 
heterogeneity model produced maximum HLODs that were lower than the 
single locus HLODs at CACNG3. This rejects the hypothesis that a mutant 
allele at a single locus (the chromosome 15 locus) alone is sufficient to cause 
the disease. These results suggest that both CACNG3 on chromosome 16 
and at least one of GABRB3, GABRA5 and GABRG3 on chromosome 15 are 
involved in the pathogenesis of absence epilepsy. 
16.11   Limitations of this study 
Although attempts were made to be as accurate as possible when 
phenotyping patients, in some cases limited data was available, particularly 
for those patients from outside the UK. When there was significant doubt 
about the diagnosis, patients were classified as unknown. In some cases, 
where all available data was consistent, it seemed reasonable to accept the   255 
diagnosis of an experienced collaborator. Inevitably it remains possible that a 
small number of patients were wrongly classified. 
The use of buccal swabs for DNA collection was clearly more acceptable and 
convenient for families than blood sampling. The reduced quantity and quality 
of DNA obtained, in addition to the use of whole genome amplification to 
increase DNA stores, may have introduced some errors into the gentotyping 
and DNA sequencing. 
The linkage analysis suggested a role for both CACNG3 and the GABAAR 
cluster on 15q in the pathogenesis of absence epilepsy. However it was not 
possible to pursue the 15q linkage with further analysis due to the limited 
time and resources available. 
Perhaps the major limitation of this study is the lack of functional work with in-
vitro systems. Again this was not possible due to time limitation, but this will 
be required in future to determine whether causal variants for CAE have 
been identified. 
16.12   Future directions for research 
As discussed above, in-vitro analysis of implicated CACNG3 variants is 
needed for futher evaluation of their functional significance. This can be 
performed by expression of variant CACNG3 cDNA in xenopus oocytes or 
HEK cells and assessing channel function by patch-clamp current 
measurement. Membrane expression of channels can also be assessed by 
fluoresecent labelling of cDNA.  
Causal variants in CACNG3 may have not been identified by the current 
sequencing. Extended sequencing to include intronic and other potential 
regulatory regions may reveal additional plausible functional variants 
The 15q GABAAR warrants further investigation by SNP genotyping, 
association analysis and DNA sequencing.   256 
It is certain that other genes are also susceptibility loci for absence epilepsy, 
and these may be identified by both candidate gene analysis and genome-
wide linkage and association analysis. Improved high-throughput genotyping 
and analytical technologies, as well as advances in bioinformatics, will 
increase the likelihood of detecting true causal variants with only modest 
genetic effects. Positive findings must be replicated in independent patient 
groups. 
Whatever genetic techniques are employed, access to additional large, well 
characterised patient cohorts is vital. There is therefore a need for ongoing 
patient recruitment and accurate phenotypying, which requires multi-centre 
collaborations and the active involvement of clinicians.  
16.13   Conclusions 
This work has provided genetic evidence that CACNG3 and at least one of 
the three GABAA receptor genes of GABRB3, GABRA5 and GABRG3 are 
susceptibility  loci  for  absence  epilepsy,  including  CAE.  These  genes  are 
strong  functional  candidates  for  absence  epilepsy.  The  data  supports  a 
digenic  effect  from  the  chromosome  16  and  15  loci,  suggesting  that 
susceptibility  alleles  at  both  loci  may  be  required  to  manifest  the  trait. 
Common variants at the CACNG3 locus showing transmission disequilibrium 
have  been  identified,  although  no  variants  as  yet  display  functional 
significance.  Replication  studies  in  similar  patient  groups  would  help  to 
confirm  that  these  loci  contribute  to  the  absence  phenotype.  Definitive 
evidence  to  confirm  or  exclude  these  loci  will  require  sequencing  across 
extended genomic regions encompassing CACNG3 and the GABAAR cluster 
in large numbers of patients,  in addition to functional analysis of potential 
causative variants.   257 
Chapter 17  Genetic  analysis  of  a  family  with 
absence epilepsy and episodic ataxia 
A syndrome of absence epilepsy and episodic ataxia was first characterised 
in  2001.  Jouvenceau  et  al  reported  an  11  year  old  boy  with  primary 
generalised  epilepsy,  episodic  and  progressive  ataxia,  and  mild  learning 
difficulties (Jouvenceau, Eunson et al. 2001). From the age of 3 years he 
developed nocturnal generalised tonic-clonic seizures and daytime absence 
seizures. The generalised tonic-clonic seizures stopped after age 8 years but 
he  continued  to  have  absence  seizures.  An  interictal  EEG  showed 
generalised  polyspike  and  wave  complexes.  From  age  8  years  he  also 
developed attacks of gait unsteadiness, dysarthria, and diplopia, lasting up to 
three  hours.  There  was  no  family  history  of  epilepsy  or  episodic  ataxia. 
Examination  between  attacks  showed  cerebellar  eye  signs  gait  and  limb 
ataxia. Sequencing of the coding region of CACNA1A, the gene encoding the 
voltage-gated  P/Q  type  calcium  channel,  identified  a  heterozygous  point 
mutation (C5733T). This mutation introduces a premature stop codon which 
was  shown  to  impair  calcium  channel  function  and  exhibit  a  dominant 
negative effect.  
Mutations in CACNA1A are known to cause a range of neurological disorders 
in  humans  (familial  hemiplegic  migraine  (Ophoff,  Terwindt  et  al.  1996), 
episodic ataxia type 2 (Ophoff, Terwindt et al. 1996), spinocerebellar ataxia 
type 6 (Zhuchenko, Bailey et al. 1997)). The tottering mouse mutant, which 
exhibits spike-wave seizures similar to those occurring in human absence 
epilepsy, is caused by mutations in Cacna1a (Fletcher, Lutz et al. 1996). 
CACNA1A was therefore an excellent candidate gene in the family identified 
by Dr Jaffe, in which absence epilepsy segregates with episodic ataxia type 2 
(EA2) in an autosomal dominant fashion through three generations (Section 
5.9).  
The  linkage  analysis  and  pattern  of  segregation  of  markers  spanning 
CACNA1A were strongly suggestive that CACNA1A was the causative gene, 
and this was confirmed by the sequence analysis. The one family member   258 
with spike-wave discharges on EEG but no clinical seizures or ataxia did not 
carry  the  “disease”  haplotype  or  the  CACNA1A  mutation.  Repeat  blood 
samples  were  obtained  from  this  patient  to  ensure  there  was  no  sample 
error. It can be argued that the spike-wave discharges in this individual, as 
well as all the affected family members, are caused by mutations in another 
gene. However, if this were the case, the putative unidentified mutation must 
be insufficient to cause clinical seizures and/or ataxia. Also, for the clinical 
phenotype  of  EAE  to  have  been  caused  by  a  digenic  effect  from  the 
CACNA1A mutation and this “second” mutation, the segregation pattern for 
both  variants  in  this  family  would  have  to  be  identical,  diverging  only  at 
individual 319. Unless the two loci were in tight linkage (itself highly unlikely), 
the likelihood of this identical segregation occurring by chance is very small, 
as there are 512 (2
9) different ways that each allele inherited from individual 
102 can segregate in the rest of the family. 
This is the first reported family in which a CACNA1A mutation that impairs 
calcium  channel  function  cosegregates  with  typical  absence  seizures  and 
3Hz  spike-wave  discharges  on  EEG.  The  ataxia  exhibited  by  affected 
members was very variable in both severity and episodic nature. In some 
cases,  cerebellar  ataxia  was  precipitated  by  AEDs  such  as  phenytoin  at 
therapeutic doses. Other individuals developed intermittent ataxia typical of 
EA2.  
The previously reported patient with absence epilepsy and episodic ataxia 
attributed to a CACNA1A mutation had a relatively severe phenotype with 
refractory seizures and progressive ataxia (Jouvenceau, Eunson et al. 2001). 
The mutation identified in this case was a premature stop codon leading to 
complete  loss  of  channel  function  and  a  dominant  negative  effect.  The 
present family members exhibit a much milder phenotype with regard to both 
epilepsy and ataxia. Imbrici et al have tested the missense mutation identified 
in this family by functional expression studies in in Xenopus oocytes using 
human  CACNA1A  cDNA  (Imbrici,  Jaffe  et  al.  2004).    E147K  alters  a 
transmembrane  segment  and  has  a  relatively  subtle  effect  on  channel 
function.  The  partial  reduction  in  calcium  channel  function  appears  to  be   259 
caused by impaired trafficking to the cell membrane, and overexpression of 
accessory  subunits  can  restore  function.  It  has  been  postulated  that  the 
ataxia may be a direct consequence of the reduced calcium channel current 
density,  whilst  the  absence  seizures  may  be  caused  by  a  compensatory 
increase  in  currents  mediated  by  other  calcium  channels.    The  latter  is 
supported  by  the  finding  of  increased  low  threshold  calcium  currents 
mediated by t-type calcium channels in mice with spike-wave seizures and 
mutations  in  Cacna1a  (Zhang,  Mori  et  al.  2002).  As  discussed  in  section 
7.2.6, nonsynonymous SNPs in CACNA1H, which encodes a t-type calcium 
channel, have been found in patients with CAE (Chen, Lu et al. 2003; Heron, 
Khosravani et al. 2007). Functional characterisation of some of these SNPs 
in rat channels demonstrated a gain of function, with increased calcium influx 
during  physiological  activation  and  an  increased  propensity  to  channel 
opening (Khosravani, Altier et al. 2004). 
This family has therefore provided additional supportive evidence for a role 
for CACNA1A mutations in some cases of human absence epilepsy. Whether 
CACNA1A  contributes  to  a  significant  proportion  of  CAE  cases  remains 
uncertain.  A  significant  association  has  been  demonstrated  between  a 
CACNA1A intragenic SNP and patients with IGE (Chioza, Wilkie et al. 2001). 
Although CACNA1A did not show positive linkage in our preliminary analysis 
of 33 families, this may reflect the limitations of this methodology in detecting 
one of perhaps several genes incorporating susceptibility alleles for human 
absence epilepsy.   260 
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Appendix 1   Invitation letters to clinicians 












Dear (name inserted) 
 
Re:  Genetic analysis of childhood absence epilepsy (Petit M al) 
 
As you may know, we have a programme of research directed towards identifying the 
genes causing certain childhood epilepsies. 
 
At present, work is focused on absence epilepsies, ie: 
 
Childhood absence epilepsy (CAE) 
Juvenile absence epilepsy (JAE) 
 
We are therefore ascertaining patients with the above diagnoses, even if there is no 
family history. Pairs of affected siblings are most informative, but single cases can 
provide vital information using recently developed techniques. All that will be 
required is some clinical information and either blood or saliva for DNA extraction. 
Full ethical permission has been granted. 
 
If you have patients who might be suitable for study, would like to collaborate, and 
wish to receive more information about the project, please complete the form below 






R.M. Gardiner           Dr R. Robinson 




I would like to receive more information about the research project on genetic 
analysis of childhood absence epilepsy. 




Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON 
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103   280 
 
Appendix 1b Letter  of  invitation  to  consultant  paediatricians  with  patients 










   
Dear  Dr (name inserted) 
 
Re: The genetic analysis of childhood absence epilepsy 
 
As you may know, we have a programme of research directed towards identifying the genes 
causing certain childhood epilepsies. We are currently collecting patients with a diagnosis of 
childhood absence epilepsy. 
 
The EEG database at «EEG_Department»  .has thrown up patients with probable absence epilepsy 
under your care namely: 
 
«Patient_1»  «DOB» 
«Patient_2»  «DOB1» 
«Patient_3»  «DOB2» 
«Patient_4»  «DOB3» 
«Patient_5»  «DOB4» 
«Patient_6»   «DOB5» 
 
 
With your permission, we could write to the families directly with information about the study. If 
the families are suitable and agree to participate, all that would be required is a sample of DNA 
from  each  patient  and  their  immediate  family.  A  simple  cheek  swab  sent  through  the  post  can 
obtain this. 
 
 Multi-centre ethics approval has been granted by the North Thames MREC. 
 
We enclose a copy of the parent information sheet. Please let us know if you feel these patients 






Dr Robert Robinson          Pauline Boland         
Clinical Research Fellow in Paediatrics      Clinical Research Nurse 
    
Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON 
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103   281 
 
Appendix 2   UK Neurophysiology Departments collaborating in study 
Neurophysiology Department  Contact 
Addenbrooke‟s Hospital, Cambridge CB2 2QQ  Dr Simon Boniface 
Birmingham Children‟s Hospital, Birmingham B4 6NL  Dr Seri 
Bristol Royal Hospital for Children, Bristol B52 8BJ  Phillip Blackwell 
Central Middlesex Hospital, London NW10 7NS  Dr Jamal 
Chelsea and Westminster Hospital, London, SW10 9NH  Dr Ian Mak 
Gloucestershire Royal Hospital  Dr Oware 
Great Ormond Street Hospital, London WC1N 3JH  Dr Stewart  Boyd 
Guy‟s Hospital, London SE1 9RT  Dr Michael O‟Brien 
Hammersmith Hospital, London W12 ONN  Dr Khalil 
King‟s College Hospital, London SE5 9RS  Professor C Binnie 
Leicester Royal Infirmary, Leicester LE1 5WW  Karen Widley 
Northampton General Hospital  Dr Bissessar 
Park Hospital, Oxford OX3 7LQ  Dr Zenobia Zaiwalla 
Queens Medical Centre, Nottingham NG7 2UH  Sylvia Remmington 
Royal Devon & Exeter Hospital  Dr Elias Ragi 
Royal London Hospital, London E1 1BB  Dr Franz Brunhuber 
Royal Surrey County Hospital, Surrey GU2 5XX  Sharon Boxall 
Southampton University Hospital, Southampton, SO16 3YD  Dr Vander Starr 
St Hellier Hospital, Surrey, SM5 1AA   Karen Widley 
St Mary‟s Hospital, London W2 1NY  Dr Steven White 
St Mary‟s Hospital, Portsmouth PO3 6AD  Dr Merton 
St Thomas‟ Hospital, London SE1 7EH  Dr C P Panyiotopoulos 
University College London Hospital, London WC1E 3DB  Dr David Holder 
York District Hospital, York YO31 8HE  Dr Sibte Hasan   282 
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Appendix 4  Project summary and call for patients circulated at BPNA Annual Meeting 2001 
 
 
Molecular genetic analysis of childhood absence epilepsy 
 
Robert Robinson, Department of Paediatrics, Royal Free & University College Medical School, University College London, WC1E 6JJ, UK. 
E-mail: robert.robinson@ucl.ac.uk 
Telephone: 44 (0)20 7679 6131           Fax: 44 (0)20 7679 6103 
 
  Genetics  of  human  epilepsy.  Epilepsy  is  one  of  the  most  common  childhood 
neurological disorders and genetic factors contribute to aetiology in about 40% of 
cases.  Over  100  single-gene  mendelian  disorders  include  epilepsy  as  one 
component  of  what  is  usually  a  more  complex  neurological  phenotype. 
Individually  these  diseases  are  rare  and  the  majority  of  common  idiopathic 
generalised  epilepsies  (IGEs)  display  a  complex,  non-mendelian  pattern  of 
inheritance. 
Childhood  absence  epilepsy  (CAE)  is  an  inherited  IGE.  Most  studies 
demonstrate a complex form of inheritance, but one recent segregation analysis 
was  consistent  with  an  autosomal  dominant  mode  of  inheritance  with  reduced 
penetrance.  
Molecular  genetics  of  inherited  epilepsies.  Idiopathic  mendelian  epilepsies  in 
human  and  mouse  have  been  identified  as  channelopathies.  Mutations  causing 
human  epilepsy  have  been  found  in  the  gene  encoding  the  4  subunit  of  the 
neuronal  nicotinic  acetylcholine  receptor  (CHRNA4),  two  voltage  gated  K
+ 
channel  genes  ( KCNQ2,  KCNQ3),  and  two  sodium  channel  genes  (SCN1B, 
SCN1A).  Mutations  in  voltage-dependent  calcium  channel  genes  have  been 
identified in both human and murine absence epilepsies. 
 
 
Our strategy is to ascertain families with childhood absence epilepsy, 
and to investigate the role of candidate genes in these families. As well 
as traditional linkage analysis, we are using intrafamilial association 
analysis which allows us to utilise the large number of families with 
only one affected individual. 
 
3 Hz spike and wave EEG in 
childhood absence epilepsy 
Diagnostic criteria 
  Absence seizures (of any type 
except myoclonic absences) 
  Onset between 2 and 12 years 
  Normal development 
  Ictal EEG showing bilateral, 
synchronous, symmetrical 
discharges of 2.5-4 Hz spike-
wave or polyspike-wave 
complexes on a normal 
background 
DNA collection 
DNA is obtained from all 
affected family members, both 
parents and, where possible, 
unaffected siblings. 
DNA is extracted from either  
blood samples or cheek swabs, 
both of which can be transported 
by mail. 
Multi-centre research ethics 
approval has been obtained. 
Call for Families 
The power of a genetic study of this type is largely dependent on the 
size of the patient resource. We have now recruited 87 families with at 
least one child with CAE from centres around the UK and abroad, but 
are aiming for up to 300 families. We are recruiting new families with 
a proband with CAE on an ongoing basis. 
These families include: 
  trios (a single affected child with both unaffected parents) 
  affected sibling pairs 
  pedigrees with two or more affected members 
Do you treat children with childhood absence epilepsy? 
Would you be interested in collaborating? 
Please contact Robert Robinson (details above). 
Molecular basis of absence seizures. Aberrant 
thalamocortical rhythms underly the generalised 
3Hz spike and wave discharges typical of 
absence seizures. Consciousness requires tonic 
firing of thalamocortical rhythms and abolition of 
rhythmic burst firing. Several classes of gene are 
involved in the generation of thalamocortical 
rhythms and absence seizures, and are thus 
candidate genes for CAE. These include voltage-
dependent calcium channels, GABA A and 
GABA B receptors, potas sium channels, sodium 
channels and hyperpolarisation -activated cyclic -
nucleotide gated channels.   
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Appendix 5  Collaborators outside the UK 
Collaborator   Department 
Europe:    
Professor Jean Aicardi   Hopital Robert Debré, Paris, France 
Dr M Feucht, Professor H Aschauer  University Hospital for Child and Adolescent Neuropsychiatry, Vienna, Austria 
Dr PMC Tijink-Callenbach, Professor OF Brouwer  Leiden University Medical Centre, Leiden, The Netherlands 
Dr A Covanis  The Children‟s Hospital Agia Sophia, Goudi, Athens, Greece 
Professor Olivier Dulac  Hopital Necker Enfants Malades, Paris, France 
Professor Orvar Eeg-Olofsson  Uppsala University, Sweden 
Dr Auli Siren, Dr Mogens Laue Friis   University Hospital of Tampere, Tampere, Finland 
Dr Françoise Goutières   Hôpital des Enfants Malades, Paris, France 
Professor Renzo Guerrini  University of Pisa, Italy 
Dr Armin Heils   University Clinic of Epileptology, Bonn, Germany  
Dr Marianne Juel Kjeldsen   Odense University Hospital, Odense, Denmark 
Professor Anna-Elina Lehesjoki  
Folkhälsan Institute of Genetics & Dept of Medical Genetics, Haartman Institute, 
University of Helsinki, Finland 
Dr Thomas Sander   University Hospital Charité, Virchow Clinic, Berlin, Germany 
Dr Anders Sundquist  Soder Hospital, Stockholm, Sweden 
Canada:    
Professor JM Dooley  Dalhousie University and IWK Health Centre, Halifax, Nova Scotia 
Dr Elaine Wirrell  Alberta Childrens Hospital, Calgary, Canada   285 
 




                       












Dear «Title» «AASurname» and «Child»,                                                                               <<Date>> 
 
Re: The genetic analysis of absence epilepsy 
 
«Consultant» suggested we write to you about our study, and we very much hope you will agree to participate. 
At University College London, research is currently progressing in the molecular genetics of epilepsy. W e are 
interested in the genetics of individuals who have, or have had, mainly absence seizures, and are ascertaining 
children with absence epilepsy. 
 
40%  of  all  epilepsies  are  genetic,  even  when  no  other  family  members  have  epilepsy.  Our aim  is  to  identify 
which  genes  in  the  body  are  different  between  those  affected  and  those  not  affected  with  absence  epilepsy. 
Identifying  abnormal  genes  may  allow  us  to  develop  more  effective  treatments  and  improve  diagnostic  and 
prognostic methods. 
 
W e have enclosed some more information but will gladly discuss matters further and answer any questions you 
may have. If you agree to take part, all that is required are some cheek swabs from «Child», and if possible mum, 
dad and any brothers or sisters, all of which can be done at home. No extra hospital visits are required.  
 
All information collected is confidential. W e will keep you informed about the general results of the research 
project. If a genetic test is developed which is of proven benefit, we will provide guidance on how testing can be 
obtained in a clinical setting with appropriate counselling. If at any stage individuals decide that they no long er 
want to participate in the trial all their details will be removed immediately and there will be no interference with 
their medical management 
. 





Pauline Boland            Dr Robert Robinson 
Clinical Research Nurse         Clinical Research Fellow in Paediatrics 
--------------------------------------------------------------------------------------------------------------------------- - 
W e would like to know more about the research project on genetic analysis of childhood absence epilepsy 
 
Telephone No: ……………………………..    email: …………………………………. 
Contact Times……………………………………  
«Title» «AASurname» and «Child».  
Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON 
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103   286 
 
Appendix 7  Family information sheets 









INFORM ATION SHEET FOR CHILDREN UP TO 12 YEARS PARTICIPATING IN EPILEPSY 
STUDY 
 
W e are conducting a study of epilepsy in families, and invite you to take part. 
 
Your genes make up a special code that is in every cell in your body, which you get partly from your 
mother and partly from your father. This code stores all the information that makes you “you”. 
 
The project is looking at the genes of people with epilepsy, and the genes of their brothers and sisters, and 
parents. This is to discover if there is part of the code that makes some people more likely to develop 
epilepsy. 
 
This is important as it may help us to understand more about epilepsy, and hopefully develop better drugs 
to treat people with epilepsy. 
 
If you agree to take part in the study, you, your mum and dad, and your brothers and sisters will be 
contacted by a doctor. The doctor will ask some questions about your health (how you feel), and take a 
cheek swab or a small blood sample from each of you. A special cream will mean that you hard ly feel a 
thing if a blood sample is taken. 
 
We will look at a special part of your sample, which contains your genes (the special code). We will 
compare it to the codes of people in your family, and codes from other families who are also taking part 
in the study. 
 
This will allow us to find out if there is a special part of the code that carries information about epilepsy.  
 
The results of the study may be published in a medical journal. Your name would never be given out to 
anyone unless you said it was OK. 
 
You do not have to take part in this study if you do not want to. If you decide to take part you can 
stop at any time, without having to give a reason. W hether you decide to take part or not will not 
affect the way you are looked after normally by your doctors. 
 
FOR FURTHER INFORM ATION CONTACT: Dr Robert Robinson at the above address. 
 
An ethics committee looks at all studies involving people before they can go ahead, to make sure that 
everything is fair and done for a good reason. This study was approved by the North Thames Multi-centre 
Research Ethics Committee. 
The ethics committee may need to check your medical records to make sure all our information is correct. 
However no details about you will be passed on to anyone else.  
 
 
Head of Department Professor RM Gardiner MD, FRCP 
Royal Free and University College Medical School 
U N IV ERSITY CO LLEG E LO N D O N  
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103   287 
 









INFORM ATION SHEET FOR TEENAGERS PARTICIPATING IN EPILEPSY STUDY 
 
W e are conducting a study of epilepsy in families, and invite you to take part. 
 
Your genes make up a special code that is in every cell in your body, which you get partly from your 
mother and partly from your father. This code stores all the information that makes you “you”. 
 
The project is looking at the genes of people with epilepsy, and the genes of their brothers and sisters, and 
parents. This is to discover if there is part of the code that makes some people more likely to develop 
epilepsy. 
 
This is important as it may help us to understand more about epilepsy, and hopefully develop better drugs 
to treat people with epilepsy. 
 
If you agree to take part in the study, you, your mum and dad, and your brothers and sisters will be seen 
by a doctor. The doctor will ask you some questions about your health (how you feel), and take some 
cheek swabs or a blood sample (5-20ml) from each of you. 
 
We will look at a special part of your sample, which contains the DNA which makes up your genes. We 
will compare it to the genes of people in your family, and genes from other families who are also taking 
part in the study. 
 
This will allow us to find out if there is a special gene that carries information about epilepsy. 
 
The results of the study may be published in a medical journal. Your name would never be identified 
from published results without your agreeing to this. 
 
You do not have to take part in this study if you do not want to. If you decide to take part you may 
withdraw at any time, without having to give a reason. Your decision whether to take part or not 
will not affect your care and management in any way. 
 
FOR FURTHER INFORM ATION CONTACT: Dr Robert Robinson at the above address. 
 
An ethics committee reviews all proposals for research involving people before they can proceed. This 
proposal was approved by the North Thames Multi-centre Research Ethics Committee. 
The ethics committee and regulatory authorities may need to see your medical records to make sure all 
our information is correct. However your medical details will not be seen by anyone else. 
 
Royal Free and University College Medical School 
U N IV ERSITY CO LLEG E LO N D O N  
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103 
Head of Department Professor RM Gardiner MD, FRCP   288 
 









INFORM ATION SHEET FOR ADULTS PARTICIPATING IN EPILEPSY STUDY 
 
We are conducting a study of epilepsy in families, and invite you to take part. 
 
WHY IS THE STUDY BEING DONE?  The aim of our study is to find genes that make certain 
individuals susceptible to having seizures. Once genes are identified we can determine how they work 
and discover exactly what goes wrong when a seizure occurs. 
 
HOW IS THE STUDY TO BE DONE?  The first step in identifying genes is to find a large number 
of families in which there is one or more family member with epilepsy. We ask family members for 
descriptions of their seizures, at what age they started, how long they last, how often they occur, and 
whether they had any serious illnesses, head injuries or birth difficulties. If we then think that we have 
enough information to be able to include them in our study, we will ask for some cheek swabs or a blood 
sample (5-20ml) from as many family members as possible, both affected and unaffected by epilepsy. If 
required, the blood sample will be taken at a routine outpatient appointment or by your GP (we will not 
contact your GP without your permission). From the samples we will extract DNA, the material of which 
genes are made. Many thousands of genes exist, and these are grouped together to form chromosomes. 
Humans have 23 pairs of chromosomes (46 in total). We will analyse the DNA to see if we can first work 
out on which chromosomes genes causing epilepsy are to be found, and then to work out exactly what 
type of genes they are. The results of the study may be published in a medical journal. Your name would 
never be identified from published results without your consent. 
 
WHAT ARE THE POSSIBLE BENEFITS OF THE STUDY?  By identifying genes that cause 
epilepsy, we can work out what goes wrong to cause a seizure and why some people have seizures and 
others do not. Then, hopefully, we would be able to develop better drugs to treat epilepsy, and even 
prevent epilepsy developing at all. However all these developments are a long way off, and it may be 
many years before we really understand what causes epilepsy. 
 
WHAT ARE THE RISKS OF THE STUDY? There are no real risks associated with participation in 
the study. 
 
You do not have to take part in this study if you do not want to. If you decide to take part you may 
withdraw at any time, without having to give a reason. Your decision whether to take part or not 
will not affect your care and management in any way. 
 
FOR FURTHER INFORM ATION CONTACT: Dr Robert Robinson at the above address. 
 
An ethics committee reviews all proposals for research using human subjects before they can proceed. 
This proposal was approved by the North Thames Multi-centre Research Ethics Committee. 
The ethics committee and regulatory authorities may require access to your medical records for purposes 
of verification. However this will not violate the confidentiality of any medical information. 
 
Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON 
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103 
Head of Department Professor RM Gardiner MD, FRCP   289 
 











CONSENT FORM FOR FAMILIES PARTICIPATING IN EPILEPSY STUDY 
 
 
Please answer all the questions below before agreeing to take part in the study. 
 
 
Have you read the information sheet about this study?      YES/NO 
 
Have you had an opportunity to ask questions and discuss this study?  YES/NO 
 
Have you received enough information about this study?      YES/NO 
 
Have you received satisfactory answers to all your questions?    YES/NO 
 
Which doctor/nurse have you spoken to about this study?………………………………… 
 
Do you understand that 
you are free to withdraw from this study at any time 
without giving a reason for withdrawing 
without affecting you future medical care?          YES/NO 
 
Do you agree to take part in this study?          YES/NO 
 
 




print)………………………………………………………Date of Birth……………. 
 
Relationship to child (if under 16 years  
old)…………………………………………………………………………………… 
 





Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON 
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103 
Head of Department Professor RM Gardiner MD, FRCP   290 
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Epilepsy 
 
Family Clinical Data Set   291 
Instructions for completing the family clinical data sets 
 
One clinical data set should be completed for each family. 
 
Each set comprises: 
 
Sheet one:  Family name/code. Referring physicians’ details. 
 
Sheet two:  Family overview 
    - please enter the local code for each different family member 
 
Sheet three:  Pedigree diagram 
    - instructions for drawing pedigrees below 
 
Clinical documentation sets for 3 individuals: 
 
  Please complete one clinical documentation set for: 
a)  Each affected family member. 
b)  Each asymptomatic family member on whom an EEG has been performed. 
 
Each set comprises: 
 
Sheet one:  Clinical information 
    - please give as full clinical information as possible 
Sheet two:  Seizure descriptions 
    - boxes are provided for 3 seizure types (absences and two others) 
Sheet three:  EEG data 
- please include most informative EEGs 
 
 
Symbols for drawing pedigrees: 
- underneath each affected person indicate the diagnosis if known. 
 
  Normal male  Normal female 
 
  Affected male  Affected female 
 
  Stillbirth  3  3 unaffected females 
 
  Abortion  Deceased 
 
  Marriage  Sex uncertain 
 
  Illegitimate offspring  Pregnant 
 
   
  Consanguinous marriage 
    Non-identical twins 
  No offspring   
    Identical twins 
     
  Marriage with 3 children 
    Twins of uncertain zygosity 
?   292 
Genetic Analysis of Absence Epilepsy 
 
Family Clinical Data Set 
 
 
Family name:   
 
(may be left blank)  
 
 




































Telephone:            Fax: 
 
 




Name  Local code  Date of birth  Sex  Date of last  EEG 
        Observation 
      D  M  Y    D  M  Y 
 
           ♂  ♀    Y  N   
 
 
♂             ♂  ♀    Y  N   
 
 
            ♂  ♀    Y  N   
 
 
            ♂  ♀    Y  N   
 
 
            ♂  ♀    Y  N   
 
 
            ♂  ♀    Y  N   
 
 
            ♂  ♀    Y  N   
 
 
            ♂  ♀    Y  N   
 
 
            ♂  ♀    Y  N   
 
 
            ♂  ♀  Y  Y  N 
 
 
EPILEPSIES  Childhood Absence Epilepsy (Petit Mal) 
 
  Juvenile Absence Epilepsy 
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CLINICAL DOCUMENTATION SET 
 
Subject  Local 
name:  Code: 
 
Mother’s  Father’s 
Code:  Code: 
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Absence Seizures:  Typical?  Atypical?    Eyelid myoclonia? 
 
Age of onset:  Age of last seizure:  Total number:  1  2-6  >6 
 
Average duration:  mins  secs  Frequency:  per  yr  mth  wk  day  hr 
 











Other Seizures:   Type: 
 
Age of onset:  Age of last seizure:  Total number:  1  2-6  >6 
 
Average duration:  mins  secs  Frequency:  per  yr  mth  wk  day  hr 
 











Other Seizures:   Type: 
 
Age of onset:  Age of last seizure:  Total number:  1  2-6  >6 
 
Average duration:  mins  secs  Frequency:  per  yr  mth  wk  day  hr 
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Date of EEG:  Age at recording:  yrs  mths 
 
Medication:  N  Y   Specify_______________________________________________ 
 
Patient state:  Awake  Sleep-deprived  Sleep  Inter-ictal  Ictal 
 
Background:  Normal    Abnormal     Give details: 
 
  ___________________________________________________________________ 
 
Abnormalities:  Spontaneous  Provoked by:  hyperventilation  photic stimulation 
 
  Generalised spike and wave discharges  Frequency 
 




Conclusion:  __________________________________________________________________ 
 
  __________________________________________________________________ 
 




Date of EEG:  Age at recording:  yrs  mths 
 
Medication:  N  Y   Specify_______________________________________________ 
 
Patient state:  Awake  Sleep-deprived  Sleep  Inter-ictal  Ictal 
 
Background:  Normal    Abnormal     Give details: 
 
  ___________________________________________________________________ 
 
Abnormalities:  Spontaneous  Provoked by:  hyperventilation  photic stimulation 
 
  Generalised spike and wave discharges  Frequency 
 




Conclusion:  __________________________________________________________________ 
 
  __________________________________________________________________ 
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                                  Dr Robert Robinson 
Department of Paediatrics 
Royal Free and University College London Medical School 
Gower Street Campus 
  5 University Street 
             London 
       WC1E 6JJ 
    UK 
 
    Tel: 44 (0)20 7679 6131 
   Fax: 44 (0)20 7679 6103 
Email: robert.robinson@ucl.ac.uk 
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Appendix 10   Instructions for entering data into clinical database 
  Entering data into Access database 
 
Open database in Microsoft Access. 
Password ####### 
Ensure „Forms‟ is selected in left hand menu (Objects) 
Enter data in each of the three forms 
Within each form, to scroll through previous records use arrows at bottom of screen 
To delete a record, in „edit‟ menu click „select record‟, then „delete‟ 
 
1. Family Investigator 
  One record per family 
  Family ID is a 3-figure number (numbers to be allocated) 
  Epilepsies – this represents all the epilepsies/seizures in the family, each 
represented by a 2-letter code (eg CAFCIG). Select from drop-down list or, if 
correct combination of epilepsies is not present in list, type directly into box. 
o  CA:  CAE 
o  JA:  JAE 
o  JM:  JME 
o  IG:  IGE 
o  EM:  Eyelid myoclonis with absence 
o  FC:  Febrile convulsions 
o  PS:  Photosensitive seizures 
o  OE:  Other epilepsy 
 
2. Family Overview 
  One record for every individual in the family (with or without seizures) 
  Full ID is a 6-figure number – a combination of the family ID and the 
individual ID. The usual individual ID s are: father – 101, mother – 102, 
children 201, 202, 203 etc. 
  Epilepsies – this represents all epilepsies/seizures for that individual. 
  Relationship: P – proband, PP – parent of proband, SP – sib of proband. More 
complicated pedigrees must be drawn by hand! 
 
3. Clinical Data 
  One record for each individual with epilepsy/seizures 
  It may be necessary to maximise the clinical data window to access the scroll 
bar on the right 
  Full ID – as in Family Overview 
  Clinical History – use Clinical Comments box to give details of any 
abnormalities 
  Seizures: Up to five different seizure types (three in detail) 
  Seizure types: 
o  GSA:    generalised seizure, absence 
o  GSM:    generalised seizure, myoclonic 
o  GTCS:   generalised tonic-clonic seizure 
o  FC:    febrile convulsion 
o  GSAmy:  generalised seizure, absence + myoclonus 
o  OS:    other seizure 
  Use Seizure Comments box for any additional details 
  EEG: Use EEG Comments box for additional details 
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Appendix 11   Sample collection 












Collection of blood samples for DNA analysis 
 
Volume:    5-20 mls 
      (but even 1-2 mls is sufficient on small infants) 
 
Anti-coagulant:  Ca – EDTA 
      Tubes used for full blood count estimations are fine and 
usually have a purple top (in the UK). 
 
Storage:    Room temperature. 
It is not necessary to freeze or put at 4C 
 
Labeling:    Ensure bottles labeled including full name and date of birth. 
 
Transfer:  Samples need to arrive in the UK not more than three days from the 
time of sampling. Samples should be shipped to the following 
address: 
 
  Dr Robert Robinson 
  Department of Paediatrics 
  Royal Free and University College M edical School 
  The Rayne Institute 
  5 University Street 
  London 
  W C1E 6JJ 
  UK 
 
  Tel: 44 (0)20 7679 6131 
  Fax: 44 (0)20 7679 6103 
  Email: robert.robinson@ucl.ac.uk 
 
Consent forms should be included with the samples. Shipping costs 
will be reimbursed. 
Thank you for your time and effort. 
 
 
Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON 
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103 
Head of Department Professor RM Gardiner MD, FRCP   301 
 











Collection of DNA samples by mouth swab method 
 
Dr Robert Robinson  
Department of Paediatrics 
Rayne Institute 
5 University Street 
London WC1E 6JJ 
UK 
Tel  44 (0)20 7679 6131 
Fax  44 (0)20 7679 6103 
e-mail  robert.robinson@ucl.ac.uk 
 
Padded envelope contains (one set for each person) 
 
  Tube containing 5 swabs 
  Tube marked P on top containing preservative solution, labelled with name 
  Cotton wool or tissue to wrap tube in 




1.  Each family member providing cheek swabs should take their swabs on the same 
day, or within a day or two of each other, so that all the swabs can be returned in 
the same envelope. 
2.  Collect sample first thing in the morning before drinking, eating or doing teeth. 
3.  Please wear gloves provided whenever handling swabs to avoid contamination. 
4.  Each person should use all 5 swabs on one morning. 
5.  Remove each swab from tube and rub along both cheeks inside mouth for about 
20 seconds. 
6.  Place used swab in CORRECTLY NAM ED TUBE containing preservative 
solution. M AKE SURE THAT THE COTTON W OOL END IS INSERTED 
DOW NW ARDS INTO THE LIQUID. 
7.  All 5 swabs should fit in the tube with the preservative. 
8.  Be sure to do the lid up tightly once all five swabs are in the tube. 
9.  Make sure the swabs are covered in the solution. 
10. The empty tubes can be discarded. 
11. Wrap outside of swab tube in cotton wool/tissue provided and sellotape together. 
12. Send back to Dr Robert Robinson in padded envelope provided with consent form. 
 
Thank you for your time and effort. 
Royal Free and University College Medical School 
U N IV ERSITY CO LLEG E LO N D O N  
 
DEPARTMENT OF PAEDIATRICS 
 
Gower Street Campus 
The Rayne Institute 
5 University Street 
London WC1E 6JJ 
 
Direct Line Telephone 0207 679 6131 
Fax 0207 679 6103   302 
Appendix 12   Absence pedigree clinical data 
CAE: childhood absence epilepsy; JAE: juvenile absence epilepsy; AE: absence epilepsy; GSA: generalised absence seizure; 
GSAmy: generalised absence seizure with myoclonus; FS: febrile seizure; GSWD: generalised spike-wave discharges; GPSWD: 
generalised polyspike-wave discharges 
Country of Origin:   FR=France (Généthon);  












Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






5  5204  F  FR  CAE    GSA  4    GSWD  3  ?mild eyelid myoclonus 
5  5207  M  FR  CAE    GSA  5    GSWD  3    
9  9201  F  UK  AE  GSAmy  4    GPSWD     
9  9202  F  UK  AE  GSA 
GTCS 
2    GSWD, PS       303 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






26  26202  M  UK  CAE          GSA      
FS 
6    GSWD  3  Mild learning difficulties 
26  26204  F  UK  CAE          GSA      
FS 
6    GSWD  3  Frequent paroxysms of bilaterally synchronous 3 sec 
spike&slow wave activity associated with absence 
27  27202  F  UK  AE  GSA  
GTCS 
4    GSWD, PS     Some  generalised  theta  activity..Photic  stimulation 
produced  bursts  of  generalised  spike&wave 
complexes 
27  27301  F  UK  CAE          GSA  
GTCS   
7    GSWD, PS  3  GTCS. Loss of consciousness, generalised shaking of 
all limbs. No incontinence or tongue biting 
27  27302  F  UK  CAE          GSA 
GTCS 
7    GSWD  3    
92  92102  F  UK  IGE  GTCS           
92  92201  F  UK  CAE  GSA  2-12    GSWD     
92  92202  F  UK  CAE    GSA  2-12    GSWD       
96  96301  F  UK  AE    GSA  7    GPSWD     Numerous  generalised  polyspike  &  slow  waves 
sometimes associated with eyelid flutter and impaired 
awareness 
96  96302  M  UK  AE  GSA  6    GPSWD  3-5  Bursts  of  spike,  polyspike  activity.  Twitch  of  the 
mouth evident 
137  137101  M  UK  IGE  GTCS, 
MS 
18    GSWD     
137  137202  F  UK  IGE  GTCS, 
MS 
12    GSWD     
137  137301  F  UK  AE  GSAmy  1    GPSWD       304 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






137  137302  M  UK  AE  GSAmy  1    GPSWD     
173  173201  F  UK  CAE    GSA  6    SW  3-3.5    
173  173202  F  UK  CAE    GSA  5    PSW  3    
202  202101  M  FI  CAE       GSA  
GTCS   
5    GSWD       
                     
202  202201  F  FI  CAE       GSA      
FS 
3    GSWD       
202  202202  F  FI  CAE       GSA 
FS 
3    GSWD       
202  202203  F  FI  CAE       GSA  
FS 
6    GSWD       
317  317201  F  FI  CAE       GSA  
GTCS 
5    GSWD  3    
317  317202  M  FI  CAE       GSA  5    GSWD  3 - 2.5    
321  321101  M  DK  CAE    GSA  
GTCS 
9    GSWD  3    
321  321201  F  DK  CAE    GSA  6    GSWD       
321  321202  F  DK  CAE    GSA  3    GSWD       
321  321204  F  DK  CAE          GSA      
FS 
3    GSWD  3    
342  342201  F  UK  AE  GSAmy  11    GPSWD       305 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






342  342202  F  UK  AE  GSAmy  <13    GPSWD     
346  346201  F  UK  CAE    GSA  2    GSWD  3   
346  346202  F  UK  CAE    GSA  2-12    GSWD  3  mild visuo-perceptual problems 
348  348203  M  UK  CAE    GSA  3    GSWD       
348  348206  M  UK  CAE    GSA  3    GSWD  3  absences causing some interference with school work 
353  353101  M  UK  CAE    GSA  10    GSWD       
353  353201  M  UK  CAE    GSA  6  Y  GSWD  3  aged 7/12 suspected sepsis, septic screen NAD 
353  353202  M  UK  CAE    GSA  9    GSWD  3    
358  358102  F  UK  CAE    GSA  4    GSWD       
358  358201  F  UK  CAE    GSA  5    GSWD  3  Definite abnormality of spike & wave activity 
372  372102  F  DE  CAE    GSA 
GTCS 
6    GSWD  3    
372  372201  F  DE  CAE    GSA  4    GSWD  3    
372  372202  F  DE  CAE    GSA 
GTCS 
5    GSWD  3    
381  381101  M  DE  CAE  GSA 
GTCS 
2-12    GSWD     
381  381201  F  DE  CAE  GSA  5    GSWD     
381  381202  M  DE  CAE  GSA  5    GSWD     
381  381203  M  DE  CAE  GSA  6    GSWD     
382  382102  F  DE            GSWD  3   No definite seizures 
382  382201  M  DE  CAE    GSA  7    GSWD        306 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






382  382202  F  DE  CAE    GSA  6    GSWD  3    
393  393201  F  DE  CAE    GSA  8    GSWD       
393  393202  M  DE  JAE  GSA  
GTCS 
15    GPSWD       
394  394301  M  DE  CAE    GSA  7    GSWD       
394  394302  M  DE  CAE    GSA  8    GSWD       
395  395102  F  DE             GSWD      No definite seizures 
395  395201  M  DE  CAE    GSA  4    GSWD       
395  395203  M  DE  CAE    GSA  3    GSWD       
396  396101  M  DE  CAE    GSA       GSWD       
396  396201  F  DE  AE  GSA  3    GPSWD       
396  396202  M  DE  CAE    GSA  6    GSWD       
397  397102  F  DE  CAE    GSA  5    GSWD       
397  397201  F  DE  CAE    GSA  
GTCS 
3    GSWD       
397  397202  F  DE  CAE    GSA  3    GSWD       
400  400201  M  DE  AE    GSA  
GTCS 
5    GPSWD       
400  400202  F  DE  CAE    GSA  
GTCS 
5    GSWD       
401  401101  F  DE  IGE  GTCS  20            
401  401201  M  DE  CAE    GSA   4    GSWD         307 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  







401  401202  F  DE  CAE    GSA  
GTCS 
3    GSWD       
402  402201  F  DE  CAE  GSA  
GTCS 
12    GSWD     
402  402202  F  DE  CAE  GSA   11    GSWD     
403  403201  F  DE  CAE    GSA   
GTCS 
3    GSWD       
403  403202  M  DE  CAE          GSA      
FS 
3    GSWD       
404  404101  M  DE  IGE  GTCS  20            
404  404202  F  DE  CAE    GSA  
GTCS 
6    GSWD        
404  404302  F  DE  CAE    GSA  7    GSWD       
404  404303  M  DE  CAE    GSA  7    GSWD       
404  404304  M  DE  CAE    GSA  5    GSWD       
405  405201  M  DE  CAE    GSA  6    GSWD       
405  405202  M  DE  CAE    GSA  3    GSWD       
407  407102  F  UK  CAE    GSA  5    GSWD     Separation anxiety aged 4 years. ?jerks limbs started 
after first pregnancy, stopped spontaneously 
407  407201  F  UK  CAE    GSA  3    GSWD  3  Absence attacks associated with 3 second spike and 
wave. 3+ years behavioural problems 
407  407202  F  UK  CAE    GSA  5    GSWD  3     308 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






421  421201  F  IT  CAE    GSA  2-12    GSWD       
421  421202  F  IT  CAE    GSA  2-12    GSWD       
422  422103  M  IT  IGE  GTCS  9            
422  422201  F  IT  CAE    GSA  6    GSWD       
422  422202  M  IT  CAE    GSA  13    SW       
426  426103  F  UK  AE    GSA  <13    GPSWD     Paternal  aunt  thought  to  have  absence  attacks 
although never confirmed on EEG  
426  426201  F  UK  CAE    GSA  6    GSWD  3  Hyperventilation provides  3 episodes of generalised 
spike  &  wave,  associated  with  clinical  absences. 
Maternal  Toxoplasmosis  during  pregnancy.                                             
Seizures  did  affect  schooling  but  no  extra  help 
required 
429  429101  M  FR  AE    GSA   <13    GPSWD        
429  429203  F  FR  AE    GSA   <13    GPSWD       
430  430202  F  FR  AE    GSA   <13    GPSWD       
430  430301  M  FR  AE    GSA   <13    GPSWD       
431  431201  F  FR  JAE  GSA 
FS 
13+    GPSWD     
431  431202  F  FR  JAE  GSA 
FS 
13+    GPSWD     
432  432201  F  FR  CAE    GSA  2-12    GSWD       
432  432202  F  FR  CAE    GSA  2-12    GSWD         309 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






433  433202  F  FR  CAE    GSA  2-12    GSWD       
433  433301  F  FR  CAE    GSA  2-12    GSWD       
434  434201  M  FR  CAE    GSA  2-12    GSWD       
434  434202  F  FR  CAE    GSA  2-12    GSWD       
435  435201  M  FR  CAE    GSA  2-12    GSWD       
435  435202  F  FR  CAE  GSA   2-12    GSWD       
436  436201  F  FR  CAE    GSA  2-12    GSWD       
436  436202  M  FR  CAE    GSA  2-12    GSWD       
437  437201  M  FR  CAE    GSA  2-12    GSWD       
437  437202  M  FR  CAE    GSA  
GTCS 
2-12    GSWD       
438  438201  F  FR  JAE  GSA 
GTCS 
13+    GPSWD     
438  438301  F  FR  JAE  GSA 
GTCS 
13+    GPSWD     
438  438302  M  FR  JAE  GSA 
GTCS 
13+    GPSWD     
439  439201  F  FR  JAE  GSA      GPSWD     
439  439202  F  FR  JAE  GSA 
GTCS 
    GPSWD     
440  440202  F  FR  CAE    GSA       SW         310 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






440  440203  M  FR  JAE  GSA       SW       
441  441202  F  FR  CAE    GSA       SW       
441  441203  M  FR  JAE  GSA       SW       
442  442201  F  FR  CAE    GSA 
GTCS 
2-12    GSWD       
442  442202  M  FR  CAE    GSA 
GTCS 
2-12    GSWD       
443  443202  F  FR  CAE    GSA  2-12    GSWD       
443  443203  F  FR  CAE    GSA  2-12    GSWD       
444  444201  M  FR  AE  GSA  <13    GPSWD     
444  444202  M  FR  AE  GSA  <13    GPSWD     
445  445202  M  FR  CAE          GSA      
FS 
2-12    GSWD       
445  445203  F  FR  CAE    GSA  2-12    GSWD       
446  446201  M  FR  CAE    GSA  2-12    GSWD       
446  446202  M  FR  CAE    GSA  2-12    GSWD       
447  447201  F  FR  CAE    GSA  2-12    GSWD       
447  447202  F  FR  CAE    GSA  2-12    GSWD       
448  448201  M  FR  AE  GSA 
FS 
<13    GPSWD     
448  448202  M  FR  AE  GSA  <13    GPSWD     
449  449201  F  FR  JAE  GSA  13+    GPSWD       311 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  







449  449202  F  FR  JAE  GSA  13+    GPSWD     
450  450201  M  FR  CAE    GSA  2-12    GSWD       
450  450202  M  FR  CAE    GSA  2-12    GSWD       
451  451202  F  FR  JAE  GSA 
FS 
13+         
451  451203  F  FR  JAE  GSA  13+         
452  452995  M  FR  AE    GSA  <13    GPSWD       
452  452996  F  FR  AE    GSA  <13    GPSWD       
461  461201  F  SE  CAE    GSA  2-12    GSWD       
461  461202  M  SE  CAE    GSA  2-12    GSWD       
466  466201  F  SE  CAE    GSA  2-12    GSWD       
466  466202  F  SE  CAE    GSA  2-12    GSWD       
525  525201  F  NL  AE  GSA  10    GPSWD     
525  525202  F  NL  AE  GSA 
GTCS 
12    GSWD     
525  525203  F  NL  CAE  GSA  6    GSWD     
527  527201  F  NL  CAE    GSA  7  Y  GSWD       
527  527202  F  NL  CAE    GSA  3  Y  GSWD  3-4    
528  528101  M  NL  IGE  GSA 
GTCS 
11           312 
Fam 
ID 
Full ID  Sex  Country 
of 
Origin 
Epilepsy  Seizure  Age  at 
onset  






528  528204  F  NL  AE  GSA  5    GPSWD     
528  528301  M  NL  IGE  GSA 
GTCS 
2    Non-specific 
abnormalities 
   
528  528302  M  NL  AE  GSA  1    GSWD     
529  529202  F  NL  CAE    GSA  7    GSWD      
529  529301  M  NL  CAE    GSA  5    GSWD  2-3  Absences  - primary generalised epilepsy 
530  530201  M  NL  CAE    GSA  5:5    GSWD  3   
530  530202  M  NL  CAE    GSA  4  Y  GSWD  2.5-3  Frontal sharp waves and spikes 
577  577201  M  GR  CAE    GSA  10    GSWD       
577  577202  F  GR  CAE    GSA  7    GSWD       
586  586202  F  NL  CAE    GSA  5    GSWD     GTCS often preceded by headaches 
586  586301  F  NL  AE  GSAmy  5    GPSWD       
586  586302  M  NL  CAE    GSA  7.5    GSWD       
871  871201  F  FR  CAE  GSA  2-12    GSWD       
871  871202  F  FR  CAE    GSA  2-12    GSWD       
872  872201  M  FR  CAE  GSA  2-12    GSWD       
872  872203  F  FR  CAE  GSA  2-12    GSWD       
873  873101  M  FR  JAE  GSA  13+    GPSWD     
873  873201  F  FR  JAE  GSA  13+    GPSWD     
873  873202  F  FR  JAE  GSA  13+    GPSWD     
874  874102  F  FR  CAE  GSA  2-12    GSWD       313 
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874  874201  M  FR  CAE  GSA  2-12    GSWD     
874  874202  F  FR  IGE  GTCS  2-12         
875  875201  F  FR  CAE   GSA  2-12    GSWD        
875  875301  F  FR  CAE  GSA  2-12    GSWD       
875  875302  F  FR  CAE  GSA  2-12    GSWD       
876  876201  M  FR  JAE  GSA  13+    GPSWD       
876  876202  F  FR  JAE    GSA  13+    GPSWD       
877  877201  F  FR  CAE  GSA  2-12    GSWD       
877  877202  F  FR  CAE  GSA  2-12    GSWD       
878  878201  M  FR  CAE  GSA  2-12    GSWD       
878  878202  M  FR  CAE  GSA  2-12    GSWD       
879  879102  F  FR  CAE       GSA 
FS 
2-12    GSWD       
879  879103  F  FR  CAE       GSA 
FS 
2-12    GSWD       
879  879201  F  FR  CAE  GSA  2-12    GSWD       
880  880201  F  FR  CAE  GSA  2-12    GSWD       
880  880202  F  FR  CAE       GSA 
GTCS 
FS 
2-12    GSWD       
881  881201  M  FR  JAE       GSA  13+    GPSWD         314 
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881  881202  F  FR  JAE  GSA  13+    GPSWD       
881  881203  M  FR  JAE    GSA 
GTCS 
13+    GPSWD       
882  882201  M  FR  JAE  GSA  13+    GPSWD     
882  882202  M  FR  JAE  GSA  13+    GPSWD     
883  883201  F  FR  JAE  GSA  13+    GPSWD       
883  883202  F  FR  JAE  GSA  13+    GPSWD     
884  884201  F  FR  CAE    GSA 
GTCS 
13+    GPSWD       
884  884202  F  FR  JAE  GSA  13+    GPSWD       
885  885102  F  FR  CAE  GSA  2-12    GSWD       
885  885201  F  FR  CAE  GSA   2-12    GSWD       
 
   315 
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126  126302  UK  CAE      GSA 
GTCS  
8    GSWD    Hyperventilation caused build up of slow waves/spikes. GTCS, 
making  a  funny  noise.Rigid  and  shaking  all  over.speech 
difficulties post& shaky on feet. 
128  128101  SE  JAE  GSA 
GTCS 
13    GSWD  3  3HZ  bilateral  generalised  spike  waves  slight  L  dominance 
associated with clinical absence 
128  128203  SE  JAE  GSA 
GTCS 
10    GSWD  3  one episode when fell repeatedly without loss of consciousness 
when playing over period of 15 mins single day 
132  132101  SE  JAE  GSAmy      GSWD    Generalised paroxysmal theta & delta activity with sharp waves 
132  132203  SE  JAE  GSA 
GTCS 
11    GSWD  3-4  Episodes of irregular 3-4Hz GSW enhanced by hyperventilation 
133  133202  SE  CAE      
JME 
AS  5    GSWD  3  Generalised spike waves. Slow waves posterior 
234  234208  UK  JME  GSA 
MS  
GTCS 
12    Excess  of  B 
activity 
  Excess  of  generalised  B  activity,  otherwise  NAD.  AS  always 
follows MS . GTCS no warnings, often bites tongue 
234  234313  UK  JAE  GSA 
GTCS 
18        Asthma  from  aged  6-7  On  no  RX.  Feels  nauseated,  eyes  roll 
upwards following GTCS, incontinent of urine 
339  339201  UK  CAE    GSA  8    GSWD  3  Supports diagnosis of CAE 
340  340202  UK  CAE    GSA  6    GSWD  0.5  Several bursts of 3 second spike & wave 
343  343202  UK  CAE    GSA  7  Y  GSWD      
345  345201  UK  CAE    GSA  9    GSWD  3  Compatible with primary generalised epilepsy 
349  349201  UK  CAE    GSA  6    GSWD  2.5  Prolonged runs of 2.5 spike& wave 
350  350202  UK  CAE    GSA  6  Y  GSWD  3  Spike and slow wave activity confirm CAE 
352  352202  UK  CAE    GSA  12  Y  GSWD  3  Number  of  typical  absences  associated  with  3Hz  generalised 
spike&wave 
354  354201  UK  CAE    GSA  3  Y  GSWD  2.5-3  Definite abnormality /generalised spike&wave complexes at 3/s 
355  355201  UK  CAE    GSA  8    GSWD  3  Spike & wave complexes at 3/s accompanied by clinical absence   316 
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356  356201  UK  CAE    GSA  5  Y  GSWD  3  Frontally dominated spike&wave activity associated with clinical 
signs.Suggest CAE 
357  357201  UK  CAE    GSA  1  Y  GSWD  3  Compatible with petit mal 3/sec spike wave. Measles at 10/12 
360  360202  UK  CAE    GSA  10    GSWD  3-3.5  3-3.5 second spike and wave complexes generalised over the 2 
hemispheres.some  lateralised  abnormalities.  Typical  petit    mal 
absence 
361  361202  UK  CAE    GSA  8    GSWD  3  Definite abnormality with runs of 3 second spike wave 
362  362201  GR  CAE    GSA  5    GSWD      
364  364202  UK  CAE    GSA  6    GSWD  3  Confirms  the  clinical  suspicion  of  childhood  absence  epilepsy. 
Language delay 
365  365202  UK  CAE    GSA  3  Y  GSWD  3  Clinical attacks associated with approx 3/s spike & waves 
366  366202  UK  CAE    GSA  4    GSWD    Support clinical diagnosis of primary generalised epilepsy in the 
form of absence attacks 
367  367202  UK  CAE    GSA  7    GSWD      
368  368201  UK  CAE    GSA  5  Y  GSWD  3  Generalised epileptic discharges supporting absence type primary 
generalised epilepsy. Forceps delivery  No SCBU 
369  369201  UK  CAE    GSA  6    GSWD  3-3.5  Vaginal delivery 36/40 mild jaundice 
371  371201  UK  CAE    GSA  7    GSWD    Brief generalised discharges up to 0.5 second in duration of spike 
and slow waves.-typical absences 
380  380201  DE  CAE    GSA  8    GSWD      
385  385201  UK  CAE    GSA  2  Y  GSWD  3  Emergency  LSCS-delay  in  labour.Resus+Low  apgar  score  at1 
minute, @normal at 10minutes. Asbergers syndrome & fine motor 
dyspraxia,  occasionally requires PR diazepam to stop fitting 
387  387202  UK  CAE    GSA  8    GSWD    sharpened slow wave posteriorly 
388  388203  UK  CAE    GSA  10    GSWD  3    
389  389201  UK  CAE    GSA  4    GSWD  2.5-3  EEG findings pathognomonic of childhood absence epilepsy 
390  390202  UK  CAE    GSA  11    GSWD  3  Petit mal epilepsy 
391  391202  UK  CAE    GSA  3    GSWD      
392  392202  UK  CAE    GSA  5    GSWD  3  Supports the diagnosis of CAE 
406  406202  UK  CAE    GSA  5  Y  GSWD  3.5  Definite abnormality associated with overbreathing  
408  408201  UK  CAE    GSA  9    GSWD  2-3  generalised paroxysms from the occipital focus    317 
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409  409201  UK  CAE    GSA  5    GSWD  3  Typical absence epilepsy 
410  410202  UK  CAE    GSA  5    GSWD  3  EEG changes confirm diagnosis of CAE 
412  412202  UK  CAE    GSA  11    GSWD  2.5-3  2.5-3Hz spike & wave activity with clinical absences 
414  414201  UK  CAE    GSA  7    GSWD      
415  415201  UK  CAE    GSA 
GTCS 
12    GSWD  3  Prolonged  spike  &  wave  discharges  occur  in  response  to 
hyperventilation. Support CAE 
417  417201  UK  CAE    GSA  6    GSWD  3  Suggest  a  potential  for  an  idiopathic  epilepsy  syndrome  with 
absence epilepsy 
418  418201  UK  CAE    GSA  4    GSWD  3-4  Diagnostic  of  childhood  absence  epilepsy,  mild  learning 
difficulties 
453  453201  UK  CAE    GSA  9    GSWD  3  Abnormal EEG with 2 attacks of petit mal absence consistent with 
primary generalised epileptic discharges 
456  456202  UK  CAE    GSA  4  Y  GSWD  3   Record  show  clear  changes  of  3/second  spike  &  wave  with 
clinical  changes.  Other  Provoking  Factors:  Going  into  bright 
lights and very cold things 
457  457201  UK  CAE    GSA  4  Y  GSWD    Hypoxic  at  birth  no  resus  needed  no  SCBU          
Neurodevelopment: Requires Speech therapy and poor short term 
memory. Medication Regime: Started on Sodium Valproate with 
no response so was changed to Epilim Chrono 
459  459201  SE  CAE    GSA  2-12    GSWD      
462  462201  SE  CAE    GSA  2-12    GSWD      
463  463202  SE  CAE    GSA  2-12    GSWD      
464  464201  SE  CAE    GSA  2-12    GSWD      
465  465201  SE  CAE    GSA  2-12    GSWD      
468  468201  AT  CAE    GSA  2-12    GSWD      
469  469201  AT  CAE    GSA  2-12    GSWD      
470  470201  AT  CAE    GSA  2-12    GSWD      
471  471201  AT  CAE    GSA  2-12    GSWD      
472  472201  AT  CAE    GSA  2-12    GSWD      
473  473201  AT  CAE    GSA  2-12    GSWD      
474  474201  AT  CAE    GSA  2-12    GSWD      
475  475201  AT  CAE    GSA  2-12    GSWD        318 
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476  476201  AT  CAE    GSA  2-12    GSWD      
477  477201  AT  CAE    GSA  2-12    GSWD      
478  478201  AT  CAE    GSA  2-12    GSWD      
479  479201  AT  CAE    GSA  2-12    GSWD      
480  480201  AT  CAE    GSA  2-12    GSWD      
481  481201  AT  CAE    GSA  2-12    GSWD      
482  482201  AT  CAE    GSA  2-12    GSWD      
483  483201  AT  CAE    GSA  2-12    GSWD      
484  484201  AT  CAE    GSA  2-12    GSWD      
485  485201  AT  CAE    GSA  2-12    GSWD      
486  486201  AT  CAE    GSA  2-12    GSWD      
487  487201  AT  CAE    GSA  2-12    GSWD      
488  488201  AT  CAE    GSA  2-12    GSWD      
489  489201  AT  CAE    GSA  2-12    GSWD      
490  490201  AT  CAE    GSA  2-12    GSWD      
491  491201  AT  CAE    GSA  2-12    GSWD      
492  492201  AT  CAE    GSA  2-12    GSWD      
493  493201  AT  CAE    GSA  2-12    GSWD      
494  494201  AT  CAE    GSA  2-12    GSWD      
495  495201  AT  CAE    GSA  2-12    GSWD      
496  496201  AT  CAE    GSA  2-12    GSWD      
497  497201  AT  CAE    GSA  2-12    GSWD      
498  498201  AT  CAE    GSA  2-12    GSWD      
499  499201  AT  CAE    GSA  2-12    GSWD      
500  500201  AT  CAE    GSA  2-12    GSWD      
501  501201  AT  CAE    GSA  2-12    GSWD      
502  502201  AT  CAE    GSA  2-12    GSWD      
503  503201  AT  CAE    GSA  2-12    GSWD      
504  504201  AT  CAE    GSA  2-12    GSWD      
505  505201  AT  CAE    GSA  2-12    GSWD      
506  506201  AT  CAE    GSA  2-12    GSWD      
507  507201  AT  CAE    GSA  2-12    GSWD        319 
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508  508201  AT  CAE    GSA  2-12    GSWD      
509  509201  AT  CAE    GSA  2-12    GSWD      
510  510201  AT  CAE    GSA  2-12    GSWD      
511  511201  AT  CAE    GSA  2-12    GSWD      
512  512201  AT  CAE    GSA  2-12    GSWD      
519  519201  SE  CAE    GSA  2-12    GSWD      
520  520201  SE  CAE    GSA  2-12    GSWD      
522  522201  SE  CAE    GSA  2-12    GSWD      
533  533201  UK  CAE    GSA  2-12    GSWD      
573  573201  GR  CAE    GSA  2-12    GSWD      
574  574201  GR  CAE    GSA  2-12    GSWD      
576  576201  GR  AE  GSA  2-12    GSWD      
587  587202  UK  CAE    GSA  2-12    GSWD  2-3    
589  589202  UK  CAE    GSA  6  Y  GSWD    Generalised spike and wave activity most during hyperventilation. 
Single slight burst during photic stimulation but this was probably 
coincidental.  Full term baby,  "went blue"-aspirated. In  scub x 
1/52 otherwise well 
595  595201  UK  CAE    GSA 
GTCS 
8    GSWD  3  Findings consistent with primary generalised epilepsy. Nephrotic 
Syndrome 
596  596201  UK  CAE    GSA 
GTCS 
7  Y  GSWD  3  Abnormal  record  with  3  bilateral  bursts  of  high  voltage 
rhythmical  spike  and  slow  wave  activity.  Forceps  delivery. 
?Provoked by onset of puberty 
597  597201  UK  CAE    GSA  3  Y  GSWD  2.5 -4  Primary generalised CAE with mildly atypical features 
598  598202  UK  CAE    GSA  6    GSWD  3-6  Treat for CAE. 41 weeks gestation Normal development 
599  599201  UK  CAE    GSA  5  Y  GSWD  3  Abnormality  with  a  run  of  3  second  spike  wave  complexes 
associated with clinical absences. Breech delivery 
600  600201  UK  JAE  GSA 
GTCS 
12+    GPSWD  3  EEG  confirms  epileptic  absences  and  now  probably  juvenile 
absence  epilepsy  spectrum.  High  Forceps  Delivery  for  "long 
labour"  Bruising  to  face  and  head.  ?  Provoked  by  watching 
movement-at race tract/watching TV 
601  601201  UK  CAE    GSA  7    GSWD  3  Definite  abnormality  with  frequent  generalised  spike  &  slow 
wave  discharges  around  3  sec  greatly  facilitated  by   320 
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hyperventilation.  LSCS  at  32  weeks  gestation  (4lbs  at  birth). 
SCBU for 1 week- no problems 
603  603202  UK  CAE    GSA  6    GSWD  3  Habitual  absences  during  hyperventilation,  associated  with 
generalised regular3-4C/S spike & Wave activity 
604  604203  UK  CAE    GSA  8    GSWD  3  generalised  regular  3-4c/  spike  &  wave  activity,  implies  the 
potential for generalised seizures and is consistent with childhood 
absence epilepsy 
605  605201  UK  CAE    GSA  
GTCS 
3  Y  GSWD  3  Likely  'Petit  mal'  syndrome,  several  paroxysms  of  3  sec 
discharges. Delayed Speech, Undergoing Speech Therapy. Mild 
global  development  delay.  Fell  down  and  unresponsive  ,  PR 
Diazepam controlled fit. Total time 20 minutes 
606  606202  UK  CAE    GSA  7    GSWD    Current EEG support the clinical picture of CAE responding well 
to sodium valproate 
608  608201  UK  CAE    GSA  6    GSWD  3  Generalised  3HZ  Regular  Spike  &  Wave.  LSCS  for  Breech 
presentation 
609  609204  UK  CAE    GSA 
FS 
6  Y  GSWD  2.5- 3  Bursts of generalised 2.5-3Hz spike & Wave. Findings consistent 
with primary/secondary generalisation, former being most likely. 
Normal  delivery.  MRI/  arachnoid  cyst.  School  work-slightly 
behind  due  to  frequent  absences.  Febrile  convulsion  aged  9 
months 
610  610201  UK  CAE    GSA  5  Y  GSWD  3  EEG  suggests  a  potential  for  a  primary  generalised  epilepsy 
syndrome with epileptic absences and possible photosensitivity. 3 
weeks premature, LBW-not in SCBU-normal development 
611  611203  UK  JAE  GSA  13    GSWD    Generalised spike & Wave. Findings imply primary generalised 
epilepsy consistent with juvenile absence epilepsy 
612  612201  UK  CAE    GSA  10    GSWD  4-5  Pathological EEG. During drowsiness and several times  during 
photic  stimulation,  short  lasting  irregular  activity,  mixed  with 
epileptiform spike activity occurred lasting up to 2.5 seconds. 
614  614203  UK  CAE    GSA  6    GSWD  2-3  Bursts of spikes, one with intermittent slow waves. Generalised 2-
3Hz  spike/wave.  Photic  stimulation  produced  some  following 
more  left  than  right.  Support  a  seizure  disorder  of  primary 
generalised  type.  Delay  in  reaching  milestones.  Needing  extra   321 
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help at school 
615  615202  UK  CAE    GSA  10    GSWD  3  Evidence for seizures of the primary generalised type, with ictal 
generalised 3 per second, at rest and during photic stimulation. 41 
weeks gestation Normal development 
617  617203  UK  CAE    GSA  8    GSWD  ?  Generalised  Frontally  maximal  spike  and  wave  activity  , 
consistent  with  Primary  generalised  type.  Statemented  due  to 
epilepsy. Psychological report -15 extra hours help at school as 
behind peers/regular school 
618  618201  UK  JAE  GSA      GSWD  3  EEG findings confirm epileptic absences consistent with absence 
epilepsy syndrome 
619  619202  UK  CAE    GSA  6    GSWD  3  EEG indicates primary generalised epilepsy with absence seizures 
and  frequent  subclinical  discharges.  2  1/2,  years  behind  peers, 
awaiting special help at school- regular school 
620  620201  UK  CAE    GSA  10    GSWD  3  An abnormal EEG diagnostic primary generalised epilepsy. 
621  621202  UK  CAE    GSA  4    GSWD  2.5-4  An abnormal EEG which is diagnostic of some form of absence 
epilepsy.  4  secs  of  generalised    frontally  predominant 
spike/polyspike  and  slow  wave  activity.  In  process  of  being 
statemented  2+ years behind peers 
622  622204  UK  CAE    GSA  6    GSWD  3  An  EEG  diagnostic  of    primary  generalised  epilepsy.    No 
reproducible photosensitivity. . SCBU short term post delivery. 
Increased heart rate at birth. 
623  623201  UK  CAE    GSA  9    GSWD  2-4  Record  continues  to  show  frequent  generalised  runs  of  spikes 
waves complexes. LSCS/delay in labour, Dyslexia. 
624  624202  UK  CAE    GSA  3    GSWD  3  Three  bursts  of  generalised  3Hz  spike  &  wave  activity. 
Overbreathing produced a brief episode of frontal polyspike and 
wave.  Head  injury  aged  2  1/2  years.    (banged  into  glass 
pane/unconscious  briefly)Mum  convinced  this  is  a  factor  in 
development of CAE 
625  625202  UK  CAE    GSA  7    GSWD  3  Background show frequent generalised spikes. Bursts of regular 
generalised  regular  3-4  C/S  spike  &  wave  occur  throughout 
record, supports CAE. Scarlet fever at 36 months. Suffers from 
childhood migraines   322 
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626  626201  UK  CAE    GSA  7    GSWD  3   EEG more unstable than usually seen in CAE 
632  632205  DK  CAE      GSA  
GTCS 
10    GSWD  3-5  During  hyperventilation  and  photic  stimulation    generalised 
paroxysms seen.  
635  635202  UK  CAE    GSA  5    GSWD  3-5  Features remain typical of childhood absence syndrome.  Home 
birth  NAD.  Up  with  peers  at  school  but  poor  to  register 
information. onset 1999, poor response to ethosuximide, Sodium 
valproate  initial  good  response,  deteriorated-lamotrigine  added- 
good response. Typical CAE. 
636  636201  UK  CAE    GSA  4    GSWD  3-4  Several  brief  bursts  of  regular  3-4  C/S  spike  &  wave  occur 
throughout the record. Imply the potential for generalised seizures 
and are consistent with CAE. No extra support at school but in 
last year mum notes school work deteriorating 
637  637202  UK  CAE    GSA  10    GSWD  3  Typical clinical events associated with 3Hz spike and waves, 2 
spontaneously  and  2  with  overbreathing-consistent  with  CAE. 
Chicken- Pox quite severe but otherwise NAD 
638  638202  UK  CAE    GSA 
GTCS 
5  Y  GSWD  3  2 bursts of 3/second spike & wave with a feature of there being 2 
spikes for each wave. MRI -no structural abnormality in cerebral 
area- mild cerebellar ectopia noted. Speech therapy aged 3 years-
couldn't  pronounce  "G's"-  otherwise  NAD.  Lack  of  sleep-  one 
GTCS, lasting 2 minutes approx, lips blue, LOC. 
639  639201  UK  CAE    GSA  5    GSWD  2.5-3  During  hyperventilation  typical  3  per  second  spike  &  wave 
discharges are seen as in petit mal syndrome. 42 weeks gestation-
nil of note 
640  640202  UK  CAE    GSA  4    GSWD  3-4  Support  clinical  diagnosis  of  petit  mal-"paroxysms  are  a  little 
unusual"  Induced  42  week-"Vernix  ++",    Aged  2:6  Language 
delay, Behind peers at school "dyscalculi"- needs extra help at 
school-  Regular  school.  Ethosuximide  controlled  Absences  x  2 
years-seizures  reoccurred-Ethosuximide  restarted  seizured  now 
controlled once again on higher dose. 
642  642201  UK  CAE    GSA  4  Y  SW  3  3 second spike & wave seizure confirmed on EEG. MRI normal.  
41weeks gestation. Well baby. 
644  644102  UK  GTCS  GTCS          one GTCS aged 9 years. Never repeated.   323 
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644  644201  UK  CAE   GSA  3    GSWD  3   Suggest  primary  generalised  epilepsy.  May  have  CAE  but 
atypical features. Birth asphyxia-SCUB x 24 hours. Has extra help 
at  school/  one-one  sessions  &  speech  therapy.  vacant  spells 
increased frequency. 
646  646202  UK  CAE    GSA  7    GSWD  2.5-3  4  bursts  of  generalised  spike  &  slow  wave  activity.  1  during 
overbreathing,  1  during  photic  stimulation-  liability  to  primary 
generalised  seizures  fairly  typical  of  CAE.  1  FS  aged  18/12- 
associated with tonsillitis/ raised temp. 
647  647202  UK  CAE          GSA 
FS 
3  Y  GSWD  3  3 typical 3Hz spike wave disturbance with a normal background- 
activity commensurate with the typical petit mal syndrome. Strep 
throat  queried  to  have  meningitis  but  transpired  not  to  be  so. 
Statemented - educationally has stayed static x 3 years. 1 FS aged 
2 years associated with strep' throat infection. 
648  648201  UK  CAE    GSA 
GTCS 
    GSWD  2-3  Features of primary generalised seizure present. Family history of 
petit  mal  on  maternal  side-great  grandfather,  great  aunt  and 
cousins. 4 GTCS ever. Provoked by being hot and sweaty. 
649  649202  UK  CAE    GSA  7    GSWD  3-4  Features typical of those seen in petit mal syndrome. "held breath 
at 3/12", Speech impediment corrected with speech therapy. 
650  650202  UK  CAE    GSA  10    GSWD  2-4    
652  652201  UK  CAE    GSA  4    GSWD  3  Most  of  the  features  strongly  suggest  the  clinical  diagnosis  of 
childhood  absence  epilepsy.  Breech  presentation  and  delivery/ 
Mother had LSCS ( Raised BP prior to delivery) 
653  653201  UK  CAE    GSA  4  Y  GSWD  3  Abnormal Records. Multiple clinical attacks with 3Hz Spike and 
slow wave activity. One episode of polyspike activity. Consistent 
with clinical diagnosis of CAE. MRI normal. Slow at school. Was 
to be statemented but didn't happen. Behind peers 
657  657201  UK  CAE    GSA  12    GSWD  2.5-4  Record indicates an ongoing liability to primary seizure disorder 
and  changes  are  consistent  with  absence  seizures.  Still  having 
absences- nostrils flare/ appears absent for a short period. 
658  658101  UK  CAE   GSA  
GTCS 
6    GSWD    Diagnosed as having petit mal as a child. GTCS aged 14. 2-3 in 
total  controlled  with  epilim  and  phenytoin.  Presently  being 
weaned off phenytoin.   324 
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658  658202  UK  CAE    GSA  5    GSWD  3-4  Features suggest the presence of petit mal. SVD-Term baby. Nil 
of note 
659  659102  UK  CAE    GSA  8    GSWD  3  Diagnosed  petit  mal  aged  8  years  with  2-3  sec  spike  &  wave. 
SVD. Well child 
659  659202  UK  CAE    GSA  3    GSWD  3  Multiple  spike  and  slow  waves  at  3Hz.  Support  diagnosis  of  
CAE. SVD .Term baby. Insignificant heart murmur diagnosed as 
neonate. 
660  660201  UK  CAE   GSA  
GTCS 
8  Y  GSWD  3  Episodes of generalised  spike and slow waves in keeping with 
CAE.  42/40  gestation.  Behind  peers  at  school/  difficult  to 
concentrate- extra help in classroom. GTCS , whole body would 
shake, mouth drop, put himself on the floor Some LOC 
661  661202  UK  CAE    GSA  7    GSWD  3-4  Few  brief  bursts  of  spike  &  slow  wave  discharges  during 
hyperventilation  accompanied  with  eyelid  flicker.  Compatible 
with  CAE.  SVD  Term.  Well  in  childhood.  Absences-  blank, 
continued in activity. Came around & was aware he had had an 
absence 
662  662201  UK  CAE    GSA  8    GSWD  2.5-3  Abnormal  Record.  Generalised  predominant  spike  &  wave 
activity  typical  of  CAE.  41+3/40.  Well  child.  School  work 
slightly below average in past but now up with peers 
663  663201  UK  CAE    GSA  9    GSWD  3  3  episodes  of  typical  3/s  generalised  spike  &  Wave  activity 
consistent  with  primary  generalised  absence  epilepsy.  SVD  at 
term.  Well  child.  Separation  anxiety  aged  9/12  (  Mother  spent 
time in Hosp) Very bright student. Absences stopped very soon 
having started medication. 
664  664203  UK  CAE    GSA  3    GSWD  3  Clinically  and  electrographically  the  EEG  confirms  typical 
childhood absence epilepsy. SVD at term. Nil of note 
666  666203  UK  CAE    GSA  6    GSWD  3  Features present are typical of those seen in CAE. Term Baby, 
SVD. Henoch-Schonlen Purpura aged 4 years-Resolved with no 
problems. Absences down from 40 a day to 10/15 since on epilim. 
667  667201  UK  CAE    GSA  9    GSWD  3-4  Typical  of  primary  generalised  epilepsy  of  the  petit  mal  type. 
42/40 gestation-induced. Forceps delivery.  
669  669201  UK  CAE    GSA  9    GSWD  3  Spike  &  wave  3c/s.  Hyperventilation  associated  with  clinical   325 
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absences. Consistent with CAE. SVD Term. School work slightly 
below average/ regular school. Absences controlled with epilim- 
Changing dose presently due to weight gain. 
670  670201  UK  CAE   GSA  
GTCS 
2  Y  GSWD  3  Whilst not absolutely typical of true CAE this should be viewed 
as very similar. SVD Term. Nil of note in early childhood. Cat 
Scan  NAD.  Absences-  Mother  says  more  like  Day-Dreaming. 
GTCS x 5 from 11-15 years. LOC 2-3 MINUTES. Followed by 
headache. 
671  671202  UK  CAE   GSA  
GTCS 
4  Y  GSWD  3  The EEG and clinical changes indicate CAE. SVT-Term. Early 
childhood  NAD.  Normal  for  age.  Special  eds  due  to  absences. 
LOC x 3. 2-3 minutes. Sept 2002 had an aura but no seizure. 
674  674203  UK  CAE    GSA  8  Y  GSWD  3-4  Paroxysms exacerbated by hyperventilation and elicited by photic 
stimulation. Overall indicative of a primary seizure disorder but 
some unusual features for CAE. SVD Term. Asthmatic. Had extra 
help  at  school  but  now  up  with  peers  since  D/C  medication. 
Absences  resolved  with  Rx.  School  work  improved  since  Rx 
stopped. MRI NAD. Brother  no Corpus Callosum on MRI.    
676  676202  UK  CAE     GSA 
GTCS 
3  Y  GSWD  3-6  Abnormal  record.Changes  are  consistent  with  absence  seizures, 
there are a few atypical features for CAE. SVD( Long labour) at 
term.  Well  child.  LOC.  While  in  bed  sleeping,  was  shaking, 
foaming. Eyes opened staring. 1 GTCS ever. 
677  677203  UK  CAE    GSA  3  Y  GSWD  3  Spike in  mid-frontal-temporal regions. Findings consistent  with 
clinical diagnosis of absence seizures. SVD, Term. Nil of note in 
early  childhood.  Sodium  Valproate  &  Ethosuximide  together 
controlled absences. 
678  678203  UK  CAE    GSA  11    GSWD  3  Hyperventilation evokes bursts of multispike & slow waves at 3 -
4 Hz. Viral meningitis as a baby. Well following same. Slightly 
below peers at school. Absences controlled well with epilim. 
679  679202  UK  CAE    GSA  7    GSWD  3  Several  bursts  of  3  per  second  spike  &  wave  activity  with  an 
anterior  predominance.  In  addition  several  bursts  spike/waves 
especially during photostimulation. FS from aged 6/12- 5 years of 
age. ? May be statemented  due to poor progress at school. FS   326 
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associated  with  acute  illnesses.  LOC  with  cynsis.  Tired  after 
same++. 
680  680203  UK  CAE    GSA  8    GSWD  3  Clinically & electronically typical CAE. SVD Term + 10/7. Held 
back at school . Was behind his peers x 18/12. Now catching up 
681  681201  UK  CAE    GSA  5    GSWD  3-4  Changes  are  compatible  with  typical  CAE.  SVD  at  37/40  . 
Neonatal  jaundice  under  UV  lights.Left  Dacryocystorhinosomy 
12/96. Slightly below average at school due to inattentiveness. FH 
Maternal aunts GTCS X 3 maternal aunts. 
682  682101  UK  CAE    GSA      GSWD    Diagnosed as having petit mal  in childhood 
682  682203  UK  CAE    GSA  7    GSWD  3  Clinical findings indicate CAE. Prolonged bursts of generalised 
spike  &  wave  discharges.  Isolated  polyspike,  spike  &  wave 
discharges over one or other hemisphere. SVD term. Generally 
lacks concentration. Slightly behind peers at school. 
683  683202  UK  CAE    GSA  8    GSWD  3  3 per second spike & wave paroxysms typical of those seen in 
petit  mal.    SVD-Term.  Nil  of  note  in  early  development. 
Advanced  -speaking  at  8/12.  Now  up  with  peers  with  the 
exception  of  maths.    Maternal  Aunt  had  CAE  in  childhood.  ? 
Maternal Grandmother CAE. 
686  686201  UK  CAE     GSA       
FS 
5+    GSWD  2-4  Wakeful period synchronous spike & slow wave activity. During 
sleep  frequent  1-3  second  bursts  of  spike  &  slow  wave.  SVD 
term. Doing OK at school generally-did fall behind peers due to 
absences but now catching up. ? FS. With high temp  appeared to 
be shaking++. ? 
687  687201  UK  CAE    GSA  9    GSWD  3  Abnormal  record.  Bursts  of  anterior  predominant  spike/wave 
activity at 3 c/s recorded.  SVD Term. Above average at school, 
Got into grammar school 
688  688202  UK  CAE     GSA       
FS 
6    GSWD  3  Abnormal record. Recurrent bursts of generalised spike & wave 
occur with HV. Compatible with CAE. SVD term.  Well child. 
Below peers at school- reading particularly bad. With raised temp 
FC. Eyes roll " goes blue" 
689  689201  UK  CAE    GSA  6    GSWD  3  Absence seizures with 3Hz spike & wave were seen associated 
with  lip  smacking  &  blinking.  This  is  primary  generalised   327 
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690  690202  UK  CAE    GSA  3    GSWD  3-4  Abnormal record, fairly brief generalised bursts of spike & wave 
discharges. In addition isolated polyspike/spike  &  wave  appear 
over one or other hemispheres. Findings consistent with primary 
generalised epilepsy. SVD Term. Septic arthritis viral infection in 
knee. Special need at school ?ADHA Rx with dexamphetamine. 
691  691201  UK  CAE    GSA  3  Y  GSWD  3  Frequent  bursts  of  generalised  3C/S  spike  &  slow  wave 
discharges. Consistent with CAE. SVD-Term. Statemented Oro-
motor dyspraxia. Occasional absences still when tired 
693  693201  UK  CAE    GSA  8    GSWD  3-4  Bursts  of  generalised  spike/wave  discharges  at  3-4  secs.  The 
changes  indicate  liability  to  generalised  seizure  disorder and  is 
consistent with CAE. SVD 38/40. Intelligent child 
694  694204  UK  CAE   GSA  
GTCS 
5  Y  GSWD  2-3  Findings consistent with seizure disorder of primary generalised 
type with clinical diagnosis of CAE. C/S elective due to mums 
past history. Special Care x 3 days Oxygen x 3 days. Behind peers 
at school/Regular school. MRI -NAD. 2 episodes of GTCS aged 3 
&  5  years.Became  stiff  and  body  shaking.  No  loss  of  bowel 
function. Post ictal tiredness++ 
695  695201  UK  CAE    GSA  4  Y  GSWD  3-4  Abnormal Record. Frequent bursts of generalised spike & wave 
discharges at 3-4hZ. Some associated with clinical absences and  
jerks. These changes indicate CAE. Term +10/7. Fell aged 18/12 
?Convulsion.    Aged  3  Years  eyes  twitching.  Behind  peers  at 
school, extra help given-behavioural problems. Convulsion aged 
18/12-  never  diagnosed  but  mother  report  fall  for  n  apparent 
reason with shaking limbs. Eyes twitching aged 3 years 
696  696203  UK  CAE   GSA  
GTCS 
6  Y  GSWD  3  Prolonged  3  /sec  spike  /wave  seen,  accompanied  by  staring  & 
chewing.EEG  consistent  with  primary  absence  epilepsy.  Twin 
delivery. SVD- Asthmatic. Doing well at school, top 20%. GTCS 
1 every 2-4 weeks/ LOC , pale sweaty.  Also has automatisms at 
other times.Hands in the air, mimics -unaware he is doing same. 
697  697201  UK  CAE    GSA  7    GSWD  3  During HV a paroxysm of bilateral 3/sec spike &  wave occurred, 
typical of CAE except duration prolonged. SVD , term + 13/7.   328 
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Went  into  distress  during  labour.  Suctioned,  O2  at  birth-No 
further Rx required. Above average at school. 
698  698201  UK  CAE    GSA  7    GSWD  2-3.5  Clinical  absence  ,  generalised  spike  &  wave  activity 
recorded,Compatible with CAE. SVD Term. Hospital letter says 
"some special needs at school". Mum says "at regular school but 
slow" 
699  699201  UK  CAE    GSA  7    GSWD  3-4  Significantly  abnormal  EEG  with  brief    'paroxysmal'  complex 
discharges  seen  spontaneously  (once)  and  during  HV  (once). 
Suggests  a  liability  to  epilepsy  with    absence.  Moderate 
photosensitivity.  While  some  features  support  a  diagnosis  of 
typical absence. SVD 38/40- well child 
700  700202  UK  CAE    GSA  9    GSWD  3  During the recording  had a brief episode of staring and blinking 
associated with 3Hz spike & wave . This is CAE. LSCS Difficult 
delivery, (mother has small pelvis) Well baby. Speech Therapy 
aged 5 years. High IQ, struggles with reading. FH Grandmother ? 
Petit mal ? Fainting attacks, Grand-uncle GTCS. 
701  701201  UK  CAE    GSA  5    GSWD  3-4  Four bursts of generalised anterior predominant 3-4 cps spike & 
slow  wave-  provoked  by  hyperventilation.  Highly  suggested  of 
CAE. SVD term, 10 lbs, 8oz baby- Needed resus at birth.Spent  3-
4 days  in SCBU. Well child following same. Normal schooling, 
up with peers. No FH 
703  703202  UK  CAE    GSA 
GTCS 
8    GSWD  3-4  Abnormal record. Single brief bursts of generalised spik and wave 
activity over one or other hemisphere. Changes indicate liability 
to  generalised  seizure  disorder.  Normal  background  favours 
primary generalised epilepsy. Migraine aged 9 LOC, sleeping post 
episode +++. 
704  704201  UK  CAE    GSA  9    GSWD  3  EEG confirms the clinical diagnosis of absence seizures showing 
photosensitivity. Paternal Grandmother developed epilepsy aged 
55 years.  
706  706201  UK  CAE    GSA  4    GSWD  3  EEG shows several episodes of high voltage spike/waves at 3c/s. 
Compatible with absence, petit mal epilepsy. SVD 38/40. Well 
Child.  Up  with  peers  at  school/doing  fine.  Paternal  Uncle  has   329 
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707  707202  UK  CAE    GSA  5  Y  GSWD  -  On  normal  background  generalised  paroxysms  of  high  voltage 
spike & wave on overbreathing. Compatible with petit mal. SVD 
37+/40.  Well  baby.  Struggles  at  school-Statemented.  Due  to 
absences.  Recently  added  sodium  valproate  and  no  seizure  in 
3/52. Great Paternal Aunt ? CAE. 
708  708201  UK  CAE   GSA  
GTCS 
11    GSWD  3   Abnormality compatible with primary generalised epilepsy with 
absences as well as GTCS. SVD term. Heart murmur-nil else. Up 
with peers at  school. 1 GTCS ?? Associated  with dehydration. 
Fell to floor, eyes rolling, shaking, unconscious x 1 hr 
709  709201  UK  CAE   GSA  
GTCS 
12  Y  GSWD  3  The  abnormality  in  the  EEG  is  that  of  primary  epilepsy  with 
absences, GTCS as well as averse effect on cognition and memory 
aside  from  overt  absence  seizures.  Emergency  section  at 
34/40.Well child despite premature delivery. Doing very well at 
school.  Father  says  Loss  of  awareness  and  drops  to  floor  x  1 
minute - 6 episodes in total ever. 
710  710201  UK  CAE    GSA  8+    GSWD  3  Abnormal  EEG,  4  brief  typical  absences  evoked  by 
hyperventilation    consistent  with  primary  generalised  seizure 
disorder. SVD 41/40. Well Child. Doing well at school. No FH. 
Started Sodium Valproate 3/52 ago. No absences since beginning 
Rx. 
711  711201  UK  CAE      GSA       
FS 
3    GSWD    Previous abnormal with spike & wave. SVD Term. NAD. Up with 
peers  at  school.  FS  aged  18/12.  1  ever.  Shaking/  sweating. 
Hospitalised x 24 hours . Nil of note. 
712  712202  UK  CAE    GSA  3    GSWD  3  EEG impressively abnormal with electro-clinical features of CAE. 
SVD  at  term.  Well  baby.  Doing  very  well  at  school.  ECG 
revealed monophasic ventricular ectopic beat every few seconds 
throughout  recording.  Absences  more  difficult  to  detect  since 
beginning  Rx.  Still  having  as  many  per  day  but  trying  out 
different  doses  of  medication.  Maternal  Uncle  had  GTCS  in 
childhood. Now nil. 
713  713201  UK  CAE    GSA  7    GSWD  3-3.3  Generalised seizures associated with clinical changes, lasting 10-  330 
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20  seconds.  Findings  suggest  primary  generalised  Epilepsy. 
Emergency    Caesarean    Section  assume  had  pre-eclampsia. 
Gestation 32/40. 5+ weeks in SCBU, ventilated x 3/7. Nil else- 
Doing OK at school with specific problem with poor spelling. Nil 
else. Absences with fixed stare, trembling. School noticed quite a 
few but mum says 1 or less per month, On 3 occasions "big ones" 
whereby there  was episodes of urine incontinence . Never loss 
consciousness but was drowsy following episodes. 
714  714202  UK  CAE    GSA  9    GSWD  3  Background  EEG  normal.  3 episodes  of  3  per  second  spike  & 
wave consistent with primary generalised epilepsy. SVD Term. 
Jaundiced  post  delivery/  Rx  under  lights.  Otherwise  NAD. 
Absences  with  arrested  movement/conversation.  Flutter  of 
eyelids. Lasting seconds- unaware. Paternal Grandfather ?? JAE 
in teenage years."Taboo subject" therefore not discussed in detail. 
838  838102  UK  IGE  GTCS  18        GTCS  from  18  years.  Still  medicated  with  tegretol.  Seizures 
resolved but RX continues. GTCS from 18 years. LOC Rx with 
tegretol some years now since last seizure. Mother also ? GTCS. 
838  838202  UK  CAE    GSA  6    GSWD    Normal  Background.  Numerous  short  episodes  of  high  voltage 
generalised  spike,    wave  associated  with  eyelid  flicker. 
Compatible with epilepsy with absences. SVD term. Cord around 
neck  but  no  consequence.  Doing  OK  at  School.  Absences 
resolved  with  epilim.FH  GTCS  Mother  and  maternal 
Grandmother. 
839  839102  UK  CAE    GSA  7    GSWD    IGE. SVD term. NAD in early childhood. Idiopathic generalised 
epilepsy diagnosed aged 7 years. Absences since aged 7 years. 
Also  Currently  has  occasional  fit  like  seizures  while  sleeping 
particularly when unwell. Aware same is happening but unable to 
communicate. 
839  839202  UK  CAE    GSA  6  Y  GSWD  3-3.5  Brief  absence  attacks  with  normal  background,  consistent  with 
Primary  generalised  seizure.  n  evidence  of  abnormal 
photosensitivity. LSCS for placenta Previa. Mild developmental 
delay due to intrauterine exposure to valproate.( Fine at school).   331 
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Dairy  intolerance  .  Congenital  Dislocation  hip.  MRI  normal. 
Absences slightly improved since starting Rx 6/52 ago. Blinks/ 
arrested movement and stops talking. Unaware 
840  840203  UK  CAE    GSA  5  Y  GSWD  2.5-3  The  record  shows  changes  fully  compatible  with  childhood 
absence epilepsy. Forceps Delivery at term.  Cord around neck. 
Cystic  Fibrosis  diagnosed  at  6/52.  Absences  worsen  when 
problematic breathing. Does well at school generally. Absences, 
eyes roll,  Stops talking, continues to walk. Has cystic fibrosis and 
when breathing deteriorated absences were worse. 
841  841202  UK  CAE    GSA  2  Y  GSWD  2.5-3.5  Previous EEG shows typical discharges compatible with absence 
epilepsy. Now on Rx ? Change in EEG. SVD Term. Nil of note 
medically.  MRI-Normal.  Behind  at  school  ?due  to 
absences/awaiting  statementing.  Tiredness  provokes  absences. 
Eyes  flutter,  raised  eyebrows  slowly,  conversation  cessation. 
Currently titrating RX and some improvement obvious. 
842  842102  UK    FS    Y      FS in childhood.  
842  842201  UK  CAE          GSA       
FS 
5    GSWD  3  Irregular  spike  wave  complexes  around  3c/s  provoked  by 
overbreathing. From present record it would appear that this child 
is having more atypical absence attacks than are being recorded. 
SVD 41/40. Aged 14/12 had FC x 1 with septaemia. Admitted to 
GOS x  3/7.right arm jerks. LOC 1-2 minutes. X 2 episodes. More 
recently  parents  noticed  brief  episodes  of  unresponsiveness, 
staring and occasional eye blinking. EEG report purports seizures 
are  more  frequent  than  are  being  reported  and  are  atypical  in 
nature. Irregular spike-wave complexes around 3c/s provoked by 
overbreathing 
843  843201  UK  CAE       GSA       
FS 
2    GSWD  2.5-3  normal Background with changes of mild drowsiness. £ episodes 
of  generalised  spike/wave  discharges  (  2  provoked  by 
hyperventilation) associated with vacant facial expression . One 
with  additional  body  jerk.  Consistent  with  Primary  generalised 
epilepsy with abs. LSCS 33/40 for severe pre-eclampsia. SCBU 
needing oxygen for 5/7. In Scub x 2/52 only. Generally well baby   332 
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with Hernia ops at 6/12 & 9/12 ( inguanil and umbilical). Three 
episodes  generalised  spike/wave  (  2  provoked  by  Hyper-
ventilation)  associated  with  vacant  facial  expression.  One  with 
upper  body  jerk.  Consistent  with  primary  generalised  epilepsy 
with absence attacks, 
844  844201  UK  CAE    GSA  9  Y  GSWD  3  EEG demonstrates 3c/s spike /wave discharge during  a clinical 
event.  Normal  background  supporting  primary  generalised  ( 
absence  )  epilepsy.  SVD  term.  U/S  brain  NAD  aged  6  years. 
Above  average  at  school.  Paternal  aunt  30+  years  developed 
epilepsy following fall. 
845  845201  UK  CAE    GSA  5+    GSWD  3  Record shows abnormality with runs of irregular spike and slower 
components  at  3c's  associated  with  typical  absence  seizures 
induced  by  overbreathing.  Interictal  record  -  frequent  isolated 
spikes with variable laterisation but n constant focal signs. Mosaic 
marker ring chromosome. LSCS for poor progress in labour failed 
to dilate. Term approx. Well baby . Average at school. FH nil.  
Clinical absence seizures . Mosaic marker ring chromosome. 
846  846201  UK  CAE   GSA  
GTCS 
13  Y  GSWD  2-3  During HV 2 episodes of generalised activity at 3c/s associated 
with  clinical  absences.  In  keeping  with  Primary  generalised 
epilepsy.  Forceps  Delivery  for  foetal  Distress.  Term  baby. 
Migraine  aged  5  years.  Bright  child  doing  well  at  school  but 
absences  does  disturb  school  achievements.  Being  referred  to 
Queen  square  for  investigations.  Simple  Partial  and  Complex 
partial since aged 14. LOC Violent seizures with biting of tongue 
and arm. In last year happens in sleep and awakening.  
847  847102  UK  IGE  GTCS  13        GTCS  aged  13  years.  Lasted  x  approx  1  year.  Rx  with 
Carbamazipine.  Resolved  aged  14  years.  GTCS  aged  13  years 
resolved 14 years. D/C medication. No further seizures. 
847  847201  UK  CAE   GSA       
FS 
3  Y  GSWD  3  Abnormality in the form of generalised approx 3/seconds. Occur 
spontaneously  but  most  prominently  with  photic  stimulation. 
Strongly  supports  an  idiopathic  generalised  epilepsy  such  as 
typical  Childhood  absence.  39/40  gestation.  Small  for  Dates   333 
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baby..  Global  Delay-statemented.  FC  x  1  aged  5  years.  LOC 
lasted seconds associated with pryrexia. 
848  848202  UK  CAE    GSA  9    GSWD  3  EEG consistent with CAE. 3 events 2 during HV.Staring, finger 
fiddling movements. SVD Term baby. No medical History. Doing 
well at school. Normal development with no regression of skills. 
FH  nil.  CAE  from  age  9-10  years.  Sod  Valproate  titrated  and 
Absences  stopped.  Arrest,  unresponsive,  non-purposeful  hand 
movements and hand movements. 
849  849201  UK  CAE    GSA  10    GSWD  3  On Normal cerebral activity numerous paroxysms of generalised 
high -voltage spike & polyspike waves at about 3s/c compatible 
with epilepsy with absences. Vantouse Delivery for delay in 2nd 
stage. Well baby. Doing very well at school. Absences only. On 
Rx but no resolve. Goes blank, arrested conversation. Unaware 
come around and resumes activity 
850  850201  UK  CAE    GSA  2.6  Y  GSWD  3  Record shows changes of childhood absence epilepsy. SVD term. 
Well young child with delayed milestones- speaking at 4 years.( ? 
Autistic  features)  Full  statement.  Assessed  at  Wolfden  unit 
assessed to be 4.9 years ( actual age 7 years). EEG states CAE, Dr 
Letter july 03 ? Myoclonic jerks and complex epilepsy ( Mother 
denies jerks says absences only) 
851  851201  UK  CAE    GSA  1    GSWD  3  Abnormal  with  frequent  unprovoked  subclinical  spike  wave 
discharges. Largely generalised. Overall consistent with Primary 
generalised  epilepsy.  SVD  38/40.  Mother  says  absences  since 
aged  1  noticed.  Statemented  (3).  Poor  at  school.  FH  of  GTCS 
Maternal Uncle ( RIP aged 19 years with GTCS) and Paternal 
Aunt GTCS. 
854  854201  UK  CAE    GSA  8    GSWD  3  EEG  accompaniment  of  clinical  absences  is  typical  of  CAE. 
Photosensitivity  is  atypical  as  is  rhythmic  eyebrow  movement. 
Vantouse  Delivery  delay  in  2nd  stage.  Statemented  at  school, 
special  needs  at  "normal  School".  FH  Maternal  Grandfather  
Seizures  onset  35  years  Rx  with  Phenytoin/  Phenbarbitoin. 
Paternal Great Grandmother GTCS.   334 
Fam 
ID 
Full ID  Country 
of  
Origin 
Epilepsy  Seizure  Age 
at 
onset  






857  857201  UK  CAE    GSA  7    GSWD  3  EEG  typical  of  CAE  except  paroxysms  relatively  brief.1  burst 
coinciding  with  photic  stimulation  .  Possibly  may  evolve  into 
JAE.  EEG  would  do  for  typical  CAE.  Vantouse  Delivery 
41/40.Average at school. FH 2nd cousin had absences. 
860  860201  UK  CAE    GSA  6    GSWD  3  Abnormal EEG. Confirms Typical CAE and is having frequent 
attacks. SVD -Term. Well child. Bright Child - doing very well at 
school.  Absences  now  much  lesser-  occurring  only  when 
exceedingly  tired! 
861  861201  UK  CAE    GSA  5  Y  GSWD  3  Background normal. Generalised spike & wave both clinical and 
sub clinical consistent with primary generalised seizure disorder 
with absence attacks. No focal abnormalities. LSCS for Breech 
Presentation 37/40 gestation. Asthma- otherwise NAD. Top end 
of  average  at  school.  Absences  worse  if  taking  diet  coke.  ( 
Aspartame). Brother allergic to Aspartame 
862  862201  UK  CAE      GSA       
FS 
4    GSWD  3  Frequent  brief  episodes  in  resting  record  with  discharges 
sometimes  limited  to  frontal  cortex-  Generalised  during 
HV/regular  3HZ.  EEG  suggest  a  potential  for  JAE.  Vantouse 
Delivery. Term + 10/7. Glandular fever aged 3 years. Top end of 
class at school. Absences occasional 
863  863201  UK  CAE   GSA  
GTCS 
3    GSWD  3  Recurrence  of  Absences?-EEG  show  definite  epileptiform 
abnormality.  Discharges  L&  R  also  several  bursts  of  3  second 
spike & wave. There is no clear photosensitivity. Preterm 32/40 
gestation,  SCBU  weight  4  1/2lbs.  Respiratory  problems.  Well 
otherwise  in  early  childhood.  Normal  development  but  school 
work affected by absences. GTCS x 4 in total Last episode 1996. 
LOC  provokes  by  flashing  lights.-Known  diagnosis  of  absence 
epilepsy. Sodium Valproate stopped after 2 years fit free in 1999.   335 
 
Appendix 14   Blood samples sent for EBV transformed lymphocyte cell 
lines 
 
Individual ID  Epilepsy  Country 
009201  CAEatyp  UK 
027302  CAE  UK 
357201  CAE  UK 
363201  CAE  UK 
364202  CAE  UK 
366202  CAE  UK 
371201  CAE  UK 
388203  CAE  UK 
390202  CAE  UK 
392202  CAE  UK 
572201  CAE  Greece 
575102  CAE  Greece 
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Appendix 15   Novel  SSLP  markers  designed  using  Primer3  software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) 
Novel SSLP  Gene  Repeat  Forward primer  Reverse primer 
Size 
(bp) 
CACNG3EX1CA  CACNG3  CA  aagcctaggcgttaagacga  ctctgggtttctttgccttg  333 
UCL10321  CACNG3  CA  tgcaaacagactaggaccac  gagctcaggagtttgagacc  213 
A1GUCL  CACNA1G  GT  ggtgttagggcggggtcgg  ggtattaagattaagaggggccaa  268 
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Appendix 16   Examples of input files required for GAS software 
Appendix 16a  GAS locus data file (.gas) 
set logfile = chr16; 
set locus cae affection 
2   0.995   0.005 
1 
0.001 0.7  0.7 
set locus D16S420 named 
7  0.14 0.14 0.14 0.14 0.14 0.14 0.16 
nodata; 
set locus CACNG3EX1CA named 
7  0.14 0.14 0.14 0.14 0.14 0.14 0.16 
nodata; 
set locus UCL10321 named 
7  0.14 0.14 0.14 0.14 0.14 0.14 0.16 
nodata; 
read ( pedigree cae77.ped ) ; 
read ( alsize chr16.siz locus D16S420 CACNG3EX1CA UCL10321 samesize 
= 0.9 diffsize = 1.3 orderfirst global ) ; 
write ( lpedigree chr16.ped ) ; 
 
 
Appendix 16b  GAS  pedigree  file  (.ped).  Data  is  shown  for  three 
families. 
5  101  0  0  2  1 
5  102  0  0  1  1 
5  202  102  101  2  1 
5  204  102  101  2  2 
5  207  102  101  1  2 
9  101  0  0  1  1 
9  102  0  0  2  1 
9  201  101  102  2  2 
9  202  101  102  2  2 
26  101  0  0  1  1 
26  102  0  0  2  1 
26  202  101  102  1  2 
26  204  101  102  2  2 
26  206  101  102  1  1 
26  207  101  102  1  1 
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Appendix 16c  GAS  allele  data  file  (.siz).  The  data  in  each  row 
comprises the marker number in correct chromosomal order, the pedigree 
number  and  the  allele  sizes  generated  by  the  genescan  and  genotyper 
programmes. 
 
D16S420  5.101 180  198 
D16S420  5.102 184  192 
D16S420  5.202 180  192 
D16S420  5.204 180  184 
D16S420  5.207 180  192 
D16S420  9.101 190  192 
D16S420  9.102 180  198 
D16S420  9.201 192  198 
D16S420  9.202 190  198 
D16S420  26.101  188  198 
D16S420  26.102  180  188 
D16S420  26.202  180  198 
D16S420  26.204  180  198 
D16S420  26.206  180  188 
D16S420  26.207  180  188 
CACNG3EX1CA 5.101 x  x 
CACNG3EX1CA 5.102 333  335 
CACNG3EX1CA 5.202 333  335 
CACNG3EX1CA 5.204 x  x 
CACNG3EX1CA 5.207 333  335 
CACNG3EX1CA 9.101 x  x 
CACNG3EX1CA 9.102 x  x 
CACNG3EX1CA 9.201 335  335 
CACNG3EX1CA 9.202 x  x 
CACNG3EX1CA 26.101  335  335 
CACNG3EX1CA 26.102  333  335 
CACNG3EX1CA 26.202  335  335 
CACNG3EX1CA 26.204  335  335 
CACNG3EX1CA 26.206  335  335 
CACNG3EX1CA 26.207  335  335 
UCL10321  5.101 210  214 
UCL10321  5.102 212  214 
UCL10321  5.202 212  214 
UCL10321  5.204 x  x 
UCL10321  5.207 214  214 
UCL10321  9.101 208  214 
UCL10321  9.102 208  214 
UCL10321  9.201 208  214 
UCL10321  9.202 208  214 
UCL10321  26.101  208  214 
UCL10321  26.102  208  214 
UCL10321  26.202  208  214 
UCL10321  26.204  208  214 
UCL10321  26.206  208  208 
UCL10321  26.207  208  208 
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Appendix 17   Locus  data  file  for  GENEHUNTER.  The  penultimate  line 
gives the recombination fractions between the four markers 
5 0 0 1   
0 0.0 0.0 0   
2 3 4 5 
1 2   
0.99 0.01  
1  
0.001 0.5 0.5   
3 11  # D16S420 
0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.091 0.09 
3 3  # CACNG3EX1CA 
0.33 0.33 0.34 
3 9  # UCL10321 
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.12 
3 8  # D16S401 
0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
0  0   
0.0003 0.0025 0.0017 
1  0.1  0.45   340 
 
Appendix 18   Additional  data  file  required  for  GENEHUNTER-
TWOLOCUS. 
0.995 0.005 (w-t, mutant allele frequencies for disease locus 1) 
0.995 0.005 (w-t, mutant allele frequencies for disease locus 2) 
1    (liability classes) 
0.00  0.00  0.00  0.00  (two-locus, parent-of-origin specific  
0.00  0.90  0.90  0.90  penetrances matrix) 
0.00  0.90  0.90  0.90 
0.00  0.90  0.90  0.90   341 
Appendix 19   Individuals selected for CACNG3 exonic sequencing 
    Family: 
Individual 
ID  Epilepsy  CAE linkage  AE linkage  CAE Trio 
5204  CAE  y  y  y 
5207  CAE  y  y  y 
26202  CAE  y  y  y 
26204  CAE  y  y  y 
27301  CAE  y  y  y 
92202  CAE  y  y  y 
202201  CAE  y  y  y 
317201  CAE  y  y  y 
321201  CAE  y  y  y 
346202  CAE  y  y  y 
348206  CAE  y  y  y 
353201  CAE  y  y  y 
372201  CAE  y  y  y 
381201  CAE  y  y  y 
382201  CAE  y  y  y 
394302  CAE  y  y  y 
395201  CAE  y  y  y 
397201  CAE  y  y  y 
401201  CAE  y  y  y 
402201  CAE  y  y  y 
403201  CAE  y  y  y 
404302  CAE  y  y  y 
405201  CAE  y  y  y 
407201  CAE  y  y  y 
421201  CAE  y  y  y 
422201  CAE  y  y  y 
432201  CAE  y  y  y 
433301  CAE  y  y  y 
434201  CAE  y  y  y 
435201  CAE  y  y  y 
436201  CAE  y  y  y 
436202  CAE  y  y  y 
437201  CAE  y  y  y 
442201  CAE  y  y  y 
443202  CAE  y  y  y 
445202  CAE  y  y  y 
446201  CAE  y  y  y 
447201  CAE  y  y  y 
450201  CAE  y  y  y 
461201  CAE  y  y  y 
466201  CAE  y  y  y 
527201  CAE  y  y  y 
529301  CAE  y  y  y 
530201  CAE  y  y  y 
577201  CAE  y  y  y 
586302  CAE  y  y  y 
         
           342 
    Family: 
Individual 
ID  Epilepsy  CAE linkage  AE linkage  CAE Trio 
173201  CAE    y  y 
358201  CAE    y  y 
393201  CAE    y  y 
426201  CAE    y  y 
440202  CAE    y  y 
441202  CAE    y  y 
525203  CAE    y  y 
431202  JAE    y  y 
438301  JAE    y  y 
439201  JAE    y  y 
449201  JAE    y  y 
451202  JAE    y  y 
9201  AE    y  y 
96301  AE    y  y 
137301  AE    y  y 
137302  AE    y  y 
342201  AE    y  y 
396201  AE    y  y 
400201  AE    y  y 
429203  AE    y  y 
430301  AE    y  y 
444201  AE    y  y 
448201  AE    y  y 
525202  AE    y  y 
528302  AE    y  y 
357201  CAE      y 
364202  CAE        y 
   343 
Appendix 20     TDT  results  at  CACNG3  locus  on  chromosome 
16p12-13.3 for 53 CAE pedigrees and 82 AE pedigrees, generated by 
GENEHUNTER 2.1. 





*                                                                      
* 
*                                GENEHUNTER  -  Complete  Linkage  Analysis                
* 
*                                                  (version  2.1_r5  beta)                        
* 






npl:10> TDT Summary - (0 non-original affecteds): 
Marker D16S420         trans untrans  Chi2  p-val 
D16S420   - Allele 1      26    27     0.02  0.890746   
D16S420   - Allele 2      30    42     2.00  0.157299   
D16S420   - Allele 3      27    17     2.27  0.131668   
D16S420   - Allele 4      14    21     1.40  0.236724   
D16S420   - Allele 5      17    19     0.11  0.738883   
D16S420   - Allele 6      16     7     3.52  0.060569   
D16S420   - Allele 7       8     3     2.27  0.131668   
D16S420   - Allele 8       2     5     1.29  0.256839   
D16S420   - Allele 9       3     2     0.20  0.654721   
D16S420   - Allele 10      1     1     0.00  1.000000   
Marker CACNG3EX1CA     trans untrans  Chi2  p-val 
CACNG3EX1CA- Allele 1      45    21     8.73  0.003135  ++ 
CACNG3EX1CA- Allele 2      22    44     7.33  0.006769  -- 
CACNG3EX1CA- Allele 3       8    10     0.22  0.637352   
Marker UCL10321        trans untrans  Chi2  p-val 
UCL10321  - Allele 1      44    39     0.30  0.583128   
UCL10321  - Allele 2      37    27     1.56  0.211300   
UCL10321  - Allele 3      27    49     6.37  0.011617  - 
UCL10321  - Allele 4      10     8     0.22  0.637352   
UCL10321  - Allele 5       9     2     4.45  0.034808  + 
UCL10321  - Allele 6       5     6     0.09  0.763025   
UCL10321  - Allele 7       0     1     1.00  0.317311   
 
npl:11> 'photo' is off. 
 
npl:12>  
        ...goodbye... 
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*                                                                      
* 
*                                GENEHUNTER  -  Complete  Linkage  Analysis                
* 
*                                                  (version  2.1_r5  beta)                        
* 





npl:10> TDT Summary - (0 non-original affecteds): 
Marker D16S420         trans untrans  Chi2  p-val 
D16S420   - Allele 1      49    44     0.27  0.604126   
D16S420   - Allele 2      37    54     3.18  0.074735   
D16S420   - Allele 3      37    28     1.25  0.264288   
D16S420   - Allele 4      26    32     0.62  0.430791   
D16S420   - Allele 5      21    24     0.20  0.654721   
D16S420   - Allele 6      24    13     3.27  0.070546   
D16S420   - Allele 7      11     7     0.89  0.345779   
D16S420   - Allele 8       3     6     1.00  0.317311   
D16S420   - Allele 9       3     2     0.20  0.654721   
D16S420   - Allele 10      1     1     0.00  1.000000   
D16S420   - Allele 11      0     1     1.00  0.317311   
Marker CACNG3EX1CA     trans untrans  Chi2  p-val 
CACNG3EX1CA- Allele 1      63    36     7.36  0.006656  ++ 
CACNG3EX1CA- Allele 2      38    63     6.19  0.012861  - 
CACNG3EX1CA- Allele 3      11    13     0.17  0.683091   
Marker UCL10321        trans untrans  Chi2  p-val 
UCL10321  - Allele 1      63    59     0.13  0.717245   
UCL10321  - Allele 2      59    48     1.13  0.287596   
UCL10321  - Allele 3      42    60     3.18  0.074706   
UCL10321  - Allele 4      13    12     0.04  0.841481   
UCL10321  - Allele 5      10     8     0.22  0.637352   
UCL10321  - Allele 6       7     8     0.07  0.796253   
UCL10321  - Allele 7       3     3     0.00  1.000000   
UCL10321  - Allele 9       2     1     0.33  0.563703   
 
npl:11> 'photo' is off. 
 
npl:12>  
        ...goodbye... 
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Appendix 21   TDT results at GABAAR gene cluster, GABRB3, GABRA5 
and GABRG3 on chromosome 15q11-13 for 53 CAE pedigrees and 82 
AE pedigrees, generated by GENEHUNTER 2.1. 





*                                                                      
* 
*                                GENEHUNTER  -  Complete  Linkage  Analysis                
* 
*                                                  (version  2.1_r5  beta)                        
* 





npl:10> TDT Summary - (0 non-original affecteds): 
Marker GABRB3          trans untrans  Chi2  p-val 
GABRB3    - Allele 1      46    43     0.10  0.750485   
GABRB3    - Allele 2      23    27     0.32  0.571608   
GABRB3    - Allele 3      19    14     0.76  0.384088   
GABRB3    - Allele 4      16    15     0.03  0.857462   
GABRB3    - Allele 5      14    18     0.50  0.479500   
GABRB3    - Allele 6      11    12     0.04  0.834827   
GABRB3    - Allele 7       2     6     2.00  0.157299   
GABRB3    - Allele 8      12     5     2.88  0.089555   
GABRB3    - Allele 9       4     6     0.40  0.527089   
GABRB3    - Allele 10      4     6     0.40  0.527089   
GABRB3    - Allele 11      2     1     0.33  0.563703   
Marker D155            trans untrans  Chi2  p-val 
D155      - Allele 1      48    41     0.55  0.458088   
D155      - Allele 2      34    33     0.01  0.902765   
D155      - Allele 3      27    16     2.81  0.093448   
D155      - Allele 4       8    20     5.14  0.023342  - 
D155      - Allele 5      13    10     0.39  0.531615   
D155      - Allele 6       9     4     1.92  0.165518   
D155      - Allele 7       1    10     7.36  0.006656  -- 
D155      - Allele 8       2     4     0.67  0.414216   
D155      - Allele 9       2     5     1.29  0.256839   
D155      - Allele 10      0     2     2.00  0.157299   
D155      - Allele 11      2     3     0.20  0.654721   
D155      - Allele 15      2     0     2.00  0.157299   
Marker DA55            trans untrans  Chi2  p-val 
DA55      - Allele 1      46    34     1.80  0.179713   
DA55      - Allele 2      38    31     0.71  0.399396   
DA55      - Allele 3      19    37     5.79  0.016157  - 
DA55      - Allele 4       8    11     0.47  0.491297   
DA55      - Allele 5       6     8     0.29  0.592980   
DA55      - Allele 6       6    11     1.47  0.225253   
DA55      - Allele 7      14     5     4.26  0.038947  + 
DA55      - Allele 8       4     2     0.67  0.414216     346 
DA55      - Allele 9       5     1     2.67  0.102470   
DA55      - Allele 10      2     7     2.78  0.095581   
DA55      - Allele 11      0     2     2.00  0.157299   
DA55      - Allele 12      3     2     0.20  0.654721   
DA55      - Allele 13      3     0     3.00  0.083264   
DA55      - Allele 14      0     1     1.00  0.317311   
DA55      - Allele 15      0     2     2.00  0.157299   
DA55      - Allele 16      2     0     2.00  0.157299   
DA55      - Allele 17      0     2     2.00  0.157299   
Marker D15S156         trans untrans  Chi2  p-val 
D15S156   - Allele 1      44    57     1.67  0.195821   
D15S156   - Allele 2      50    41     0.89  0.345448   
D15S156   - Allele 3       7     6     0.08  0.781511   
D15S156   - Allele 4       2     2     0.00  1.000000   
D15S156   - Allele 5       2     0     2.00  0.157299   
D15S156   - Allele 7       1     1     0.00  1.000000   
D15S156   - Allele 10      1     0     1.00  0.317311   
 
npl:11> 'photo' is off. 
 
npl:12>  
        ...goodbye... 
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*                                                                      
* 
*                                GENEHUNTER  -  Complete  Linkage  Analysis                
* 
*                                                  (version  2.1_r5  beta)                        
* 





npl:10> TDT Summary - (0 non-original affecteds): 
Marker GABRB3          trans untrans  Chi2  p-val 
GABRB3    - Allele 1      62    66     0.12  0.723674   
GABRB3    - Allele 2      34    35     0.01  0.904177   
GABRB3    - Allele 3      30    30     0.00  1.000000   
GABRB3    - Allele 4      23    18     0.61  0.434880   
GABRB3    - Allele 5      23    23     0.00  1.000000   
GABRB3    - Allele 6      17    17     0.00  1.000000   
GABRB3    - Allele 7      11    11     0.00  1.000000   
GABRB3    - Allele 8      14     5     4.26  0.038947  + 
GABRB3    - Allele 9       6    10     1.00  0.317311   
GABRB3    - Allele 10      5     9     1.14  0.285049   
GABRB3    - Allele 11      2     1     0.33  0.563703   
GABRB3    - Allele 12      0     2     2.00  0.157299   
Marker D155            trans untrans  Chi2  p-val 
D155      - Allele 1      67    67     0.00  1.000000   
D155      - Allele 2      43    47     0.18  0.673290   
D155      - Allele 3      41    28     2.45  0.117579   
D155      - Allele 4      18    28     2.17  0.140369   
D155      - Allele 5      24    23     0.02  0.884028   
D155      - Allele 6      14     7     2.33  0.126630   
D155      - Allele 7       6    10     1.00  0.317311   
D155      - Allele 8       5     7     0.33  0.563703   
D155      - Allele 9       4     5     0.11  0.738883   
D155      - Allele 10      0     2     2.00  0.157299   
D155      - Allele 11      2     3     0.20  0.654721   
D155      - Allele 13      1     1     0.00  1.000000   
D155      - Allele 15      3     0     3.00  0.083264   
Marker DA55            trans untrans  Chi2  p-val 
DA55      - Allele 1      68    48     3.45  0.063318   
DA55      - Allele 2      53    49     0.16  0.692061   
DA55      - Allele 3      26    46     5.56  0.018422  - 
DA55      - Allele 4      15    13     0.14  0.705457   
DA55      - Allele 5       9    15     1.50  0.220671   
DA55      - Allele 6      10    17     1.81  0.177932   
DA55      - Allele 7      18     9     3.00  0.083264   
DA55      - Allele 8       9     4     1.92  0.165518   
DA55      - Allele 9       5     3     0.50  0.479500   
DA55      - Allele 10      5    10     1.67  0.196706   
DA55      - Allele 11      2     4     0.67  0.414216   
DA55      - Allele 12      3     2     0.20  0.654721     348 
DA55      - Allele 13      3     2     0.20  0.654721   
DA55      - Allele 14      0     2     2.00  0.157299   
DA55      - Allele 15      0     2     2.00  0.157299   
DA55      - Allele 16      2     0     2.00  0.157299   
DA55      - Allele 17      0     2     2.00  0.157299   
Marker D15S156         trans untrans  Chi2  p-val 
D15S156   - Allele 1      67    68     0.01  0.931414   
D15S156   - Allele 2      61    62     0.01  0.928155   
D15S156   - Allele 3      11    14     0.36  0.548506   
D15S156   - Allele 4       6     4     0.40  0.527089   
D15S156   - Allele 5       2     0     2.00  0.157299   
D15S156   - Allele 6       2     0     2.00  0.157299   
D15S156   - Allele 7       2     2     0.00  1.000000   
D15S156   - Allele 8       0     1     1.00  0.317311   
D15S156   - Allele 9       0     2     2.00  0.157299   
D15S156   - Allele 10      2     0     2.00  0.157299   
 
npl:11> 'photo' is off. 
 
npl:12>  
        ...goodbye... 
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Appendix 22   PDT results at CACNG3 locus on chromosome 16p12-13.3 for 53 CAE pedigrees and 82 AE pedigrees, 
generated by PDT 5.1 
Appendix 22a  53 CAE pedigrees 
Marker D16S420: 
AVE PDT 
                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1      42      42        27      15     1     0.554    0.5797    06/08/06   avePDT 
               2/   2      31      43        18      20     1    -1.746    0.0809    06/08/06   avePDT 
               3/   3      31      18         7       2     1     1.738    0.0823    06/08/06   avePDT 
               4/   4      10      22         6      10     1    -1.919    0.0550    06/08/06   avePDT 
               5/   5      21      25         5       7     1    -0.733    0.4638    06/08/06   avePDT 
               6/   6      19      10         9       5     1     1.750    0.0801    06/08/06   avePDT 
               7/   7      10       4         6       2     1     1.800    0.0719    06/08/06   avePDT 
               8/   8       2       3         1       1     1    -1.236    0.2164    06/08/06   avePDT 
               9/   9       3       2         2       4     1     0.175    0.8608    06/08/06   avePDT 
              10/  10       1       1         1       0     1     1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       170     170        41      33 
 
Global score:   
 
Marker              DF     ChiSq    Pvalue      Date 









                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1     132     108        74      51     1     2.949    0.0032    06/08/06   avePDT 
               2/   2      28      50        11      17     1    -2.496    0.0126    06/08/06   avePDT 
               3/   3       8      10         1       0     1    -0.277    0.7815    06/08/06   avePDT 
 
  IND COUNTS:       168     168        43      34 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                     2    10.001    0.0067    06/08/06   GLOBAL_AVE_PDT 





        
                 Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1      70      63        40      23     1     0.745    0.4561    06/08/06   avePDT 
               2/   2      35      29        18      10     1     1.296    0.1950    06/08/06   avePDT 
               3/   3      33      54        11      23     1    -2.807    0.0050    06/08/06   avePDT 
               4/   4      10       8         2       2     1     0.473    0.6363    06/08/06   avePDT 
               5/   5       9       2         8       2     1     1.504    0.1326    06/08/06   avePDT 
               6/   6       5       5         3       6     1     0.493    0.6219    06/08/06   avePDT 
               7/   7       0       1         0       0     1    -1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       162     162        41      33 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                     6    11.866    0.0650    06/08/06   GLOBAL_AVE_PDT   352 
 
 
Appendix 22b  82 AE pegrees 
Marker D16S420: 
AVE PDT 
                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1      77      71        36      20     1     1.115    0.2650    06/08/06   avePDT 
               2/   2      44      61        24      30     1    -2.042    0.0411    06/08/06   avePDT 
               3/   3      44      32        13       5     1     1.544    0.1225    06/08/06   avePDT 
               4/   4      25      36        12      15     1    -1.737    0.0823    06/08/06   avePDT 
               5/   5      27      32         7      10     1    -0.868    0.3856    06/08/06   avePDT 
               6/   6      27      16        11       6     1     1.811    0.0701    06/08/06   avePDT 
               7/   7      13       8         9       5     1     1.050    0.2935    06/08/06   avePDT 
               8/   8       3       4         1       1     1    -1.236    0.2164    06/08/06   avePDT 
               9/   9       3       2         2       4     1     0.175    0.8608    06/08/06   avePDT 
              10/  10       1       1         1       0     1     1.000    0.3173    06/08/06   avePDT 
              11/  11       0       1         0       0     1    -1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       264     264        58      48 
 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 





                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1     195     168        99      76     1     2.598    0.0094    06/08/06   avePDT 
               2/   2      46      71        20      28     1    -2.387    0.0170    06/08/06   avePDT 
               3/   3      11      13         3       0     1     0.034    0.9729    06/08/06   avePDT 
 
  IND COUNTS:       252     252        61      52 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                     2     8.300    0.0158    06/08/06   GLOBAL_AVE_PDT 





                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1     104      98        55      42     1     0.249    0.8036    06/08/06   avePDT 
               2/   2      67      60        26      18     1     0.867    0.3860    06/08/06   avePDT 
               3/   3      56      73        20      30     1    -1.617    0.1059    06/08/06   avePDT 
               4/   4      13      12         2       2     1     0.212    0.8318    06/08/06   avePDT 
               5/   5      10       8         8       2     1     0.711    0.4768    06/08/06   avePDT 
               6/   6       7       7         5       6     1     0.361    0.7180    06/08/06   avePDT 
               7/   7       3       3         0       0     1     0.525    0.5994    06/08/06   avePDT 
               9/   9       2       1         0       0     1     1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       262     262        58      50 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                     7          4.712        0.6951        06/08/06      GLOBAL_AVE_PDT  355 
 
 
Appendix 23   PDT results at GABAAR gene cluster, GABRB3, GABRA5 and GABRG3 on chromosome 15q11-13 for 
53 CAE pedigrees and 82 AE pedigrees, generated by PDT 5.1. 




                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1      74      71        37      29     1     0.520    0.6031    06/08/06   avePDT 
               2/   2      25      29        15      10     1    -0.688    0.4918    06/08/06   avePDT 
               3/   3      19      14         6       8     1     1.334    0.1821    06/08/06   avePDT 
               4/   4      16      16         7       3     1     0.506    0.6131    06/08/06   avePDT 
               5/   5      14      18         6       6     1    -1.258    0.2083    06/08/06   avePDT 
               6/   6      11      12         7       3     1    -0.385    0.7001    06/08/06   avePDT 
               7/   7       2       6         3       3     1    -1.127    0.2596    06/08/06   avePDT 
               8/   8      11       5         4       4     1     1.271    0.2039    06/08/06   avePDT 
               9/   9       4       4         1       1     1    -0.174    0.8618    06/08/06   avePDT 
              10/  10       4       6         2       1     1    -0.756    0.4497    06/08/06   avePDT 
              11/  11       2       1         0       0     1     1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       182     182        44      34 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                    10     8.179    0.6114    06/08/06   GLOBAL_AVE_PDT 









                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1      76      71        37      31     1     0.474    0.6355    06/08/06   avePDT 
               2/   2      36      33        15      12     1    -0.090    0.9283    06/08/06   avePDT 
               3/   3      30      18        15      11     1     1.896    0.0580    06/08/06   avePDT 
               4/   4      11      23         4       6     1    -2.357    0.0184    06/08/06   avePDT 
               5/   5      15      12         9       2     1     0.636    0.5245    06/08/06   avePDT 
               6/   6       9       4         2       1     1     1.050    0.2935    06/08/06   avePDT 
               7/   7       3      12         0       1     1    -2.137    0.0326    06/08/06   avePDT 
               8/   8       1       3         1       1     1    -1.342    0.1797    06/08/06   avePDT 
               9/   9       4       7         1       1     1    -1.633    0.1025    06/08/06   avePDT 
              10/  10       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              11/  11       2       3         3       3     1    -1.414    0.1573    06/08/06   avePDT 
              13/  13       0       0         0       1     1    -1.000    0.3173    06/08/06   avePDT 
              15/  15       1       0         1       0     1     1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       188     188        44      35 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                    12    23.009    0.0277    06/08/06   GLOBAL_AVE_PDT 
 
 





                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1      72      58        39      26     1     0.983    0.3258    06/08/06   avePDT 
               2/   2      47      39        17      13     1     1.309    0.1905    06/08/06   avePDT 
               3/   3      20      37         7      10     1    -2.429    0.0152    06/08/06   avePDT 
               4/   4       6      11         0       5     1    -0.896    0.3701    06/08/06   avePDT 
               5/   5       6      10         5       3     1    -0.588    0.5566    06/08/06   avePDT 
               6/   6       6      11         5       6     1    -0.697    0.4858    06/08/06   avePDT 
               7/   7      14       5         9       5     1     1.541    0.1234    06/08/06   avePDT 
               8/   8       4       2         3       1     1     1.342    0.1797    06/08/06   avePDT 
               9/   9       5       1         2       1     1     1.342    0.1797    06/08/06   avePDT 
              10/  10       2       7         1       0     1    -1.413    0.1576    06/08/06   avePDT 
              11/  11       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              12/  12       3       2         0       0     1     0.632    0.5271    06/08/06   avePDT 
              13/  13       3       0         0       0     1     1.000    0.3173    06/08/06   avePDT 
              14/  14       0       1         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              15/  15       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              16/  16       2       0         0       0     1     1.000    0.3173    06/08/06   avePDT 
              17/  17       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       190     190        44      35 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                    16    23.136    0.1101    06/08/06   GLOBAL_AVE_PDT 







                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1      81      94        39      29     1    -0.685    0.4930    06/08/06   avePDT 
               2/   2      74      65        40      36     1     0.172    0.8635    06/08/06   avePDT 
               3/   3       7       6         1       1     1     0.218    0.8273    06/08/06   avePDT 
               4/   4       2       2         0       0     1     0.000    1.0000    06/08/06   avePDT 
               5/   5       2       0         3       1     1     1.571    0.1161    06/08/06   avePDT 
               7/   7       1       1         1       1     1    -1.000    0.3173    06/08/06   avePDT 
              10/  10       1       0         0       0     1     1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       168     168        42      34 
 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                     6     4.300    0.6362    06/08/06   GLOBAL_AVE_PDT 
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                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1     100     105        45      35     1    -0.165    0.8690    06/08/06   avePDT 
               2/   2      36      38        21      21     1    -0.498    0.6182    06/08/06   avePDT 
               3/   3      30      30         8      11     1     0.652    0.5142    06/08/06   avePDT 
               4/   4      23      18        10      10     1     0.747    0.4548    06/08/06   avePDT 
               5/   5      20      22        10       7     1    -0.953    0.3407    06/08/06   avePDT 
               6/   6      17      16        11       4     1     0.292    0.7705    06/08/06   avePDT 
               7/   7      12      10         6       4     1     0.224    0.8224    06/08/06   avePDT 
               8/   8      13       5         6       4     1     1.590    0.1119    06/08/06   avePDT 
               9/   9       6       8         3       1     1    -0.556    0.5785    06/08/06   avePDT 
              10/  10       5       9         2       1     1    -1.000    0.3173    06/08/06   avePDT 
              11/  11       2       1         0       0     1     1.000    0.3173    06/08/06   avePDT 
              12/  12       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       264     264        61      49 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                    11     7.461    0.7606    06/08/06   GLOBAL_AVE_PDT 
 






                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1     102     105        51      44     1    -0.114    0.9089    06/08/06   avePDT 
               2/   2      47      49        17      12     1    -0.451    0.6523    06/08/06   avePDT 
               3/   3      44      27        20      16     1     1.797    0.0723    06/08/06   avePDT 
               4/   4      23      32         7       9     1    -1.001    0.3166    06/08/06   avePDT 
               5/   5      27      27        11       5     1    -0.136    0.8917    06/08/06   avePDT 
               6/   6      13       7         5       2     1     1.439    0.1500    06/08/06   avePDT 
               7/   7       8      12         3       5     1    -1.000    0.3173    06/08/06   avePDT 
               8/   8       4       6         3       2     1    -1.265    0.2059    06/08/06   avePDT 
               9/   9       6       7         1       1     1     0.000    1.0000    06/08/06   avePDT 
              10/  10       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              11/  11       2       3         3       3     1    -1.414    0.1573    06/08/06   avePDT 
              13/  13       1       1         0       1     1    -1.000    0.3173    06/08/06   avePDT 
              15/  15       1       0         1       0     1     1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       278     278        61      50 
 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                    12    13.052    0.3652    06/08/06   GLOBAL_AVE_PDT 
 
 






                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1     108      87        57      40     1     1.214    0.2248    06/08/06   avePDT 
               2/   2      68      62        26      23     1     0.945    0.3445    06/08/06   avePDT 
               3/   3      27      46        10      11     1    -2.392    0.0167    06/08/06   avePDT 
               4/   4      13      13         1       8     1    -0.028    0.9776    06/08/06   avePDT 
               5/   5       9      17         9       7     1    -0.904    0.3661    06/08/06   avePDT 
               6/   6      10      17         5       6     1    -0.985    0.3248    06/08/06   avePDT 
               7/   7      18       9        10       5     1     1.343    0.1792    06/08/06   avePDT 
               8/   8       9       4         3       2     1     1.406    0.1599    06/08/06   avePDT 
               9/   9       5       3         2       1     1     0.333    0.7389    06/08/06   avePDT 
              10/  10       5      10         1       0     1    -1.020    0.3078    06/08/06   avePDT 
              11/  11       2       4         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              12/  12       3       2         0       0     1     0.632    0.5271    06/08/06   avePDT 
              13/  13       3       2         0       1     1     0.068    0.9459    06/08/06   avePDT 
              14/  14       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              15/  15       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
              16/  16       2       0         0       0     1     1.000    0.3173    06/08/06   avePDT 
              17/  17       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       282     282        62      52 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 







                        Parental Contrib  Discordant Sibs   
Marker     Allele/Band  Trans  Not trans    Aff   Unaff    DF      Z      Pvalue         Date 
 
               1/   1     136     136        58      38     1     0.368    0.7130    06/08/06   avePDT 
               2/   2      97      97        53      55     1    -0.548    0.5834    06/08/06   avePDT 
               3/   3      13      16         3       5     1    -0.284    0.7761    06/08/06   avePDT 
               4/   4       6       4         2       1     1     0.602    0.5472    06/08/06   avePDT 
               5/   5       2       0         3       1     1     1.571    0.1161    06/08/06   avePDT 
               6/   6       2       0         0       0     1     1.000    0.3173    06/08/06   avePDT 
               7/   7       2       2         1       1     1    -1.000    0.3173    06/08/06   avePDT 
               8/   8       0       1         0       1     1    -1.000    0.3173    06/08/06   avePDT 
               9/   9       0       2         0       0     1    -1.000    0.3173    06/08/06   avePDT 
 
  IND COUNTS:       258     258        60      51 
 
 
Global score:   
Marker              DF     ChiSq    Pvalue      Date 
                     8     6.532    0.5878    06/08/06   GLOBAL_AVE_PDT 
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Appendix 24   Predicted  tagging  SNPs  based  on  whole  resource  and 
subset of 31 trios, using two strategies incorporated in Haploview 
 
Appendix 24a  Comparison of tag SNPs selected by two strategies 
 
Whole resource:    Subset of 31 trios: 








threshold  Tagger 
1      1   
2      2   
3      3   
4       4     
5      5   
6      6   
7       7    
8       8    
9      9   
10      10   
11      11   
12      12    
13      13   
14      14   
15      15   
16      16   
17      17   
18      18   
19      19   
20      20   
21      21   
22      22   
23      23   
Total  tag 
SNPs  19  18   
Total  tag 
SNPs  20  19   364 
Appendix 24b  SNPs  captured  by  tag  SNPs  based  on  whole 
resource 
 









1  1    1  1 
2  2    2  2 
3  3    4  4 
5  5    6  6 
6  6    7  3,8,7 
9  9    9  9 
10  10    12  11,12 
11  11    13  13 
13  13    14  14 
14  14    15  15 
15  15    16  16 
16  16    17  17 
17  17    18  18 
19  19    19  19 
20  20    20  20 
21  21    21  21 
22  22    22  22 
23  23    23  23 
2,3,5,6  4,7,8    7,4,9  5 
10,11,13  12    13,7,12  10 
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Appendix 25   Results  from  the  PDT  analysis  of  each  CACNG3  SNP 
independently. 
 
Appendix 25a  Affectedness criteria CAE 
        SUM PDT  AVE PDT 
SNP  Allele  Transmitted 
Not 
transmitted  Z (1df)  p-value  Z (1df)  p-value 
1  2(A)  238  230  0.75  0.454  0.75  0.454 
2  2(A)  199  168  1.67  0.094  1.74  0.083 
3  2(G)  276  235  2.41  0.016  2.18  0.029 
4  1(A)  375  354  1.76  0.078  1.63  0.103 
5  1(T)  394  378  0.82  0.411  0.58  0.560 
6  1(T)  453  435  1.52  0.128  1.69  0.091 
7  2(G)  247  208  2.40  0.016  2.23  0.026 
8  2(A)  266  222  2.64  0.008  2.47  0.013 
9  1(G)  232  227  0.41  0.682  0.41  0.682 
10  2(A)  286  260  1.25  0.213  1.59  0.113 
11  2(G)  179  139  2.90  0.004  2.49  0.013 
12  1(A)  99  86  1.21  0.225  1.21  0.225 
13  1(T)  399  381  1.62  0.105  1.29  0.199 
14  2(G)  317  300  0.89  0.376  0.86  0.391 
15  2(T)  345  335  1.26  0.207  0.22  0.827 
16  1(T)  409  380  2.14  0.033  2.38  0.017 
17  2(C)  239  227  0.79  0.431  1.07  0.286 
18  1(G)  401  390  0.36  0.717  0.67  0.503 
19  1(T)  317  299  1.54  0.123  0.82  0.411 
20  1(C)  361  358  0.37  0.710  0.62  0.533 
21  1(T)  296  272  1.24  0.215  1.08  0.282 
22  1(C)  245  244  0.10  0.919  0.10  0.919 
23  2(C)  141  135  0.48  0.633  0.48  0.633   366 
 
Appendix 25b  Affectedness criteria CAE, JAE or AE 
        SUM PDT  AVE PDT 
SNP  Allele  Transmitted 
Not 
transmitted  Z (1df)  p-value  Z (1df)  p-value 
1  2(A)  252  242  0.92  0.357  0.92  0.357 
2  2(A)  240  200  2.17  0.030  1.86  0.063 
3  2(G)  331  279  2.68  0.007  2.46  0.014 
4  1(A)  454  428  2.05  0.040  1.80  0.072 
5  1(T)  465  448  0.63  0.530  0.36  0.720 
6  1(T)  535  520  1.50  0.134  1.74  0.081 
7  2(G)  298  248  2.67  0.008  2.52  0.012 
8  2(A)  312  256  2.98  0.003  2.75  0.006 
9  1(G)  244  237  0.56  0.576  0.56  0.576 
10  2(A)  335  310  0.89  0.372  1.21  0.227 
11  2(G)  209  167  2.37  0.018  2.34  0.019 
12  1(A)  106  92  1.23  0.220  1.23  0.220 
13  1(T)  479  462  1.40  0.162  1.20  0.230 
14  2(G)  367  359  0.15  0.885  0.38  0.703 
15  2(T)  408  392  1.29  0.198  0.31  0.755 
16  1(T)  481  452  1.62  0.105  2.18  0.030 
17  2(C)  292  276  1.28  0.202  1.46  0.145 
18  1(G)  483  463  1.15  0.250  1.19  0.233 
19  1(T)  377  359  1.52  0.129  1.22  0.223 
20  1(C)  443  445  0.14  0.893  0.22  0.827 
21  1(T)  358  320  1.85  0.065  1.63  0.102 
22  2(G)  66  62  0.39  0.695  0.39  0.695 
23  2(C)  150  141  0.68  0.494  0.68  0.494   367 
Appendix 26   SNP-based haplotypes in LD blocks 1 and 2 of CACNG3 showing significant (p0.05) transmission 
disequilibrium in the entire resource when analysed using the PDT with affectedness criteria CAE 
a) LD block 1 
SNPs  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
2  3  4  5  6  7  8 
in  parents 



















1  1            48.2  246  288  -2.53  0.011      -2.14  0.032     
1  2            16.2  88  92  0.33  0.741      -0.82  0.413     
2  1            4.1  25  20  0.87  0.387      0.33  0.739     
2  2            31.5  195  154  2.18  0.029  9.00(3)  0.029  2.69  0.007  9.43(3)  0.024 
  1  1          30.6  144  160  -0.90  0.367      -0.61  0.543     
  1  2          21.2  93  117  -1.92  0.056      -1.80  0.072     
  2  1          46.2  250  208  2.54  0.011      2.38  0.017     
  2  2          2.0  9  11  -0.58  0.564  8.44(3)  0.038  -0.58  0.564  7.21(3)  0.066 
    1  1        49.2  263  223  2.41  0.016      2.24  0.025     
    1  2        27.8  129  146  -0.91  0.364      -0.71  0.481     
    2  1        22.3  98  122  -1.90  0.057      -1.77  0.076     
    2  2        0.7  4  3  0.38  0.706  7.80(3)  0.050  0.38  0.706  6.62(3)  0.085 
    1  1  1      41.9  215  167  2.90  0.004      2.83  0.005     
    1  1  2      7.0  27  37  -0.84  0.401      -1.05  0.293     
    1  2  1      27.1  117  130  -0.72  0.472      -0.47  0.640     
    1  2  2      0.5  0  5  -1.89  0.059      -2.00  0.046     
    2  1  1      22.4  94  110  -1.48  0.139      -1.22  0.222     
    2  1  2      0.4  0  4  -1.63  0.103      -1.73  0.083     
    2  2  1      0.7  3  3  0.00  1.000  15.46(6)  0.017  0.00  1.000  15.29(6)  0.018 
      1  1  1    26.2  112  133  -1.84  0.066      -1.59  0.111     
      1  1  2    38.6  206  155  3.09  0.002      3.08  0.002     
      1  2  1    0.5  0  5  -1.89  0.059      -2.00  0.046       368 
SNPs  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
2  3  4  5  6  7  8 
in  parents 



















      1  2  2    6.7  27  36  -0.76  0.450      -1.05  0.293     
      2  1  1    24.8  112  120  -0.44  0.659      0.05  0.957     
      2  1  2    2.4  10  12  -0.63  0.527      -0.63  0.527     
      2  2  1    0.7  1  6  -1.89  0.059      -2.00  0.046     
      2  2  2    0.1  0  1  -1.00  0.317  19.47(7)  0.007  -1.00  0.317  19.71(7)  0.006 
      1  1  1  1  26.0  106  129  -1.96  0.050      -1.71  0.088     
      1  1  1  2  0.2  1  1  0.00  1.000      0.00  1.000     
      1  1  2  1  0.4  1  3  -1.41  0.157      -1.41  0.157     
      1  1  2  2  37.9  198  145  3.26  0.001      3.35  0.001     
      1  2  1  1  0.6  0  5  -1.89  0.059      -2.00  0.046     
      1  2  2  1  0.1  0  1  -1.00  0.317      -1.00  0.317     
      1  2  2  2  6.5  26  33  -0.57  0.567      -0.85  0.397     
      2  1  1  1  24.7  107  116  -0.56  0.579      -0.16  0.875     
      2  1  1  2  0.2  2  0  1.00  0.317      1.00  0.317     
      2  1  2  1  0.1  0  1  -1.00  0.317      -1.00  0.317     
      2  1  2  2  2.3  10  11  -0.33  0.739      -0.33  0.739     
      2  2  1  1  0.8  1  6  -1.89  0.059      -2.00  0.046     
      2  2  2  2  0.1  0  1  -1.00  0.317  26.20(12)  0.010  -1.00  0.317  26.76(12)  0.008 
        1  1    51.0  225  256  -2.04  0.042      -1.66  0.098     
        1  2    41.0  219  168  3.09  0.002      3.08  0.002     
        2  1    1.3  1  11  -2.67  0.008      -2.83  0.005     
        2  2    6.8  27  37  -0.85  0.397  16.19(3)  0.001  -1.20  0.230  16.25(3)  0.001 
        1  1  1  50.7  214  248  -2.25  0.024      -1.98  0.048     
        1  1  2  0.4  3  1  0.82  0.414      0.82  0.414     
        1  2  1  0.5  1  4  -1.73  0.083      -1.73  0.083     
        1  2  2  40.4  211  157  3.31  0.001      3.43  0.001     
        2  1  1  1.3  1  11  -2.67  0.008      -2.83  0.005     
        2  2  1  0.1  0  1  -1.00  0.317      -1.00  0.317     
        2  2  2  6.6  26  34  -0.66  0.506  24.24(6)  0.001  -1.00  0.318  25.12(6)  0.000   369 
SNPs  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
2  3  4  5  6  7  8 
in  parents 



















          1  1  52.1  237  284  -2.86  0.004      -2.76  0.006     
          1  2  0.4  3  1  0.82  0.414      0.82  0.414     
          2  1  0.6  1  5  -1.63  0.103      -1.63  0.103     
          2  2  46.9  259  210  2.95  0.003  15.15(3)  0.002  2.91  0.004  14.58(3)  0.002 
   370 
b) LD block 2 
SNP  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
10  11  12  13 
 in parents 



















1  1      42.3  190  223  -1.72  0.086      -1.98  0.048     
1  2      1.4  6  8  -0.30  0.763      -0.54  0.593     
2  1      26.3  123  134  -0.93  0.353      -0.73  0.469     
2  2      29.9  169  123  3.32  0.001  11.21(3)  0.011  3.09  0.002  10.72(3)  0.013 
  1  1    5.1  16  20  -1.63  0.103      -1.63  0.103     
  1  2    65.7  217  243  -2.32  0.020      -2.30  0.022     
  2  1    23.9  96  71  2.27  0.023      2.23  0.026     
  2  2    5.3  21  16  1.89  0.059  12.58(3)  0.006  1.89  0.059  12.37(3)  0.006 
1  1  1    1.5  4  6  -1.00  0.317      -1.00  0.317     
1  1  2    41.6  128  158  -1.84  0.066      -2.05  0.041     
1  2  1    0.7  2  3  -0.45  0.655      -0.45  0.655     
1  2  2    1.0  2  5  -1.04  0.297      -0.71  0.480     
2  1  1    3.8  12  14  -0.71  0.480      -0.71  0.480     
2  1  2    23.7  84  79  0.00  1.000      -0.03  0.973     
2  2  1    23.4  93  68  2.30  0.021      2.30  0.021     
2  2  2    4.4  19  11  2.13  0.033  14.01(7)  0.051  2.65  0.008  16.36(7)  0.022 
  1  1  1  4.6  14  17  -1.00  0.317      -1.00  0.317     
  1  1  2  0.7  2  3  -0.45  0.655      -0.45  0.655     
  1  2  1  49.0  149  180  -1.63  0.103      -2.11  0.035     
  1  2  2  15.8  55  51  -0.44  0.664      -0.03  0.978     
  2  1  1  24.4  95  69  2.35  0.019      2.35  0.019     
  2  2  1  4.2  15  13  0.00  1.000      1.00  0.317     
  2  2  2  1.3  6  3  1.21  0.225  9.45(6)  0.150  1.41  0.157  12.14(6)  0.059 
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Appendix 27   SNP-based haplotypes in LD blocks 1 and 2 of CACNG3 showing significant (p0.05) transmission 
disequilibrium in the entire resource when analysed using the PDT with affectedness criteria CAE, JAE or AE 
a) LD block 1 
SNP  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
2  3  4  5  6  7  8 
 in  parents 



















1  1            296  346  48.3  -2.66  0.008      -2.31  0.021     
1  2            104  108  16.0  0.06  0.953      -0.69  0.491     
2  1            28  23  3.8  0.85  0.396      0.38  0.705     
2  2            236  187  31.9  2.56  0.011  10.74(3)  0.013  2.67  0.008  9.83(3)  0.020 
1  1  1          166  180  29.0  -0.55  0.582      -0.11  0.913     
1  1  2          98  131  19.2  -2.52  0.012      -2.30  0.021     
1  2  1          86  87  14.5  0.24  0.809      -0.44  0.663     
1  2  2          4  9  1.1  -1.89  0.059      -1.89  0.059     
2  1  1          11  11  1.8  0.00  1.000      0.00  1.000     
2  1  2          13  10  1.9  0.69  0.493      0.26  0.795     
2  2  1          212  165  31.6  2.55  0.011      2.67  0.008     
2  2  2          6  3  0.8  1.00  0.317  15.97(7)  0.025  1.00  0.317  15.10(7)  0.035 
  1  1          177  195  30.9  -0.73  0.464      -0.47  0.638     
  1  2          112  142  21.1  -2.25  0.025      -2.07  0.039     
  2  1          303  252  46.1  2.70  0.007      2.60  0.009     
  2  2          10  13  1.9  -0.83  0.405  10.19(3)  0.017  -0.83  0.405  8.96(3)  0.030 
  1  1  1  1      29  29  5.3  -0.28  0.782      0.00  1.000     
  1  1  2  1      133  142  25.3  -0.15  0.881      0.00  0.998     
  1  1  2  2      0  4  0.4  -1.63  0.103      -1.73  0.083     
  1  2  1  1      102  121  20.5  -1.68  0.094      -1.53  0.127       372 
SNP  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
2  3  4  5  6  7  8 
 in  parents 



















  1  2  1  2      0  3  0.3  -1.34  0.180      -1.41  0.157     
  1  2  2  1      3  3  0.6  0.00  1.000      0.00  1.000     
  2  1  1  1      224  172  36.4  3.22  0.001      3.15  0.002     
  2  1  1  2      29  43  6.6  -1.40  0.161      -1.52  0.128     
  2  1  2  1      12  14  2.4  -0.71  0.480      -0.71  0.480     
  2  1  2  2      2  1  0.3  1.00  0.317      1.00  0.317     
  2  2  1  1      10  10  1.8  0.00  1.000      0.00  1.000     
  2  2  1  2      0  2  0.2  -1.41  0.157  21.27(11)  0.031  -1.41  0.157  21.12(11)  0.032 
    1  1        313  269  48.8  2.42  0.016      2.26  0.024     
    1  2        161  177  28.4  -0.60  0.549      -0.38  0.703     
    2  1        118  147  22.2  -2.20  0.028      -2.04  0.042     
    2  2        4  3  0.6  0.38  0.706  8.38(3)  0.039  0.38  0.706  7.17(3)  0.067 
    1  1  1      255  204  41.9  3.08  0.002      2.93  0.003     
    1  1  2      29  43  6.6  -1.40  0.161      -1.52  0.128     
    1  2  1      146  157  27.6  -0.25  0.805      -0.21  0.837     
    1  2  2      2  5  0.6  -1.13  0.257      -1.00  0.317     
    2  1  1      113  131  22.3  -1.60  0.109      -1.37  0.172     
    2  1  2      0  5  0.5  -1.89  0.059      -2.00  0.046     
    2  2  1      3  3  0.5  0.00  1.000  16.21(6)  0.013  0.00  1.000  15.25(6)  0.018 
    1  1  1  1    30  29  5.5  0.00  1.000      0.30  0.763     
    1  1  1  2    224  174  36.9  3.11  0.002      2.93  0.003     
    1  1  2  2    29  41  6.5  -1.25  0.210      -1.38  0.169     
    1  2  1  1    129  137  24.6  -0.10  0.920      0.10  0.917     
    1  2  1  2    12  15  2.5  -1.00  0.317      -1.00  0.317     
    1  2  2  1    0  4  0.4  -1.63  0.103      -1.73  0.083     
    1  2  2  2    2  1  0.3  1.00  0.317      1.00  0.317     
    2  1  1  1    100  122  20.6  -1.84  0.066      -1.71  0.087     
    2  1  1  2    11  9  1.9  0.58  0.564      0.58  0.564     
    2  1  2  1    0  3  0.3  -1.34  0.180      -1.41  0.157       373 
SNP  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
2  3  4  5  6  7  8 
 in  parents 



















    2  1  2  2    0  2  0.2  -1.41  0.157      -1.41  0.157     
    2  2  1  1    3  3  0.6  0.00  1.000  21.49(11)  0.029  0.00  1.000  20.97(11)  0.034 
    1  1  1  1  1  30  29  5.6  0.00  1.000      0.30  0.763     
    1  1  1  2  1  1  2  0.3  -1.00  0.317      -1.00  0.317     
    1  1  1  2  2  217  167  36.5  3.17  0.002      3.03  0.003     
    1  1  2  2  1  0  2  0.2  -1.34  0.180      -1.21  0.225     
    1  1  2  2  2  28  37  6.2  -0.94  0.347      -1.13  0.257     
    1  2  1  1  1  124  133  24.4  -0.20  0.841      -0.11  0.911     
    1  2  1  1  2  2  0  0.2  1.00  0.317      1.00  0.317     
    1  2  1  2  1  0  1  0.1  -1.00  0.317      -1.00  0.317     
    1  2  1  2  2  12  14  2.5  -0.71  0.480      -0.71  0.480     
    1  2  2  1  1  0  4  0.4  -1.63  0.103      -1.73  0.083     
    1  2  2  2  2  2  1  0.3  1.00  0.317      1.00  0.317     
    2  1  1  1  1  96  118  20.3  -1.85  0.065      -1.64  0.101     
    2  1  1  1  2  0  1  0.1  -1.00  0.317      -1.00  0.317     
    2  1  1  2  2  11  9  1.9  0.58  0.564      0.58  0.564     
    2  1  2  1  1  0  3  0.3  -1.34  0.180      -1.41  0.157     
    2  1  2  2  2  0  2  0.2  -1.41  0.157      -1.41  0.157     
    2  2  1  1  1  3  3  0.6  0.00  1.000  26.82(16)  0.044  0.00  1.000  25.93(16)  0.055 
      1  1  1    136  159  26.4  -1.91  0.056      -1.73  0.085     
      1  1  2    242  188  38.5  3.27  0.001      3.17  0.002     
      1  2  1    0  5  0.4  -1.89  0.059      -2.00  0.046     
      1  2  2    29  43  6.5  -1.41  0.158      -1.66  0.097     
      2  1  1    136  141  24.8  0.05  0.961      0.40  0.690     
      2  1  2    12  15  2.4  -1.00  0.317      -1.00  0.317     
      2  2  1    1  6  0.6  -1.89  0.059      -2.00  0.046     
      2  2  2    2  1  0.3  1.00  0.317  22.30(7)  0.002  1.00  0.317  22.71(7)  0.002 
      1  1  1  1  130  155  26.3  -2.02  0.044      -1.84  0.066     
      1  1  1  2  1  1  0.2  0.00  1.000      0.00  1.000       374 
SNP  Frequency      SUM PDT  GLOBAL  AVE PDT  GLOBAL 
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      1  1  2  1  1  3  0.4  -1.41  0.157      -1.41  0.157     
      1  1  2  2  234  178  38.0  3.44  0.001      3.44  0.001     
      1  2  1  1  0  5  0.5  -1.89  0.059      -2.00  0.046     
      1  2  2  1  0  2  0.2  -1.34  0.180      -1.21  0.225     
      1  2  2  2  28  39  6.2  -1.10  0.270      -1.43  0.153     
      2  1  1  1  131  137  24.7  -0.05  0.961      0.20  0.840     
      2  1  1  2  2  0  0.2  1.00  0.317      1.00  0.317     
      2  1  2  1  0  1  0.1  -1.00  0.317      -1.00  0.317     
      2  1  2  2  12  14  2.4  -0.71  0.480      -0.71  0.480     
      2  2  1  1  1  6  0.6  -1.89  0.059      -2.00  0.046     
      2  2  2  2  2  1  0.3  1.00  0.317  29.11(12)  0.004  1.00  0.317  29.78(12)  0.003 
        1  1    273  307  51.2  -1.95  0.052      -1.67  0.094     
        1  2    259  204  40.9  3.31  0.001      3.17  0.002     
        2  1    1  11  1.1  -2.67  0.008      -2.83  0.005     
        2  2    33  44  6.8  -1.15  0.250  17.40(3)  0.001  -1.34  0.180  16.99(3)  0.001 
        1  1  1  262  299  51.0  -2.15  0.032      -1.99  0.047     
        1  1  2  3  1  0.4  0.82  0.414      0.82  0.414     
        1  2  1  1  4  0.5  -1.73  0.083      -1.73  0.083     
        1  2  2  251  193  40.4  3.52  0.000      3.52  0.000     
        2  1  1  1  11  1.1  -2.67  0.008      -2.83  0.005     
        2  2  1  0  2  0.2  -1.34  0.180      -1.21  0.225     
        2  2  2  32  40  6.5  -0.84  0.401  25.96(6)  0.000  -1.10  0.270  26.28(6)  0.000 
          1  1  287  344  52.2  -3.01  0.003      -3.03  0.003     
          1  2  3  1  0.3  0.82  0.414      0.82  0.414     
          2  1  1  6  0.6  -1.90  0.058      -1.73  0.084     
          2  2  313  253  46.9  3.19  0.001  17.64(3)  0.001  3.19  0.001  17.23(3)  0.001 
   375 
b) LD block 2 
SNP  Frequency      SUM PDT  GLOBAL    AVE PDT  GLOBAL   
10  11  12  13 
 in parents 



















1  1      42.7  237  269  -1.31  0.191      -1.68  0.093     
1  2      1.4  8  9  -0.15  0.882      -0.26  0.796     
2  1      26.3  148  163  -0.93  0.354      -0.95  0.343     
2  2      29.6  199  151  2.72  0.007  7.50(3)  0.058  2.87  0.004  9.04(3)  0.029 
  1  1    5.3  17  23  -1.90  0.058      -1.90  0.058     
  1  2    65.7  234  263  -2.51  0.012      -2.41  0.016     
  2  1    23.5  103  75  2.45  0.014      2.35  0.019     
  2  2    5.4  24  17  2.11  0.035  15.27(3)  0.002  2.11  0.035  14.52(3)  0.002 
1  1  1    1.3  4  6  -1.00  0.317      -1.00  0.317     
1  1  2    41.7  140  170  -1.81  0.070      -1.91  0.056     
1  2  1    0.7  2  3  -0.45  0.655      -0.45  0.655     
1  2  2    1.1  3  5  -0.82  0.414      -0.33  0.739     
2  1  1    4.0  13  17  -1.16  0.248      -1.16  0.248     
2  1  2    23.7  89  87  -0.21  0.838      -0.25  0.805     
2  2  1    23.1  100  72  2.49  0.013      2.42  0.015     
2  2  2    4.4  21  12  2.12  0.034  15.07(7)  0.035  2.31  0.021  15.36(7)  0.032 
  1  1  1  4.8  15  20  -1.39  0.166      -1.39  0.166     
  1  1  2  0.7  2  3  -0.45  0.655      -0.45  0.655     
  1  2  1  48.9  161  195  -1.77  0.077      -2.13  0.033     
  1  2  2  15.9  60  56  -0.43  0.667      -0.03  0.979     
  2  1  1  24.0  102  73  2.53  0.011      2.46  0.014     
  2  2  1  4.0  16  13  0.20  0.842      1.27  0.206     
  2  2  2  1.6  8  4  1.28  0.201  11.59(6)  0.072  1.13  0.257  13.36(6)  0.038   376 
 
Appendix 28   Molecular Biology Solutions and reagents 
 
ACD solution: 
    Trisodium citrate      13.2g/L 
    Citric acid        4.8g/L 
    Dextrose      1  4.7g/L 
 
Agarose:   
GibcoBRL electrophoresis grade  10% w/v 
 
10% APS:  Ammonium persulphate 
 
Blue dextran loading buffer: 
    De-ionised formamide    10ml 
    50mM EDTA (pH8.0)    2ml 
    Blue Dextran       360mg 
 
0.5M EDTA:   
EDTA.Na2.2H2O (pH8.0) 
186.12g disodium ethylenediaminetetra-acetate/litre of water. 
Adjust pH to 8.0 with NaOH to allow disodium salt to go into 
solution 
 
Ethidium bromide (10mg/ml): 
1g of ethidium bromide to 100ml of water. Stir for several hours. 
Place in dark bottle or wrap in aluminium foil and store at 4
oC. 
 
Proteinase K:  20mg/ml in water. 
 
Reaction buffer:   
0.01M Tris,  
0.005M EDTA,  




10% SDS:   Sodium dodecyl sulphate 
100g of electrophoresis grade SDS in 900 ml of water. Heat to 
68
oC.  Add  HCL  to  adjust  pH  to  7.2.  Make  up  to  1  litre  with 
water. 
   
TE buffer:  10mM Tris-HCl (pH7.6) 
1.0mM EDTA (pH8.0) 
 
10X TBE:   Tris-borate-EDTA electrophoresis buffer 
    Tris base        54g 
Boric acid         27.5g 
0.5M EDTA        20ml   377 
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